TW202304982A - 一種能與人內皮素受體特異性結合的抗體及其在糖尿病腎病及慢性腎病治療中的應用 - Google Patents
一種能與人內皮素受體特異性結合的抗體及其在糖尿病腎病及慢性腎病治療中的應用 Download PDFInfo
- Publication number
- TW202304982A TW202304982A TW111112218A TW111112218A TW202304982A TW 202304982 A TW202304982 A TW 202304982A TW 111112218 A TW111112218 A TW 111112218A TW 111112218 A TW111112218 A TW 111112218A TW 202304982 A TW202304982 A TW 202304982A
- Authority
- TW
- Taiwan
- Prior art keywords
- seq
- cdata
- amino acid
- ser
- thr
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 17
- 201000010099 disease Diseases 0.000 title claims description 15
- 239000000203 mixture Substances 0.000 title description 14
- 206010012601 diabetes mellitus Diseases 0.000 title description 7
- 230000001225 therapeutic effect Effects 0.000 title description 4
- 210000003734 kidney Anatomy 0.000 title description 3
- 208000035475 disorder Diseases 0.000 title description 2
- 238000000034 method Methods 0.000 claims abstract description 67
- 208000024891 symptom Diseases 0.000 claims abstract description 22
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims abstract description 19
- 208000033679 diabetic kidney disease Diseases 0.000 claims abstract description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 264
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical group C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 claims description 106
- 230000027455 binding Effects 0.000 claims description 78
- 150000007523 nucleic acids Chemical class 0.000 claims description 64
- 102000039446 nucleic acids Human genes 0.000 claims description 56
- 108020004707 nucleic acids Proteins 0.000 claims description 56
- 102000040430 polynucleotide Human genes 0.000 claims description 45
- 108091033319 polynucleotide Proteins 0.000 claims description 45
- 239000002157 polynucleotide Substances 0.000 claims description 45
- 241000282414 Homo sapiens Species 0.000 claims description 34
- 239000013598 vector Substances 0.000 claims description 23
- 108091026890 Coding region Proteins 0.000 claims description 22
- 230000014509 gene expression Effects 0.000 claims description 21
- 239000013604 expression vector Substances 0.000 claims description 17
- 241001529936 Murinae Species 0.000 claims description 11
- 208000020832 chronic kidney disease Diseases 0.000 claims description 9
- 238000003259 recombinant expression Methods 0.000 claims description 8
- 230000003247 decreasing effect Effects 0.000 claims description 7
- 230000024924 glomerular filtration Effects 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 201000001474 proteinuria Diseases 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000019491 signal transduction Effects 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 abstract description 3
- 208000017169 kidney disease Diseases 0.000 abstract description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 192
- 108020004414 DNA Proteins 0.000 description 123
- 210000004027 cell Anatomy 0.000 description 115
- 108090000765 processed proteins & peptides Proteins 0.000 description 115
- 102000004196 processed proteins & peptides Human genes 0.000 description 102
- 229920001184 polypeptide Polymers 0.000 description 91
- 102000002045 Endothelin Human genes 0.000 description 83
- 108050009340 Endothelin Proteins 0.000 description 82
- 235000001014 amino acid Nutrition 0.000 description 79
- 108090000623 proteins and genes Proteins 0.000 description 67
- 229940024606 amino acid Drugs 0.000 description 62
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 57
- 150000001413 amino acids Chemical class 0.000 description 54
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 51
- 102000004169 proteins and genes Human genes 0.000 description 50
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 45
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 description 45
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 description 45
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 description 45
- 235000018102 proteins Nutrition 0.000 description 45
- 239000012634 fragment Substances 0.000 description 43
- 108050001739 Endothelin receptor Proteins 0.000 description 37
- 102000010180 Endothelin receptor Human genes 0.000 description 36
- 238000006467 substitution reaction Methods 0.000 description 35
- 125000003729 nucleotide group Chemical group 0.000 description 33
- 239000000427 antigen Substances 0.000 description 32
- 102000036639 antigens Human genes 0.000 description 32
- 108091007433 antigens Proteins 0.000 description 32
- 239000002773 nucleotide Substances 0.000 description 32
- 125000000539 amino acid group Chemical group 0.000 description 23
- 241000880493 Leptailurus serval Species 0.000 description 19
- 210000004408 hybridoma Anatomy 0.000 description 19
- 102000005962 receptors Human genes 0.000 description 19
- 108020003175 receptors Proteins 0.000 description 19
- 239000006228 supernatant Substances 0.000 description 19
- 230000000694 effects Effects 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 17
- 239000003814 drug Substances 0.000 description 17
- 108010003137 tyrosyltyrosine Proteins 0.000 description 16
- -1 FR3 Proteins 0.000 description 15
- 239000002253 acid Substances 0.000 description 15
- 108010068265 aspartyltyrosine Proteins 0.000 description 15
- 238000012217 deletion Methods 0.000 description 15
- 230000037430 deletion Effects 0.000 description 15
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Chemical compound NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 15
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 14
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 14
- 241000283973 Oryctolagus cuniculus Species 0.000 description 14
- 229940079593 drug Drugs 0.000 description 14
- 238000011282 treatment Methods 0.000 description 13
- WNZOCXUOGVYYBJ-CDMKHQONSA-N Gly-Phe-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CN)O WNZOCXUOGVYYBJ-CDMKHQONSA-N 0.000 description 12
- 108060003951 Immunoglobulin Proteins 0.000 description 12
- 230000000295 complement effect Effects 0.000 description 12
- 238000009396 hybridization Methods 0.000 description 12
- 102000018358 immunoglobulin Human genes 0.000 description 12
- 230000001105 regulatory effect Effects 0.000 description 12
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 11
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 11
- 102000037865 fusion proteins Human genes 0.000 description 11
- 108020001507 fusion proteins Proteins 0.000 description 11
- 230000011664 signaling Effects 0.000 description 11
- 101100505161 Caenorhabditis elegans mel-32 gene Proteins 0.000 description 10
- 241000699673 Mesocricetus auratus Species 0.000 description 10
- SPSSJSICDYYTQN-HJGDQZAQSA-N Met-Thr-Gln Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(N)=O SPSSJSICDYYTQN-HJGDQZAQSA-N 0.000 description 10
- 241000700159 Rattus Species 0.000 description 10
- 238000001514 detection method Methods 0.000 description 10
- 108010078144 glutaminyl-glycine Proteins 0.000 description 10
- 108010037850 glycylvaline Proteins 0.000 description 10
- 238000003752 polymerase chain reaction Methods 0.000 description 10
- 210000002700 urine Anatomy 0.000 description 10
- 102400000686 Endothelin-1 Human genes 0.000 description 9
- 101800004490 Endothelin-1 Proteins 0.000 description 9
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 description 9
- 108010008355 arginyl-glutamine Proteins 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 108010050848 glycylleucine Proteins 0.000 description 9
- 230000002485 urinary effect Effects 0.000 description 9
- FEHQLKKBVJHSEC-SZMVWBNQSA-N Leu-Glu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 FEHQLKKBVJHSEC-SZMVWBNQSA-N 0.000 description 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 8
- XXXAXOWMBOKTRN-XPUUQOCRSA-N Ser-Gly-Val Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O XXXAXOWMBOKTRN-XPUUQOCRSA-N 0.000 description 8
- 230000004071 biological effect Effects 0.000 description 8
- 238000004113 cell culture Methods 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 108010089804 glycyl-threonine Proteins 0.000 description 8
- 108010025306 histidylleucine Proteins 0.000 description 8
- 108010034529 leucyl-lysine Proteins 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 238000001890 transfection Methods 0.000 description 8
- 208000009304 Acute Kidney Injury Diseases 0.000 description 7
- CREYEAPXISDKSB-FQPOAREZSA-N Ala-Thr-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O CREYEAPXISDKSB-FQPOAREZSA-N 0.000 description 7
- 108010088751 Albumins Proteins 0.000 description 7
- 102000009027 Albumins Human genes 0.000 description 7
- AOHKLEBWKMKITA-IHRRRGAJSA-N Arg-Phe-Ser Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N AOHKLEBWKMKITA-IHRRRGAJSA-N 0.000 description 7
- GGAPHLIUUTVYMX-QWRGUYRKSA-N Gly-Phe-Ser Chemical compound OC[C@@H](C([O-])=O)NC(=O)[C@@H](NC(=O)C[NH3+])CC1=CC=CC=C1 GGAPHLIUUTVYMX-QWRGUYRKSA-N 0.000 description 7
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 7
- WZBLRQQCDYYRTD-SIXJUCDHSA-N His-Ile-Trp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC3=CN=CN3)N WZBLRQQCDYYRTD-SIXJUCDHSA-N 0.000 description 7
- KIZIOFNVSOSKJI-CIUDSAMLSA-N Leu-Ser-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N KIZIOFNVSOSKJI-CIUDSAMLSA-N 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 208000033626 Renal failure acute Diseases 0.000 description 7
- YUJLIIRMIAGMCQ-CIUDSAMLSA-N Ser-Leu-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YUJLIIRMIAGMCQ-CIUDSAMLSA-N 0.000 description 7
- IEZVHOULSUULHD-XGEHTFHBSA-N Thr-Ser-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O IEZVHOULSUULHD-XGEHTFHBSA-N 0.000 description 7
- MNYNCKZAEIAONY-XGEHTFHBSA-N Thr-Val-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O MNYNCKZAEIAONY-XGEHTFHBSA-N 0.000 description 7
- 201000011040 acute kidney failure Diseases 0.000 description 7
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 7
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 235000018417 cysteine Nutrition 0.000 description 7
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 108010070409 phenylalanyl-glycyl-glycine Proteins 0.000 description 7
- 108010051242 phenylalanylserine Proteins 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 241000894007 species Species 0.000 description 7
- GIVATXIGCXFQQA-FXQIFTODSA-N Arg-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N GIVATXIGCXFQQA-FXQIFTODSA-N 0.000 description 6
- HUZGPXBILPMCHM-IHRRRGAJSA-N Asn-Arg-Phe Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O HUZGPXBILPMCHM-IHRRRGAJSA-N 0.000 description 6
- MNQMTYSEKZHIDF-GCJQMDKQSA-N Asp-Thr-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O MNQMTYSEKZHIDF-GCJQMDKQSA-N 0.000 description 6
- SZQCDCKIGWQAQN-FXQIFTODSA-N Cys-Arg-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O SZQCDCKIGWQAQN-FXQIFTODSA-N 0.000 description 6
- HNAUFGBKJLTWQE-IFFSRLJSSA-N Gln-Val-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)N)N)O HNAUFGBKJLTWQE-IFFSRLJSSA-N 0.000 description 6
- BYYNJRSNDARRBX-YFKPBYRVSA-N Gly-Gln-Gly Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O BYYNJRSNDARRBX-YFKPBYRVSA-N 0.000 description 6
- UQJNXZSSGQIPIQ-FBCQKBJTSA-N Gly-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)CN UQJNXZSSGQIPIQ-FBCQKBJTSA-N 0.000 description 6
- XHVONGZZVUUORG-WEDXCCLWSA-N Gly-Thr-Lys Chemical compound NCC(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CCCCN XHVONGZZVUUORG-WEDXCCLWSA-N 0.000 description 6
- MQFGXJNSUJTXDT-QSFUFRPTSA-N Ile-Gly-Ile Chemical compound N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)O MQFGXJNSUJTXDT-QSFUFRPTSA-N 0.000 description 6
- NZGTYCMLUGYMCV-XUXIUFHCSA-N Ile-Lys-Arg Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N NZGTYCMLUGYMCV-XUXIUFHCSA-N 0.000 description 6
- 108010065920 Insulin Lispro Proteins 0.000 description 6
- FQZPTCNSNPWHLJ-AVGNSLFASA-N Leu-Gln-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O FQZPTCNSNPWHLJ-AVGNSLFASA-N 0.000 description 6
- GQZMPWBZQALKJO-UWVGGRQHSA-N Lys-Gly-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O GQZMPWBZQALKJO-UWVGGRQHSA-N 0.000 description 6
- 241000282567 Macaca fascicularis Species 0.000 description 6
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 6
- FGWUALWGCZJQDJ-URLPEUOOSA-N Phe-Thr-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FGWUALWGCZJQDJ-URLPEUOOSA-N 0.000 description 6
- SPLBRAKYXGOFSO-UNQGMJICSA-N Pro-Phe-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H]2CCCN2)O SPLBRAKYXGOFSO-UNQGMJICSA-N 0.000 description 6
- QEDMOZUJTGEIBF-FXQIFTODSA-N Ser-Arg-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O QEDMOZUJTGEIBF-FXQIFTODSA-N 0.000 description 6
- YMTLKLXDFCSCNX-BYPYZUCNSA-N Ser-Gly-Gly Chemical compound OC[C@H](N)C(=O)NCC(=O)NCC(O)=O YMTLKLXDFCSCNX-BYPYZUCNSA-N 0.000 description 6
- UBRMZSHOOIVJPW-SRVKXCTJSA-N Ser-Leu-Lys Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O UBRMZSHOOIVJPW-SRVKXCTJSA-N 0.000 description 6
- MUJQWSAWLLRJCE-KATARQTJSA-N Ser-Leu-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MUJQWSAWLLRJCE-KATARQTJSA-N 0.000 description 6
- ADJDNJCSPNFFPI-FXQIFTODSA-N Ser-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO ADJDNJCSPNFFPI-FXQIFTODSA-N 0.000 description 6
- KRPKYGOFYUNIGM-XVSYOHENSA-N Thr-Asp-Phe Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N)O KRPKYGOFYUNIGM-XVSYOHENSA-N 0.000 description 6
- GXUWHVZYDAHFSV-FLBSBUHZSA-N Thr-Ile-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GXUWHVZYDAHFSV-FLBSBUHZSA-N 0.000 description 6
- BIBYEFRASCNLAA-CDMKHQONSA-N Thr-Phe-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CC=CC=C1 BIBYEFRASCNLAA-CDMKHQONSA-N 0.000 description 6
- JAWUQFCGNVEDRN-MEYUZBJRSA-N Thr-Tyr-Leu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(C)C)C(=O)O)N)O JAWUQFCGNVEDRN-MEYUZBJRSA-N 0.000 description 6
- YOPQYBJJNSIQGZ-JNPHEJMOSA-N Thr-Tyr-Tyr Chemical compound C([C@H](NC(=O)[C@@H](N)[C@H](O)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 YOPQYBJJNSIQGZ-JNPHEJMOSA-N 0.000 description 6
- MBLJBGZWLHTJBH-SZMVWBNQSA-N Trp-Val-Arg Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)=CNC2=C1 MBLJBGZWLHTJBH-SZMVWBNQSA-N 0.000 description 6
- QOIKZODVIPOPDD-AVGNSLFASA-N Tyr-Cys-Gln Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(O)=O QOIKZODVIPOPDD-AVGNSLFASA-N 0.000 description 6
- QUILOGWWLXMSAT-IHRRRGAJSA-N Tyr-Gln-Gln Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O QUILOGWWLXMSAT-IHRRRGAJSA-N 0.000 description 6
- OWFGFHQMSBTKLX-UFYCRDLUSA-N Val-Tyr-Tyr Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)N OWFGFHQMSBTKLX-UFYCRDLUSA-N 0.000 description 6
- WBPFYNYTYASCQP-CYDGBPFRSA-N Val-Val-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N WBPFYNYTYASCQP-CYDGBPFRSA-N 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 108010077245 asparaginyl-proline Proteins 0.000 description 6
- 230000003185 calcium uptake Effects 0.000 description 6
- 229940105442 cisplatin injection Drugs 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 6
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 6
- XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 description 6
- 108010087823 glycyltyrosine Proteins 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 108010044374 isoleucyl-tyrosine Proteins 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 108010020755 prolyl-glycyl-glycine Proteins 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 108010044292 tryptophyltyrosine Proteins 0.000 description 6
- 108010073969 valyllysine Proteins 0.000 description 6
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 5
- VNFSAYFQLXPHPY-CIQUZCHMSA-N Ala-Thr-Ile Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VNFSAYFQLXPHPY-CIQUZCHMSA-N 0.000 description 5
- UXJCMQFPDWCHKX-DCAQKATOSA-N Arg-Arg-Glu Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(O)=O)C(O)=O UXJCMQFPDWCHKX-DCAQKATOSA-N 0.000 description 5
- SLKLLQWZQHXYSV-CIUDSAMLSA-N Asn-Ala-Lys Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(O)=O SLKLLQWZQHXYSV-CIUDSAMLSA-N 0.000 description 5
- JBDLMLZNDRLDIX-HJGDQZAQSA-N Asn-Thr-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O JBDLMLZNDRLDIX-HJGDQZAQSA-N 0.000 description 5
- 241000282693 Cercopithecidae Species 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- FQCILXROGNOZON-YUMQZZPRSA-N Gln-Pro-Gly Chemical compound NC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O FQCILXROGNOZON-YUMQZZPRSA-N 0.000 description 5
- VLOLPWWCNKWRNB-LOKLDPHHSA-N Gln-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)N)N)O VLOLPWWCNKWRNB-LOKLDPHHSA-N 0.000 description 5
- MIIVFRCYJABHTQ-ONGXEEELSA-N Gly-Leu-Val Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O MIIVFRCYJABHTQ-ONGXEEELSA-N 0.000 description 5
- OMOZPGCHVWOXHN-BQBZGAKWSA-N Gly-Met-Ser Chemical compound CSCC[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)CN OMOZPGCHVWOXHN-BQBZGAKWSA-N 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 5
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 5
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 5
- TYYLDKGBCJGJGW-UHFFFAOYSA-N L-tryptophan-L-tyrosine Natural products C=1NC2=CC=CC=C2C=1CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 TYYLDKGBCJGJGW-UHFFFAOYSA-N 0.000 description 5
- AXZGZMGRBDQTEY-SRVKXCTJSA-N Leu-Gln-Met Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(O)=O AXZGZMGRBDQTEY-SRVKXCTJSA-N 0.000 description 5
- HPBCTWSUJOGJSH-MNXVOIDGSA-N Leu-Glu-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O HPBCTWSUJOGJSH-MNXVOIDGSA-N 0.000 description 5
- QVFGXCVIXXBFHO-AVGNSLFASA-N Leu-Glu-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O QVFGXCVIXXBFHO-AVGNSLFASA-N 0.000 description 5
- NRFGTHFONZYFNY-MGHWNKPDSA-N Leu-Ile-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 NRFGTHFONZYFNY-MGHWNKPDSA-N 0.000 description 5
- GZRABTMNWJXFMH-UVOCVTCTSA-N Leu-Thr-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GZRABTMNWJXFMH-UVOCVTCTSA-N 0.000 description 5
- PDIDTSZKKFEDMB-UWVGGRQHSA-N Lys-Pro-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O PDIDTSZKKFEDMB-UWVGGRQHSA-N 0.000 description 5
- GILLQRYAWOMHED-DCAQKATOSA-N Lys-Val-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN GILLQRYAWOMHED-DCAQKATOSA-N 0.000 description 5
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 5
- 108010079364 N-glycylalanine Proteins 0.000 description 5
- 101100068676 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) gln-1 gene Proteins 0.000 description 5
- MCIXMYKSPQUMJG-SRVKXCTJSA-N Phe-Ser-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O MCIXMYKSPQUMJG-SRVKXCTJSA-N 0.000 description 5
- KDGARKCAKHBEDB-NKWVEPMBSA-N Ser-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CO)N)C(=O)O KDGARKCAKHBEDB-NKWVEPMBSA-N 0.000 description 5
- UIGMAMGZOJVTDN-WHFBIAKZSA-N Ser-Gly-Ser Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O UIGMAMGZOJVTDN-WHFBIAKZSA-N 0.000 description 5
- MOQDPPUMFSMYOM-KKUMJFAQSA-N Ser-His-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CO)N MOQDPPUMFSMYOM-KKUMJFAQSA-N 0.000 description 5
- UIPXCLNLUUAMJU-JBDRJPRFSA-N Ser-Ile-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O UIPXCLNLUUAMJU-JBDRJPRFSA-N 0.000 description 5
- QYSFWUIXDFJUDW-DCAQKATOSA-N Ser-Leu-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O QYSFWUIXDFJUDW-DCAQKATOSA-N 0.000 description 5
- MQUZANJDFOQOBX-SRVKXCTJSA-N Ser-Phe-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(O)=O MQUZANJDFOQOBX-SRVKXCTJSA-N 0.000 description 5
- VGQVAVQWKJLIRM-FXQIFTODSA-N Ser-Ser-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O VGQVAVQWKJLIRM-FXQIFTODSA-N 0.000 description 5
- DJDSEDOKJTZBAR-ZDLURKLDSA-N Thr-Gly-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O DJDSEDOKJTZBAR-ZDLURKLDSA-N 0.000 description 5
- YOOAQCZYZHGUAZ-KATARQTJSA-N Thr-Leu-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YOOAQCZYZHGUAZ-KATARQTJSA-N 0.000 description 5
- 108010081404 acein-2 Proteins 0.000 description 5
- 238000001042 affinity chromatography Methods 0.000 description 5
- 230000006229 amino acid addition Effects 0.000 description 5
- 125000003277 amino group Chemical group 0.000 description 5
- 239000011230 binding agent Substances 0.000 description 5
- 210000004899 c-terminal region Anatomy 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 5
- 229960004316 cisplatin Drugs 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 239000000539 dimer Substances 0.000 description 5
- 108010015792 glycyllysine Proteins 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 108010071207 serylmethionine Proteins 0.000 description 5
- 108010072986 threonyl-seryl-lysine Proteins 0.000 description 5
- OINVDEKBKBCPLX-JXUBOQSCSA-N Ala-Lys-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OINVDEKBKBCPLX-JXUBOQSCSA-N 0.000 description 4
- RAQMSGVCGSJKCL-FOHZUACHSA-N Asn-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(N)=O RAQMSGVCGSJKCL-FOHZUACHSA-N 0.000 description 4
- PNHQRQTVBRDIEF-CIUDSAMLSA-N Asn-Leu-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)N PNHQRQTVBRDIEF-CIUDSAMLSA-N 0.000 description 4
- MRQQMVZUHXUPEV-IHRRRGAJSA-N Asp-Arg-Phe Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O MRQQMVZUHXUPEV-IHRRRGAJSA-N 0.000 description 4
- AYFVRYXNDHBECD-YUMQZZPRSA-N Asp-Leu-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O AYFVRYXNDHBECD-YUMQZZPRSA-N 0.000 description 4
- RXBGWGRSWXOBGK-KKUMJFAQSA-N Asp-Lys-Tyr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O RXBGWGRSWXOBGK-KKUMJFAQSA-N 0.000 description 4
- GCACQYDBDHRVGE-LKXGYXEUSA-N Asp-Thr-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H]([C@H](O)C)NC(=O)[C@@H](N)CC(O)=O GCACQYDBDHRVGE-LKXGYXEUSA-N 0.000 description 4
- GEEXORWTBTUOHC-FXQIFTODSA-N Cys-Arg-Ser Chemical compound C(C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CS)N)CN=C(N)N GEEXORWTBTUOHC-FXQIFTODSA-N 0.000 description 4
- BBQIWFFTTQTNOC-AVGNSLFASA-N Cys-Phe-Gln Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CS)N BBQIWFFTTQTNOC-AVGNSLFASA-N 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- LKDIBBOKUAASNP-FXQIFTODSA-N Glu-Ala-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O LKDIBBOKUAASNP-FXQIFTODSA-N 0.000 description 4
- INGJLBQKTRJLFO-UKJIMTQDSA-N Glu-Ile-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCC(O)=O INGJLBQKTRJLFO-UKJIMTQDSA-N 0.000 description 4
- FFALDIDGPLUDKV-ZDLURKLDSA-N Gly-Thr-Ser Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O FFALDIDGPLUDKV-ZDLURKLDSA-N 0.000 description 4
- ASCFJMSGKUIRDU-ZPFDUUQYSA-N Ile-Arg-Gln Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(O)=O ASCFJMSGKUIRDU-ZPFDUUQYSA-N 0.000 description 4
- QIHJTGSVGIPHIW-QSFUFRPTSA-N Ile-Asn-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)O)N QIHJTGSVGIPHIW-QSFUFRPTSA-N 0.000 description 4
- PXKACEXYLPBMAD-JBDRJPRFSA-N Ile-Ser-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PXKACEXYLPBMAD-JBDRJPRFSA-N 0.000 description 4
- HVHRPWQEQHIQJF-AVGNSLFASA-N Leu-Lys-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O HVHRPWQEQHIQJF-AVGNSLFASA-N 0.000 description 4
- IWMJFLJQHIDZQW-KKUMJFAQSA-N Leu-Ser-Phe Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 IWMJFLJQHIDZQW-KKUMJFAQSA-N 0.000 description 4
- LINKCQUOMUDLKN-KATARQTJSA-N Leu-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(C)C)N)O LINKCQUOMUDLKN-KATARQTJSA-N 0.000 description 4
- LCNASHSOFMRYFO-WDCWCFNPSA-N Leu-Thr-Gln Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(N)=O LCNASHSOFMRYFO-WDCWCFNPSA-N 0.000 description 4
- MVJRBCJCRYGCKV-GVXVVHGQSA-N Leu-Val-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O MVJRBCJCRYGCKV-GVXVVHGQSA-N 0.000 description 4
- SKRGVGLIRUGANF-AVGNSLFASA-N Lys-Leu-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O SKRGVGLIRUGANF-AVGNSLFASA-N 0.000 description 4
- PNDCUTDWYVKBHX-IHRRRGAJSA-N Met-Asp-Tyr Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 PNDCUTDWYVKBHX-IHRRRGAJSA-N 0.000 description 4
- GHQFLTYXGUETFD-UFYCRDLUSA-N Met-Tyr-Tyr Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)N GHQFLTYXGUETFD-UFYCRDLUSA-N 0.000 description 4
- XMBSYZWANAQXEV-UHFFFAOYSA-N N-alpha-L-glutamyl-L-phenylalanine Natural products OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-UHFFFAOYSA-N 0.000 description 4
- XDMMOISUAHXXFD-SRVKXCTJSA-N Phe-Ser-Asp Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O XDMMOISUAHXXFD-SRVKXCTJSA-N 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 229920002873 Polyethylenimine Polymers 0.000 description 4
- JMVQDLDPDBXAAX-YUMQZZPRSA-N Pro-Gly-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 JMVQDLDPDBXAAX-YUMQZZPRSA-N 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- HBOABDXGTMMDSE-GUBZILKMSA-N Ser-Arg-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(O)=O HBOABDXGTMMDSE-GUBZILKMSA-N 0.000 description 4
- BNFVPSRLHHPQKS-WHFBIAKZSA-N Ser-Asp-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O BNFVPSRLHHPQKS-WHFBIAKZSA-N 0.000 description 4
- CDVFZMOFNJPUDD-ACZMJKKPSA-N Ser-Gln-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O CDVFZMOFNJPUDD-ACZMJKKPSA-N 0.000 description 4
- BMKNXTJLHFIAAH-CIUDSAMLSA-N Ser-Ser-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O BMKNXTJLHFIAAH-CIUDSAMLSA-N 0.000 description 4
- PAXANSWUSVPFNK-IUKAMOBKSA-N Thr-Ile-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N PAXANSWUSVPFNK-IUKAMOBKSA-N 0.000 description 4
- FQPDRTDDEZXCEC-SVSWQMSJSA-N Thr-Ile-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O FQPDRTDDEZXCEC-SVSWQMSJSA-N 0.000 description 4
- MECLEFZMPPOEAC-VOAKCMCISA-N Thr-Leu-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N)O MECLEFZMPPOEAC-VOAKCMCISA-N 0.000 description 4
- DEGCBBCMYWNJNA-RHYQMDGZSA-N Thr-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)[C@@H](C)O DEGCBBCMYWNJNA-RHYQMDGZSA-N 0.000 description 4
- 101710120037 Toxin CcdB Proteins 0.000 description 4
- VEYXZZGMIBKXCN-UBHSHLNASA-N Trp-Asp-Asp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N VEYXZZGMIBKXCN-UBHSHLNASA-N 0.000 description 4
- SVGAWGVHFIYAEE-JSGCOSHPSA-N Trp-Gly-Gln Chemical compound C1=CC=C2C(C[C@H](N)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)=CNC2=C1 SVGAWGVHFIYAEE-JSGCOSHPSA-N 0.000 description 4
- CXPJPTFWKXNDKV-NUTKFTJISA-N Trp-Leu-Ala Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O)=CNC2=C1 CXPJPTFWKXNDKV-NUTKFTJISA-N 0.000 description 4
- VTFWAGGJDRSQFG-MELADBBJSA-N Tyr-Asn-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)O VTFWAGGJDRSQFG-MELADBBJSA-N 0.000 description 4
- NXRGXTBPMOGFID-CFMVVWHZSA-N Tyr-Ile-Asn Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(O)=O NXRGXTBPMOGFID-CFMVVWHZSA-N 0.000 description 4
- OVLIFGQSBSNGHY-KKHAAJSZSA-N Val-Asp-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C(C)C)N)O OVLIFGQSBSNGHY-KKHAAJSZSA-N 0.000 description 4
- SSYBNWFXCFNRFN-GUBZILKMSA-N Val-Pro-Ser Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O SSYBNWFXCFNRFN-GUBZILKMSA-N 0.000 description 4
- HTONZBWRYUKUKC-RCWTZXSCSA-N Val-Thr-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O HTONZBWRYUKUKC-RCWTZXSCSA-N 0.000 description 4
- 108010070944 alanylhistidine Proteins 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 238000010353 genetic engineering Methods 0.000 description 4
- 108010057083 glutamyl-aspartyl-leucine Proteins 0.000 description 4
- 108010079547 glutamylmethionine Proteins 0.000 description 4
- 230000013595 glycosylation Effects 0.000 description 4
- 238000006206 glycosylation reaction Methods 0.000 description 4
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 4
- 229940072221 immunoglobulins Drugs 0.000 description 4
- 229940090044 injection Drugs 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000012160 loading buffer Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 230000003285 pharmacodynamic effect Effects 0.000 description 4
- 210000002706 plastid Anatomy 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 108010069117 seryl-lysyl-aspartic acid Proteins 0.000 description 4
- 238000002741 site-directed mutagenesis Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 108010038745 tryptophylglycine Proteins 0.000 description 4
- 108010045269 tryptophyltryptophan Proteins 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- AXFMEGAFCUULFV-BLFANLJRSA-N (2s)-2-[[(2s)-1-[(2s,3r)-2-amino-3-methylpentanoyl]pyrrolidine-2-carbonyl]amino]pentanedioic acid Chemical compound CC[C@@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O AXFMEGAFCUULFV-BLFANLJRSA-N 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- SSSROGPPPVTHLX-FXQIFTODSA-N Ala-Arg-Asp Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O SSSROGPPPVTHLX-FXQIFTODSA-N 0.000 description 3
- BTYTYHBSJKQBQA-GCJQMDKQSA-N Ala-Asp-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)N)O BTYTYHBSJKQBQA-GCJQMDKQSA-N 0.000 description 3
- DVJSJDDYCYSMFR-ZKWXMUAHSA-N Ala-Ile-Gly Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(O)=O DVJSJDDYCYSMFR-ZKWXMUAHSA-N 0.000 description 3
- MNZHHDPWDWQJCQ-YUMQZZPRSA-N Ala-Leu-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O MNZHHDPWDWQJCQ-YUMQZZPRSA-N 0.000 description 3
- HOVPGJUNRLMIOZ-CIUDSAMLSA-N Ala-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)N HOVPGJUNRLMIOZ-CIUDSAMLSA-N 0.000 description 3
- LSMDIAAALJJLRO-XQXXSGGOSA-N Ala-Thr-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O LSMDIAAALJJLRO-XQXXSGGOSA-N 0.000 description 3
- KTXKIYXZQFWJKB-VZFHVOOUSA-N Ala-Thr-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O KTXKIYXZQFWJKB-VZFHVOOUSA-N 0.000 description 3
- VWVPYNGMOCSSGK-GUBZILKMSA-N Arg-Arg-Asn Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(O)=O VWVPYNGMOCSSGK-GUBZILKMSA-N 0.000 description 3
- HKRXJBBCQBAGIM-FXQIFTODSA-N Arg-Asp-Ser Chemical compound C(C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)O)N)CN=C(N)N HKRXJBBCQBAGIM-FXQIFTODSA-N 0.000 description 3
- GDVDRMUYICMNFJ-CIUDSAMLSA-N Arg-Cys-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(O)=O GDVDRMUYICMNFJ-CIUDSAMLSA-N 0.000 description 3
- FFEUXEAKYRCACT-PEDHHIEDSA-N Arg-Ile-Ile Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(O)=O FFEUXEAKYRCACT-PEDHHIEDSA-N 0.000 description 3
- JEOCWTUOMKEEMF-RHYQMDGZSA-N Arg-Leu-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O JEOCWTUOMKEEMF-RHYQMDGZSA-N 0.000 description 3
- FRBAHXABMQXSJQ-FXQIFTODSA-N Arg-Ser-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O FRBAHXABMQXSJQ-FXQIFTODSA-N 0.000 description 3
- PYDIIVKGTBRIEL-SZMVWBNQSA-N Arg-Trp-Pro Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N1CCC[C@H]1C(O)=O PYDIIVKGTBRIEL-SZMVWBNQSA-N 0.000 description 3
- UVTGNSWSRSCPLP-UHFFFAOYSA-N Arg-Tyr Natural products NC(CCNC(=N)N)C(=O)NC(Cc1ccc(O)cc1)C(=O)O UVTGNSWSRSCPLP-UHFFFAOYSA-N 0.000 description 3
- QMQZYILAWUOLPV-JYJNAYRXSA-N Arg-Tyr-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)CC1=CC=C(O)C=C1 QMQZYILAWUOLPV-JYJNAYRXSA-N 0.000 description 3
- XYOVHPDDWCEUDY-CIUDSAMLSA-N Asn-Ala-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O XYOVHPDDWCEUDY-CIUDSAMLSA-N 0.000 description 3
- JZRLLSOWDYUKOK-SRVKXCTJSA-N Asn-Asp-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)N)N JZRLLSOWDYUKOK-SRVKXCTJSA-N 0.000 description 3
- FJIRXKVEDFLLOQ-SRVKXCTJSA-N Asn-Cys-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CC(=O)N)N FJIRXKVEDFLLOQ-SRVKXCTJSA-N 0.000 description 3
- GJFYPBDMUGGLFR-NKWVEPMBSA-N Asn-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CC(=O)N)N)C(=O)O GJFYPBDMUGGLFR-NKWVEPMBSA-N 0.000 description 3
- DJIMLSXHXKWADV-CIUDSAMLSA-N Asn-Leu-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(N)=O DJIMLSXHXKWADV-CIUDSAMLSA-N 0.000 description 3
- NJSNXIOKBHPFMB-GMOBBJLQSA-N Asn-Pro-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(=O)N)N NJSNXIOKBHPFMB-GMOBBJLQSA-N 0.000 description 3
- MKJBPDLENBUHQU-CIUDSAMLSA-N Asn-Ser-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O MKJBPDLENBUHQU-CIUDSAMLSA-N 0.000 description 3
- XYBJLTKSGFBLCS-QXEWZRGKSA-N Asp-Arg-Val Chemical compound NC(N)=NCCC[C@@H](C(=O)N[C@@H](C(C)C)C(O)=O)NC(=O)[C@@H](N)CC(O)=O XYBJLTKSGFBLCS-QXEWZRGKSA-N 0.000 description 3
- QNFRBNZGVVKBNJ-PEFMBERDSA-N Asp-Ile-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)O)N QNFRBNZGVVKBNJ-PEFMBERDSA-N 0.000 description 3
- RQHLMGCXCZUOGT-ZPFDUUQYSA-N Asp-Leu-Ile Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O RQHLMGCXCZUOGT-ZPFDUUQYSA-N 0.000 description 3
- IVPNEDNYYYFAGI-GARJFASQSA-N Asp-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)O)N IVPNEDNYYYFAGI-GARJFASQSA-N 0.000 description 3
- UZFHNLYQWMGUHU-DCAQKATOSA-N Asp-Lys-Arg Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O UZFHNLYQWMGUHU-DCAQKATOSA-N 0.000 description 3
- XWSIYTYNLKCLJB-CIUDSAMLSA-N Asp-Lys-Asn Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O XWSIYTYNLKCLJB-CIUDSAMLSA-N 0.000 description 3
- USNJAPJZSGTTPX-XVSYOHENSA-N Asp-Phe-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O USNJAPJZSGTTPX-XVSYOHENSA-N 0.000 description 3
- WMLFFCRUSPNENW-ZLUOBGJFSA-N Asp-Ser-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O WMLFFCRUSPNENW-ZLUOBGJFSA-N 0.000 description 3
- QSFHZPQUAAQHAQ-CIUDSAMLSA-N Asp-Ser-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O QSFHZPQUAAQHAQ-CIUDSAMLSA-N 0.000 description 3
- MJJIHRWNWSQTOI-VEVYYDQMSA-N Asp-Thr-Arg Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O MJJIHRWNWSQTOI-VEVYYDQMSA-N 0.000 description 3
- GIKOVDMXBAFXDF-NHCYSSNCSA-N Asp-Val-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O GIKOVDMXBAFXDF-NHCYSSNCSA-N 0.000 description 3
- GGBQDSHTXKQSLP-NHCYSSNCSA-N Asp-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)O)N GGBQDSHTXKQSLP-NHCYSSNCSA-N 0.000 description 3
- 101100315624 Caenorhabditis elegans tyr-1 gene Proteins 0.000 description 3
- 102000014914 Carrier Proteins Human genes 0.000 description 3
- AMRLSQGGERHDHJ-FXQIFTODSA-N Cys-Ala-Arg Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O AMRLSQGGERHDHJ-FXQIFTODSA-N 0.000 description 3
- NOCCABSVTRONIN-CIUDSAMLSA-N Cys-Ala-Leu Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CS)N NOCCABSVTRONIN-CIUDSAMLSA-N 0.000 description 3
- SMYXEYRYCLIPIL-ZLUOBGJFSA-N Cys-Cys-Cys Chemical compound SC[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(O)=O SMYXEYRYCLIPIL-ZLUOBGJFSA-N 0.000 description 3
- NMPSRDYYNIYOSJ-IHPCNDPISA-N Cys-Trp-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)NC(=O)[C@H](CS)N NMPSRDYYNIYOSJ-IHPCNDPISA-N 0.000 description 3
- 108010090461 DFG peptide Proteins 0.000 description 3
- 101100012887 Drosophila melanogaster btl gene Proteins 0.000 description 3
- 101100012878 Drosophila melanogaster htl gene Proteins 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 108010020195 FLAG peptide Proteins 0.000 description 3
- NPTGGVQJYRSMCM-GLLZPBPUSA-N Gln-Gln-Thr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O NPTGGVQJYRSMCM-GLLZPBPUSA-N 0.000 description 3
- JXFLPKSDLDEOQK-JHEQGTHGSA-N Gln-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCC(N)=O JXFLPKSDLDEOQK-JHEQGTHGSA-N 0.000 description 3
- GQZDDFRXSDGUNG-YVNDNENWSA-N Gln-Ile-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(O)=O GQZDDFRXSDGUNG-YVNDNENWSA-N 0.000 description 3
- FNAJNWPDTIXYJN-CIUDSAMLSA-N Gln-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCC(N)=O FNAJNWPDTIXYJN-CIUDSAMLSA-N 0.000 description 3
- MFHVAWMMKZBSRQ-ACZMJKKPSA-N Gln-Ser-Cys Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N MFHVAWMMKZBSRQ-ACZMJKKPSA-N 0.000 description 3
- KPNWAJMEMRCLAL-GUBZILKMSA-N Gln-Ser-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)N)N KPNWAJMEMRCLAL-GUBZILKMSA-N 0.000 description 3
- IESFZVCAVACGPH-PEFMBERDSA-N Glu-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CCC(O)=O IESFZVCAVACGPH-PEFMBERDSA-N 0.000 description 3
- SUIAHERNFYRBDZ-GVXVVHGQSA-N Glu-Lys-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(O)=O SUIAHERNFYRBDZ-GVXVVHGQSA-N 0.000 description 3
- CGWHAXBNGYQBBK-JBACZVJFSA-N Glu-Trp-Tyr Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(O)=O)N)C(O)=O)C1=CC=C(O)C=C1 CGWHAXBNGYQBBK-JBACZVJFSA-N 0.000 description 3
- YQPFCZVKMUVZIN-AUTRQRHGSA-N Glu-Val-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O YQPFCZVKMUVZIN-AUTRQRHGSA-N 0.000 description 3
- RJIVPOXLQFJRTG-LURJTMIESA-N Gly-Arg-Gly Chemical compound OC(=O)CNC(=O)[C@@H](NC(=O)CN)CCCN=C(N)N RJIVPOXLQFJRTG-LURJTMIESA-N 0.000 description 3
- UXJHNZODTMHWRD-WHFBIAKZSA-N Gly-Asn-Ala Chemical compound [H]NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(O)=O UXJHNZODTMHWRD-WHFBIAKZSA-N 0.000 description 3
- UESJMAMHDLEHGM-NHCYSSNCSA-N Gly-Ile-Leu Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O UESJMAMHDLEHGM-NHCYSSNCSA-N 0.000 description 3
- SCWYHUQOOFRVHP-MBLNEYKQSA-N Gly-Ile-Thr Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SCWYHUQOOFRVHP-MBLNEYKQSA-N 0.000 description 3
- IUZGUFAJDBHQQV-YUMQZZPRSA-N Gly-Leu-Asn Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O IUZGUFAJDBHQQV-YUMQZZPRSA-N 0.000 description 3
- CCBIBMKQNXHNIN-ZETCQYMHSA-N Gly-Leu-Gly Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O CCBIBMKQNXHNIN-ZETCQYMHSA-N 0.000 description 3
- TVTZEOHWHUVYCG-KYNKHSRBSA-N Gly-Thr-Thr Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O TVTZEOHWHUVYCG-KYNKHSRBSA-N 0.000 description 3
- GBYYQVBXFVDJPJ-WLTAIBSBSA-N Gly-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)CN)O GBYYQVBXFVDJPJ-WLTAIBSBSA-N 0.000 description 3
- BNMRSWQOHIQTFL-JSGCOSHPSA-N Gly-Val-Phe Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 BNMRSWQOHIQTFL-JSGCOSHPSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 3
- VAXBXNPRXPHGHG-BJDJZHNGSA-N Ile-Ala-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)O)N VAXBXNPRXPHGHG-BJDJZHNGSA-N 0.000 description 3
- HDOYNXLPTRQLAD-JBDRJPRFSA-N Ile-Ala-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)O)N HDOYNXLPTRQLAD-JBDRJPRFSA-N 0.000 description 3
- KLBVGHCGHUNHEA-BJDJZHNGSA-N Ile-Leu-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)O)N KLBVGHCGHUNHEA-BJDJZHNGSA-N 0.000 description 3
- TVYWVSJGSHQWMT-AJNGGQMLSA-N Ile-Leu-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N TVYWVSJGSHQWMT-AJNGGQMLSA-N 0.000 description 3
- WYUHAXJAMDTOAU-IAVJCBSLSA-N Ile-Phe-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N WYUHAXJAMDTOAU-IAVJCBSLSA-N 0.000 description 3
- VZSDQFZFTCVEGF-ZEWNOJEFSA-N Ile-Phe-Tyr Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O VZSDQFZFTCVEGF-ZEWNOJEFSA-N 0.000 description 3
- ZLFNNVATRMCAKN-ZKWXMUAHSA-N Ile-Ser-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)NCC(=O)O)N ZLFNNVATRMCAKN-ZKWXMUAHSA-N 0.000 description 3
- VGSPNSSCMOHRRR-BJDJZHNGSA-N Ile-Ser-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)O)N VGSPNSSCMOHRRR-BJDJZHNGSA-N 0.000 description 3
- XVUAQNRNFMVWBR-BLMTYFJBSA-N Ile-Trp-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N XVUAQNRNFMVWBR-BLMTYFJBSA-N 0.000 description 3
- JCGMFFQQHJQASB-PYJNHQTQSA-N Ile-Val-His Chemical compound N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)O JCGMFFQQHJQASB-PYJNHQTQSA-N 0.000 description 3
- FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 3
- LHSGPCFBGJHPCY-UHFFFAOYSA-N L-leucine-L-tyrosine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 LHSGPCFBGJHPCY-UHFFFAOYSA-N 0.000 description 3
- SENJXOPIZNYLHU-UHFFFAOYSA-N L-leucyl-L-arginine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CCCN=C(N)N SENJXOPIZNYLHU-UHFFFAOYSA-N 0.000 description 3
- WNGVUZWBXZKQES-YUMQZZPRSA-N Leu-Ala-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O WNGVUZWBXZKQES-YUMQZZPRSA-N 0.000 description 3
- WUFYAPWIHCUMLL-CIUDSAMLSA-N Leu-Asn-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(O)=O WUFYAPWIHCUMLL-CIUDSAMLSA-N 0.000 description 3
- NHHKSOGJYNQENP-SRVKXCTJSA-N Leu-Cys-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)O)N NHHKSOGJYNQENP-SRVKXCTJSA-N 0.000 description 3
- KAFOIVJDVSZUMD-DCAQKATOSA-N Leu-Gln-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O KAFOIVJDVSZUMD-DCAQKATOSA-N 0.000 description 3
- KAFOIVJDVSZUMD-UHFFFAOYSA-N Leu-Gln-Gln Natural products CC(C)CC(N)C(=O)NC(CCC(N)=O)C(=O)NC(CCC(N)=O)C(O)=O KAFOIVJDVSZUMD-UHFFFAOYSA-N 0.000 description 3
- PPQRKXHCLYCBSP-IHRRRGAJSA-N Leu-Leu-Met Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)O)N PPQRKXHCLYCBSP-IHRRRGAJSA-N 0.000 description 3
- RXGLHDWAZQECBI-SRVKXCTJSA-N Leu-Leu-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O RXGLHDWAZQECBI-SRVKXCTJSA-N 0.000 description 3
- ZGUMORRUBUCXEH-AVGNSLFASA-N Leu-Lys-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O ZGUMORRUBUCXEH-AVGNSLFASA-N 0.000 description 3
- IDGZVZJLYFTXSL-DCAQKATOSA-N Leu-Ser-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCN=C(N)N IDGZVZJLYFTXSL-DCAQKATOSA-N 0.000 description 3
- RDFIVFHPOSOXMW-ACRUOGEOSA-N Leu-Tyr-Phe Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O RDFIVFHPOSOXMW-ACRUOGEOSA-N 0.000 description 3
- AIMGJYMCTAABEN-GVXVVHGQSA-N Leu-Val-Glu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O AIMGJYMCTAABEN-GVXVVHGQSA-N 0.000 description 3
- LMVOVCYVZBBWQB-SRVKXCTJSA-N Lys-Asp-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN LMVOVCYVZBBWQB-SRVKXCTJSA-N 0.000 description 3
- NRQRKMYZONPCTM-CIUDSAMLSA-N Lys-Asp-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O NRQRKMYZONPCTM-CIUDSAMLSA-N 0.000 description 3
- NDSNUWJPZKTFAR-DCAQKATOSA-N Lys-Cys-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCCN NDSNUWJPZKTFAR-DCAQKATOSA-N 0.000 description 3
- ITWQLSZTLBKWJM-YUMQZZPRSA-N Lys-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](N)CCCCN ITWQLSZTLBKWJM-YUMQZZPRSA-N 0.000 description 3
- GQFDWEDHOQRNLC-QWRGUYRKSA-N Lys-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN GQFDWEDHOQRNLC-QWRGUYRKSA-N 0.000 description 3
- NCZIQZYZPUPMKY-PPCPHDFISA-N Lys-Ile-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O NCZIQZYZPUPMKY-PPCPHDFISA-N 0.000 description 3
- AZOFEHCPMBRNFD-BZSNNMDCSA-N Lys-Phe-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CC=CC=C1 AZOFEHCPMBRNFD-BZSNNMDCSA-N 0.000 description 3
- JMNRXRPBHFGXQX-GUBZILKMSA-N Lys-Ser-Glu Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O JMNRXRPBHFGXQX-GUBZILKMSA-N 0.000 description 3
- VHTOGMKQXXJOHG-RHYQMDGZSA-N Lys-Thr-Val Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O VHTOGMKQXXJOHG-RHYQMDGZSA-N 0.000 description 3
- SUZVLFWOCKHWET-CQDKDKBSSA-N Lys-Tyr-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(O)=O SUZVLFWOCKHWET-CQDKDKBSSA-N 0.000 description 3
- QZPXMHVKPHJNTR-DCAQKATOSA-N Met-Leu-Asn Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O QZPXMHVKPHJNTR-DCAQKATOSA-N 0.000 description 3
- YYEIFXZOBZVDPH-DCAQKATOSA-N Met-Lys-Asp Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O YYEIFXZOBZVDPH-DCAQKATOSA-N 0.000 description 3
- YLDSJJOGQNEQJK-AVGNSLFASA-N Met-Pro-Leu Chemical compound CSCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O YLDSJJOGQNEQJK-AVGNSLFASA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- BBDSZDHUCPSYAC-QEJZJMRPSA-N Phe-Ala-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O BBDSZDHUCPSYAC-QEJZJMRPSA-N 0.000 description 3
- VUYCNYVLKACHPA-KKUMJFAQSA-N Phe-Asp-His Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N VUYCNYVLKACHPA-KKUMJFAQSA-N 0.000 description 3
- NHCKESBLOMHIIE-IRXDYDNUSA-N Phe-Gly-Phe Chemical compound C([C@H](N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 NHCKESBLOMHIIE-IRXDYDNUSA-N 0.000 description 3
- BIYWZVCPZIFGPY-QWRGUYRKSA-N Phe-Gly-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H](CO)C(O)=O BIYWZVCPZIFGPY-QWRGUYRKSA-N 0.000 description 3
- LRBSWBVUCLLRLU-BZSNNMDCSA-N Phe-Leu-Lys Chemical compound CC(C)C[C@H](NC(=O)[C@@H](N)Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(O)=O LRBSWBVUCLLRLU-BZSNNMDCSA-N 0.000 description 3
- DOXQMJCSSYZSNM-BZSNNMDCSA-N Phe-Lys-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O DOXQMJCSSYZSNM-BZSNNMDCSA-N 0.000 description 3
- RTUWVJVJSMOGPL-KKUMJFAQSA-N Phe-Met-Glu Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N RTUWVJVJSMOGPL-KKUMJFAQSA-N 0.000 description 3
- CKJACGQPCPMWIT-UFYCRDLUSA-N Phe-Pro-Phe Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CKJACGQPCPMWIT-UFYCRDLUSA-N 0.000 description 3
- IAOZOFPONWDXNT-IXOXFDKPSA-N Phe-Ser-Thr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O IAOZOFPONWDXNT-IXOXFDKPSA-N 0.000 description 3
- KLYYKKGCPOGDPE-OEAJRASXSA-N Phe-Thr-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O KLYYKKGCPOGDPE-OEAJRASXSA-N 0.000 description 3
- AOKZOUGUMLBPSS-PMVMPFDFSA-N Phe-Trp-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(O)=O AOKZOUGUMLBPSS-PMVMPFDFSA-N 0.000 description 3
- QUUCAHIYARMNBL-FHWLQOOXSA-N Phe-Tyr-Gln Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N QUUCAHIYARMNBL-FHWLQOOXSA-N 0.000 description 3
- FYPGHGXAOZTOBO-IHRRRGAJSA-N Pro-Leu-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@@H]2CCCN2 FYPGHGXAOZTOBO-IHRRRGAJSA-N 0.000 description 3
- RMODQFBNDDENCP-IHRRRGAJSA-N Pro-Lys-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O RMODQFBNDDENCP-IHRRRGAJSA-N 0.000 description 3
- JIWJRKNYLSHONY-KKUMJFAQSA-N Pro-Phe-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O JIWJRKNYLSHONY-KKUMJFAQSA-N 0.000 description 3
- BGWKULMLUIUPKY-BQBZGAKWSA-N Pro-Ser-Gly Chemical compound OC(=O)CNC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1 BGWKULMLUIUPKY-BQBZGAKWSA-N 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- KAEGGIFPLJZUOZ-UHFFFAOYSA-N Renilla luciferin Chemical compound C1=CC(O)=CC=C1C(N1)=CN2C(=O)C(CC=3C=CC=CC=3)=NC2=C1CC1=CC=CC=C1 KAEGGIFPLJZUOZ-UHFFFAOYSA-N 0.000 description 3
- VAUMZJHYZQXZBQ-WHFBIAKZSA-N Ser-Asn-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O VAUMZJHYZQXZBQ-WHFBIAKZSA-N 0.000 description 3
- INCNPLPRPOYTJI-JBDRJPRFSA-N Ser-Cys-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CO)N INCNPLPRPOYTJI-JBDRJPRFSA-N 0.000 description 3
- MPPHJZYXDVDGOF-BWBBJGPYSA-N Ser-Cys-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CO MPPHJZYXDVDGOF-BWBBJGPYSA-N 0.000 description 3
- FMDHKPRACUXATF-ACZMJKKPSA-N Ser-Gln-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O FMDHKPRACUXATF-ACZMJKKPSA-N 0.000 description 3
- UICKAKRRRBTILH-GUBZILKMSA-N Ser-Glu-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)N UICKAKRRRBTILH-GUBZILKMSA-N 0.000 description 3
- UQFYNFTYDHUIMI-WHFBIAKZSA-N Ser-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](N)CO UQFYNFTYDHUIMI-WHFBIAKZSA-N 0.000 description 3
- CJINPXGSKSZQNE-KBIXCLLPSA-N Ser-Ile-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(O)=O CJINPXGSKSZQNE-KBIXCLLPSA-N 0.000 description 3
- XXNYYSXNXCJYKX-DCAQKATOSA-N Ser-Leu-Met Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(O)=O XXNYYSXNXCJYKX-DCAQKATOSA-N 0.000 description 3
- KCGIREHVWRXNDH-GARJFASQSA-N Ser-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CO)N KCGIREHVWRXNDH-GARJFASQSA-N 0.000 description 3
- XQJCEKXQUJQNNK-ZLUOBGJFSA-N Ser-Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O XQJCEKXQUJQNNK-ZLUOBGJFSA-N 0.000 description 3
- SQHKXWODKJDZRC-LKXGYXEUSA-N Ser-Thr-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(O)=O SQHKXWODKJDZRC-LKXGYXEUSA-N 0.000 description 3
- UKKROEYWYIHWBD-ZKWXMUAHSA-N Ser-Val-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O UKKROEYWYIHWBD-ZKWXMUAHSA-N 0.000 description 3
- LGIMRDKGABDMBN-DCAQKATOSA-N Ser-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CO)N LGIMRDKGABDMBN-DCAQKATOSA-N 0.000 description 3
- PXQUBKWZENPDGE-CIQUZCHMSA-N Thr-Ala-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)N PXQUBKWZENPDGE-CIQUZCHMSA-N 0.000 description 3
- TZKPNGDGUVREEB-FOHZUACHSA-N Thr-Asn-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O TZKPNGDGUVREEB-FOHZUACHSA-N 0.000 description 3
- DHPPWTOLRWYIDS-XKBZYTNZSA-N Thr-Cys-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(O)=O DHPPWTOLRWYIDS-XKBZYTNZSA-N 0.000 description 3
- XFTYVCHLARBHBQ-FOHZUACHSA-N Thr-Gly-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O XFTYVCHLARBHBQ-FOHZUACHSA-N 0.000 description 3
- MEJHFIOYJHTWMK-VOAKCMCISA-N Thr-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)[C@@H](C)O MEJHFIOYJHTWMK-VOAKCMCISA-N 0.000 description 3
- FIFDDJFLNVAVMS-RHYQMDGZSA-N Thr-Leu-Met Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(O)=O FIFDDJFLNVAVMS-RHYQMDGZSA-N 0.000 description 3
- PCMDGXKXVMBIFP-VEVYYDQMSA-N Thr-Met-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(O)=O PCMDGXKXVMBIFP-VEVYYDQMSA-N 0.000 description 3
- ILUOMMDDGREELW-OSUNSFLBSA-N Thr-Val-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)[C@@H](C)O ILUOMMDDGREELW-OSUNSFLBSA-N 0.000 description 3
- YPBYQWFZAAQMGW-XIRDDKMYSA-N Trp-Lys-Asn Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)O)N YPBYQWFZAAQMGW-XIRDDKMYSA-N 0.000 description 3
- ADMHZNPMMVKGJW-BPUTZDHNSA-N Trp-Ser-Arg Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N ADMHZNPMMVKGJW-BPUTZDHNSA-N 0.000 description 3
- FBHHJGOJWXHGDO-TUSQITKMSA-N Trp-Trp-Leu Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CC=3C4=CC=CC=C4NC=3)C(=O)N[C@@H](CC(C)C)C(O)=O)=CNC2=C1 FBHHJGOJWXHGDO-TUSQITKMSA-N 0.000 description 3
- GHUNBABNQPIETG-MELADBBJSA-N Tyr-Cys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CS)NC(=O)[C@H](CC2=CC=C(C=C2)O)N)C(=O)O GHUNBABNQPIETG-MELADBBJSA-N 0.000 description 3
- CRHFOYCJGVJPLE-AVGNSLFASA-N Tyr-Gln-Asn Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)O CRHFOYCJGVJPLE-AVGNSLFASA-N 0.000 description 3
- CNLKDWSAORJEMW-KWQFWETISA-N Tyr-Gly-Ala Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(=O)N[C@@H](C)C(O)=O CNLKDWSAORJEMW-KWQFWETISA-N 0.000 description 3
- LMKKMCGTDANZTR-BZSNNMDCSA-N Tyr-Phe-Asp Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(O)=O)C(O)=O)C1=CC=C(O)C=C1 LMKKMCGTDANZTR-BZSNNMDCSA-N 0.000 description 3
- UPODKYBYUBTWSV-BZSNNMDCSA-N Tyr-Phe-Cys Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CS)C(O)=O)C1=CC=C(O)C=C1 UPODKYBYUBTWSV-BZSNNMDCSA-N 0.000 description 3
- MDXLPNRXCFOBTL-BZSNNMDCSA-N Tyr-Ser-Tyr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O MDXLPNRXCFOBTL-BZSNNMDCSA-N 0.000 description 3
- KHPLUFDSWGDRHD-SLFFLAALSA-N Tyr-Tyr-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)N)C(=O)O KHPLUFDSWGDRHD-SLFFLAALSA-N 0.000 description 3
- RMRFSFXLFWWAJZ-HJOGWXRNSA-N Tyr-Tyr-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 RMRFSFXLFWWAJZ-HJOGWXRNSA-N 0.000 description 3
- AZSHAZJLOZQYAY-FXQIFTODSA-N Val-Ala-Ser Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O AZSHAZJLOZQYAY-FXQIFTODSA-N 0.000 description 3
- IRLYZKKNBFPQBW-XGEHTFHBSA-N Val-Cys-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](C(C)C)N)O IRLYZKKNBFPQBW-XGEHTFHBSA-N 0.000 description 3
- XEYUMGGWQCIWAR-XVKPBYJWSA-N Val-Gln-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)NCC(=O)O)N XEYUMGGWQCIWAR-XVKPBYJWSA-N 0.000 description 3
- FXVDGDZRYLFQKY-WPRPVWTQSA-N Val-Gly-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)C(C)C FXVDGDZRYLFQKY-WPRPVWTQSA-N 0.000 description 3
- FEXILLGKGGTLRI-NHCYSSNCSA-N Val-Leu-Asn Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](C(C)C)N FEXILLGKGGTLRI-NHCYSSNCSA-N 0.000 description 3
- MJFSRZZJQWZHFQ-SRVKXCTJSA-N Val-Met-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)O)N MJFSRZZJQWZHFQ-SRVKXCTJSA-N 0.000 description 3
- YQMILNREHKTFBS-IHRRRGAJSA-N Val-Phe-Cys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CS)C(=O)O)N YQMILNREHKTFBS-IHRRRGAJSA-N 0.000 description 3
- VHIZXDZMTDVFGX-DCAQKATOSA-N Val-Ser-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)N VHIZXDZMTDVFGX-DCAQKATOSA-N 0.000 description 3
- QTPQHINADBYBNA-DCAQKATOSA-N Val-Ser-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCCN QTPQHINADBYBNA-DCAQKATOSA-N 0.000 description 3
- DVLWZWNAQUBZBC-ZNSHCXBVSA-N Val-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C(C)C)N)O DVLWZWNAQUBZBC-ZNSHCXBVSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 108010005233 alanylglutamic acid Proteins 0.000 description 3
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 3
- 108010093581 aspartyl-proline Proteins 0.000 description 3
- 108010047857 aspartylglycine Proteins 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 108091008324 binding proteins Proteins 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 229940109239 creatinine Drugs 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 108010004073 cysteinylcysteine Proteins 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 108010010147 glycylglutamine Proteins 0.000 description 3
- 108010081551 glycylphenylalanine Proteins 0.000 description 3
- 108010018006 histidylserine Proteins 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 229940027941 immunoglobulin g Drugs 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000005462 in vivo assay Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 210000003292 kidney cell Anatomy 0.000 description 3
- 108010000761 leucylarginine Proteins 0.000 description 3
- 108010012058 leucyltyrosine Proteins 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 108010003700 lysyl aspartic acid Proteins 0.000 description 3
- 108010054155 lysyllysine Proteins 0.000 description 3
- 108010038320 lysylphenylalanine Proteins 0.000 description 3
- 108010017391 lysylvaline Proteins 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000006384 oligomerization reaction Methods 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 108010029020 prolylglycine Proteins 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 210000004989 spleen cell Anatomy 0.000 description 3
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- GJLXVWOMRRWCIB-MERZOTPQSA-N (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanamide Chemical compound C([C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=C(O)C=C1 GJLXVWOMRRWCIB-MERZOTPQSA-N 0.000 description 2
- SKPQXOSVPKPXML-ULQDDVLXSA-N 2-[[(2s)-1-[(2s)-3-phenyl-2-[[(2s)-pyrrolidine-2-carbonyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NCCC1)CC1=CC=CC=C1 SKPQXOSVPKPXML-ULQDDVLXSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- UGLPMYSCWHTZQU-AUTRQRHGSA-N Ala-Ala-Tyr Chemical compound C[C@H]([NH3+])C(=O)N[C@@H](C)C(=O)N[C@H](C([O-])=O)CC1=CC=C(O)C=C1 UGLPMYSCWHTZQU-AUTRQRHGSA-N 0.000 description 2
- GSCLWXDNIMNIJE-ZLUOBGJFSA-N Ala-Asp-Asn Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O GSCLWXDNIMNIJE-ZLUOBGJFSA-N 0.000 description 2
- OYJCVIGKMXUVKB-GARJFASQSA-N Ala-Leu-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N OYJCVIGKMXUVKB-GARJFASQSA-N 0.000 description 2
- DCVYRWFAMZFSDA-ZLUOBGJFSA-N Ala-Ser-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O DCVYRWFAMZFSDA-ZLUOBGJFSA-N 0.000 description 2
- NZGRHTKZFSVPAN-BIIVOSGPSA-N Ala-Ser-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N NZGRHTKZFSVPAN-BIIVOSGPSA-N 0.000 description 2
- SYIFFFHSXBNPMC-UWJYBYFXSA-N Ala-Ser-Tyr Chemical compound C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N SYIFFFHSXBNPMC-UWJYBYFXSA-N 0.000 description 2
- IASNWHAGGYTEKX-IUCAKERBSA-N Arg-Arg-Gly Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(O)=O IASNWHAGGYTEKX-IUCAKERBSA-N 0.000 description 2
- CPSHGRGUPZBMOK-CIUDSAMLSA-N Arg-Asn-Gln Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O CPSHGRGUPZBMOK-CIUDSAMLSA-N 0.000 description 2
- UAOSDDXCTBIPCA-QXEWZRGKSA-N Arg-Ile-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CCCN=C(N)N)N UAOSDDXCTBIPCA-QXEWZRGKSA-N 0.000 description 2
- HGKHPCFTRQDHCU-IUCAKERBSA-N Arg-Pro-Gly Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O HGKHPCFTRQDHCU-IUCAKERBSA-N 0.000 description 2
- HRCIIMCTUIAKQB-XGEHTFHBSA-N Arg-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)O HRCIIMCTUIAKQB-XGEHTFHBSA-N 0.000 description 2
- AYZAWXAPBAYCHO-CIUDSAMLSA-N Asn-Asn-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)N AYZAWXAPBAYCHO-CIUDSAMLSA-N 0.000 description 2
- QNJIRRVTOXNGMH-GUBZILKMSA-N Asn-Gln-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(N)=O QNJIRRVTOXNGMH-GUBZILKMSA-N 0.000 description 2
- DXVMJJNAOVECBA-WHFBIAKZSA-N Asn-Gly-Asn Chemical compound NC(=O)C[C@H](N)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O DXVMJJNAOVECBA-WHFBIAKZSA-N 0.000 description 2
- MDDXKBHIMYYJLW-FXQIFTODSA-N Asn-Met-Asp Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CC(=O)N)N MDDXKBHIMYYJLW-FXQIFTODSA-N 0.000 description 2
- VCJCPARXDBEGNE-GUBZILKMSA-N Asn-Pro-Pro Chemical compound NC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 VCJCPARXDBEGNE-GUBZILKMSA-N 0.000 description 2
- QYRMBFWDSFGSFC-OLHMAJIHSA-N Asn-Thr-Asn Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N)O QYRMBFWDSFGSFC-OLHMAJIHSA-N 0.000 description 2
- PIABYSIYPGLLDQ-XVSYOHENSA-N Asn-Thr-Phe Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O PIABYSIYPGLLDQ-XVSYOHENSA-N 0.000 description 2
- DAYDURRBMDCCFL-AAEUAGOBSA-N Asn-Trp-Gly Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CC(=O)N)N DAYDURRBMDCCFL-AAEUAGOBSA-N 0.000 description 2
- KRXIWXCXOARFNT-ZLUOBGJFSA-N Asp-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O KRXIWXCXOARFNT-ZLUOBGJFSA-N 0.000 description 2
- NYQHSUGFEWDWPD-ACZMJKKPSA-N Asp-Gln-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)O)N NYQHSUGFEWDWPD-ACZMJKKPSA-N 0.000 description 2
- PZXPWHFYZXTFBI-YUMQZZPRSA-N Asp-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(O)=O PZXPWHFYZXTFBI-YUMQZZPRSA-N 0.000 description 2
- ICZWAZVKLACMKR-CIUDSAMLSA-N Asp-His-Ser Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CO)C(O)=O)CC1=CN=CN1 ICZWAZVKLACMKR-CIUDSAMLSA-N 0.000 description 2
- KYQNAIMCTRZLNP-QSFUFRPTSA-N Asp-Ile-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(O)=O KYQNAIMCTRZLNP-QSFUFRPTSA-N 0.000 description 2
- MGSVBZIBCCKGCY-ZLUOBGJFSA-N Asp-Ser-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O MGSVBZIBCCKGCY-ZLUOBGJFSA-N 0.000 description 2
- JSHWXQIZOCVWIA-ZKWXMUAHSA-N Asp-Ser-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O JSHWXQIZOCVWIA-ZKWXMUAHSA-N 0.000 description 2
- HTSSXFASOUSJQG-IHPCNDPISA-N Asp-Tyr-Trp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O HTSSXFASOUSJQG-IHPCNDPISA-N 0.000 description 2
- ALMIMUZAWTUNIO-BZSNNMDCSA-N Asp-Tyr-Tyr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ALMIMUZAWTUNIO-BZSNNMDCSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- UFOBYROTHHYVGW-CIUDSAMLSA-N Cys-Cys-His Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC1=CNC=N1)C(O)=O UFOBYROTHHYVGW-CIUDSAMLSA-N 0.000 description 2
- CMYVIUWVYHOLRD-ZLUOBGJFSA-N Cys-Ser-Ala Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O CMYVIUWVYHOLRD-ZLUOBGJFSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000030168 Endothelin A Receptor Human genes 0.000 description 2
- 108010090549 Endothelin A Receptor Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- XZWYTXMRWQJBGX-VXBMVYAYSA-N FLAG peptide Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=C(O)C=C1 XZWYTXMRWQJBGX-VXBMVYAYSA-N 0.000 description 2
- 108010008177 Fd immunoglobulins Proteins 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 108091006027 G proteins Proteins 0.000 description 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
- XOKGKOQWADCLFQ-GARJFASQSA-N Gln-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(=O)N)N)C(=O)O XOKGKOQWADCLFQ-GARJFASQSA-N 0.000 description 2
- WMOMPXKOKASNBK-PEFMBERDSA-N Gln-Asn-Ile Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WMOMPXKOKASNBK-PEFMBERDSA-N 0.000 description 2
- MADFVRSKEIEZHZ-DCAQKATOSA-N Gln-Gln-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)N)N MADFVRSKEIEZHZ-DCAQKATOSA-N 0.000 description 2
- ZQPOVSJFBBETHQ-CIUDSAMLSA-N Gln-Glu-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O ZQPOVSJFBBETHQ-CIUDSAMLSA-N 0.000 description 2
- FFVXLVGUJBCKRX-UKJIMTQDSA-N Gln-Ile-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CCC(=O)N)N FFVXLVGUJBCKRX-UKJIMTQDSA-N 0.000 description 2
- UESYBOXFJWJVSB-AVGNSLFASA-N Gln-Phe-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(O)=O UESYBOXFJWJVSB-AVGNSLFASA-N 0.000 description 2
- OSCLNNWLKKIQJM-WDSKDSINSA-N Gln-Ser-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(O)=O OSCLNNWLKKIQJM-WDSKDSINSA-N 0.000 description 2
- PAQUJCSYVIBPLC-AVGNSLFASA-N Glu-Asp-Phe Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 PAQUJCSYVIBPLC-AVGNSLFASA-N 0.000 description 2
- WATXSTJXNBOHKD-LAEOZQHASA-N Glu-Asp-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O WATXSTJXNBOHKD-LAEOZQHASA-N 0.000 description 2
- CJWANNXUTOATSJ-DCAQKATOSA-N Glu-Gln-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)N CJWANNXUTOATSJ-DCAQKATOSA-N 0.000 description 2
- PJBVXVBTTFZPHJ-GUBZILKMSA-N Glu-Leu-Asp Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CCC(=O)O)N PJBVXVBTTFZPHJ-GUBZILKMSA-N 0.000 description 2
- ZYRXTRTUCAVNBQ-GVXVVHGQSA-N Glu-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N ZYRXTRTUCAVNBQ-GVXVVHGQSA-N 0.000 description 2
- QSDKBRMVXSWAQE-BFHQHQDPSA-N Gly-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)CN QSDKBRMVXSWAQE-BFHQHQDPSA-N 0.000 description 2
- SABZDFAAOJATBR-QWRGUYRKSA-N Gly-Cys-Phe Chemical compound [H]NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O SABZDFAAOJATBR-QWRGUYRKSA-N 0.000 description 2
- YWAQATDNEKZFFK-BYPYZUCNSA-N Gly-Gly-Ser Chemical compound NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O YWAQATDNEKZFFK-BYPYZUCNSA-N 0.000 description 2
- DGKBSGNCMCLDSL-BYULHYEWSA-N Gly-Ile-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)CN DGKBSGNCMCLDSL-BYULHYEWSA-N 0.000 description 2
- FXGRXIATVXUAHO-WEDXCCLWSA-N Gly-Lys-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCCN FXGRXIATVXUAHO-WEDXCCLWSA-N 0.000 description 2
- FKYQEVBRZSFAMJ-QWRGUYRKSA-N Gly-Ser-Tyr Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 FKYQEVBRZSFAMJ-QWRGUYRKSA-N 0.000 description 2
- NVTPVQLIZCOJFK-FOHZUACHSA-N Gly-Thr-Asp Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O NVTPVQLIZCOJFK-FOHZUACHSA-N 0.000 description 2
- DBUNZBWUWCIELX-JHEQGTHGSA-N Gly-Thr-Glu Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O DBUNZBWUWCIELX-JHEQGTHGSA-N 0.000 description 2
- RHRLHXQWHCNJKR-PMVVWTBXSA-N Gly-Thr-His Chemical compound NCC(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 RHRLHXQWHCNJKR-PMVVWTBXSA-N 0.000 description 2
- HUFUVTYGPOUCBN-MBLNEYKQSA-N Gly-Thr-Ile Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O HUFUVTYGPOUCBN-MBLNEYKQSA-N 0.000 description 2
- ZZWUYQXMIFTIIY-WEDXCCLWSA-N Gly-Thr-Leu Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O ZZWUYQXMIFTIIY-WEDXCCLWSA-N 0.000 description 2
- OCRQUYDOYKCOQG-IRXDYDNUSA-N Gly-Tyr-Phe Chemical compound C([C@H](NC(=O)CN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 OCRQUYDOYKCOQG-IRXDYDNUSA-N 0.000 description 2
- DNAZKGFYFRGZIH-QWRGUYRKSA-N Gly-Tyr-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=C(O)C=C1 DNAZKGFYFRGZIH-QWRGUYRKSA-N 0.000 description 2
- NGBGZCUWFVVJKC-IRXDYDNUSA-N Gly-Tyr-Tyr Chemical compound C([C@H](NC(=O)CN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 NGBGZCUWFVVJKC-IRXDYDNUSA-N 0.000 description 2
- RYAOJUMWLWUGNW-QMMMGPOBSA-N Gly-Val-Gly Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O RYAOJUMWLWUGNW-QMMMGPOBSA-N 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- HRGGKHFHRSFSDE-CIUDSAMLSA-N His-Asn-Ser Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)O)N HRGGKHFHRSFSDE-CIUDSAMLSA-N 0.000 description 2
- FFKJUTZARGRVTH-KKUMJFAQSA-N His-Ser-Tyr Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O FFKJUTZARGRVTH-KKUMJFAQSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- DFFTXLCCDFYRKD-MBLNEYKQSA-N Ile-Gly-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)O)N DFFTXLCCDFYRKD-MBLNEYKQSA-N 0.000 description 2
- GTSAALPQZASLPW-KJYZGMDISA-N Ile-His-Trp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)O)N GTSAALPQZASLPW-KJYZGMDISA-N 0.000 description 2
- RMNMUUCYTMLWNA-ZPFDUUQYSA-N Ile-Lys-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)O)N RMNMUUCYTMLWNA-ZPFDUUQYSA-N 0.000 description 2
- NXRNRBOKDBIVKQ-CXTHYWKRSA-N Ile-Tyr-Tyr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)N NXRNRBOKDBIVKQ-CXTHYWKRSA-N 0.000 description 2
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 2
- IBMVEYRWAWIOTN-UHFFFAOYSA-N L-Leucyl-L-Arginyl-L-Proline Natural products CC(C)CC(N)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(O)=O IBMVEYRWAWIOTN-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- HXWALXSAVBLTPK-NUTKFTJISA-N Leu-Ala-Trp Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC(C)C)N HXWALXSAVBLTPK-NUTKFTJISA-N 0.000 description 2
- USTCFDAQCLDPBD-XIRDDKMYSA-N Leu-Asn-Trp Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N USTCFDAQCLDPBD-XIRDDKMYSA-N 0.000 description 2
- CQGSYZCULZMEDE-UHFFFAOYSA-N Leu-Gln-Pro Natural products CC(C)CC(N)C(=O)NC(CCC(N)=O)C(=O)N1CCCC1C(O)=O CQGSYZCULZMEDE-UHFFFAOYSA-N 0.000 description 2
- CSFVADKICPDRRF-KKUMJFAQSA-N Leu-His-Leu Chemical compound CC(C)C[C@H]([NH3+])C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C([O-])=O)CC1=CN=CN1 CSFVADKICPDRRF-KKUMJFAQSA-N 0.000 description 2
- WXUOJXIGOPMDJM-SRVKXCTJSA-N Leu-Lys-Asn Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O WXUOJXIGOPMDJM-SRVKXCTJSA-N 0.000 description 2
- PPGBXYKMUMHFBF-KATARQTJSA-N Leu-Ser-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PPGBXYKMUMHFBF-KATARQTJSA-N 0.000 description 2
- ILDSIMPXNFWKLH-KATARQTJSA-N Leu-Thr-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O ILDSIMPXNFWKLH-KATARQTJSA-N 0.000 description 2
- FBNPMTNBFFAMMH-UHFFFAOYSA-N Leu-Val-Arg Natural products CC(C)CC(N)C(=O)NC(C(C)C)C(=O)NC(C(O)=O)CCCN=C(N)N FBNPMTNBFFAMMH-UHFFFAOYSA-N 0.000 description 2
- AAKRWBIIGKPOKQ-ONGXEEELSA-N Leu-Val-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O AAKRWBIIGKPOKQ-ONGXEEELSA-N 0.000 description 2
- VKVDRTGWLVZJOM-DCAQKATOSA-N Leu-Val-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O VKVDRTGWLVZJOM-DCAQKATOSA-N 0.000 description 2
- MYZMQWHPDAYKIE-SRVKXCTJSA-N Lys-Leu-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O MYZMQWHPDAYKIE-SRVKXCTJSA-N 0.000 description 2
- WGILOYIKJVQUPT-DCAQKATOSA-N Lys-Pro-Asp Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O WGILOYIKJVQUPT-DCAQKATOSA-N 0.000 description 2
- YTJFXEDRUOQGSP-DCAQKATOSA-N Lys-Pro-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O YTJFXEDRUOQGSP-DCAQKATOSA-N 0.000 description 2
- 241000282560 Macaca mulatta Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- UYAKZHGIPRCGPF-CIUDSAMLSA-N Met-Glu-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)N UYAKZHGIPRCGPF-CIUDSAMLSA-N 0.000 description 2
- BCRQJDMZQUHQSV-STQMWFEESA-N Met-Gly-Tyr Chemical compound [H]N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O BCRQJDMZQUHQSV-STQMWFEESA-N 0.000 description 2
- WXJXYMFUTRXRGO-UWVGGRQHSA-N Met-His-Gly Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(=O)NCC(O)=O)CC1=CNC=N1 WXJXYMFUTRXRGO-UWVGGRQHSA-N 0.000 description 2
- 102000007474 Multiprotein Complexes Human genes 0.000 description 2
- 108010085220 Multiprotein Complexes Proteins 0.000 description 2
- AUEJLPRZGVVDNU-UHFFFAOYSA-N N-L-tyrosyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CC1=CC=C(O)C=C1 AUEJLPRZGVVDNU-UHFFFAOYSA-N 0.000 description 2
- 108010002311 N-glycylglutamic acid Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- YHIPILPTUVMWQT-UHFFFAOYSA-N Oplophorus luciferin Chemical compound C1=CC(O)=CC=C1CC(C(N1C=C(N2)C=3C=CC(O)=CC=3)=O)=NC1=C2CC1=CC=CC=C1 YHIPILPTUVMWQT-UHFFFAOYSA-N 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- LXUJDHOKVUYHRC-KKUMJFAQSA-N Phe-Cys-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CC1=CC=CC=C1)N LXUJDHOKVUYHRC-KKUMJFAQSA-N 0.000 description 2
- JJHVFCUWLSKADD-ONGXEEELSA-N Phe-Gly-Ala Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H](C)C(O)=O JJHVFCUWLSKADD-ONGXEEELSA-N 0.000 description 2
- NAXPHWZXEXNDIW-JTQLQIEISA-N Phe-Gly-Gly Chemical compound OC(=O)CNC(=O)CNC(=O)[C@@H](N)CC1=CC=CC=C1 NAXPHWZXEXNDIW-JTQLQIEISA-N 0.000 description 2
- KAJLHCWRWDSROH-BZSNNMDCSA-N Phe-Phe-Asp Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(O)=O)C(O)=O)C1=CC=CC=C1 KAJLHCWRWDSROH-BZSNNMDCSA-N 0.000 description 2
- QARPMYDMYVLFMW-KKUMJFAQSA-N Phe-Pro-Glu Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C1=CC=CC=C1 QARPMYDMYVLFMW-KKUMJFAQSA-N 0.000 description 2
- BPCLGWHVPVTTFM-QWRGUYRKSA-N Phe-Ser-Gly Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)NCC(O)=O BPCLGWHVPVTTFM-QWRGUYRKSA-N 0.000 description 2
- UNBFGVQVQGXXCK-KKUMJFAQSA-N Phe-Ser-Leu Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O UNBFGVQVQGXXCK-KKUMJFAQSA-N 0.000 description 2
- JHSRGEODDALISP-XVSYOHENSA-N Phe-Thr-Asn Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(O)=O JHSRGEODDALISP-XVSYOHENSA-N 0.000 description 2
- GNRMAQSIROFNMI-IXOXFDKPSA-N Phe-Thr-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O GNRMAQSIROFNMI-IXOXFDKPSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- VXCHGLYSIOOZIS-GUBZILKMSA-N Pro-Ala-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 VXCHGLYSIOOZIS-GUBZILKMSA-N 0.000 description 2
- AMBLXEMWFARNNQ-DCAQKATOSA-N Pro-Asn-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@@H]1CCCN1 AMBLXEMWFARNNQ-DCAQKATOSA-N 0.000 description 2
- ZCXQTRXYZOSGJR-FXQIFTODSA-N Pro-Asp-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O ZCXQTRXYZOSGJR-FXQIFTODSA-N 0.000 description 2
- HJSCRFZVGXAGNG-SRVKXCTJSA-N Pro-Gln-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1 HJSCRFZVGXAGNG-SRVKXCTJSA-N 0.000 description 2
- PULPZRAHVFBVTO-DCAQKATOSA-N Pro-Glu-Arg Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O PULPZRAHVFBVTO-DCAQKATOSA-N 0.000 description 2
- BRJGUPWVFXKBQI-XUXIUFHCSA-N Pro-Leu-Ile Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O BRJGUPWVFXKBQI-XUXIUFHCSA-N 0.000 description 2
- VTFXTWDFPTWNJY-RHYQMDGZSA-N Pro-Leu-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VTFXTWDFPTWNJY-RHYQMDGZSA-N 0.000 description 2
- FDMKYQQYJKYCLV-GUBZILKMSA-N Pro-Pro-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 FDMKYQQYJKYCLV-GUBZILKMSA-N 0.000 description 2
- RCYUBVHMVUHEBM-RCWTZXSCSA-N Pro-Pro-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O RCYUBVHMVUHEBM-RCWTZXSCSA-N 0.000 description 2
- VBZXFFYOBDLLFE-HSHDSVGOSA-N Pro-Trp-Thr Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H]([C@H](O)C)C(O)=O)C(=O)[C@@H]1CCCN1 VBZXFFYOBDLLFE-HSHDSVGOSA-N 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 108010007127 Pulmonary Surfactant-Associated Protein D Proteins 0.000 description 2
- 101800001693 R-peptide Proteins 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- OHKLFYXEOGGGCK-ZLUOBGJFSA-N Ser-Asp-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O OHKLFYXEOGGGCK-ZLUOBGJFSA-N 0.000 description 2
- ZIFYDQAFEMIZII-GUBZILKMSA-N Ser-Leu-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O ZIFYDQAFEMIZII-GUBZILKMSA-N 0.000 description 2
- XUDRHBPSPAPDJP-SRVKXCTJSA-N Ser-Lys-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CO XUDRHBPSPAPDJP-SRVKXCTJSA-N 0.000 description 2
- FPCGZYMRFFIYIH-CIUDSAMLSA-N Ser-Lys-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O FPCGZYMRFFIYIH-CIUDSAMLSA-N 0.000 description 2
- RWDVVSKYZBNDCO-MELADBBJSA-N Ser-Phe-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CO)N)C(=O)O RWDVVSKYZBNDCO-MELADBBJSA-N 0.000 description 2
- NMZXJDSKEGFDLJ-DCAQKATOSA-N Ser-Pro-Lys Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CO)N)C(=O)N[C@@H](CCCCN)C(=O)O NMZXJDSKEGFDLJ-DCAQKATOSA-N 0.000 description 2
- NVNPWELENFJOHH-CIUDSAMLSA-N Ser-Ser-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)N NVNPWELENFJOHH-CIUDSAMLSA-N 0.000 description 2
- CUXJENOFJXOSOZ-BIIVOSGPSA-N Ser-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CO)N)C(=O)O CUXJENOFJXOSOZ-BIIVOSGPSA-N 0.000 description 2
- PYTKULIABVRXSC-BWBBJGPYSA-N Ser-Ser-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PYTKULIABVRXSC-BWBBJGPYSA-N 0.000 description 2
- NADLKBTYNKUJEP-KATARQTJSA-N Ser-Thr-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O NADLKBTYNKUJEP-KATARQTJSA-N 0.000 description 2
- BEBVVQPDSHHWQL-NRPADANISA-N Ser-Val-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O BEBVVQPDSHHWQL-NRPADANISA-N 0.000 description 2
- 101150052859 Slc9a1 gene Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
- KEGBFULVYKYJRD-LFSVMHDDSA-N Thr-Ala-Phe Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 KEGBFULVYKYJRD-LFSVMHDDSA-N 0.000 description 2
- DGDCHPCRMWEOJR-FQPOAREZSA-N Thr-Ala-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 DGDCHPCRMWEOJR-FQPOAREZSA-N 0.000 description 2
- PKXHGEXFMIZSER-QTKMDUPCSA-N Thr-Arg-His Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N)O PKXHGEXFMIZSER-QTKMDUPCSA-N 0.000 description 2
- KBBRNEDOYWMIJP-KYNKHSRBSA-N Thr-Gly-Thr Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)O)N)O KBBRNEDOYWMIJP-KYNKHSRBSA-N 0.000 description 2
- UDNVOQMPQBEITB-MEYUZBJRSA-N Thr-His-Phe Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O UDNVOQMPQBEITB-MEYUZBJRSA-N 0.000 description 2
- AMXMBCAXAZUCFA-RHYQMDGZSA-N Thr-Leu-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O AMXMBCAXAZUCFA-RHYQMDGZSA-N 0.000 description 2
- KPNSNVTUVKSBFL-ZJDVBMNYSA-N Thr-Met-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N)O KPNSNVTUVKSBFL-ZJDVBMNYSA-N 0.000 description 2
- JMBRNXUOLJFURW-BEAPCOKYSA-N Thr-Phe-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@@H]2C(=O)O)N)O JMBRNXUOLJFURW-BEAPCOKYSA-N 0.000 description 2
- XHWCDRUPDNSDAZ-XKBZYTNZSA-N Thr-Ser-Glu Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N)O XHWCDRUPDNSDAZ-XKBZYTNZSA-N 0.000 description 2
- IQPWNQRRAJHOKV-KATARQTJSA-N Thr-Ser-Lys Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCCN IQPWNQRRAJHOKV-KATARQTJSA-N 0.000 description 2
- HUPLKEHTTQBXSC-YJRXYDGGSA-N Thr-Ser-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 HUPLKEHTTQBXSC-YJRXYDGGSA-N 0.000 description 2
- BBPCSGKKPJUYRB-UVOCVTCTSA-N Thr-Thr-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O BBPCSGKKPJUYRB-UVOCVTCTSA-N 0.000 description 2
- KVEWWQRTAVMOFT-KJEVXHAQSA-N Thr-Tyr-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(O)=O KVEWWQRTAVMOFT-KJEVXHAQSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- MKDXQPMIQPTTAW-SIXJUCDHSA-N Trp-Ile-His Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)N MKDXQPMIQPTTAW-SIXJUCDHSA-N 0.000 description 2
- UOXPLPBMEPLZBW-WDSOQIARSA-N Trp-Val-Lys Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(O)=O)=CNC2=C1 UOXPLPBMEPLZBW-WDSOQIARSA-N 0.000 description 2
- LGEYOIQBBIPHQN-UWJYBYFXSA-N Tyr-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 LGEYOIQBBIPHQN-UWJYBYFXSA-N 0.000 description 2
- YGKVNUAKYPGORG-AVGNSLFASA-N Tyr-Asp-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O YGKVNUAKYPGORG-AVGNSLFASA-N 0.000 description 2
- UABYBEBXFFNCIR-YDHLFZDLSA-N Tyr-Asp-Val Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O UABYBEBXFFNCIR-YDHLFZDLSA-N 0.000 description 2
- OLWFDNLLBWQWCP-STQMWFEESA-N Tyr-Gly-Met Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(=O)N[C@@H](CCSC)C(O)=O OLWFDNLLBWQWCP-STQMWFEESA-N 0.000 description 2
- OSXNCKRGMSHWSQ-ACRUOGEOSA-N Tyr-His-Tyr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O OSXNCKRGMSHWSQ-ACRUOGEOSA-N 0.000 description 2
- VTCKHZJKWQENKX-KBPBESRZSA-N Tyr-Lys-Gly Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O VTCKHZJKWQENKX-KBPBESRZSA-N 0.000 description 2
- VYQQQIRHIFALGE-UWJYBYFXSA-N Tyr-Ser-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 VYQQQIRHIFALGE-UWJYBYFXSA-N 0.000 description 2
- PWKMJDQXKCENMF-MEYUZBJRSA-N Tyr-Thr-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O PWKMJDQXKCENMF-MEYUZBJRSA-N 0.000 description 2
- KUXCBJFJURINGF-PXDAIIFMSA-N Tyr-Trp-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CC3=CC=C(C=C3)O)N KUXCBJFJURINGF-PXDAIIFMSA-N 0.000 description 2
- VJOWWOGRNXRQMF-UVBJJODRSA-N Val-Ala-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](N)C(C)C)C(O)=O)=CNC2=C1 VJOWWOGRNXRQMF-UVBJJODRSA-N 0.000 description 2
- QGFPYRPIUXBYGR-YDHLFZDLSA-N Val-Asn-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N QGFPYRPIUXBYGR-YDHLFZDLSA-N 0.000 description 2
- JVYIGCARISMLMV-HOCLYGCPSA-N Val-Gly-Trp Chemical compound CC(C)[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N JVYIGCARISMLMV-HOCLYGCPSA-N 0.000 description 2
- HQYVQDRYODWONX-DCAQKATOSA-N Val-His-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CO)C(=O)O)N HQYVQDRYODWONX-DCAQKATOSA-N 0.000 description 2
- PZTZYZUTCPZWJH-FXQIFTODSA-N Val-Ser-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PZTZYZUTCPZWJH-FXQIFTODSA-N 0.000 description 2
- HWNYVQMOLCYHEA-IHRRRGAJSA-N Val-Ser-Tyr Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N HWNYVQMOLCYHEA-IHRRRGAJSA-N 0.000 description 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000009824 affinity maturation Effects 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 108010024078 alanyl-glycyl-serine Proteins 0.000 description 2
- 108010047495 alanylglycine Proteins 0.000 description 2
- 150000001412 amines Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 210000000628 antibody-producing cell Anatomy 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 108010029539 arginyl-prolyl-proline Proteins 0.000 description 2
- 238000000423 cell based assay Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 108010016616 cysteinylglycine Proteins 0.000 description 2
- 108010060455 des-Tyr- beta-casomorphin Proteins 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 108010040030 histidinoalanine Proteins 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 108010090333 leucyl-lysyl-proline Proteins 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229940055729 papain Drugs 0.000 description 2
- 235000019834 papain Nutrition 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 239000000816 peptidomimetic Substances 0.000 description 2
- 108010024654 phenylalanyl-prolyl-alanine Proteins 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 238000002708 random mutagenesis Methods 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 108010048818 seryl-histidine Proteins 0.000 description 2
- 108010026333 seryl-proline Proteins 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 108010033670 threonyl-aspartyl-tyrosine Proteins 0.000 description 2
- 108010061238 threonyl-glycine Proteins 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 239000013638 trimer Substances 0.000 description 2
- 108010020532 tyrosyl-proline Proteins 0.000 description 2
- 108010077037 tyrosyl-tyrosyl-phenylalanine Proteins 0.000 description 2
- 108010009962 valyltyrosine Proteins 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- WEZDRVHTDXTVLT-GJZGRUSLSA-N 2-[[(2s)-2-[[(2s)-2-[(2-aminoacetyl)amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)CN)CC1=CC=CC=C1 WEZDRVHTDXTVLT-GJZGRUSLSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 108010000239 Aequorin Proteins 0.000 description 1
- CVGNCMIULZNYES-WHFBIAKZSA-N Ala-Asn-Gly Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O CVGNCMIULZNYES-WHFBIAKZSA-N 0.000 description 1
- XQJAFSDFQZPYCU-UWJYBYFXSA-N Ala-Asn-Tyr Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N XQJAFSDFQZPYCU-UWJYBYFXSA-N 0.000 description 1
- NHCPCLJZRSIDHS-ZLUOBGJFSA-N Ala-Asp-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O NHCPCLJZRSIDHS-ZLUOBGJFSA-N 0.000 description 1
- LSLIRHLIUDVNBN-CIUDSAMLSA-N Ala-Asp-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN LSLIRHLIUDVNBN-CIUDSAMLSA-N 0.000 description 1
- BUDNAJYVCUHLSV-ZLUOBGJFSA-N Ala-Asp-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O BUDNAJYVCUHLSV-ZLUOBGJFSA-N 0.000 description 1
- SFNFGFDRYJKZKN-XQXXSGGOSA-N Ala-Gln-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C)N)O SFNFGFDRYJKZKN-XQXXSGGOSA-N 0.000 description 1
- NWVVKQZOVSTDBQ-CIUDSAMLSA-N Ala-Glu-Arg Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O NWVVKQZOVSTDBQ-CIUDSAMLSA-N 0.000 description 1
- PAIHPOGPJVUFJY-WDSKDSINSA-N Ala-Glu-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O PAIHPOGPJVUFJY-WDSKDSINSA-N 0.000 description 1
- XYTNPQNAZREREP-XQXXSGGOSA-N Ala-Glu-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XYTNPQNAZREREP-XQXXSGGOSA-N 0.000 description 1
- NBTGEURICRTMGL-WHFBIAKZSA-N Ala-Gly-Ser Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O NBTGEURICRTMGL-WHFBIAKZSA-N 0.000 description 1
- OBVSBEYOMDWLRJ-BFHQHQDPSA-N Ala-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N OBVSBEYOMDWLRJ-BFHQHQDPSA-N 0.000 description 1
- GRIFPSOFWFIICX-GOPGUHFVSA-N Ala-His-Trp Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O GRIFPSOFWFIICX-GOPGUHFVSA-N 0.000 description 1
- AWZKCUCQJNTBAD-SRVKXCTJSA-N Ala-Leu-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCCCN AWZKCUCQJNTBAD-SRVKXCTJSA-N 0.000 description 1
- LDLSENBXQNDTPB-DCAQKATOSA-N Ala-Lys-Arg Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N LDLSENBXQNDTPB-DCAQKATOSA-N 0.000 description 1
- REAQAWSENITKJL-DDWPSWQVSA-N Ala-Met-Asp-Tyr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O REAQAWSENITKJL-DDWPSWQVSA-N 0.000 description 1
- FFZJHQODAYHGPO-KZVJFYERSA-N Ala-Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)N FFZJHQODAYHGPO-KZVJFYERSA-N 0.000 description 1
- NCQMBSJGJMYKCK-ZLUOBGJFSA-N Ala-Ser-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O NCQMBSJGJMYKCK-ZLUOBGJFSA-N 0.000 description 1
- OEVCHROQUIVQFZ-YTLHQDLWSA-N Ala-Thr-Ala Chemical compound C[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](C)C(O)=O OEVCHROQUIVQFZ-YTLHQDLWSA-N 0.000 description 1
- IOFVWPYSRSCWHI-JXUBOQSCSA-N Ala-Thr-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)N IOFVWPYSRSCWHI-JXUBOQSCSA-N 0.000 description 1
- YCTIYBUTCKNOTI-UWJYBYFXSA-N Ala-Tyr-Asp Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N YCTIYBUTCKNOTI-UWJYBYFXSA-N 0.000 description 1
- MUGAESARFRGOTQ-IGNZVWTISA-N Ala-Tyr-Tyr Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)N MUGAESARFRGOTQ-IGNZVWTISA-N 0.000 description 1
- YEBZNKPPOHFZJM-BPNCWPANSA-N Ala-Tyr-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(O)=O YEBZNKPPOHFZJM-BPNCWPANSA-N 0.000 description 1
- 229940122816 Amylase inhibitor Drugs 0.000 description 1
- 102000008102 Ankyrins Human genes 0.000 description 1
- 108010049777 Ankyrins Proteins 0.000 description 1
- 241001156002 Anthonomus pomorum Species 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 101000725156 Aplysia californica Cerebral peptide 1 Proteins 0.000 description 1
- DFCIPNHFKOQAME-FXQIFTODSA-N Arg-Ala-Asn Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(O)=O DFCIPNHFKOQAME-FXQIFTODSA-N 0.000 description 1
- VKKYFICVTYKFIO-CIUDSAMLSA-N Arg-Ala-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N VKKYFICVTYKFIO-CIUDSAMLSA-N 0.000 description 1
- NABSCJGZKWSNHX-RCWTZXSCSA-N Arg-Arg-Thr Chemical compound NC(N)=NCCC[C@@H](C(=O)N[C@@H]([C@H](O)C)C(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N NABSCJGZKWSNHX-RCWTZXSCSA-N 0.000 description 1
- DPXDVGDLWJYZBH-GUBZILKMSA-N Arg-Asn-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O DPXDVGDLWJYZBH-GUBZILKMSA-N 0.000 description 1
- RVDVDRUZWZIBJQ-CIUDSAMLSA-N Arg-Asn-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O RVDVDRUZWZIBJQ-CIUDSAMLSA-N 0.000 description 1
- PQWTZSNVWSOFFK-FXQIFTODSA-N Arg-Asp-Asn Chemical compound C(C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)CN=C(N)N PQWTZSNVWSOFFK-FXQIFTODSA-N 0.000 description 1
- RCAUJZASOAFTAJ-FXQIFTODSA-N Arg-Asp-Cys Chemical compound C(C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CS)C(=O)O)N)CN=C(N)N RCAUJZASOAFTAJ-FXQIFTODSA-N 0.000 description 1
- JUWQNWXEGDYCIE-YUMQZZPRSA-N Arg-Gln-Gly Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O JUWQNWXEGDYCIE-YUMQZZPRSA-N 0.000 description 1
- OQCWXQJLCDPRHV-UWVGGRQHSA-N Arg-Gly-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O OQCWXQJLCDPRHV-UWVGGRQHSA-N 0.000 description 1
- WVNFNPGXYADPPO-BQBZGAKWSA-N Arg-Gly-Ser Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O WVNFNPGXYADPPO-BQBZGAKWSA-N 0.000 description 1
- YKBHOXLMMPZPHQ-GMOBBJLQSA-N Arg-Ile-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(O)=O YKBHOXLMMPZPHQ-GMOBBJLQSA-N 0.000 description 1
- GXXWTNKNFFKTJB-NAKRPEOUSA-N Arg-Ile-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O GXXWTNKNFFKTJB-NAKRPEOUSA-N 0.000 description 1
- DNLQVHBBMPZUGJ-BQBZGAKWSA-N Arg-Ser-Gly Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O DNLQVHBBMPZUGJ-BQBZGAKWSA-N 0.000 description 1
- KMFPQTITXUKJOV-DCAQKATOSA-N Arg-Ser-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O KMFPQTITXUKJOV-DCAQKATOSA-N 0.000 description 1
- SYFHFLGAROUHNT-VEVYYDQMSA-N Arg-Thr-Asn Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(O)=O SYFHFLGAROUHNT-VEVYYDQMSA-N 0.000 description 1
- AUZAXCPWMDBWEE-HJGDQZAQSA-N Arg-Thr-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O AUZAXCPWMDBWEE-HJGDQZAQSA-N 0.000 description 1
- POZKLUIXMHIULG-FDARSICLSA-N Arg-Trp-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CCCN=C(N)N)N POZKLUIXMHIULG-FDARSICLSA-N 0.000 description 1
- PSUXEQYPYZLNER-QXEWZRGKSA-N Arg-Val-Asn Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O PSUXEQYPYZLNER-QXEWZRGKSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- PFOYSEIHFVKHNF-FXQIFTODSA-N Asn-Ala-Arg Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O PFOYSEIHFVKHNF-FXQIFTODSA-N 0.000 description 1
- NUHQMYUWLUSRJX-BIIVOSGPSA-N Asn-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)N)N NUHQMYUWLUSRJX-BIIVOSGPSA-N 0.000 description 1
- ZZXMOQIUIJJOKZ-ZLUOBGJFSA-N Asn-Asn-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC(N)=O ZZXMOQIUIJJOKZ-ZLUOBGJFSA-N 0.000 description 1
- ACRYGQFHAQHDSF-ZLUOBGJFSA-N Asn-Asn-Asn Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O ACRYGQFHAQHDSF-ZLUOBGJFSA-N 0.000 description 1
- BVLIJXXSXBUGEC-SRVKXCTJSA-N Asn-Asn-Tyr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O BVLIJXXSXBUGEC-SRVKXCTJSA-N 0.000 description 1
- OLVIPTLKNSAYRJ-YUMQZZPRSA-N Asn-Gly-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)N OLVIPTLKNSAYRJ-YUMQZZPRSA-N 0.000 description 1
- OOWSBIOUKIUWLO-RCOVLWMOSA-N Asn-Gly-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O OOWSBIOUKIUWLO-RCOVLWMOSA-N 0.000 description 1
- ODBSSLHUFPJRED-CIUDSAMLSA-N Asn-His-Asn Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)N)N ODBSSLHUFPJRED-CIUDSAMLSA-N 0.000 description 1
- ZTRJUKDEALVRMW-SRVKXCTJSA-N Asn-His-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)NC(=O)[C@H](CC(=O)N)N ZTRJUKDEALVRMW-SRVKXCTJSA-N 0.000 description 1
- HDHZCEDPLTVHFZ-GUBZILKMSA-N Asn-Leu-Glu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O HDHZCEDPLTVHFZ-GUBZILKMSA-N 0.000 description 1
- HZZIFFOVHLWGCS-KKUMJFAQSA-N Asn-Phe-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O HZZIFFOVHLWGCS-KKUMJFAQSA-N 0.000 description 1
- YRTOMUMWSTUQAX-FXQIFTODSA-N Asn-Pro-Asp Chemical compound NC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O YRTOMUMWSTUQAX-FXQIFTODSA-N 0.000 description 1
- HPBNLFLSSQDFQW-WHFBIAKZSA-N Asn-Ser-Gly Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O HPBNLFLSSQDFQW-WHFBIAKZSA-N 0.000 description 1
- UGXYFDQFLVCDFC-CIUDSAMLSA-N Asn-Ser-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O UGXYFDQFLVCDFC-CIUDSAMLSA-N 0.000 description 1
- RDLYUKRPEJERMM-XIRDDKMYSA-N Asn-Trp-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(O)=O RDLYUKRPEJERMM-XIRDDKMYSA-N 0.000 description 1
- DXHINQUXBZNUCF-MELADBBJSA-N Asn-Tyr-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CC(=O)N)N)C(=O)O DXHINQUXBZNUCF-MELADBBJSA-N 0.000 description 1
- XEDQMTWEYFBOIK-ACZMJKKPSA-N Asp-Ala-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O XEDQMTWEYFBOIK-ACZMJKKPSA-N 0.000 description 1
- RDRMWJBLOSRRAW-BYULHYEWSA-N Asp-Asn-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O RDRMWJBLOSRRAW-BYULHYEWSA-N 0.000 description 1
- PXLNPFOJZQMXAT-BYULHYEWSA-N Asp-Asp-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC(O)=O PXLNPFOJZQMXAT-BYULHYEWSA-N 0.000 description 1
- LDGUZSIPGSPBJP-XVYDVKMFSA-N Asp-His-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CC(=O)O)N LDGUZSIPGSPBJP-XVYDVKMFSA-N 0.000 description 1
- OOXKFYNWRVGYFM-XIRDDKMYSA-N Asp-His-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CC3=CN=CN3)NC(=O)[C@H](CC(=O)O)N OOXKFYNWRVGYFM-XIRDDKMYSA-N 0.000 description 1
- HOBNTSHITVVNBN-ZPFDUUQYSA-N Asp-Ile-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CC(=O)O)N HOBNTSHITVVNBN-ZPFDUUQYSA-N 0.000 description 1
- SPWXXPFDTMYTRI-IUKAMOBKSA-N Asp-Ile-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SPWXXPFDTMYTRI-IUKAMOBKSA-N 0.000 description 1
- CJUKAWUWBZCTDQ-SRVKXCTJSA-N Asp-Leu-Lys Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O CJUKAWUWBZCTDQ-SRVKXCTJSA-N 0.000 description 1
- QNMKWNONJGKJJC-NHCYSSNCSA-N Asp-Leu-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O QNMKWNONJGKJJC-NHCYSSNCSA-N 0.000 description 1
- LTCKTLYKRMCFOC-KKUMJFAQSA-N Asp-Phe-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O LTCKTLYKRMCFOC-KKUMJFAQSA-N 0.000 description 1
- KPSHWSWFPUDEGF-FXQIFTODSA-N Asp-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC(O)=O KPSHWSWFPUDEGF-FXQIFTODSA-N 0.000 description 1
- FAUPLTGRUBTXNU-FXQIFTODSA-N Asp-Pro-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O FAUPLTGRUBTXNU-FXQIFTODSA-N 0.000 description 1
- KGHLGJAXYSVNJP-WHFBIAKZSA-N Asp-Ser-Gly Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O KGHLGJAXYSVNJP-WHFBIAKZSA-N 0.000 description 1
- OFYVKOXTTDCUIL-FXQIFTODSA-N Asp-Ser-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)N OFYVKOXTTDCUIL-FXQIFTODSA-N 0.000 description 1
- IWLZBRTUIVXZJD-OLHMAJIHSA-N Asp-Thr-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O IWLZBRTUIVXZJD-OLHMAJIHSA-N 0.000 description 1
- RSMZEHCMIOKNMW-GSSVUCPTSA-N Asp-Thr-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O RSMZEHCMIOKNMW-GSSVUCPTSA-N 0.000 description 1
- ITGFVUYOLWBPQW-KKHAAJSZSA-N Asp-Thr-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O ITGFVUYOLWBPQW-KKHAAJSZSA-N 0.000 description 1
- YUELDQUPTAYEGM-XIRDDKMYSA-N Asp-Trp-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CC(=O)O)N YUELDQUPTAYEGM-XIRDDKMYSA-N 0.000 description 1
- NALWOULWGHTVDA-UWVGGRQHSA-N Asp-Tyr Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 NALWOULWGHTVDA-UWVGGRQHSA-N 0.000 description 1
- CZIVKMOEXPILDK-SRVKXCTJSA-N Asp-Tyr-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(O)=O CZIVKMOEXPILDK-SRVKXCTJSA-N 0.000 description 1
- XWKPSMRPIKKDDU-RCOVLWMOSA-N Asp-Val-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O XWKPSMRPIKKDDU-RCOVLWMOSA-N 0.000 description 1
- XQFLFQWOBXPMHW-NHCYSSNCSA-N Asp-Val-His Chemical compound N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)O XQFLFQWOBXPMHW-NHCYSSNCSA-N 0.000 description 1
- GYNUXDMCDILYIQ-QRTARXTBSA-N Asp-Val-Trp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CC(=O)O)N GYNUXDMCDILYIQ-QRTARXTBSA-N 0.000 description 1
- ZUNMTUPRQMWMHX-LSJOCFKGSA-N Asp-Val-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(O)=O ZUNMTUPRQMWMHX-LSJOCFKGSA-N 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 102100021277 Beta-secretase 2 Human genes 0.000 description 1
- 101710150190 Beta-secretase 2 Proteins 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 102100021786 CMP-N-acetylneuraminate-poly-alpha-2,8-sialyltransferase Human genes 0.000 description 1
- 101100512078 Caenorhabditis elegans lys-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000005367 Carboxypeptidases Human genes 0.000 description 1
- 108010006303 Carboxypeptidases Proteins 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- XEEIQMGZRFFSRD-XVYDVKMFSA-N Cys-Ala-His Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CS)N XEEIQMGZRFFSRD-XVYDVKMFSA-N 0.000 description 1
- GHUVBPIYQYXXEF-SRVKXCTJSA-N Cys-Cys-Tyr Chemical compound SC[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 GHUVBPIYQYXXEF-SRVKXCTJSA-N 0.000 description 1
- BPHKULHWEIUDOB-FXQIFTODSA-N Cys-Gln-Gln Chemical compound SC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O BPHKULHWEIUDOB-FXQIFTODSA-N 0.000 description 1
- VTJLJQGUMBWHBP-GUBZILKMSA-N Cys-His-Gln Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CS)N VTJLJQGUMBWHBP-GUBZILKMSA-N 0.000 description 1
- NIXHTNJAGGFBAW-CIUDSAMLSA-N Cys-Lys-Ser Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CS)N NIXHTNJAGGFBAW-CIUDSAMLSA-N 0.000 description 1
- PEZINYWZBQNTIX-NAKRPEOUSA-N Cys-Met-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)N PEZINYWZBQNTIX-NAKRPEOUSA-N 0.000 description 1
- RESAHOSBQHMOKH-KKUMJFAQSA-N Cys-Phe-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CS)N RESAHOSBQHMOKH-KKUMJFAQSA-N 0.000 description 1
- NDNZRWUDUMTITL-FXQIFTODSA-N Cys-Ser-Val Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O NDNZRWUDUMTITL-FXQIFTODSA-N 0.000 description 1
- KFYPRIGJTICABD-XGEHTFHBSA-N Cys-Thr-Val Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CS)N)O KFYPRIGJTICABD-XGEHTFHBSA-N 0.000 description 1
- XKDHARKYRGHLKO-QEJZJMRPSA-N Cys-Trp-Gln Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CS)N XKDHARKYRGHLKO-QEJZJMRPSA-N 0.000 description 1
- RIONIAPMMKVUCX-IHPCNDPISA-N Cys-Trp-Tyr Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CS)N)C(O)=O)C1=CC=C(O)C=C1 RIONIAPMMKVUCX-IHPCNDPISA-N 0.000 description 1
- NGOIQDYZMIKCOK-NAKRPEOUSA-N Cys-Val-Ile Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O NGOIQDYZMIKCOK-NAKRPEOUSA-N 0.000 description 1
- ALTQTAKGRFLRLR-GUBZILKMSA-N Cys-Val-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)O)NC(=O)[C@H](CS)N ALTQTAKGRFLRLR-GUBZILKMSA-N 0.000 description 1
- 102100025287 Cytochrome b Human genes 0.000 description 1
- 108010075028 Cytochromes b Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 1
- 102100029764 DNA-directed DNA/RNA polymerase mu Human genes 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229940118365 Endothelin receptor antagonist Drugs 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000034286 G proteins Human genes 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- MLZRSFQRBDNJON-GUBZILKMSA-N Gln-Ala-Lys Chemical compound C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)N)N MLZRSFQRBDNJON-GUBZILKMSA-N 0.000 description 1
- OYTPNWYZORARHL-XHNCKOQMSA-N Gln-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)N)N OYTPNWYZORARHL-XHNCKOQMSA-N 0.000 description 1
- CRRFJBGUGNNOCS-PEFMBERDSA-N Gln-Asp-Ile Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O CRRFJBGUGNNOCS-PEFMBERDSA-N 0.000 description 1
- WLODHVXYKYHLJD-ACZMJKKPSA-N Gln-Asp-Ser Chemical compound C(CC(=O)N)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)O)N WLODHVXYKYHLJD-ACZMJKKPSA-N 0.000 description 1
- LOJYQMFIIJVETK-WDSKDSINSA-N Gln-Gln Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(O)=O LOJYQMFIIJVETK-WDSKDSINSA-N 0.000 description 1
- LVNILKSSFHCSJZ-IHRRRGAJSA-N Gln-Gln-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)N)N LVNILKSSFHCSJZ-IHRRRGAJSA-N 0.000 description 1
- QFJPFPCSXOXMKI-BPUTZDHNSA-N Gln-Gln-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)N)N QFJPFPCSXOXMKI-BPUTZDHNSA-N 0.000 description 1
- GNMQDOGFWYWPNM-LAEOZQHASA-N Gln-Gly-Ile Chemical compound CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@@H](N)CCC(N)=O)C(O)=O GNMQDOGFWYWPNM-LAEOZQHASA-N 0.000 description 1
- GFLNKSQHOBOMNM-AVGNSLFASA-N Gln-His-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)NC(=O)[C@H](CCC(=O)N)N GFLNKSQHOBOMNM-AVGNSLFASA-N 0.000 description 1
- ICDIMQAMJGDHSE-GUBZILKMSA-N Gln-His-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(O)=O ICDIMQAMJGDHSE-GUBZILKMSA-N 0.000 description 1
- ZNTDJIMJKNNSLR-RWRJDSDZSA-N Gln-Ile-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](CCC(=O)N)N ZNTDJIMJKNNSLR-RWRJDSDZSA-N 0.000 description 1
- IOFDDSNZJDIGPB-GVXVVHGQSA-N Gln-Leu-Val Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O IOFDDSNZJDIGPB-GVXVVHGQSA-N 0.000 description 1
- KLKYKPXITJBSNI-CIUDSAMLSA-N Gln-Met-Ala Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(O)=O KLKYKPXITJBSNI-CIUDSAMLSA-N 0.000 description 1
- XUMFMAVDHQDATI-DCAQKATOSA-N Gln-Pro-Arg Chemical compound NC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O XUMFMAVDHQDATI-DCAQKATOSA-N 0.000 description 1
- VNTGPISAOMAXRK-CIUDSAMLSA-N Gln-Pro-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O VNTGPISAOMAXRK-CIUDSAMLSA-N 0.000 description 1
- SXFPZRRVWSUYII-KBIXCLLPSA-N Gln-Ser-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)N)N SXFPZRRVWSUYII-KBIXCLLPSA-N 0.000 description 1
- LPIKVBWNNVFHCQ-GUBZILKMSA-N Gln-Ser-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O LPIKVBWNNVFHCQ-GUBZILKMSA-N 0.000 description 1
- DYVMTEWCGAVKSE-HJGDQZAQSA-N Gln-Thr-Arg Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CCC(=O)N)N)O DYVMTEWCGAVKSE-HJGDQZAQSA-N 0.000 description 1
- UEILCTONAMOGBR-RWRJDSDZSA-N Gln-Thr-Ile Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O UEILCTONAMOGBR-RWRJDSDZSA-N 0.000 description 1
- NSEKYCAADBNQFE-XIRDDKMYSA-N Gln-Trp-Arg Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(N)=O)N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)=CNC2=C1 NSEKYCAADBNQFE-XIRDDKMYSA-N 0.000 description 1
- WTJIWXMJESRHMM-XDTLVQLUSA-N Gln-Tyr-Ala Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(O)=O WTJIWXMJESRHMM-XDTLVQLUSA-N 0.000 description 1
- GTBXHETZPUURJE-KKUMJFAQSA-N Gln-Tyr-Arg Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O GTBXHETZPUURJE-KKUMJFAQSA-N 0.000 description 1
- AKDOUBMVLRCHBD-SIUGBPQLSA-N Gln-Tyr-Ile Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O AKDOUBMVLRCHBD-SIUGBPQLSA-N 0.000 description 1
- UTKUTMJSWKKHEM-WDSKDSINSA-N Glu-Ala-Gly Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O UTKUTMJSWKKHEM-WDSKDSINSA-N 0.000 description 1
- MXOODARRORARSU-ACZMJKKPSA-N Glu-Ala-Ser Chemical compound C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCC(=O)O)N MXOODARRORARSU-ACZMJKKPSA-N 0.000 description 1
- FYBSCGZLICNOBA-XQXXSGGOSA-N Glu-Ala-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O FYBSCGZLICNOBA-XQXXSGGOSA-N 0.000 description 1
- VPKBCVUDBNINAH-GARJFASQSA-N Glu-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(=O)O)N)C(=O)O VPKBCVUDBNINAH-GARJFASQSA-N 0.000 description 1
- WOSRKEJQESVHGA-CIUDSAMLSA-N Glu-Arg-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O WOSRKEJQESVHGA-CIUDSAMLSA-N 0.000 description 1
- DYFJZDDQPNIPAB-NHCYSSNCSA-N Glu-Arg-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(O)=O DYFJZDDQPNIPAB-NHCYSSNCSA-N 0.000 description 1
- AFODTOLGSZQDSL-PEFMBERDSA-N Glu-Asn-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)O)N AFODTOLGSZQDSL-PEFMBERDSA-N 0.000 description 1
- ZJICFHQSPWFBKP-AVGNSLFASA-N Glu-Asn-Tyr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ZJICFHQSPWFBKP-AVGNSLFASA-N 0.000 description 1
- RDPOETHPAQEGDP-ACZMJKKPSA-N Glu-Asp-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O RDPOETHPAQEGDP-ACZMJKKPSA-N 0.000 description 1
- RQNYYRHRKSVKAB-GUBZILKMSA-N Glu-Cys-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(O)=O RQNYYRHRKSVKAB-GUBZILKMSA-N 0.000 description 1
- PXHABOCPJVTGEK-BQBZGAKWSA-N Glu-Gln-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O PXHABOCPJVTGEK-BQBZGAKWSA-N 0.000 description 1
- HNVFSTLPVJWIDV-CIUDSAMLSA-N Glu-Glu-Gln Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O HNVFSTLPVJWIDV-CIUDSAMLSA-N 0.000 description 1
- MUSGDMDGNGXULI-DCAQKATOSA-N Glu-Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O MUSGDMDGNGXULI-DCAQKATOSA-N 0.000 description 1
- UHVIQGKBMXEVGN-WDSKDSINSA-N Glu-Gly-Asn Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O UHVIQGKBMXEVGN-WDSKDSINSA-N 0.000 description 1
- WVYJNPCWJYBHJG-YVNDNENWSA-N Glu-Ile-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(O)=O WVYJNPCWJYBHJG-YVNDNENWSA-N 0.000 description 1
- HVYWQYLBVXMXSV-GUBZILKMSA-N Glu-Leu-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O HVYWQYLBVXMXSV-GUBZILKMSA-N 0.000 description 1
- NWOUBJNMZDDGDT-AVGNSLFASA-N Glu-Leu-His Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 NWOUBJNMZDDGDT-AVGNSLFASA-N 0.000 description 1
- GJBUAAAIZSRCDC-GVXVVHGQSA-N Glu-Leu-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O GJBUAAAIZSRCDC-GVXVVHGQSA-N 0.000 description 1
- SJJHXJDSNQJMMW-SRVKXCTJSA-N Glu-Lys-Arg Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O SJJHXJDSNQJMMW-SRVKXCTJSA-N 0.000 description 1
- GMVCSRBOSIUTFC-FXQIFTODSA-N Glu-Ser-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(O)=O GMVCSRBOSIUTFC-FXQIFTODSA-N 0.000 description 1
- HMJULNMJWOZNFI-XHNCKOQMSA-N Glu-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CCC(=O)O)N)C(=O)O HMJULNMJWOZNFI-XHNCKOQMSA-N 0.000 description 1
- ZGXGVBYEJGVJMV-HJGDQZAQSA-N Glu-Thr-Met Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)[C@H](CCC(=O)O)N)O ZGXGVBYEJGVJMV-HJGDQZAQSA-N 0.000 description 1
- MXJYXYDREQWUMS-XKBZYTNZSA-N Glu-Thr-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O MXJYXYDREQWUMS-XKBZYTNZSA-N 0.000 description 1
- DLISPGXMKZTWQG-IFFSRLJSSA-N Glu-Thr-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O DLISPGXMKZTWQG-IFFSRLJSSA-N 0.000 description 1
- ZNOHKCPYDAYYDA-BPUTZDHNSA-N Glu-Trp-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCC(N)=O)C(O)=O ZNOHKCPYDAYYDA-BPUTZDHNSA-N 0.000 description 1
- UCZXXMREFIETQW-AVGNSLFASA-N Glu-Tyr-Asn Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(O)=O UCZXXMREFIETQW-AVGNSLFASA-N 0.000 description 1
- RXJFSLQVMGYQEL-IHRRRGAJSA-N Glu-Tyr-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(O)=O)CC1=CC=C(O)C=C1 RXJFSLQVMGYQEL-IHRRRGAJSA-N 0.000 description 1
- VXEFAWJTFAUDJK-AVGNSLFASA-N Glu-Tyr-Ser Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCC(=O)O)N)O VXEFAWJTFAUDJK-AVGNSLFASA-N 0.000 description 1
- ZALGPUWUVHOGAE-GVXVVHGQSA-N Glu-Val-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CCC(=O)O)N ZALGPUWUVHOGAE-GVXVVHGQSA-N 0.000 description 1
- QXUPRMQJDWJDFR-NRPADANISA-N Glu-Val-Ser Chemical compound CC(C)[C@H](NC(=O)[C@@H](N)CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O QXUPRMQJDWJDFR-NRPADANISA-N 0.000 description 1
- SOYWRINXUSUWEQ-DLOVCJGASA-N Glu-Val-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCC(O)=O SOYWRINXUSUWEQ-DLOVCJGASA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- PYTZFYUXZZHOAD-WHFBIAKZSA-N Gly-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)CN PYTZFYUXZZHOAD-WHFBIAKZSA-N 0.000 description 1
- YMUFWNJHVPQNQD-ZKWXMUAHSA-N Gly-Ala-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)CN YMUFWNJHVPQNQD-ZKWXMUAHSA-N 0.000 description 1
- JXYMPBCYRKWJEE-BQBZGAKWSA-N Gly-Arg-Ala Chemical compound [H]NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O JXYMPBCYRKWJEE-BQBZGAKWSA-N 0.000 description 1
- OCQUNKSFDYDXBG-QXEWZRGKSA-N Gly-Arg-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCN=C(N)N OCQUNKSFDYDXBG-QXEWZRGKSA-N 0.000 description 1
- KRRMJKMGWWXWDW-STQMWFEESA-N Gly-Arg-Phe Chemical compound NC(=N)NCCC[C@H](NC(=O)CN)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 KRRMJKMGWWXWDW-STQMWFEESA-N 0.000 description 1
- VXKCPBPQEKKERH-IUCAKERBSA-N Gly-Arg-Pro Chemical compound NC(N)=NCCC[C@H](NC(=O)CN)C(=O)N1CCC[C@H]1C(O)=O VXKCPBPQEKKERH-IUCAKERBSA-N 0.000 description 1
- KKBWDNZXYLGJEY-UHFFFAOYSA-N Gly-Arg-Pro Natural products NCC(=O)NC(CCNC(=N)N)C(=O)N1CCCC1C(=O)O KKBWDNZXYLGJEY-UHFFFAOYSA-N 0.000 description 1
- FMNHBTKMRFVGRO-FOHZUACHSA-N Gly-Asn-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CN FMNHBTKMRFVGRO-FOHZUACHSA-N 0.000 description 1
- IXKRSKPKSLXIHN-YUMQZZPRSA-N Gly-Cys-Leu Chemical compound [H]NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(O)=O IXKRSKPKSLXIHN-YUMQZZPRSA-N 0.000 description 1
- LGQZOQRDEUIZJY-YUMQZZPRSA-N Gly-Cys-Lys Chemical compound NCCCC[C@H](NC(=O)[C@H](CS)NC(=O)CN)C(O)=O LGQZOQRDEUIZJY-YUMQZZPRSA-N 0.000 description 1
- PABFFPWEJMEVEC-JGVFFNPUSA-N Gly-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)CN)C(=O)O PABFFPWEJMEVEC-JGVFFNPUSA-N 0.000 description 1
- CCQOOWAONKGYKQ-BYPYZUCNSA-N Gly-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)CN CCQOOWAONKGYKQ-BYPYZUCNSA-N 0.000 description 1
- KMSGYZQRXPUKGI-BYPYZUCNSA-N Gly-Gly-Asn Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CC(N)=O KMSGYZQRXPUKGI-BYPYZUCNSA-N 0.000 description 1
- BHPQOIPBLYJNAW-NGZCFLSTSA-N Gly-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN BHPQOIPBLYJNAW-NGZCFLSTSA-N 0.000 description 1
- TWTPDFFBLQEBOE-IUCAKERBSA-N Gly-Leu-Gln Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O TWTPDFFBLQEBOE-IUCAKERBSA-N 0.000 description 1
- LIXWIUAORXJNBH-QWRGUYRKSA-N Gly-Leu-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)CN LIXWIUAORXJNBH-QWRGUYRKSA-N 0.000 description 1
- LOEANKRDMMVOGZ-YUMQZZPRSA-N Gly-Lys-Asp Chemical compound NCCCC[C@H](NC(=O)CN)C(=O)N[C@@H](CC(O)=O)C(O)=O LOEANKRDMMVOGZ-YUMQZZPRSA-N 0.000 description 1
- GMTXWRIDLGTVFC-IUCAKERBSA-N Gly-Lys-Glu Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O GMTXWRIDLGTVFC-IUCAKERBSA-N 0.000 description 1
- PDUHNKAFQXQNLH-ZETCQYMHSA-N Gly-Lys-Gly Chemical compound NCCCC[C@H](NC(=O)CN)C(=O)NCC(O)=O PDUHNKAFQXQNLH-ZETCQYMHSA-N 0.000 description 1
- HHRODZSXDXMUHS-LURJTMIESA-N Gly-Met-Gly Chemical compound CSCC[C@H](NC(=O)C[NH3+])C(=O)NCC([O-])=O HHRODZSXDXMUHS-LURJTMIESA-N 0.000 description 1
- LPHQAFLNEHWKFF-QXEWZRGKSA-N Gly-Met-Ile Chemical compound [H]NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O LPHQAFLNEHWKFF-QXEWZRGKSA-N 0.000 description 1
- 108010009504 Gly-Phe-Leu-Gly Proteins 0.000 description 1
- OHUKZZYSJBKFRR-WHFBIAKZSA-N Gly-Ser-Asp Chemical compound [H]NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O OHUKZZYSJBKFRR-WHFBIAKZSA-N 0.000 description 1
- JSLVAHYTAJJEQH-QWRGUYRKSA-N Gly-Ser-Phe Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 JSLVAHYTAJJEQH-QWRGUYRKSA-N 0.000 description 1
- ABPRMMYHROQBLY-NKWVEPMBSA-N Gly-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)CN)C(=O)O ABPRMMYHROQBLY-NKWVEPMBSA-N 0.000 description 1
- WCORRBXVISTKQL-WHFBIAKZSA-N Gly-Ser-Ser Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O WCORRBXVISTKQL-WHFBIAKZSA-N 0.000 description 1
- ZLCLYFGMKFCDCN-XPUUQOCRSA-N Gly-Ser-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CO)NC(=O)CN)C(O)=O ZLCLYFGMKFCDCN-XPUUQOCRSA-N 0.000 description 1
- YXTFLTJYLIAZQG-FJXKBIBVSA-N Gly-Thr-Arg Chemical compound NCC(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N YXTFLTJYLIAZQG-FJXKBIBVSA-N 0.000 description 1
- KOYUSMBPJOVSOO-XEGUGMAKSA-N Gly-Tyr-Ile Chemical compound [H]NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KOYUSMBPJOVSOO-XEGUGMAKSA-N 0.000 description 1
- DNVDEMWIYLVIQU-RCOVLWMOSA-N Gly-Val-Asp Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O DNVDEMWIYLVIQU-RCOVLWMOSA-N 0.000 description 1
- FULZDMOZUZKGQU-ONGXEEELSA-N Gly-Val-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)CN FULZDMOZUZKGQU-ONGXEEELSA-N 0.000 description 1
- MUGLKCQHTUFLGF-WPRPVWTQSA-N Gly-Val-Met Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)O)NC(=O)CN MUGLKCQHTUFLGF-WPRPVWTQSA-N 0.000 description 1
- IZVICCORZOSGPT-JSGCOSHPSA-N Gly-Val-Tyr Chemical compound [H]NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O IZVICCORZOSGPT-JSGCOSHPSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- PROLDOGUBQJNPG-RWMBFGLXSA-N His-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC2=CN=CN2)N)C(=O)O PROLDOGUBQJNPG-RWMBFGLXSA-N 0.000 description 1
- AAXMRLWFJFDYQO-GUBZILKMSA-N His-Asp-Gln Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O AAXMRLWFJFDYQO-GUBZILKMSA-N 0.000 description 1
- NELVFWFDOKRTOR-SDDRHHMPSA-N His-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC2=CN=CN2)N)C(=O)O NELVFWFDOKRTOR-SDDRHHMPSA-N 0.000 description 1
- IMPKSPYRPUXYAP-SZMVWBNQSA-N His-Gln-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC3=CN=CN3)N IMPKSPYRPUXYAP-SZMVWBNQSA-N 0.000 description 1
- AKEDPWJFQULLPE-IUCAKERBSA-N His-Glu-Gly Chemical compound N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O AKEDPWJFQULLPE-IUCAKERBSA-N 0.000 description 1
- QPSCMXDWVKWVOW-BZSNNMDCSA-N His-His-Tyr Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O QPSCMXDWVKWVOW-BZSNNMDCSA-N 0.000 description 1
- YAALVYQFVJNXIV-KKUMJFAQSA-N His-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CN=CN1 YAALVYQFVJNXIV-KKUMJFAQSA-N 0.000 description 1
- BKOVCRUIXDIWFV-IXOXFDKPSA-N His-Lys-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC1=CN=CN1 BKOVCRUIXDIWFV-IXOXFDKPSA-N 0.000 description 1
- SLFSYFJKSIVSON-SRVKXCTJSA-N His-Met-Glu Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N SLFSYFJKSIVSON-SRVKXCTJSA-N 0.000 description 1
- FJCGVRRVBKYYOU-DCAQKATOSA-N His-Met-Ser Chemical compound CSCC[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N FJCGVRRVBKYYOU-DCAQKATOSA-N 0.000 description 1
- PFOUFRJYHWZJKW-NKIYYHGXSA-N His-Thr-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N)O PFOUFRJYHWZJKW-NKIYYHGXSA-N 0.000 description 1
- FOCSWPCHUDVNLP-PMVMPFDFSA-N His-Trp-Tyr Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)O)NC(=O)[C@H](CC4=CN=CN4)N FOCSWPCHUDVNLP-PMVMPFDFSA-N 0.000 description 1
- DAKSMIWQZPHRIB-BZSNNMDCSA-N His-Tyr-Leu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(O)=O DAKSMIWQZPHRIB-BZSNNMDCSA-N 0.000 description 1
- KDDKJKKQODQQBR-NHCYSSNCSA-N His-Val-Asp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N KDDKJKKQODQQBR-NHCYSSNCSA-N 0.000 description 1
- SYPULFZAGBBIOM-GVXVVHGQSA-N His-Val-Glu Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CC1=CN=CN1)N SYPULFZAGBBIOM-GVXVVHGQSA-N 0.000 description 1
- 101000616698 Homo sapiens CMP-N-acetylneuraminate-poly-alpha-2,8-sialyltransferase Proteins 0.000 description 1
- 101000740205 Homo sapiens Sal-like protein 1 Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- JXUGDUWBMKIJDC-NAKRPEOUSA-N Ile-Ala-Arg Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O JXUGDUWBMKIJDC-NAKRPEOUSA-N 0.000 description 1
- BOTVMTSMOUSDRW-GMOBBJLQSA-N Ile-Arg-Asn Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(N)=O)C(O)=O BOTVMTSMOUSDRW-GMOBBJLQSA-N 0.000 description 1
- QYZYJFXHXYUZMZ-UGYAYLCHSA-N Ile-Asn-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)O)N QYZYJFXHXYUZMZ-UGYAYLCHSA-N 0.000 description 1
- NKRJALPCDNXULF-BYULHYEWSA-N Ile-Asp-Gly Chemical compound [H]N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O NKRJALPCDNXULF-BYULHYEWSA-N 0.000 description 1
- DFJJAVZIHDFOGQ-MNXVOIDGSA-N Ile-Glu-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N DFJJAVZIHDFOGQ-MNXVOIDGSA-N 0.000 description 1
- CDGLBYSAZFIIJO-RCOVLWMOSA-N Ile-Gly-Gly Chemical compound CC[C@H](C)[C@H]([NH3+])C(=O)NCC(=O)NCC([O-])=O CDGLBYSAZFIIJO-RCOVLWMOSA-N 0.000 description 1
- URWXDJAEEGBADB-TUBUOCAGSA-N Ile-His-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)N URWXDJAEEGBADB-TUBUOCAGSA-N 0.000 description 1
- GVKKVHNRTUFCCE-BJDJZHNGSA-N Ile-Leu-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)O)N GVKKVHNRTUFCCE-BJDJZHNGSA-N 0.000 description 1
- NPAYJTAXWXJKLO-NAKRPEOUSA-N Ile-Met-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)O)N NPAYJTAXWXJKLO-NAKRPEOUSA-N 0.000 description 1
- QQFSKBMCAKWHLG-UHFFFAOYSA-N Ile-Phe-Pro-Pro Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(NC(=O)C(N)C(C)CC)CC1=CC=CC=C1 QQFSKBMCAKWHLG-UHFFFAOYSA-N 0.000 description 1
- IVXJIMGDOYRLQU-XUXIUFHCSA-N Ile-Pro-Leu Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O IVXJIMGDOYRLQU-XUXIUFHCSA-N 0.000 description 1
- FQYQMFCIJNWDQZ-CYDGBPFRSA-N Ile-Pro-Pro Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 FQYQMFCIJNWDQZ-CYDGBPFRSA-N 0.000 description 1
- CAHCWMVNBZJVAW-NAKRPEOUSA-N Ile-Pro-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)O)N CAHCWMVNBZJVAW-NAKRPEOUSA-N 0.000 description 1
- AKQFLPNANHNTLP-VKOGCVSHSA-N Ile-Pro-Trp Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)O)N AKQFLPNANHNTLP-VKOGCVSHSA-N 0.000 description 1
- JZNVOBUNTWNZPW-GHCJXIJMSA-N Ile-Ser-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)O)N JZNVOBUNTWNZPW-GHCJXIJMSA-N 0.000 description 1
- FBGXMKUWQFPHFB-JBDRJPRFSA-N Ile-Ser-Cys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N FBGXMKUWQFPHFB-JBDRJPRFSA-N 0.000 description 1
- SAEWJTCJQVZQNZ-IUKAMOBKSA-N Ile-Thr-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N SAEWJTCJQVZQNZ-IUKAMOBKSA-N 0.000 description 1
- NAFIFZNBSPWYOO-RWRJDSDZSA-N Ile-Thr-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N NAFIFZNBSPWYOO-RWRJDSDZSA-N 0.000 description 1
- QGXQHJQPAPMACW-PPCPHDFISA-N Ile-Thr-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)O)N QGXQHJQPAPMACW-PPCPHDFISA-N 0.000 description 1
- WCNWGAUZWWSYDG-SVSWQMSJSA-N Ile-Thr-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)O)N WCNWGAUZWWSYDG-SVSWQMSJSA-N 0.000 description 1
- NURNJECQNNCRBK-FLBSBUHZSA-N Ile-Thr-Thr Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O NURNJECQNNCRBK-FLBSBUHZSA-N 0.000 description 1
- REXAUQBGSGDEJY-IGISWZIWSA-N Ile-Tyr-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N REXAUQBGSGDEJY-IGISWZIWSA-N 0.000 description 1
- ZGKVPOSSTGHJAF-HJPIBITLSA-N Ile-Tyr-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CO)C(=O)O)N ZGKVPOSSTGHJAF-HJPIBITLSA-N 0.000 description 1
- NJGXXYLPDMMFJB-XUXIUFHCSA-N Ile-Val-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N NJGXXYLPDMMFJB-XUXIUFHCSA-N 0.000 description 1
- RQZFWBLDTBDEOF-RNJOBUHISA-N Ile-Val-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N RQZFWBLDTBDEOF-RNJOBUHISA-N 0.000 description 1
- 235000003332 Ilex aquifolium Nutrition 0.000 description 1
- 241000209027 Ilex aquifolium Species 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
- 108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- RCFDOSNHHZGBOY-UHFFFAOYSA-N L-isoleucyl-L-alanine Natural products CCC(C)C(N)C(=O)NC(C)C(O)=O RCFDOSNHHZGBOY-UHFFFAOYSA-N 0.000 description 1
- KFKWRHQBZQICHA-STQMWFEESA-N L-leucyl-L-phenylalanine Natural products CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 KFKWRHQBZQICHA-STQMWFEESA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- BQSLGJHIAGOZCD-CIUDSAMLSA-N Leu-Ala-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O BQSLGJHIAGOZCD-CIUDSAMLSA-N 0.000 description 1
- IBMVEYRWAWIOTN-RWMBFGLXSA-N Leu-Arg-Pro Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@@H]1C(O)=O IBMVEYRWAWIOTN-RWMBFGLXSA-N 0.000 description 1
- OGCQGUIWMSBHRZ-CIUDSAMLSA-N Leu-Asn-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O OGCQGUIWMSBHRZ-CIUDSAMLSA-N 0.000 description 1
- PPBKJAQJAUHZKX-SRVKXCTJSA-N Leu-Cys-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@H](C(O)=O)CC(C)C PPBKJAQJAUHZKX-SRVKXCTJSA-N 0.000 description 1
- YORLGJINWYYIMX-KKUMJFAQSA-N Leu-Cys-Phe Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O YORLGJINWYYIMX-KKUMJFAQSA-N 0.000 description 1
- VPKIQULSKFVCSM-SRVKXCTJSA-N Leu-Gln-Arg Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O VPKIQULSKFVCSM-SRVKXCTJSA-N 0.000 description 1
- KUEVMUXNILMJTK-JYJNAYRXSA-N Leu-Gln-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 KUEVMUXNILMJTK-JYJNAYRXSA-N 0.000 description 1
- PRZVBIAOPFGAQF-SRVKXCTJSA-N Leu-Glu-Met Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(O)=O PRZVBIAOPFGAQF-SRVKXCTJSA-N 0.000 description 1
- POZULHZYLPGXMR-ONGXEEELSA-N Leu-Gly-Val Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O POZULHZYLPGXMR-ONGXEEELSA-N 0.000 description 1
- KXODZBLFVFSLAI-AVGNSLFASA-N Leu-His-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(C)C)CC1=CN=CN1 KXODZBLFVFSLAI-AVGNSLFASA-N 0.000 description 1
- LKXANTUNFMVCNF-IHPCNDPISA-N Leu-His-Trp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O LKXANTUNFMVCNF-IHPCNDPISA-N 0.000 description 1
- HRTRLSRYZZKPCO-BJDJZHNGSA-N Leu-Ile-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O HRTRLSRYZZKPCO-BJDJZHNGSA-N 0.000 description 1
- QNBVTHNJGCOVFA-AVGNSLFASA-N Leu-Leu-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCC(O)=O QNBVTHNJGCOVFA-AVGNSLFASA-N 0.000 description 1
- JLWZLIQRYCTYBD-IHRRRGAJSA-N Leu-Lys-Arg Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O JLWZLIQRYCTYBD-IHRRRGAJSA-N 0.000 description 1
- VCHVSKNMTXWIIP-SRVKXCTJSA-N Leu-Lys-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O VCHVSKNMTXWIIP-SRVKXCTJSA-N 0.000 description 1
- HDHQQEDVWQGBEE-DCAQKATOSA-N Leu-Met-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(O)=O HDHQQEDVWQGBEE-DCAQKATOSA-N 0.000 description 1
- ZAVCJRJOQKIOJW-KKUMJFAQSA-N Leu-Phe-Asp Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CC(O)=O)C(O)=O)CC1=CC=CC=C1 ZAVCJRJOQKIOJW-KKUMJFAQSA-N 0.000 description 1
- YUTNOGOMBNYPFH-XUXIUFHCSA-N Leu-Pro-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(O)=O YUTNOGOMBNYPFH-XUXIUFHCSA-N 0.000 description 1
- SBANPBVRHYIMRR-UHFFFAOYSA-N Leu-Ser-Pro Natural products CC(C)CC(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O SBANPBVRHYIMRR-UHFFFAOYSA-N 0.000 description 1
- QWWPYKKLXWOITQ-VOAKCMCISA-N Leu-Thr-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(C)C QWWPYKKLXWOITQ-VOAKCMCISA-N 0.000 description 1
- KLSUAWUZBMAZCL-RHYQMDGZSA-N Leu-Thr-Pro Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(O)=O KLSUAWUZBMAZCL-RHYQMDGZSA-N 0.000 description 1
- RNYLNYTYMXACRI-VFAJRCTISA-N Leu-Thr-Trp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O RNYLNYTYMXACRI-VFAJRCTISA-N 0.000 description 1
- AIQWYVFNBNNOLU-RHYQMDGZSA-N Leu-Thr-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O AIQWYVFNBNNOLU-RHYQMDGZSA-N 0.000 description 1
- JGKHAFUAPZCCDU-BZSNNMDCSA-N Leu-Tyr-Leu Chemical compound CC(C)C[C@H]([NH3+])C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C([O-])=O)CC1=CC=C(O)C=C1 JGKHAFUAPZCCDU-BZSNNMDCSA-N 0.000 description 1
- YIRIDPUGZKHMHT-ACRUOGEOSA-N Leu-Tyr-Tyr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O YIRIDPUGZKHMHT-ACRUOGEOSA-N 0.000 description 1
- TUIOUEWKFFVNLH-DCAQKATOSA-N Leu-Val-Cys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(O)=O TUIOUEWKFFVNLH-DCAQKATOSA-N 0.000 description 1
- LMDVGHQPPPLYAR-IHRRRGAJSA-N Leu-Val-His Chemical compound N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)O LMDVGHQPPPLYAR-IHRRRGAJSA-N 0.000 description 1
- 102000019298 Lipocalin Human genes 0.000 description 1
- 108050006654 Lipocalin Proteins 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- KCXUCYYZNZFGLL-SRVKXCTJSA-N Lys-Ala-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O KCXUCYYZNZFGLL-SRVKXCTJSA-N 0.000 description 1
- IXHKPDJKKCUKHS-GARJFASQSA-N Lys-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCCN)N IXHKPDJKKCUKHS-GARJFASQSA-N 0.000 description 1
- KNKHAVVBVXKOGX-JXUBOQSCSA-N Lys-Ala-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KNKHAVVBVXKOGX-JXUBOQSCSA-N 0.000 description 1
- YNNPKXBBRZVIRX-IHRRRGAJSA-N Lys-Arg-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O YNNPKXBBRZVIRX-IHRRRGAJSA-N 0.000 description 1
- NTSPQIONFJUMJV-AVGNSLFASA-N Lys-Arg-Val Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(O)=O NTSPQIONFJUMJV-AVGNSLFASA-N 0.000 description 1
- YKIRNDPUWONXQN-GUBZILKMSA-N Lys-Asn-Gln Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N YKIRNDPUWONXQN-GUBZILKMSA-N 0.000 description 1
- QUCDKEKDPYISNX-HJGDQZAQSA-N Lys-Asn-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QUCDKEKDPYISNX-HJGDQZAQSA-N 0.000 description 1
- QUYCUALODHJQLK-CIUDSAMLSA-N Lys-Asp-Asp Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O QUYCUALODHJQLK-CIUDSAMLSA-N 0.000 description 1
- ZXEUFAVXODIPHC-GUBZILKMSA-N Lys-Glu-Asn Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O ZXEUFAVXODIPHC-GUBZILKMSA-N 0.000 description 1
- OVAOHZIOUBEQCJ-IHRRRGAJSA-N Lys-Leu-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O OVAOHZIOUBEQCJ-IHRRRGAJSA-N 0.000 description 1
- WRODMZBHNNPRLN-SRVKXCTJSA-N Lys-Leu-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O WRODMZBHNNPRLN-SRVKXCTJSA-N 0.000 description 1
- LUTDBHBIHHREDC-IHRRRGAJSA-N Lys-Pro-Lys Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(O)=O LUTDBHBIHHREDC-IHRRRGAJSA-N 0.000 description 1
- LOGFVTREOLYCPF-RHYQMDGZSA-N Lys-Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-RHYQMDGZSA-N 0.000 description 1
- MGKFCQFVPKOWOL-CIUDSAMLSA-N Lys-Ser-Asp Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)O)N MGKFCQFVPKOWOL-CIUDSAMLSA-N 0.000 description 1
- SBQDRNOLGSYHQA-YUMQZZPRSA-N Lys-Ser-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SBQDRNOLGSYHQA-YUMQZZPRSA-N 0.000 description 1
- LKDXINHHSWFFJC-SRVKXCTJSA-N Lys-Ser-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)N LKDXINHHSWFFJC-SRVKXCTJSA-N 0.000 description 1
- JOSAKOKSPXROGQ-BJDJZHNGSA-N Lys-Ser-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JOSAKOKSPXROGQ-BJDJZHNGSA-N 0.000 description 1
- IOQWIOPSKJOEKI-SRVKXCTJSA-N Lys-Ser-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O IOQWIOPSKJOEKI-SRVKXCTJSA-N 0.000 description 1
- WZVSHTFTCYOFPL-GARJFASQSA-N Lys-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CCCCN)N)C(=O)O WZVSHTFTCYOFPL-GARJFASQSA-N 0.000 description 1
- DIBZLYZXTSVGLN-CIUDSAMLSA-N Lys-Ser-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O DIBZLYZXTSVGLN-CIUDSAMLSA-N 0.000 description 1
- MIFFFXHMAHFACR-KATARQTJSA-N Lys-Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CCCCN MIFFFXHMAHFACR-KATARQTJSA-N 0.000 description 1
- PLOUVAYOMTYJRG-JXUBOQSCSA-N Lys-Thr-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O PLOUVAYOMTYJRG-JXUBOQSCSA-N 0.000 description 1
- TVOOGUNBIWAURO-KATARQTJSA-N Lys-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCCCN)N)O TVOOGUNBIWAURO-KATARQTJSA-N 0.000 description 1
- RPWTZTBIFGENIA-VOAKCMCISA-N Lys-Thr-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O RPWTZTBIFGENIA-VOAKCMCISA-N 0.000 description 1
- YKBSXQFZWFXFIB-VOAKCMCISA-N Lys-Thr-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CCCCN)C(O)=O YKBSXQFZWFXFIB-VOAKCMCISA-N 0.000 description 1
- YUTZYVTZDVZBJJ-IHPCNDPISA-N Lys-Trp-Lys Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O)=CNC2=C1 YUTZYVTZDVZBJJ-IHPCNDPISA-N 0.000 description 1
- UGCIQUYEJIEHKX-GVXVVHGQSA-N Lys-Val-Glu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O UGCIQUYEJIEHKX-GVXVVHGQSA-N 0.000 description 1
- RIPJMCFGQHGHNP-RHYQMDGZSA-N Lys-Val-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCCN)N)O RIPJMCFGQHGHNP-RHYQMDGZSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- DNDVVILEHVMWIS-LPEHRKFASA-N Met-Asp-Pro Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N DNDVVILEHVMWIS-LPEHRKFASA-N 0.000 description 1
- VOOINLQYUZOREH-SRVKXCTJSA-N Met-Gln-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCSC)N VOOINLQYUZOREH-SRVKXCTJSA-N 0.000 description 1
- SJDQOYTYNGZZJX-SRVKXCTJSA-N Met-Glu-Leu Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O SJDQOYTYNGZZJX-SRVKXCTJSA-N 0.000 description 1
- JPCHYAUKOUGOIB-HJGDQZAQSA-N Met-Glu-Thr Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O JPCHYAUKOUGOIB-HJGDQZAQSA-N 0.000 description 1
- BMHIFARYXOJDLD-WPRPVWTQSA-N Met-Gly-Val Chemical compound [H]N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O BMHIFARYXOJDLD-WPRPVWTQSA-N 0.000 description 1
- FGAMAYQCWQCUNF-DCAQKATOSA-N Met-His-Asn Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC(=O)N)C(=O)O)N FGAMAYQCWQCUNF-DCAQKATOSA-N 0.000 description 1
- CFRRIZLGFGJEDB-SRVKXCTJSA-N Met-His-Gln Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(N)=O)C(O)=O CFRRIZLGFGJEDB-SRVKXCTJSA-N 0.000 description 1
- JHDNAOVJJQSMMM-GMOBBJLQSA-N Met-Ile-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CCSC)N JHDNAOVJJQSMMM-GMOBBJLQSA-N 0.000 description 1
- WRXOPYNEKGZWAZ-FXQIFTODSA-N Met-Ser-Cys Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(O)=O WRXOPYNEKGZWAZ-FXQIFTODSA-N 0.000 description 1
- LHXFNWBNRBWMNV-DCAQKATOSA-N Met-Ser-His Chemical compound CSCC[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N LHXFNWBNRBWMNV-DCAQKATOSA-N 0.000 description 1
- SMVTWPOATVIXTN-NAKRPEOUSA-N Met-Ser-Ile Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O SMVTWPOATVIXTN-NAKRPEOUSA-N 0.000 description 1
- RIIFMEBFDDXGCV-VEVYYDQMSA-N Met-Thr-Asn Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(N)=O RIIFMEBFDDXGCV-VEVYYDQMSA-N 0.000 description 1
- ATBJCCFCJXCNGZ-UFYCRDLUSA-N Met-Tyr-Phe Chemical compound C([C@H](NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 ATBJCCFCJXCNGZ-UFYCRDLUSA-N 0.000 description 1
- 101100370002 Mus musculus Tnfsf14 gene Proteins 0.000 description 1
- WUGMRIBZSVSJNP-UHFFFAOYSA-N N-L-alanyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C)C(O)=O)=CNC2=C1 WUGMRIBZSVSJNP-UHFFFAOYSA-N 0.000 description 1
- WYBVBIHNJWOLCJ-UHFFFAOYSA-N N-L-arginyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCCN=C(N)N WYBVBIHNJWOLCJ-UHFFFAOYSA-N 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 108010065395 Neuropep-1 Proteins 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- JEGFCFLCRSJCMA-IHRRRGAJSA-N Phe-Arg-Ser Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(=O)O)N JEGFCFLCRSJCMA-IHRRRGAJSA-N 0.000 description 1
- CDNPIRSCAFMMBE-SRVKXCTJSA-N Phe-Asn-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O CDNPIRSCAFMMBE-SRVKXCTJSA-N 0.000 description 1
- IUVYJBMTHARMIP-PCBIJLKTSA-N Phe-Asp-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O IUVYJBMTHARMIP-PCBIJLKTSA-N 0.000 description 1
- LLGTYVHITPVGKR-RYUDHWBXSA-N Phe-Gln-Gly Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O LLGTYVHITPVGKR-RYUDHWBXSA-N 0.000 description 1
- OPEVYHFJXLCCRT-AVGNSLFASA-N Phe-Gln-Ser Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O OPEVYHFJXLCCRT-AVGNSLFASA-N 0.000 description 1
- YYKZDTVQHTUKDW-RYUDHWBXSA-N Phe-Gly-Gln Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)NCC(=O)N[C@@H](CCC(=O)N)C(=O)O)N YYKZDTVQHTUKDW-RYUDHWBXSA-N 0.000 description 1
- VJLLEKDQJSMHRU-STQMWFEESA-N Phe-Gly-Met Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)N[C@@H](CCSC)C(O)=O VJLLEKDQJSMHRU-STQMWFEESA-N 0.000 description 1
- CJAHQEZWDZNSJO-KKUMJFAQSA-N Phe-Lys-Cys Chemical compound NCCCC[C@@H](C(=O)N[C@@H](CS)C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 CJAHQEZWDZNSJO-KKUMJFAQSA-N 0.000 description 1
- SZYBZVANEAOIPE-UBHSHLNASA-N Phe-Met-Ala Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(O)=O SZYBZVANEAOIPE-UBHSHLNASA-N 0.000 description 1
- JLLJTMHNXQTMCK-UBHSHLNASA-N Phe-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC1=CC=CC=C1 JLLJTMHNXQTMCK-UBHSHLNASA-N 0.000 description 1
- QSWKNJAPHQDAAS-MELADBBJSA-N Phe-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CC2=CC=CC=C2)N)C(=O)O QSWKNJAPHQDAAS-MELADBBJSA-N 0.000 description 1
- YDUGVDGFKNXFPL-IXOXFDKPSA-N Phe-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N)O YDUGVDGFKNXFPL-IXOXFDKPSA-N 0.000 description 1
- MSSXKZBDKZAHCX-UNQGMJICSA-N Phe-Thr-Val Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O MSSXKZBDKZAHCX-UNQGMJICSA-N 0.000 description 1
- ZVJGAXNBBKPYOE-HKUYNNGSSA-N Phe-Trp-Gly Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(O)=O)C1=CC=CC=C1 ZVJGAXNBBKPYOE-HKUYNNGSSA-N 0.000 description 1
- GAMLAXHLYGLQBJ-UFYCRDLUSA-N Phe-Val-Tyr Chemical compound N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)O)CC1=CC=C(C=C1)O)C(C)C)CC1=CC=CC=C1 GAMLAXHLYGLQBJ-UFYCRDLUSA-N 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- DBALDZKOTNSBFM-FXQIFTODSA-N Pro-Ala-Asn Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(O)=O DBALDZKOTNSBFM-FXQIFTODSA-N 0.000 description 1
- XQLBWXHVZVBNJM-FXQIFTODSA-N Pro-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 XQLBWXHVZVBNJM-FXQIFTODSA-N 0.000 description 1
- CYQQWUPHIZVCNY-GUBZILKMSA-N Pro-Arg-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O CYQQWUPHIZVCNY-GUBZILKMSA-N 0.000 description 1
- GDXZRWYXJSGWIV-GMOBBJLQSA-N Pro-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H]1CCCN1 GDXZRWYXJSGWIV-GMOBBJLQSA-N 0.000 description 1
- SFECXGVELZFBFJ-VEVYYDQMSA-N Pro-Asp-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SFECXGVELZFBFJ-VEVYYDQMSA-N 0.000 description 1
- GQLOZEMWEBDEAY-NAKRPEOUSA-N Pro-Cys-Ile Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O GQLOZEMWEBDEAY-NAKRPEOUSA-N 0.000 description 1
- MGDFPGCFVJFITQ-CIUDSAMLSA-N Pro-Glu-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O MGDFPGCFVJFITQ-CIUDSAMLSA-N 0.000 description 1
- VPEVBAUSTBWQHN-NHCYSSNCSA-N Pro-Glu-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O VPEVBAUSTBWQHN-NHCYSSNCSA-N 0.000 description 1
- UUHXBJHVTVGSKM-BQBZGAKWSA-N Pro-Gly-Asn Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O UUHXBJHVTVGSKM-BQBZGAKWSA-N 0.000 description 1
- HAAQQNHQZBOWFO-LURJTMIESA-N Pro-Gly-Gly Chemical compound OC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1 HAAQQNHQZBOWFO-LURJTMIESA-N 0.000 description 1
- CFVRJNZJQHDQPP-CYDGBPFRSA-N Pro-Ile-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]1CCCN1 CFVRJNZJQHDQPP-CYDGBPFRSA-N 0.000 description 1
- FMLRRBDLBJLJIK-DCAQKATOSA-N Pro-Leu-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1 FMLRRBDLBJLJIK-DCAQKATOSA-N 0.000 description 1
- SUENWIFTSTWUKD-AVGNSLFASA-N Pro-Leu-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O SUENWIFTSTWUKD-AVGNSLFASA-N 0.000 description 1
- JUJCUYWRJMFJJF-AVGNSLFASA-N Pro-Lys-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]1CCCN1 JUJCUYWRJMFJJF-AVGNSLFASA-N 0.000 description 1
- ZLXKLMHAMDENIO-DCAQKATOSA-N Pro-Lys-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O ZLXKLMHAMDENIO-DCAQKATOSA-N 0.000 description 1
- XQPHBAKJJJZOBX-SRVKXCTJSA-N Pro-Lys-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O XQPHBAKJJJZOBX-SRVKXCTJSA-N 0.000 description 1
- WLJYLAQSUSIQNH-GUBZILKMSA-N Pro-Met-Ser Chemical compound CSCC[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@@H]1CCCN1 WLJYLAQSUSIQNH-GUBZILKMSA-N 0.000 description 1
- LEIKGVHQTKHOLM-IUCAKERBSA-N Pro-Pro-Gly Chemical compound OC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 LEIKGVHQTKHOLM-IUCAKERBSA-N 0.000 description 1
- GMJDSFYVTAMIBF-FXQIFTODSA-N Pro-Ser-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O GMJDSFYVTAMIBF-FXQIFTODSA-N 0.000 description 1
- MKGIILKDUGDRRO-FXQIFTODSA-N Pro-Ser-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1 MKGIILKDUGDRRO-FXQIFTODSA-N 0.000 description 1
- FDMCIBSQRKFSTJ-RHYQMDGZSA-N Pro-Thr-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O FDMCIBSQRKFSTJ-RHYQMDGZSA-N 0.000 description 1
- AJJDPGVVNPUZCR-RHYQMDGZSA-N Pro-Thr-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@@H]1CCCN1)O AJJDPGVVNPUZCR-RHYQMDGZSA-N 0.000 description 1
- VVEQUISRWJDGMX-VKOGCVSHSA-N Pro-Trp-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@@H]3CCCN3 VVEQUISRWJDGMX-VKOGCVSHSA-N 0.000 description 1
- QKWYXRPICJEQAJ-KJEVXHAQSA-N Pro-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@@H]2CCCN2)O QKWYXRPICJEQAJ-KJEVXHAQSA-N 0.000 description 1
- STGVYUTZKGPRCI-GUBZILKMSA-N Pro-Val-Cys Chemical compound SC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CCCN1 STGVYUTZKGPRCI-GUBZILKMSA-N 0.000 description 1
- YDTUEBLEAVANFH-RCWTZXSCSA-N Pro-Val-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CCCN1 YDTUEBLEAVANFH-RCWTZXSCSA-N 0.000 description 1
- 102100027845 Pulmonary surfactant-associated protein D Human genes 0.000 description 1
- 101150090155 R gene Proteins 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 102100030852 Run domain Beclin-1-interacting and cysteine-rich domain-containing protein Human genes 0.000 description 1
- 102100037204 Sal-like protein 1 Human genes 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- ZUGXSSFMTXKHJS-ZLUOBGJFSA-N Ser-Ala-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O ZUGXSSFMTXKHJS-ZLUOBGJFSA-N 0.000 description 1
- WTWGOQRNRFHFQD-JBDRJPRFSA-N Ser-Ala-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WTWGOQRNRFHFQD-JBDRJPRFSA-N 0.000 description 1
- IDQFQFVEWMWRQQ-DLOVCJGASA-N Ser-Ala-Phe Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O IDQFQFVEWMWRQQ-DLOVCJGASA-N 0.000 description 1
- YQHZVYJAGWMHES-ZLUOBGJFSA-N Ser-Ala-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YQHZVYJAGWMHES-ZLUOBGJFSA-N 0.000 description 1
- JPIDMRXXNMIVKY-VZFHVOOUSA-N Ser-Ala-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O JPIDMRXXNMIVKY-VZFHVOOUSA-N 0.000 description 1
- QVOGDCQNGLBNCR-FXQIFTODSA-N Ser-Arg-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O QVOGDCQNGLBNCR-FXQIFTODSA-N 0.000 description 1
- BCKYYTVFBXHPOG-ACZMJKKPSA-N Ser-Asn-Gln Chemical compound C(CC(=O)N)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)N BCKYYTVFBXHPOG-ACZMJKKPSA-N 0.000 description 1
- CTLVSHXLRVEILB-UBHSHLNASA-N Ser-Asn-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)N CTLVSHXLRVEILB-UBHSHLNASA-N 0.000 description 1
- BGOWRLSWJCVYAQ-CIUDSAMLSA-N Ser-Asp-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O BGOWRLSWJCVYAQ-CIUDSAMLSA-N 0.000 description 1
- OLIJLNWFEQEFDM-SRVKXCTJSA-N Ser-Asp-Phe Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 OLIJLNWFEQEFDM-SRVKXCTJSA-N 0.000 description 1
- ULVMNZOKDBHKKI-ACZMJKKPSA-N Ser-Gln-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O ULVMNZOKDBHKKI-ACZMJKKPSA-N 0.000 description 1
- XWCYBVBLJRWOFR-WDSKDSINSA-N Ser-Gln-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O XWCYBVBLJRWOFR-WDSKDSINSA-N 0.000 description 1
- KJMOINFQVCCSDX-XKBZYTNZSA-N Ser-Gln-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KJMOINFQVCCSDX-XKBZYTNZSA-N 0.000 description 1
- VDVYTKZBMFADQH-AVGNSLFASA-N Ser-Gln-Tyr Chemical compound OC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 VDVYTKZBMFADQH-AVGNSLFASA-N 0.000 description 1
- PVDTYLHUWAEYGY-CIUDSAMLSA-N Ser-Glu-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O PVDTYLHUWAEYGY-CIUDSAMLSA-N 0.000 description 1
- SQBLRDDJTUJDMV-ACZMJKKPSA-N Ser-Glu-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O SQBLRDDJTUJDMV-ACZMJKKPSA-N 0.000 description 1
- HJEBZBMOTCQYDN-ACZMJKKPSA-N Ser-Glu-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O HJEBZBMOTCQYDN-ACZMJKKPSA-N 0.000 description 1
- YQQKYAZABFEYAF-FXQIFTODSA-N Ser-Glu-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O YQQKYAZABFEYAF-FXQIFTODSA-N 0.000 description 1
- GZBKRJVCRMZAST-XKBZYTNZSA-N Ser-Glu-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GZBKRJVCRMZAST-XKBZYTNZSA-N 0.000 description 1
- WBINSDOPZHQPPM-AVGNSLFASA-N Ser-Glu-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)N)O WBINSDOPZHQPPM-AVGNSLFASA-N 0.000 description 1
- BPMRXBZYPGYPJN-WHFBIAKZSA-N Ser-Gly-Asn Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(O)=O BPMRXBZYPGYPJN-WHFBIAKZSA-N 0.000 description 1
- GZFAWAQTEYDKII-YUMQZZPRSA-N Ser-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CO GZFAWAQTEYDKII-YUMQZZPRSA-N 0.000 description 1
- UAJAYRMZGNQILN-BQBZGAKWSA-N Ser-Gly-Met Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCSC)C(O)=O UAJAYRMZGNQILN-BQBZGAKWSA-N 0.000 description 1
- SFTZWNJFZYOLBD-ZDLURKLDSA-N Ser-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CO SFTZWNJFZYOLBD-ZDLURKLDSA-N 0.000 description 1
- CLKKNZQUQMZDGD-SRVKXCTJSA-N Ser-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)CC1=CN=CN1 CLKKNZQUQMZDGD-SRVKXCTJSA-N 0.000 description 1
- WEQAYODCJHZSJZ-KKUMJFAQSA-N Ser-His-Tyr Chemical compound C([C@H](NC(=O)[C@H](CO)N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CN=CN1 WEQAYODCJHZSJZ-KKUMJFAQSA-N 0.000 description 1
- LQESNKGTTNHZPZ-GHCJXIJMSA-N Ser-Ile-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(O)=O LQESNKGTTNHZPZ-GHCJXIJMSA-N 0.000 description 1
- MOINZPRHJGTCHZ-MMWGEVLESA-N Ser-Ile-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CO)N MOINZPRHJGTCHZ-MMWGEVLESA-N 0.000 description 1
- ZOPISOXXPQNOCO-SVSWQMSJSA-N Ser-Ile-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](CO)N ZOPISOXXPQNOCO-SVSWQMSJSA-N 0.000 description 1
- NLOAIFSWUUFQFR-CIUDSAMLSA-N Ser-Leu-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O NLOAIFSWUUFQFR-CIUDSAMLSA-N 0.000 description 1
- GJFYFGOEWLDQGW-GUBZILKMSA-N Ser-Leu-Gln Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CO)N GJFYFGOEWLDQGW-GUBZILKMSA-N 0.000 description 1
- GDUZTEQRAOXYJS-SRVKXCTJSA-N Ser-Phe-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CO)N GDUZTEQRAOXYJS-SRVKXCTJSA-N 0.000 description 1
- KZPRPBLHYMZIMH-MXAVVETBSA-N Ser-Phe-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KZPRPBLHYMZIMH-MXAVVETBSA-N 0.000 description 1
- PJIQEIFXZPCWOJ-FXQIFTODSA-N Ser-Pro-Asp Chemical compound [H]N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O PJIQEIFXZPCWOJ-FXQIFTODSA-N 0.000 description 1
- RHAPJNVNWDBFQI-BQBZGAKWSA-N Ser-Pro-Gly Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O RHAPJNVNWDBFQI-BQBZGAKWSA-N 0.000 description 1
- AZWNCEBQZXELEZ-FXQIFTODSA-N Ser-Pro-Ser Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O AZWNCEBQZXELEZ-FXQIFTODSA-N 0.000 description 1
- HHJFMHQYEAAOBM-ZLUOBGJFSA-N Ser-Ser-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O HHJFMHQYEAAOBM-ZLUOBGJFSA-N 0.000 description 1
- WLJPJRGQRNCIQS-ZLUOBGJFSA-N Ser-Ser-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O WLJPJRGQRNCIQS-ZLUOBGJFSA-N 0.000 description 1
- ILZAUMFXKSIUEF-SRVKXCTJSA-N Ser-Ser-Phe Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ILZAUMFXKSIUEF-SRVKXCTJSA-N 0.000 description 1
- JURQXQBJKUHGJS-UHFFFAOYSA-N Ser-Ser-Ser-Ser Chemical compound OCC(N)C(=O)NC(CO)C(=O)NC(CO)C(=O)NC(CO)C(O)=O JURQXQBJKUHGJS-UHFFFAOYSA-N 0.000 description 1
- XJDMUQCLVSCRSJ-VZFHVOOUSA-N Ser-Thr-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O XJDMUQCLVSCRSJ-VZFHVOOUSA-N 0.000 description 1
- PCJLFYBAQZQOFE-KATARQTJSA-N Ser-Thr-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CO)N)O PCJLFYBAQZQOFE-KATARQTJSA-N 0.000 description 1
- SNXUIBACCONSOH-BWBBJGPYSA-N Ser-Thr-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CO)C(O)=O SNXUIBACCONSOH-BWBBJGPYSA-N 0.000 description 1
- UBTNVMGPMYDYIU-HJPIBITLSA-N Ser-Tyr-Ile Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O UBTNVMGPMYDYIU-HJPIBITLSA-N 0.000 description 1
- YXGCIEUDOHILKR-IHRRRGAJSA-N Ser-Tyr-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CO)N YXGCIEUDOHILKR-IHRRRGAJSA-N 0.000 description 1
- IAOHCSQDQDWRQU-GUBZILKMSA-N Ser-Val-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O IAOHCSQDQDWRQU-GUBZILKMSA-N 0.000 description 1
- HNDMFDBQXYZSRM-IHRRRGAJSA-N Ser-Val-Phe Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O HNDMFDBQXYZSRM-IHRRRGAJSA-N 0.000 description 1
- JGUWRQWULDWNCM-FXQIFTODSA-N Ser-Val-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O JGUWRQWULDWNCM-FXQIFTODSA-N 0.000 description 1
- SIEBDTCABMZCLF-XGEHTFHBSA-N Ser-Val-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SIEBDTCABMZCLF-XGEHTFHBSA-N 0.000 description 1
- ODRUTDLAONAVDV-IHRRRGAJSA-N Ser-Val-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ODRUTDLAONAVDV-IHRRRGAJSA-N 0.000 description 1
- HSWXBJCBYSWBPT-GUBZILKMSA-N Ser-Val-Val Chemical compound CC(C)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)C(O)=O HSWXBJCBYSWBPT-GUBZILKMSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 101800001707 Spacer peptide Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- NJEMRSFGDNECGF-GCJQMDKQSA-N Thr-Ala-Asp Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC(O)=O NJEMRSFGDNECGF-GCJQMDKQSA-N 0.000 description 1
- LVHHEVGYAZGXDE-KDXUFGMBSA-N Thr-Ala-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C)C(=O)N1CCC[C@@H]1C(=O)O)N)O LVHHEVGYAZGXDE-KDXUFGMBSA-N 0.000 description 1
- JNQZPAWOPBZGIX-RCWTZXSCSA-N Thr-Arg-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)[C@@H](C)O)CCCN=C(N)N JNQZPAWOPBZGIX-RCWTZXSCSA-N 0.000 description 1
- SKHPKKYKDYULDH-HJGDQZAQSA-N Thr-Asn-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O SKHPKKYKDYULDH-HJGDQZAQSA-N 0.000 description 1
- VXMHQKHDKCATDV-VEVYYDQMSA-N Thr-Asp-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O VXMHQKHDKCATDV-VEVYYDQMSA-N 0.000 description 1
- DCLBXIWHLVEPMQ-JRQIVUDYSA-N Thr-Asp-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 DCLBXIWHLVEPMQ-JRQIVUDYSA-N 0.000 description 1
- ODSAPYVQSLDRSR-LKXGYXEUSA-N Thr-Cys-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O ODSAPYVQSLDRSR-LKXGYXEUSA-N 0.000 description 1
- MMTOHPRBJKEZHT-BWBBJGPYSA-N Thr-Cys-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(O)=O MMTOHPRBJKEZHT-BWBBJGPYSA-N 0.000 description 1
- FHDLKMFZKRUQCE-HJGDQZAQSA-N Thr-Glu-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O FHDLKMFZKRUQCE-HJGDQZAQSA-N 0.000 description 1
- JMGJDTNUMAZNLX-RWRJDSDZSA-N Thr-Glu-Ile Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JMGJDTNUMAZNLX-RWRJDSDZSA-N 0.000 description 1
- HJOSVGCWOTYJFG-WDCWCFNPSA-N Thr-Glu-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N)O HJOSVGCWOTYJFG-WDCWCFNPSA-N 0.000 description 1
- OQCXTUQTKQFDCX-HTUGSXCWSA-N Thr-Glu-Phe Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N)O OQCXTUQTKQFDCX-HTUGSXCWSA-N 0.000 description 1
- QQWNRERCGGZOKG-WEDXCCLWSA-N Thr-Gly-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O QQWNRERCGGZOKG-WEDXCCLWSA-N 0.000 description 1
- BVOVIGCHYNFJBZ-JXUBOQSCSA-N Thr-Leu-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O BVOVIGCHYNFJBZ-JXUBOQSCSA-N 0.000 description 1
- HOVLHEKTGVIKAP-WDCWCFNPSA-N Thr-Leu-Gln Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O HOVLHEKTGVIKAP-WDCWCFNPSA-N 0.000 description 1
- VRUFCJZQDACGLH-UVOCVTCTSA-N Thr-Leu-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O VRUFCJZQDACGLH-UVOCVTCTSA-N 0.000 description 1
- KZSYAEWQMJEGRZ-RHYQMDGZSA-N Thr-Leu-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O KZSYAEWQMJEGRZ-RHYQMDGZSA-N 0.000 description 1
- ZSPQUTWLWGWTPS-HJGDQZAQSA-N Thr-Lys-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O ZSPQUTWLWGWTPS-HJGDQZAQSA-N 0.000 description 1
- QFEYTTHKPSOFLV-OSUNSFLBSA-N Thr-Met-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H]([C@@H](C)O)N QFEYTTHKPSOFLV-OSUNSFLBSA-N 0.000 description 1
- GUHLYMZJVXUIPO-RCWTZXSCSA-N Thr-Met-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(O)=O GUHLYMZJVXUIPO-RCWTZXSCSA-N 0.000 description 1
- WRQLCVIALDUQEQ-UNQGMJICSA-N Thr-Phe-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O WRQLCVIALDUQEQ-UNQGMJICSA-N 0.000 description 1
- WYLAVUAWOUVUCA-XVSYOHENSA-N Thr-Phe-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O WYLAVUAWOUVUCA-XVSYOHENSA-N 0.000 description 1
- ABWNZPOIUJMNKT-IXOXFDKPSA-N Thr-Phe-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(O)=O ABWNZPOIUJMNKT-IXOXFDKPSA-N 0.000 description 1
- KERCOYANYUPLHJ-XGEHTFHBSA-N Thr-Pro-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O KERCOYANYUPLHJ-XGEHTFHBSA-N 0.000 description 1
- STUAPCLEDMKXKL-LKXGYXEUSA-N Thr-Ser-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O STUAPCLEDMKXKL-LKXGYXEUSA-N 0.000 description 1
- IVDFVBVIVLJJHR-LKXGYXEUSA-N Thr-Ser-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O IVDFVBVIVLJJHR-LKXGYXEUSA-N 0.000 description 1
- SGAOHNPSEPVAFP-ZDLURKLDSA-N Thr-Ser-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SGAOHNPSEPVAFP-ZDLURKLDSA-N 0.000 description 1
- WPSKTVVMQCXPRO-BWBBJGPYSA-N Thr-Ser-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O WPSKTVVMQCXPRO-BWBBJGPYSA-N 0.000 description 1
- CSNBWOJOEOPYIJ-UVOCVTCTSA-N Thr-Thr-Lys Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(O)=O CSNBWOJOEOPYIJ-UVOCVTCTSA-N 0.000 description 1
- ZMYCLHFLHRVOEA-HEIBUPTGSA-N Thr-Thr-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O ZMYCLHFLHRVOEA-HEIBUPTGSA-N 0.000 description 1
- GRIUMVXCJDKVPI-IZPVPAKOSA-N Thr-Thr-Tyr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O GRIUMVXCJDKVPI-IZPVPAKOSA-N 0.000 description 1
- LECUEEHKUFYOOV-ZJDVBMNYSA-N Thr-Thr-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](N)[C@@H](C)O LECUEEHKUFYOOV-ZJDVBMNYSA-N 0.000 description 1
- VGNKUXWYFFDWDH-BEMMVCDISA-N Thr-Trp-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N3CCC[C@@H]3C(=O)O)N)O VGNKUXWYFFDWDH-BEMMVCDISA-N 0.000 description 1
- OGOYMQWIWHGTGH-KZVJFYERSA-N Thr-Val-Ala Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O OGOYMQWIWHGTGH-KZVJFYERSA-N 0.000 description 1
- FYBFTPLPAXZBOY-KKHAAJSZSA-N Thr-Val-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O FYBFTPLPAXZBOY-KKHAAJSZSA-N 0.000 description 1
- SPIFGZFZMVLPHN-UNQGMJICSA-N Thr-Val-Phe Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O SPIFGZFZMVLPHN-UNQGMJICSA-N 0.000 description 1
- KZTLZZQTJMCGIP-ZJDVBMNYSA-N Thr-Val-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KZTLZZQTJMCGIP-ZJDVBMNYSA-N 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- MHNHRNHJMXAVHZ-AAEUAGOBSA-N Trp-Asn-Gly Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)NCC(=O)O)N MHNHRNHJMXAVHZ-AAEUAGOBSA-N 0.000 description 1
- WPSYJHFHZYJXMW-JSGCOSHPSA-N Trp-Gln-Gly Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O WPSYJHFHZYJXMW-JSGCOSHPSA-N 0.000 description 1
- GQHAIUPYZPTADF-FDARSICLSA-N Trp-Ile-Arg Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)=CNC2=C1 GQHAIUPYZPTADF-FDARSICLSA-N 0.000 description 1
- ILDJYIDXESUBOE-HSCHXYMDSA-N Trp-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N ILDJYIDXESUBOE-HSCHXYMDSA-N 0.000 description 1
- NLLARHRWSFNEMH-NUTKFTJISA-N Trp-Lys-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N NLLARHRWSFNEMH-NUTKFTJISA-N 0.000 description 1
- UQHPXCFAHVTWFU-BVSLBCMMSA-N Trp-Phe-Val Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O UQHPXCFAHVTWFU-BVSLBCMMSA-N 0.000 description 1
- ARKBYVBCEOWRNR-UBHSHLNASA-N Trp-Ser-Ser Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O ARKBYVBCEOWRNR-UBHSHLNASA-N 0.000 description 1
- GSCPHMSPGQSZJT-JYBASQMISA-N Trp-Ser-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N)O GSCPHMSPGQSZJT-JYBASQMISA-N 0.000 description 1
- DDHFMBDACJYSKW-AQZXSJQPSA-N Trp-Thr-Asp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)N)O DDHFMBDACJYSKW-AQZXSJQPSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- NOXKHHXSHQFSGJ-FQPOAREZSA-N Tyr-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 NOXKHHXSHQFSGJ-FQPOAREZSA-N 0.000 description 1
- AKXBNSZMYAOGLS-STQMWFEESA-N Tyr-Arg-Gly Chemical compound NC(N)=NCCC[C@@H](C(=O)NCC(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 AKXBNSZMYAOGLS-STQMWFEESA-N 0.000 description 1
- IIJWXEUNETVJPV-IHRRRGAJSA-N Tyr-Arg-Ser Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(=O)O)N)O IIJWXEUNETVJPV-IHRRRGAJSA-N 0.000 description 1
- PEVVXUGSAKEPEN-AVGNSLFASA-N Tyr-Asn-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O PEVVXUGSAKEPEN-AVGNSLFASA-N 0.000 description 1
- QOEZFICGUZTRFX-IHRRRGAJSA-N Tyr-Cys-Val Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(O)=O QOEZFICGUZTRFX-IHRRRGAJSA-N 0.000 description 1
- FNWGDMZVYBVAGJ-XEGUGMAKSA-N Tyr-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC1=CC=C(C=C1)O)N FNWGDMZVYBVAGJ-XEGUGMAKSA-N 0.000 description 1
- DZKFGCNKEVMXFA-JUKXBJQTSA-N Tyr-Ile-His Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O DZKFGCNKEVMXFA-JUKXBJQTSA-N 0.000 description 1
- NKUGCYDFQKFVOJ-JYJNAYRXSA-N Tyr-Leu-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 NKUGCYDFQKFVOJ-JYJNAYRXSA-N 0.000 description 1
- OGPKMBOPMDTEDM-IHRRRGAJSA-N Tyr-Met-Ser Chemical compound CSCC[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N OGPKMBOPMDTEDM-IHRRRGAJSA-N 0.000 description 1
- XOVDRAVPGHTYLP-JYJNAYRXSA-N Tyr-Pro-Met Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(O)=O XOVDRAVPGHTYLP-JYJNAYRXSA-N 0.000 description 1
- MQGGXGKQSVEQHR-KKUMJFAQSA-N Tyr-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 MQGGXGKQSVEQHR-KKUMJFAQSA-N 0.000 description 1
- XYBNMHRFAUKPAW-IHRRRGAJSA-N Tyr-Ser-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CC=C(C=C1)O)N XYBNMHRFAUKPAW-IHRRRGAJSA-N 0.000 description 1
- HRHYJNLMIJWGLF-BZSNNMDCSA-N Tyr-Ser-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=C(O)C=C1 HRHYJNLMIJWGLF-BZSNNMDCSA-N 0.000 description 1
- LUMQYLVYUIRHHU-YJRXYDGGSA-N Tyr-Ser-Thr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LUMQYLVYUIRHHU-YJRXYDGGSA-N 0.000 description 1
- QFHRUCJIRVILCK-YJRXYDGGSA-N Tyr-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N)O QFHRUCJIRVILCK-YJRXYDGGSA-N 0.000 description 1
- WQOHKVRQDLNDIL-YJRXYDGGSA-N Tyr-Thr-Ser Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O WQOHKVRQDLNDIL-YJRXYDGGSA-N 0.000 description 1
- KLQPIEVIKOQRAW-IZPVPAKOSA-N Tyr-Thr-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N)O KLQPIEVIKOQRAW-IZPVPAKOSA-N 0.000 description 1
- NUQZCPSZHGIYTA-HKUYNNGSSA-N Tyr-Trp-Gly Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CC3=CC=C(C=C3)O)N NUQZCPSZHGIYTA-HKUYNNGSSA-N 0.000 description 1
- GPLTZEMVOCZVAV-UFYCRDLUSA-N Tyr-Tyr-Arg Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)C1=CC=C(O)C=C1 GPLTZEMVOCZVAV-UFYCRDLUSA-N 0.000 description 1
- AGDDLOQMXUQPDY-BZSNNMDCSA-N Tyr-Tyr-Ser Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(O)=O AGDDLOQMXUQPDY-BZSNNMDCSA-N 0.000 description 1
- KSGKJSFPWSMJHK-JNPHEJMOSA-N Tyr-Tyr-Thr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KSGKJSFPWSMJHK-JNPHEJMOSA-N 0.000 description 1
- REJBPZVUHYNMEN-LSJOCFKGSA-N Val-Ala-His Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](C(C)C)N REJBPZVUHYNMEN-LSJOCFKGSA-N 0.000 description 1
- XLDYBRXERHITNH-QSFUFRPTSA-N Val-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)C(C)C XLDYBRXERHITNH-QSFUFRPTSA-N 0.000 description 1
- BMGOFDMKDVVGJG-NHCYSSNCSA-N Val-Asp-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)O)N BMGOFDMKDVVGJG-NHCYSSNCSA-N 0.000 description 1
- COSLEEOIYRPTHD-YDHLFZDLSA-N Val-Asp-Tyr Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 COSLEEOIYRPTHD-YDHLFZDLSA-N 0.000 description 1
- ZEVNVXYRZRIRCH-GVXVVHGQSA-N Val-Gln-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)O)N ZEVNVXYRZRIRCH-GVXVVHGQSA-N 0.000 description 1
- VCAWFLIWYNMHQP-UKJIMTQDSA-N Val-Glu-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)N VCAWFLIWYNMHQP-UKJIMTQDSA-N 0.000 description 1
- WJVLTYSHNXRCLT-NHCYSSNCSA-N Val-His-Asp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CC(=O)O)C(=O)O)N WJVLTYSHNXRCLT-NHCYSSNCSA-N 0.000 description 1
- ZIGZPYJXIWLQFC-QTKMDUPCSA-N Val-His-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](C(C)C)N)O ZIGZPYJXIWLQFC-QTKMDUPCSA-N 0.000 description 1
- HGJRMXOWUWVUOA-GVXVVHGQSA-N Val-Leu-Gln Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](C(C)C)N HGJRMXOWUWVUOA-GVXVVHGQSA-N 0.000 description 1
- ZHQWPWQNVRCXAX-XQQFMLRXSA-N Val-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](C(C)C)N ZHQWPWQNVRCXAX-XQQFMLRXSA-N 0.000 description 1
- SYSWVVCYSXBVJG-RHYQMDGZSA-N Val-Leu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)N)O SYSWVVCYSXBVJG-RHYQMDGZSA-N 0.000 description 1
- WDIWOIRFNMLNKO-ULQDDVLXSA-N Val-Leu-Tyr Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 WDIWOIRFNMLNKO-ULQDDVLXSA-N 0.000 description 1
- DIOSYUIWOQCXNR-ONGXEEELSA-N Val-Lys-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O DIOSYUIWOQCXNR-ONGXEEELSA-N 0.000 description 1
- BGXVHVMJZCSOCA-AVGNSLFASA-N Val-Pro-Lys Chemical compound CC(C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)O)N BGXVHVMJZCSOCA-AVGNSLFASA-N 0.000 description 1
- LTTQCQRTSHJPPL-ZKWXMUAHSA-N Val-Ser-Asp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)O)N LTTQCQRTSHJPPL-ZKWXMUAHSA-N 0.000 description 1
- JQTYTBPCSOAZHI-FXQIFTODSA-N Val-Ser-Cys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N JQTYTBPCSOAZHI-FXQIFTODSA-N 0.000 description 1
- VIKZGAUAKQZDOF-NRPADANISA-N Val-Ser-Glu Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCC(O)=O VIKZGAUAKQZDOF-NRPADANISA-N 0.000 description 1
- PGQUDQYHWICSAB-NAKRPEOUSA-N Val-Ser-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)N PGQUDQYHWICSAB-NAKRPEOUSA-N 0.000 description 1
- GBIUHAYJGWVNLN-AEJSXWLSSA-N Val-Ser-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N GBIUHAYJGWVNLN-AEJSXWLSSA-N 0.000 description 1
- GBIUHAYJGWVNLN-UHFFFAOYSA-N Val-Ser-Pro Natural products CC(C)C(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O GBIUHAYJGWVNLN-UHFFFAOYSA-N 0.000 description 1
- WUFHZIRMAZZWRS-OSUNSFLBSA-N Val-Thr-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C(C)C)N WUFHZIRMAZZWRS-OSUNSFLBSA-N 0.000 description 1
- LCHZBEUVGAVMKS-RHYQMDGZSA-N Val-Thr-Leu Chemical compound CC(C)C[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(O)=O LCHZBEUVGAVMKS-RHYQMDGZSA-N 0.000 description 1
- JAIZPWVHPQRYOU-ZJDVBMNYSA-N Val-Thr-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](C(C)C)N)O JAIZPWVHPQRYOU-ZJDVBMNYSA-N 0.000 description 1
- PGBMPFKFKXYROZ-UFYCRDLUSA-N Val-Tyr-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)O)N PGBMPFKFKXYROZ-UFYCRDLUSA-N 0.000 description 1
- BGTDGENDNWGMDQ-KJEVXHAQSA-N Val-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](C(C)C)N)O BGTDGENDNWGMDQ-KJEVXHAQSA-N 0.000 description 1
- NLNCNKIVJPEFBC-DLOVCJGASA-N Val-Val-Glu Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCC(O)=O NLNCNKIVJPEFBC-DLOVCJGASA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 101710185494 Zinc finger protein Proteins 0.000 description 1
- 102100023597 Zinc finger protein 816 Human genes 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 108010008685 alanyl-glutamyl-aspartic acid Proteins 0.000 description 1
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 1
- 108010087924 alanylproline Proteins 0.000 description 1
- 239000003392 amylase inhibitor Substances 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 108010009111 arginyl-glycyl-glutamic acid Proteins 0.000 description 1
- 108010060035 arginylproline Proteins 0.000 description 1
- 238000011190 asparagine deamidation Methods 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 108010092854 aspartyllysine Proteins 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 108020001096 dihydrofolate reductase Proteins 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- FSXRLASFHBWESK-UHFFFAOYSA-N dipeptide phenylalanyl-tyrosine Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FSXRLASFHBWESK-UHFFFAOYSA-N 0.000 description 1
- 210000001840 diploid cell Anatomy 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000002308 endothelin receptor antagonist Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 108010080575 glutamyl-aspartyl-alanine Proteins 0.000 description 1
- 108010049041 glutamylalanine Proteins 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 108010090037 glycyl-alanyl-isoleucine Proteins 0.000 description 1
- 108010062266 glycyl-glycyl-argininal Proteins 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 108010092114 histidylphenylalanine Proteins 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 108010031424 isoleucyl-prolyl-proline Proteins 0.000 description 1
- 108010027338 isoleucylcysteine Proteins 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000002614 leucines Chemical class 0.000 description 1
- 108010044056 leucyl-phenylalanine Proteins 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 108010009298 lysylglutamic acid Proteins 0.000 description 1
- 108010064235 lysylglycine Proteins 0.000 description 1
- 238000010841 mRNA extraction Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 108010016686 methionyl-alanyl-serine Proteins 0.000 description 1
- 108010005942 methionylglycine Proteins 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- AEMBWNDIEFEPTH-UHFFFAOYSA-N n-tert-butyl-n-ethylnitrous amide Chemical compound CCN(N=O)C(C)(C)C AEMBWNDIEFEPTH-UHFFFAOYSA-N 0.000 description 1
- 238000011617 nephropathy animal model Methods 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000012946 outsourcing Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 108010018625 phenylalanylarginine Proteins 0.000 description 1
- 108010073101 phenylalanylleucine Proteins 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 210000004896 polypeptide structure Anatomy 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000020004 porter Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108010087846 prolyl-prolyl-glycine Proteins 0.000 description 1
- 108010031719 prolyl-serine Proteins 0.000 description 1
- 108010004914 prolylarginine Proteins 0.000 description 1
- 108010070643 prolylglutamic acid Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 108010048397 seryl-lysyl-leucine Proteins 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000002325 somatostatin-secreting cell Anatomy 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 108010031491 threonyl-lysyl-glutamic acid Proteins 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 238000005829 trimerization reaction Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 108010080629 tryptophan-leucine Proteins 0.000 description 1
- 239000000225 tumor suppressor protein Substances 0.000 description 1
- 108010035534 tyrosyl-leucyl-alanine Proteins 0.000 description 1
- 108010051110 tyrosyl-lysine Proteins 0.000 description 1
- 108010078580 tyrosylleucine Proteins 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 108700026215 vpr Genes Proteins 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
本文提供ET
AR抗體及其醫藥組合物,本文亦提供了其用於治療、預防或改善糖尿病腎病之一或多種症狀以及慢性腎病之一或多種症狀的方法。
Description
本文提供了ET
AR抗體及其醫藥組合物。本文亦提供了其用於治療、預防或改善糖尿病腎病之一或多種症狀以及慢性腎病之一或多種症狀的方法。
內皮素係由21個胺基酸組成之多肽,分子量為2,400 Da,N端為兩個二硫鍵將1-15、3-11位置之半胱胺酸連接起來,C端為一些疏水性胺基酸之殘基。N端結構決定其與受體之親和力,C端結構決定其與受體之結合位置。內皮素(endothelin,ET)有三個亞型,亦即ET-1、ET-2及ET-3。內皮素受體(endothelin receptor,ETR)有ET
AR及ET
BR兩種,屬G蛋白偶聯受體(G-protein coupled receptor,GPCR)。ET及其受體廣泛分佈於人體組織及器官,包括心血管系統、肺、腎臟系統、腦、神經組織等。腎髓質擁有機體最高之ET-1水平(Kitamura等,1989,
BiochemBiophys Res Commun161: 348–352)。相對於其他器官,腎臟對ET-1具有更高的敏感性(Speed及Pollock,2013,
Hypertension61: 1142–1145)。ET及其受體可能參與肥胖、高血壓及糖尿病等引起之腎損傷,且通常由ET
AR介導。
隨著全球經濟之發展及生活水平之提高,糖尿病發病率及流行率逐步增加,以致糖尿病已成為一個重大的公共衛生問題。糖尿病腎病係糖尿病最重要之併發症之一,影響15-25%之I型糖尿病病人及30-40%之II型糖尿病病人(Schernthaner及Schernthaner,2013,
J Nephrol26:975–985)。
本文提供了ET
AR抗體及其醫藥組合物。本文亦提供了其用於治療、預防或改善糖尿病腎病之一或多種症狀以及慢性腎病之一或多種症狀的方法。
本文提供了ET
AR抗體,其抗體包含一個、兩個、三個、四個、五個、或六個胺基酸序列,其中各胺基酸序列獨立地選自於以下所列之胺基酸序列:
a. 輕鏈CDR1胺基酸序列:SEQ ID NO: 8、SEQ ID NO: 10、SEQ ID NO: 12、SEQ ID NO: 14、SEQ ID NO: 16、SEQ ID NO: 18、SEQ ID NO: 20、SEQ ID NO: 22、SEQ ID NO: 24、SEQ ID NO: 26、SEQ ID NO: 28、及SEQ ID NO: 30;
b. 輕鏈CDR2胺基酸序列:SEQ ID NO: 32、SEQ ID NO: 34、SEQ ID NO: 36、SEQ ID NO: 38、SEQ ID NO: 40、SEQ ID NO: 42、SEQ ID NO: 44、SEQ ID NO: 46、及SEQ ID NO: 48;
c. 輕鏈CDR3胺基酸序列:SEQ ID NO: 50、SEQ ID NO: 52、SEQ ID NO: 54、SEQ ID NO: 56、SEQ ID NO: 58、SEQ ID NO: 60、SEQ ID NO: 62、SEQ ID NO: 64、SEQ ID NO: 66、及SEQ ID NO: 68;
d. 重鏈CDR1胺基酸序列:SEQ ID NO: 70、SEQ ID NO: 72、SEQ ID NO: 74、SEQ ID NO: 76、SEQ ID NO: 78、SEQ ID NO: 80、SEQ ID NO: 82、SEQ ID NO: 84、SEQ ID NO: 86、SEQ ID NO: 88、及SEQ ID NO: 90;
e. 重鏈CDR2胺基酸序列:SEQ ID NO: 92、SEQ ID NO: 94、SEQ ID NO: 96、SEQ ID NO: 98、SEQ ID NO: 100、SEQ ID NO: 102、SEQ ID NO: 104、SEQ ID NO: 106、SEQ ID NO: 108、SEQ ID NO: 110、SEQ ID NO: 112、及SEQ ID NO: 114;及
f. 重鏈CDR3胺基酸序列:SEQ ID NO: 116、SEQ ID NO: 118、SEQ ID NO: 120、SEQ ID NO: 122、SEQ ID NO: 124、SEQ ID NO: 126、SEQ ID NO: 128、SEQ ID NO: 130、SEQ ID NO: 132、SEQ ID NO: 134、及SEQ ID NO: 136。
在一個實施方案中,本文提供之ET
AR抗體包含:
a. 輕鏈CDR1胺基酸序列:SEQ ID NO: 8
b. 輕鏈CDR2胺基酸序列:SEQ ID NO: 32
c. 輕鏈CDR3胺基酸序列:SEQ ID NO: 50
d. 重鏈CDR1胺基酸序列:SEQ ID NO: 70
e. 重鏈CDR2胺基酸序列:SEQ ID NO: 92
f. 重鏈CDR3胺基酸序列:SEQ ID NO: 116
在一個實施方案中,本文提供之ET
AR抗體包含:
a. 輕鏈CDR1胺基酸序列:SEQ ID NO: 10
b. 輕鏈CDR2胺基酸序列:SEQ ID NO: 34
c. 輕鏈CDR3胺基酸序列:SEQ ID NO: 52
d. 重鏈CDR1胺基酸序列:SEQ ID NO: 72
e. 重鏈CDR2胺基酸序列:SEQ ID NO: 94
f. 重鏈CDR3胺基酸序列:SEQ ID NO: 118
在一個實施方案中,本文提供之ET
AR抗體包含:
a. 輕鏈CDR1胺基酸序列:SEQ ID NO: 12
b. 輕鏈CDR2胺基酸序列:SEQ ID NO: 36
c. 輕鏈CDR3胺基酸序列:SEQ ID NO: 54
d. 重鏈CDR1胺基酸序列:SEQ ID NO: 74
e. 重鏈CDR2胺基酸序列:SEQ ID NO: 96
f. 重鏈CDR3胺基酸序列:SEQ ID NO: 120
在一個實施方案中,本文提供之ET
AR抗體包含:
a. 輕鏈CDR1胺基酸序列:SEQ ID NO: 14
b. 輕鏈CDR2胺基酸序列:SEQ ID NO: 38
c. 輕鏈CDR3胺基酸序列:SEQ ID NO: 56
d. 重鏈CDR1胺基酸序列:SEQ ID NO: 76
e. 重鏈CDR2胺基酸序列:SEQ ID NO: 98
f. 重鏈CDR3胺基酸序列:SEQ ID NO: 122
在一個實施方案中,本文提供之ET
AR抗體包含:
a. 輕鏈CDR1胺基酸序列:SEQ ID NO: 16
b. 輕鏈CDR2胺基酸序列:SEQ ID NO: 40
c. 輕鏈CDR3胺基酸序列:SEQ ID NO: 58
d. 重鏈CDR1胺基酸序列:SEQ ID NO: 78
e. 重鏈CDR2胺基酸序列:SEQ ID NO: 100
f. 重鏈CDR3胺基酸序列:SEQ ID NO: 124
在一個實施方案中,本文提供之ET
AR抗體包含:
a. 輕鏈CDR1胺基酸序列:SEQ ID NO: 18
b. 輕鏈CDR2胺基酸序列:SEQ ID NO: 42
c. 輕鏈CDR3胺基酸序列:SEQ ID NO: 60
d. 重鏈CDR1胺基酸序列:SEQ ID NO: 80
e. 重鏈CDR2胺基酸序列:SEQ ID NO: 102
f. 重鏈CDR3胺基酸序列:SEQ ID NO: 126
在一個實施方案中,本文提供之ET
AR抗體包含:
a. 輕鏈CDR1胺基酸序列:SEQ ID NO: 20
b. 輕鏈CDR2胺基酸序列:SEQ ID NO: 44
c. 輕鏈CDR3胺基酸序列:SEQ ID NO: 62
d. 重鏈CDR1胺基酸序列:SEQ ID NO: 82
e. 重鏈CDR2胺基酸序列:SEQ ID NO: 104
f. 重鏈CDR3胺基酸序列:SEQ ID NO: 128
在一個實施方案中,本文提供之ET
AR抗體包含:
a. 輕鏈CDR1胺基酸序列:SEQ ID NO: 22
b. 輕鏈CDR2胺基酸序列:SEQ ID NO: 44
c. 輕鏈CDR3胺基酸序列:SEQ ID NO: 62
d. 重鏈CDR1胺基酸序列:SEQ ID NO: 82
e. 重鏈CDR2胺基酸序列:SEQ ID NO: 106
f. 重鏈CDR3胺基酸序列:SEQ ID NO: 128
在一個實施方案中,本文提供之ET
AR抗體包含:
a. 輕鏈CDR1胺基酸序列:SEQ ID NO: 24
b. 輕鏈CDR2胺基酸序列:SEQ ID NO: 44
c. 輕鏈CDR3胺基酸序列:SEQ ID NO: 62
d. 重鏈CDR1胺基酸序列:SEQ ID NO: 84
e. 重鏈CDR2胺基酸序列:SEQ ID NO: 108
f. 重鏈CDR3胺基酸序列:SEQ ID NO: 130
在一個實施方案中,本文提供之ET
AR抗體包含:
a. 輕鏈CDR1胺基酸序列:SEQ ID NO: 26
b. 輕鏈CDR2胺基酸序列:SEQ ID NO: 46
c. 輕鏈CDR3胺基酸序列:SEQ ID NO: 64
d. 重鏈CDR1胺基酸序列:SEQ ID NO: 86
e. 重鏈CDR2胺基酸序列:SEQ ID NO: 110
f. 重鏈CDR3胺基酸序列:SEQ ID NO: 132
在一個實施方案中,本文提供之ET
AR抗體包含:
a. 輕鏈CDR1胺基酸序列:SEQ ID NO: 28
b. 輕鏈CDR2胺基酸序列:SEQ ID NO: 46
c. 輕鏈CDR3胺基酸序列:SEQ ID NO: 66
d. 重鏈CDR1胺基酸序列:SEQ ID NO: 88
e. 重鏈CDR2胺基酸序列:SEQ ID NO: 112
f. 重鏈CDR3胺基酸序列:SEQ ID NO: 134
在另一個實施方案中,本文提供之ET
AR抗體包含:
a. 輕鏈CDR1胺基酸序列:SEQ ID NO: 30
b. 輕鏈CDR2胺基酸序列:SEQ ID NO: 48
c. 輕鏈CDR3胺基酸序列:SEQ ID NO: 68
d. 重鏈CDR1胺基酸序列:SEQ ID NO: 90
e. 重鏈CDR2胺基酸序列:SEQ ID NO: 114
f. 重鏈CDR3胺基酸序列:SEQ ID NO: 136
本文亦提供了醫藥組合物,其包含本文提供之ET
AR抗體,與一或多種可藥用載劑之組合。
本文提供了治療、預防或改善糖尿病腎病之一或多種症狀的方法,其包括投與受試者治療有效量的本文提供之醫藥組合物。
本文提供了治療、預防或改善慢性腎病之一或多種症狀的方法,其包括投與受試者治療有效量的本文提供之醫藥組合物。
本文提供了治療、預防或改善伴隨有蛋白尿之疾病之一或多種症狀的方法,其包括投與受試者治療有效量的本文提供之醫藥組合物。
本文提供了治療、預防或改善伴隨有腎小球濾過率降低之疾病之一或多種症狀的方法,其包括投與受試者治療有效量的本文提供之醫藥組合物。
本文提供了用於治療糖尿病腎病、慢性腎病、伴隨有蛋白尿或腎小球濾過率降低之疾病的套組,其包含本文提供之醫藥組合物。
本文提供了醫藥組合物在製備用於治療糖尿病腎病、慢性腎病、伴隨有蛋白尿或腎小球濾過率降低之疾病之藥物中的用途。本文提供了分離之核酸,其包含本文提供之ET
AR抗體之多聚核苷酸編碼序列。
本文提供了重組表現載體,其包含本文提供之核酸。
本文提供了宿主細胞,其包含本文提供之載體。
本文提供了生產ET
AR抗體之方法,其包括在允許表現本文提供之抗體的條件下培養本文提供之宿主細胞。
定義
除非本文另外定義,與本文相關之科學及技術術語應具有此項技術普通技術人員所理解之含義。通常,與本文所述藥物學、生物學、生物化學、細胞及組織培養學、生物學、分子生物學、免疫學、微生物學、遺傳學及蛋白質核酸化學以及雜交相關之命名法及技術為此項技術熟知及經常使用的。
本文使用標準的單字母或三字母縮寫表明多聚核苷酸及多肽序列。除非另外指明,多肽序列之胺基端在左而他們的羧基端在右,單鏈核酸序列及雙鏈核酸序列之上游鏈的5'端在左而他們的3'端在右。多肽之具體部分可由胺基酸殘基編號表示,例如胺基酸80至130,或由該位點之實際殘基表示例如Lys80至Lys130。亦可藉由解釋其與參比序列之差異描述具體之多肽或多聚核苷酸序列。
術語「肽」、「多肽」、及「蛋白」均指包含兩個或多個藉由肽鍵相互連接之胺基酸的分子。此等術語涵蓋例如天然及人工蛋白、蛋白片段及蛋白序列之多肽類似物(例如突變蛋白、變異體及融合蛋白)以及轉錄後或否則為共價或非共價修飾之蛋白。肽、多肽或蛋白可為單體或多聚體。
術語「多肽片段」指與對應的全長蛋白相比具有胺基端及/或羧基端缺失之多肽。片段長度可為例如至少5、6、7、8、9、10、11、12、13、14、15、20、50、70、80、90、100、150或200個胺基酸。片段長度可為例如最多1000、750、500、250、200、175、150、125、100、90、80、70、60、50、40、30、20、15、14、13、12、11或10個胺基酸。片段可在其一端或兩端進一步包含一或多個附加胺基酸,例如,來自不同天然蛋白質之胺基酸序列(例如,Fc或白胺酸拉鏈域)或人工胺基酸序列(例如,人工接頭序列)。
本文之多肽包括以任何原因及經任何方法修飾之多肽,例如,以:(1)降低蛋白水解敏感性,(2)降低氧化敏感性,(3)改變形成蛋白複合物之親和性,(4)改變結合親和性,以及(4)賦予或修飾其他物理化學或功能性質。類似物包含多肽之突變蛋白。例如,可在天然序列(例如在形成分子內接觸之域之外的多肽部分)中進行單個或多個胺基酸替換(例如,保守胺基酸替換)。「保守胺基酸替換」為不顯著改變母體序列結構特性者(例如,替換胺基酸不應破壞母體序列中出現的螺旋或干擾其他賦予母體序列特性或對其功能為必須之二級結構類型)。
多肽之「變異體」包含相對於另一多肽序列在胺基酸序列中插入、缺失及/或替換了一或多個胺基酸殘基之胺基酸序列。本文之變異體包括融合蛋白。
多肽之「衍生物」為經化學修飾之多肽,例如藉由與其他化學部分例如聚乙二醇、白蛋白(例如人血清白蛋白)結合、磷酸化及糖基化。
除非另外說明,術語「抗體」包括除包含兩個全長重鏈及兩個全長輕鏈之抗體外的其衍生物,變異體、片段及突變蛋白,其實例見下文。
術語「抗體」為包含與抗原結合部分並視情況為允許抗原結合部分採取促進該抗體與該抗原結合之構象之支架或構架部分的蛋白。抗體之實例包括完整抗體、抗體片段(例如抗體之抗原結合部分)、抗體衍生物、及抗體類似物。該抗體可包含例如可選擇之蛋白支架或具有移植CDR或CDR衍生物之人工支架。該支架包括但不限於包含被引入之例如以穩定化該抗體之三維結構的抗體衍生支架以及包含例如生物相容性多聚體之全合成支架。參見,例如,Korndorfer等,2003,
Proteins: Structure , Function and Bioinformatics53:121-129;Roque等,2004,
Biotechnol. Prog.20:639-654。此外,可使用類比肽抗體(「PAM」)以及基於類比抗體之支架,其如支架一樣利用纖維蛋白連接素。
抗體可具有例如天然免疫球蛋白之結構。「免疫球蛋白」為四聚體分子。在天然的免疫球蛋白中,各四聚體由兩個相同的多肽鏈對組成,各對具有一個「輕」(約25 kDa)及一個「重」鏈(約50-70 kDa)。各鏈之胺基端包括約100至110或更多胺基酸之可變域,主要與抗原識別相關。各鏈之羧基端部分確定了主要與效應器作用相關之恆定區。人之輕鏈分為κ及λ輕鏈。重鏈分為μ、δ、α或ε,並確定了抗原之同種型,例如分別為IgM、IgD、IgG、IgA及IgE。在輕鏈及重鏈中,可變及恆定區由約12或更多個胺基酸之「J」區連接,重鏈亦包括約10多個胺基酸之「D」區。參見,Fundamental Immunology Ch.7 (Paul編輯,第2版,Raven Press,1989) (其完整內容以參考形式併於本文用於任何目的)。各輕/重鏈對之可變區形成抗體結合位點,這樣一個完整的免疫球蛋白具有兩個結合位點。
天然免疫球蛋白鏈顯示出由三個高度可變區連接之相對保守骨架區(FR)之相同基本結構,亦被稱作互補決定區或CDR。自N端至C端,輕及重鏈均包含域FR1、CDR1、FR2、CDR2、FR3、CDR3及FR4。各域胺基酸之分配與Kabat等在Sequences of Proteins of Immunological Interest,第5版,US Dept. of Health and Human Services, PHS,NIH,NIH公開案第91-3242號,1991中之定義一致。
除非另外指明,「抗體」指完整的免疫球蛋白或其可與完整抗體競爭特異性結合之抗原結合部分。可由重組DNA技術或藉由酶或化學裂解完整抗體生產抗原結合部分。抗原結合部分包括,尤其是,Fab、Fab'、F(ab')
2、Fv、域抗體(dAb),包括互補決定區(CDR)之片段、單鏈抗體(scFv)、嵌合抗體、雙鏈抗體(diabody)、三鏈抗體(triabody)、四鏈抗體(tetrabody)及至少包含足以賦予多肽特異抗原結合之免疫球蛋白之一部分的多肽。
Fab片段為具有V
L、V
H、C
L及C
H1域之單價片段;F(ab')
2片段為具有兩個在鉸鏈區由二硫鍵連接之Fab片段的二價片段;Fd片段具有V
H或V
L域;dAb片段具有V
H域、V
L域,或V
H或V
L域之抗原結合片段(美國專利號6846634、6696245,美國專利申請公開號05/0202512、04/0202995、04/0038291、04/0009507、03/0039958;Ward等,1989,Nature 341:544-546)。
單鏈抗體(scFv)為其中的V
L及V
H區由接頭(例如,合成的胺基酸殘基序列)連接以形成連續蛋白質之抗體,其中該接頭足夠長以允許該蛋白鏈摺疊回自身並形成單價抗原結合位點(參見,例如,Bird等,1988,
Science242:423-26及Huston等,1988,
Proc. Natl. Acad. Sci. USA85:5879-83)。雙鏈抗體為包含兩個多肽鏈之二價抗體,其中各多肽鏈包含由接頭連接之V
H及V
L域,該接頭很短以致於不允許兩個域在相同鏈上之配對,因此允許各域與另一多肽鏈上之互補域配對(參見,例如,Holliger等,1993,
Proc. Natl. Acad. Sci. USA90:6444-48,及Poljak等,1994,
Structure2:1121-23)。若雙鏈抗體之兩個多肽鏈為相同的,則由他們配對得到的雙鏈抗體將具有相同的抗原結合位點。具有不同序列之多肽鏈可用於製備具有不同抗原結合位點之雙鏈抗體。相似地,三鏈抗體及四鏈抗體分別為包含三個及四個多肽鏈之抗體並分別形成三個及四個抗原結合位點,其可相同或不同。
可使用Kabat等在Sequences of Proteins of Immunological Interest,第5版, US Dept. of Health and Human Services, PHS, NIH, NIH公開案第91-3242號,1991中描述之方法鑑定給定抗體之互補決定區(CDR)及構架區(FR)。可向分子中共價或非共價併入一或多個CDR使其成為抗體。抗體可以較大多肽鏈併入CDR。可將CDR共價連接至另一鄉肽鏈,或非共價併入CDR。CDR允許抗體與具體的相關抗原特異性結合。
抗體可有一或多個結合位點。若多於一個結合位點,該結合位點可與另一個相同或不同。例如,天然人免疫球蛋白通常具有兩個相同的結合位點,而「雙特異性」或「雙功能」抗體具有兩個不同的結合位點。
術語「鼠源抗體」包括具有一或多個來源於小鼠免疫球蛋白序列之可變區及恆定區的所有抗體。
術語「人源化抗體」係將小鼠抗體分子之互補決定區序列移植至人抗體可變區構架中而製成之抗體。
術語「抗原結合域」、「抗原結合區」或「抗原結合位點」為包含與抗原相互作用之胺基酸殘基(或其他部分)並有助於抗體對抗原之特異性及親和力的抗體之部分。對與其抗原特異性結合之抗體而言,此將包括至少部分的至少一個其CDR域。
術語「表位」為與抗體(例如,藉由抗體)結合之分子部分。表位可包含分子之非連續部分(例如,在多肽中,在多肽之一級序列中不連續的胺基酸殘基在該多肽之三級及四級結構中相互足夠接近以致於被一個抗體結合)。
兩個多聚核苷酸或兩個多肽序列之「相同百分比」由使用GAP電腦程式(GCG Wisconsin Package;version 10.3 (Accelrys,San Diego,CA)之一部分)使用其預設參數比較序列測定。
術語「多聚核苷酸」、「寡聚核苷酸」及「核酸」可在全文中交替使用並包括DNA分子(例如,cDNA或基因組DNA)、RNA分子(例如mRNA)、使用核苷酸類似物(例如,肽核酸及非天然核苷酸類似物)生成的DNA或RNA類似物及其雜交體。核酸分子可為單鏈或雙鏈。在一個實施方案中,本文之核酸分子包含編碼本文提供抗體或其片段、衍生物、突變蛋白或變異體連續之開放閱讀框。
若他們的序列可反向平行排列,則兩個單鏈多聚核苷酸係相互「互補的」,這樣一個多聚核苷酸中之各核苷酸與另一多聚核苷酸中之互補核苷酸相反,不會引入空隙並且各序列之5'或3'端沒有未配對的核苷酸。若兩個多聚核苷酸可在中等嚴格條件下相互雜交,則一個多聚核苷酸與另一多聚核苷酸「互補」。因此,一個多聚核苷酸可與另一多聚核苷酸互補,但並非他的互補序列。
術語「載體」為可用於將與其相連之另一核酸引入細胞之核酸。載體之一種類型為「質體」,其指可連接附加核酸區段之線性或環狀雙鏈DNA分子。載體之另一類型為病毒載體(例如,複製缺陷反轉錄病毒、腺病毒及腺病毒伴隨病毒),其中可將附加DNA區段引入病毒基因組。某些載體可在他們被引入之宿主細胞中自主複製(例如,包含細菌複製起點之細菌載體以及游離型哺乳動物載體)。其他載體(例如,非游離型哺乳動物載體)在引入宿主細胞時整合入宿主細胞之基因組中並因此與宿主基因組一起複製。「表現載體」為可引導所選多聚核苷酸表現之載體類型。
若調控序列影響核苷酸序列之表現(例如,表現量、時間或位點),則核苷酸序列與調控序列「可操作地相連」。「調控序列」為可影響與其可操作相連之核酸之表現(例如,表現量、時間或位點)的核酸。調控基因,例如,直接對受調控核酸發揮作用或藉由一或多個其他分子(例如,與調控序列及/或核酸結合之多聚核苷酸)之作用。調控序列之實例包括啟動子、增強子及其他表現控制元件(例如,多腺苷酸化信號)。調控序列之進一步實例描述於例如Goeddel,1990, Gene Expression Technology: Methods in Enzymology, 第185卷, Academic Press, San Diego, CA及Baron等, 1995,
Nucleic Acids Res.23:3605-06。
術語「宿主細胞」為用於表現核酸例如本文提供核酸之細胞。宿主細胞可為原核生物,例如大腸桿菌,或者其可為真核生物,例如單細胞真核生物(例如,酵母或其他真菌)、植物細胞(例如菸草或番茄植物細胞)、動物細胞(例如,人細胞、猴細胞、倉鼠細胞、大鼠細胞、小鼠細胞或昆蟲細胞)或雜交瘤。通常,宿主細胞為可用多肽編碼核酸轉化或轉染之培養細胞,其可接著在宿主細胞中表現。短語「重組宿主細胞」可用於表述用預期表現之核酸轉化或轉染之宿主細胞。宿主細胞亦可為包含該核酸但不以期望水準表現之細胞,除非向該宿主細胞引入了調控序列這樣其與核酸可操作地相連。應理解的係術語宿主細胞不僅指具體之受試者細胞,亦指該細胞之子代或可能的子代。由於例如突變或環境影響後續世代會出現某些修飾,該子代事實上可能與母體細胞不同但仍然屬於本文使用之術語範圍。
內皮素及內皮素受體
內皮素係由21個胺基酸組成之多肽,分子量為2,400 Da,N端為兩個二硫鍵將1-15、3-11位置之半胱胺酸連接起來,C端為一些疏水性胺基酸之殘基。N端結構決定其與受體之親和力,C端結構決定其與受體之結合位置。內皮素(ET)有三個亞型,亦即ET-1、ET-2及ET-3,其差別在於個別胺基酸之殘基。內皮素受體(ET
AR)屬於7-跨膜受體家族之A亞家族,其藉由異源三聚體鳥嘌呤核苷酸結合蛋白(G蛋白)與一或多個胞內信號傳導途徑偶聯(Jelinek等,1993,
Science259:1614-1616;Segre等, 1993,
Trends Endocrinol. Metab. 4:309-314)。如本文所使用「內皮素受體」及「ET
AR」可交替使用。
在一個實施方案中,可選擇本文提供之抗體結合表現於細胞上之膜結合內皮素受體並藉由內皮素受體抑制或阻斷內皮素信號傳導。在一個實施方案中,本文提供之抗體與人內皮素受體特異性結合。在進一步之實施方案中,與人內皮素受體結合之抗體亦可與其他物種之內皮素受體結合,例如大鼠。下文中之實施例提供生成與人膜結合內皮素受體結合之鼠源抗體,在進一步之實施方案中與其他物種之內皮素受體結合。
已知數個物種之內皮素受體之多聚核苷酸及多肽序列。SEQ ID NO:1-SEQ ID NO:6顯示了人、猴子及大鼠之序列。序列資料來源於美國國立生物技術資訊中心之GeneBank資料庫。
內皮素受體A (ET
AR)如下:
人(Homo sapiens)多聚核苷酸(SEQ ID NO:1);登錄號:S63938。
人(Homo sapiens)胺基酸(SEQ ID NO:2);登錄號:AAB20278。
猴子(Rhesus macaque)多聚核苷酸(SEQ ID NO:3);登錄號:JV635771。
猴子(Rhesus macaque)胺基酸(SEQ ID NO:4);登錄號:AFJ71111。
大鼠(Rattus norvegicus)多聚核苷酸(SEQ ID NO: 5);登錄號:M60786。
大鼠(Rattus norvegicus)胺基酸(SEQ ID NO: 6);登錄號:AAA41114。
內皮素受體A (ET
AR)抗體
在一個實施方案中,本文提供了ET
AR抗體(例如,完整抗體、抗體片段、抗體衍生物、抗體突變蛋白、及抗體變異體)。
在一個實施方式中,本文提供之ET
AR抗體包含一個、兩個、三個、四個、五個、或六個胺基酸序列,其中各胺基酸序列獨立地選自於以下所列胺基酸序列:
a. 輕鏈CDR1胺基酸序列:SEQ ID NO: 8、SEQ ID NO: 10、SEQ ID NO: 12、SEQ ID NO: 14、SEQ ID NO: 16、SEQ ID NO: 18、SEQ ID NO: 20、SEQ ID NO: 22、SEQ ID NO: 24、SEQ ID NO: 26、SEQ ID NO: 28、及SEQ ID NO: 30;
b. 輕鏈CDR2胺基酸序列:SEQ ID NO: 32、SEQ ID NO: 34、SEQ ID NO: 36、SEQ ID NO: 38、SEQ ID NO: 40、SEQ ID NO: 42、SEQ ID NO: 44、SEQ ID NO: 46、及SEQ ID NO: 48;
c. 輕鏈CDR3胺基酸序列:SEQ ID NO: 50、SEQ ID NO: 52、SEQ ID NO: 54、SEQ ID NO: 56、SEQ ID NO: 58、SEQ ID NO: 60、SEQ ID NO: 62、SEQ ID NO: 64、SEQ ID NO: 66、及SEQ ID NO: 68;
d. 重鏈CDR1胺基酸序列:SEQ ID NO: 70、SEQ ID NO: 72、SEQ ID NO: 74、SEQ ID NO: 76、SEQ ID NO: 78、SEQ ID NO: 80、SEQ ID NO: 82、SEQ ID NO: 84、SEQ ID NO: 86、SEQ ID NO: 88、及SEQ ID NO: 90;
e. 重鏈CDR2胺基酸序列:SEQ ID NO: 92、SEQ ID NO: 94、SEQ ID NO: 96、SEQ ID NO: 98、SEQ ID NO: 100、SEQ ID NO: 102、SEQ ID NO: 104、SEQ ID NO: 106、SEQ ID NO: 108、SEQ ID NO: 110、SEQ ID NO: 112、及SEQ ID NO: 114;及
f. 重鏈CDR3胺基酸序列:SEQ ID NO: 116、SEQ ID NO: 118、SEQ ID NO: 120、SEQ ID NO: 122、SEQ ID NO: 124、SEQ ID NO: 126、SEQ ID NO: 128、SEQ ID NO: 130、SEQ ID NO: 132、SEQ ID NO: 134、及SEQ ID NO: 136。
表1列出本文提供之ET
AR抗體之輕鏈CDR的胺基酸序列,以及其相應的多聚核苷酸編碼序列。表2列出本文提供之ET
AR抗體之重鏈CDR的胺基酸序列,以及其相應的多聚核苷酸編碼序列。
表1:輕鏈CDR之胺基酸序列及其多聚核苷酸編碼序列
表2:重鏈CDR之胺基酸序列及其多聚核苷酸編碼序列
CDR1 | CDR2 | CDR3 | |
A-1 核苷酸 | agggccagtcagaacattggcacaagcatacac (SEQ ID NO: 7) | tatgcttctaagtctatatct (SEQ ID NO: 31) | caacatagttatagctggccgtggacg (SEQ ID NO: 49) |
A-1 胺基酸 | RASQNIGTSIH (SEQ ID NO: 8) | YASKSIS (SEQ ID NO: 32) | QHSYSWPWT (SEQ ID NO: 50) |
A-2 核苷酸 | cgagcaagtgaaaatatttacagttatttagca (SEQ ID NO: 9) | aatgcaaaaaccttagcagaa (SEQ ID NO: 33) | cagcatcattatggtattccgttcacg (SEQ ID NO: 51) |
A-2 胺基酸 | RASENIYSYLA (SEQ ID NO: 10) | NAKTLAE (SEQ ID NO: 34) | QHHYGIPFT (SEQ ID NO: 52) |
A-3 核苷酸 | cagagcctctttgatattgatggaaagacatatttgaat (SEQ ID NO: 11) | ctggtgtctgaattggactct (SEQ ID NO:35) | tggcaaggtacacattttccgctcacg (SEQ ID NO: 53) |
A-3 胺基酸 | QSLFDIDGKTYLN (SEQ ID NO: 12) | LVSELDS (SEQ ID NO: 36) | WQGTHFPLT (SEQ ID NO: 54) |
A-4 核苷酸 | cgggcaagtcaggacattggtggtagcttaaac (SEQ ID NO: 13) | gccacatccagcttagattct (SEQ ID NO: 37) | ctacaatatgctagttctccgtatacg (SEQ ID NO: 55) |
A-4 胺基酸 | RASQDIGGSLN (SEQ ID NO: 14) | ATSSLDS (SEQ ID NO: 38) | LQYASSPYT (SEQ ID NO: 56) |
A-5 核苷酸 | agggccagccagactattagcgacttcttacac (SEQ ID NO: 15) | tatgcttcccaatccatctct (SEQ ID NO: 39) | caaagtggtaacacctttccgtggacg (SEQ ID NO: 57) |
A-5 胺基酸 | RASQTISDFLH (SEQ ID NO: 16) | YASQSIS (SEQ ID NO: 40) | QSGNTFPWT (SEQ ID NO:58) |
A-6 核苷酸 | agggcaagtgaggacatacacactcaattagcc (SEQ ID NO: 17) | ggtgcagccagtttgaaaagt (SEQ ID NO: 41) | caacagtataggagtattccgtggacg (SEQ ID NO: 59) |
A-6 胺基酸 | RASEDIHTQLA (SEQ ID NO: 18) | GAASLKS (SEQ ID NO: 42) | QQYRSIPWT (SEQ ID NO: 60) |
A-7 核苷酸 | agatctagtcagtacattgttcatagtactggaaccacctatttagaa (SEQ ID NO: 19) | aaagtttccaaccgattttct (SEQ ID NO: 43) | tttcaaggttcacattttccattcacg (SEQ ID NO: 61) |
A-7 胺基酸 | RSSQYIVHSTGTTYLE (SEQ ID NO: 20) | KVSNRFS (SEQ ID NO: 44) | FQGSHFPFT (SEQ ID NO: 62) |
A-8 核苷酸 | agatctagtcattaccttgttcatgataacggaaacacctatgttgaa (SEQ ID NO: 21) | aaggtttccaaccgattttct (SEQ ID NO: 43) | tttcaaggttcacatttcccattcacg (SEQ ID NO: 63) |
A-8 胺基酸 | RSSHYLVHDNGNTYVE (SEQ ID NO: 22) | KVSNRFS (SEQ ID NO: 44) | FQGSHFPFT (SEQ ID NO: 62) |
A-9 核苷酸 | agatctagtcagaacattgtccatagtactggaaacacctatttagaa (SEQ ID NO: 23) | aaagtttccaaccgattttct (SEQ ID NO: 43) | tttcaaggttcacattttccattcacg (SEQ ID NO: 61) |
A-9 胺基酸 | RSSQNIVHSTGNTYLE (SEQ ID NO: 24) | KVSNRFS (SEQ ID NO: 44) | FQGSHFPFT (SEQ ID NO: 62) |
A-10 核苷酸 | agtgtcagctcaagtgtaagttacatacac (SEQ ID NO: 25) | gacacatccaaactggcttct (SEQ ID NO: 45) | caccagtggagtactaacccacccacg (SEQ ID NO: 63) |
A-10 胺基酸 | SVSSSVSYIH (SEQ ID NO: 26) | DTSKLAS (SEQ ID NO: 46) | HQWSTNPPT (SEQ ID NO: 64) |
A-11 核苷酸 | agtgccagctcaagtgtaagttacatgtgc (SEQ ID NO: 27) | gacacatccaaactggcttct (SEQ ID NO: 45) | cagcagtggagtagtaacccacccacg (SEQ ID NO: 65) |
A-11 胺基酸 | SASSSVSYMC (SEQ ID NO: 28) | DTSKLAS (SEQ ID NO: 46) | QQWSSNPPT (SEQ ID NO: 66) |
A-12 核苷酸 | cagggcattaacaattat (SEQ ID NO: 29) | tatacatcaactttacagtca (SEQ ID NO: 47) | cagcagtttagtaaacttcggaca (SEQ ID NO: 67) |
A-12 胺基酸 | QGINNY (SEQ ID NO: 30) | YTSTLQS (SEQ ID NO: 48) | QQFSKLRT (SEQ ID NO: 68) |
CDR1 | CDR2 | CDR3 | |
A-1 核苷酸 | gggttctcactgaccacttctggcttgggtgttgcc (SEQ ID NO: 69) | cacatttggtcggatggtgacacgcgctattacccagccctgaagaac (SEQ ID NO: 91) | atgaaggatgatagtctttactttgacaac (SEQ ID NO:115) |
A-1 胺基酸 | GFSLTTSGLGVA (SEQ ID NO: 70) | HIWSDGDTRYYPALKN (SEQ ID NO: 92) | MKDDSLYFDN (SEQ ID NO: 116) |
A-2 核苷酸 | ggctacacctttactagctactggatacac (SEQ ID NO: 71) | tacattaatcctgacactgattatagtgagtacaat (SEQ ID NO:93) | gcaagtgctggttattatttttttgacttc (SEQ ID NO: 117) |
A-2 胺基酸 | GYTFTSYWIH (SEQ ID NO:72) | YINPDTDYSEYN (SEQ ID NO: 94) | ASAGYYFFDF (SEQ ID NO: 118 |
A-3 核苷酸 | ggcctcaacattaaagacatctatattcac (SEQ ID NO: 73) | aggattgatcctgcgaacggtaagactgcatatgac (SEQ ID NO: 95) | ggtaggggggcccac (SEQ ID NO:119) |
A-3 胺基酸 | GLNIKDIYIH (SEQ ID NO:74) | RIDPANGKTAYD (SEQ ID NO: 96) | GRGAH (SEQ ID NO:120) |
A-4 核苷酸 | ggttactcattcaccaactactggatacac (SEQ ID NO: 75) | atgattgatccttccgatgctgaaactgggttaaat (SEQ ID NO:97) | gcaagaattggcgattactataatatggactac (SEQ ID NO:121) |
A-4 胺基酸 | GYSFTNYWIH (SEQ ID NO: 76) | MIDPSDAETGLN (SEQ ID NO: 98) | ARIGDYYNMDY (SEQ ID NO:122) |
A-5 核苷酸 | ggattcactttcagtgactatcccatgtct (SEQ ID NO: 77) | gttagtgatggtggtggttccacc (SEQ ID NO: 99) | acaagacatgcttcctactatagctacgaccattctatggactac (SEQ ID NO:123) |
A-5 胺基酸 | GFTFSDYPMS (SEQ ID NO: 78) | VSDGGGST (SEQ ID NO: 100) | TRHASYYSYDHSMDY (SEQ ID NO:124) |
A-6 核苷酸 | ggattcactttcagtagctttggcatgtct (SEQ ID NO: 79) | attagtagtgctggtagtttcacc (SEQ ID NO: 101) | gcaagacgggggtacgacgttgggtgctttgaccac (SEQ ID NO:125) |
A-6 胺基酸 | GFTFSSFGMS (SEQ ID NO: 80) | ISSAGSFT (SEQ ID NO: 102) | ARRGYDVGCFDH (SEQ ID NO:126) |
A-7 核苷酸 | ggattcactttcagtacctatggcatgtct (SEQ ID NO: 81) | accattaatactaatggtggtaccacctattatcgagacagtgtgaagggc (SEQ ID NO: 103) | gcaagagactacggggctatggactac (SEQ ID NO: 127) |
A-7 胺基酸 | GFTFSTYGMS (SEQ ID NO: 82) | TINTNGGTTYYRDSVKG (SEQ ID NO: 104) | ARDYGAMDY (SEQ ID NO: 128) |
A-8 核苷酸 | ggattcactttcagtacctatggcatgtct (SEQ ID NO: 81) | accataaatactaatggtggtaacacctattattcagacaatgtgaagggc (SEQ ID NO: 105) | gcaagagactacggggctatggactac (SEQ ID NO: 127) |
A-8 胺基酸 | GFTFSTYGMS (SEQ ID NO:82) | TINTNGGNTYYSDNVKG (SEQ ID NO: 106) | ARDYGAMDY (SEQ ID NO: 128) |
A-9 核苷酸 | ggattcactttcagtagttatggcatgtct (SEQ ID NO: 83) | accattagtactaatggtgccaccgccaattatccagacagtgtgaagggc (SEQ ID NO:107) | gcaactgaaaagggagctatgggctac (SEQ ID NO:129) |
A-9 胺基酸 | GFTFSSYGMS (SEQ ID NO: 84) | TISTNGATANYPDSVKG (SEQ ID NO: 108) | ATEKGAMGY (SEQ ID NO: 130) |
A-10 核苷酸 | gggttttcactgaccacttctggtatgggtgtaggc (SEQ ID NO: 85) | cacatttggtgggatgatgataagtactataatccatccctgaagagc (SEQ ID NO: 109) | gctcgaagaactgagactatgattacgacagtgctatattactatgctatggactac (SEQ ID NO:131) |
A-10 胺基酸 | GFSLTTSGMGVG (SEQ ID NO: 86) | HIWWDDDKYYNPSLKS (SEQ ID NO: 110) | ARRTETMITTVLYYYAMDY (SEQ ID NO: 132) |
A-11 核苷酸 | ggattttcactgagcacttctggtttgggtgtaggc (SEQ ID NO:87) | cacatttggtgggatgatgataagtactataatccatcccttaagaga (SEQ ID NO: 111) | gctcgaaggagggaagttaacttcggtattaactattactattctatggactac (SEQ ID NO: 133) |
A-11 胺基酸 | GFSLSTSGLGVG (SEQ ID NO: 88) | HIWWDDDKYYNPSLKR (SEQ ID NO: 112) | ARRREVNFGINYYYSMDY (SEQ ID NO: 134) |
A-12 核苷酸 | ggattcaccttcagtgattattac (SEQ ID NO: 89) | attagaaatcgggctaatggttacacaaca (SEQ ID NO: 113) | gtaagagattcctatcactacgggtacttcgatgtc (SEQ ID NO: 135) |
A-12 胺基酸 | GFTFSDYY (SEQ ID NO:90) | IRNRANGYTT (SEQ ID NO:114) | VRDSYHYGYFDV (SEQ ID NO: 136) |
在一個實施方案中,本文提供之抗體包含與表1及表2中之CDR胺基酸序列各相差5、4、3、2、或1個單胺基酸添加、替換及/或缺失之序列。在另一個實施方案中,本文提供之抗體包含與表1及表2中之CDR胺基酸序列各相差4、3、2、或1個單胺基酸添加、替換及/或缺失之序列。在另一個實施方案中,本文提供之抗體包含與表1及表2中之CDR胺基酸序列各相差3、2、或1個單胺基酸添加、替換及/或缺失之序列。在另一個實施方案中,本文提供之抗體包含與表1及表2中之CDR胺基酸序列各相差2或1個單胺基酸添加、替換及/或缺失之序列。在另一個實施方案中,本文提供之抗體包含與表1及表2中之CDR胺基酸序列各相差1個單胺基酸添加、替換及/或缺失之序列。
在另一個實施方式中,本文提供之ET
AR抗體(ET
AR-1抗體),其包含一個或兩個胺基酸序列,其中各胺基酸序列獨立地選自於以下所列胺基酸序列:
a. 輕鏈CDR1胺基酸序列:SEQ ID NO: 8、SEQ ID NO: 10、SEQ ID NO: 12、SEQ ID NO: 14、SEQ ID NO: 16、SEQ ID NO: 18、SEQ ID NO: 20、SEQ ID NO: 22、SEQ ID NO: 24、SEQ ID NO: 26、SEQ ID NO: 28、及SEQ ID NO: 30;及
b. 重鏈CDR1胺基酸序列:SEQ ID NO: 70、SEQ ID NO: 72、SEQ ID NO: 74、SEQ ID NO: 76、SEQ ID NO: 78、SEQ ID NO: 80、SEQ ID NO: 82、SEQ ID NO: 84、SEQ ID NO: 86、SEQ ID NO: 88、及SEQ ID NO: 90。
一方面,ET
AR-1抗體亦包含一個或兩個胺基酸序列,其中各胺基酸序列獨立地選自於以下所列胺基酸序列:
a. 輕鏈CDR2胺基酸序列:SEQ ID NO: 32、SEQ ID NO: 34、SEQ ID NO: 36、SEQ ID NO: 38、SEQ ID NO: 40、SEQ ID NO: 42、SEQ ID NO: 44、SEQ ID NO: 46、及SEQ ID NO: 48;及
b. 重鏈CDR2胺基酸序列:SEQ ID NO: 92、SEQ ID NO: 94、SEQ ID NO: 96、SEQ ID NO: 98、SEQ ID NO: 100、SEQ ID NO: 102、SEQ ID NO: 104、SEQ ID NO: 106、SEQ ID NO: 108、SEQ ID NO: 110、SEQ ID NO: 112、及SEQ ID NO: 114。
另一方面,ET
AR-1抗體亦包含一個或兩個胺基酸序列,其中各胺基酸序列獨立地選自於以下所列胺基酸序列:
a. 輕鏈CDR3胺基酸序列:SEQ ID NO: 50、SEQ ID NO: 52、SEQ ID NO: 54、SEQ ID NO: 56、SEQ ID NO: 58、SEQ ID NO: 60、SEQ ID NO: 62、SEQ ID NO: 64、SEQ ID NO: 66、及SEQ ID NO: 68;及
b. 重鏈CDR3胺基酸序列:SEQ ID NO: 116、SEQ ID NO: 118、SEQ ID NO: 120、SEQ ID NO: 122、SEQ ID NO: 124、SEQ ID NO: 126、SEQ ID NO: 128、SEQ ID NO: 130、SEQ ID NO: 132、SEQ ID NO: 134、及SEQ ID NO: 136。
在另一個實施方式中,本文提供之ET
AR抗體(ET
AR-2抗體),其包含一個或兩個胺基酸序列,其中各胺基酸序列獨立地選自於以下所列胺基酸序列:
a. 輕鏈CDR2胺基酸序列:SEQ ID NO: 32、SEQ ID NO: 34、SEQ ID NO: 36、SEQ ID NO: 38、SEQ ID NO: 40、SEQ ID NO: 42、SEQ ID NO: 44、SEQ ID NO: 46、及SEQ ID NO: 48;及
b. 重鏈CDR2胺基酸序列:SEQ ID NO: 92、SEQ ID NO: 94、SEQ ID NO: 96、SEQ ID NO: 98、SEQ ID NO: 100、SEQ ID NO: 102、SEQ ID NO: 104、SEQ ID NO: 106、SEQ ID NO: 108、SEQ ID NO: 110、SEQ ID NO: 112、及SEQ ID NO: 114。
一方面,ET
AR-2抗體亦包含一個或兩個胺基酸序列,其中各胺基酸序列獨立地選自於以下所列胺基酸序列:
a. 輕鏈CDR1胺基酸序列:SEQ ID NO: 8、SEQ ID NO: 10、SEQ ID NO: 12、SEQ ID NO: 14、SEQ ID NO: 16、SEQ ID NO: 18、SEQ ID NO: 20、SEQ ID NO: 22、SEQ ID NO: 24、SEQ ID NO: 26、SEQ ID NO: 28、及SEQ ID NO: 30;及
b. 重鏈CDR1胺基酸序列:SEQ ID NO: 70、SEQ ID NO: 72、SEQ ID NO: 74、SEQ ID NO: 76、SEQ ID NO: 78、SEQ ID NO: 80、SEQ ID NO: 82、SEQ ID NO: 84、SEQ ID NO: 86、SEQ ID NO: 88、及SEQ ID NO: 90。
另一方面,ET
AR-2抗體亦包含一個或兩個胺基酸序列,其中各胺基酸序列獨立地選自於以下所列胺基酸序列:
a. 輕鏈CDR3胺基酸序列:SEQ ID NO: 50、SEQ ID NO: 52、SEQ ID NO: 54、SEQ ID NO: 56、SEQ ID NO: 58、SEQ ID NO: 60、SEQ ID NO: 62、SEQ ID NO: 64、SEQ ID NO: 66、及SEQ ID NO: 68;及
b. 重鏈CDR3胺基酸序列:SEQ ID NO: 116、SEQ ID NO: 118、SEQ ID NO: 120、SEQ ID NO: 122、SEQ ID NO: 124、SEQ ID NO: 126、SEQ ID NO: 128、SEQ ID NO: 130、SEQ ID NO: 132、SEQ ID NO: 134、及SEQ ID NO: 136。
在另一個實施方式中,本文提供之ET
AR抗體(ET
AR-3抗體),其包含一個或兩個胺基酸序列,其中各胺基酸序列獨立地選自於以下所列胺基酸序列:
a. 輕鏈CDR3胺基酸序列:SEQ ID NO: 50、SEQ ID NO: 52、SEQ ID NO: 54、SEQ ID NO: 56、SEQ ID NO: 58、SEQ ID NO: 60、SEQ ID NO: 62、SEQ ID NO: 64、SEQ ID NO: 66、及SEQ ID NO: 68;及
b. 重鏈CDR3胺基酸序列:SEQ ID NO: 116、SEQ ID NO: 118、SEQ ID NO: 120、SEQ ID NO: 122、SEQ ID NO: 124、SEQ ID NO: 126、SEQ ID NO: 128、SEQ ID NO: 130、SEQ ID NO: 132、SEQ ID NO: 134、及SEQ ID NO: 136。
一方面,ET
AR-3抗體亦包含一個或兩個胺基酸序列,其中各胺基酸序列獨立地選自於以下所列胺基酸序列:
a. 輕鏈CDR1胺基酸序列:SEQ ID NO: 8、SEQ ID NO: 10、SEQ ID NO: 12、SEQ ID NO: 14、SEQ ID NO: 16、SEQ ID NO: 18、SEQ ID NO: 20、SEQ ID NO: 22、SEQ ID NO: 24、SEQ ID NO: 26、SEQ ID NO: 28、及SEQ ID NO: 30;及
b. 重鏈CDR1胺基酸序列:SEQ ID NO: 70、SEQ ID NO: 72、SEQ ID NO: 74、SEQ ID NO: 76、SEQ ID NO: 78、SEQ ID NO: 80、SEQ ID NO: 82、SEQ ID NO: 84、SEQ ID NO: 86、SEQ ID NO: 88、及SEQ ID NO: 90。
另一方面,ET
AR-3抗體亦包含一個或兩個胺基酸序列,其中各胺基酸序列獨立地選自於以下所列胺基酸序列:
a. 輕鏈CDR2胺基酸序列:SEQ ID NO: 32、SEQ ID NO: 34、SEQ ID NO: 36、SEQ ID NO: 38、SEQ ID NO: 40、SEQ ID NO: 42、SEQ ID NO: 44、SEQ ID NO: 46、及SEQ ID NO: 48;及
b. 重鏈CDR2胺基酸序列:SEQ ID NO: 92、SEQ ID NO: 94、SEQ ID NO: 96、SEQ ID NO: 98、SEQ ID NO: 100、SEQ ID NO: 102、SEQ ID NO: 104、SEQ ID NO: 106、SEQ ID NO: 108、SEQ ID NO: 110、SEQ ID NO: 112、及SEQ ID NO: 114。
在一個實施方式中,本文提供之ET
AR抗體包含:
a. 一個獨立地選自於以下所列之輕鏈CDR1胺基酸序列:SEQ ID NO: 8、SEQ ID NO: 10、SEQ ID NO: 12、SEQ ID NO: 14、SEQ ID NO: 16、SEQ ID NO: 18、SEQ ID NO: 20、SEQ ID NO: 22、SEQ ID NO: 24、SEQ ID NO: 26、SEQ ID NO: 28、及SEQ ID NO: 30;
b. 一個獨立地選自於以下所列之輕鏈CDR2胺基酸序列:SEQ ID NO: 32、SEQ ID NO: 34、SEQ ID NO: 36、SEQ ID NO: 38、SEQ ID NO: 40、SEQ ID NO: 42、SEQ ID NO: 44、SEQ ID NO: 46、及SEQ ID NO: 48;
c. 一個獨立地選自於以下所列之輕鏈CDR3胺基酸序列:SEQ ID NO: 50、SEQ ID NO: 52、SEQ ID NO: 54、SEQ ID NO: 56、SEQ ID NO: 58、SEQ ID NO: 60、SEQ ID NO: 62、SEQ ID NO: 64、SEQ ID NO: 66、及SEQ ID NO: 68;
d. 一個獨立地選自於以下所列之重鏈CDR1胺基酸序列:SEQ ID NO: 70、SEQ ID NO: 72、SEQ ID NO: 74、SEQ ID NO: 76、SEQ ID NO: 78、SEQ ID NO: 80、SEQ ID NO: 82、SEQ ID NO: 84、SEQ ID NO: 86、SEQ ID NO: 88、及SEQ ID NO: 90;
e. 一個獨立地選自於以下所列之重鏈CDR2胺基酸序列:SEQ ID NO: 92、SEQ ID NO: 94、SEQ ID NO: 96、SEQ ID NO: 98、SEQ ID NO: 100、SEQ ID NO: 102、SEQ ID NO: 104、SEQ ID NO: 106、SEQ ID NO: 108、SEQ ID NO: 110、SEQ ID NO: 112、及SEQ ID NO: 114;及
f. 一個獨立地選自於以下所列之重鏈CDR3胺基酸序列:SEQ ID NO: 116、SEQ ID NO: 118、SEQ ID NO: 120、SEQ ID NO: 122、SEQ ID NO: 124、SEQ ID NO: 126、SEQ ID NO: 128、SEQ ID NO: 130、SEQ ID NO: 132、SEQ ID NO: 134、及SEQ ID NO: 136。
在一個實施方式中,本文提供之ET
AR抗體包含一個獨立地選自於以下所列之輕鏈CDR3胺基酸序列:SEQ ID NO: 50、SEQ ID NO: 52、SEQ ID NO: 54、SEQ ID NO: 56、SEQ ID NO: 58、SEQ ID NO: 60、SEQ ID NO: 62、SEQ ID NO: 64、SEQ ID NO: 66、及SEQ ID NO: 68。在另一個實施方式中,本文提供之ET
AR抗體包含一個獨立地選自於以下所列之重鏈CDR3胺基酸序列:SEQ ID NO: 116、SEQ ID NO: 118、SEQ ID NO: 120、SEQ ID NO: 122、SEQ ID NO: 124、SEQ ID NO: 126、SEQ ID NO: 128、SEQ ID NO: 130、SEQ ID NO: 132、SEQ ID NO: 134、及SEQ ID NO: 136。在另一個實施方式中,本文提供之ET
AR抗體包含一個獨立地選自於以下所列之輕鏈與重鏈CDR3胺基酸序列之組合:SEQ ID NO: 50與SEQ ID NO: 116、SEQ ID NO: 62與SEQ ID NO: 128、SEQ ID NO: 62與SEQ ID NO: 130、SEQ ID NO: 64與SEQ ID NO: 132、SEQ ID NO: 66與SEQ ID NO: 134、及SEQ ID NO: 68與SEQ ID NO: 136。
在另一個實施方式中,本文提供之ET
AR抗體,其包含一個或兩個胺基酸序列,其中各胺基酸序列獨立地選自於以下所列胺基酸序列:
a. 輕鏈可變域胺基酸序列:SEQ ID NO: 138 (L1)、SEQ ID NO: 140 (L2)、SEQ ID NO: 142 (L3)、SEQ ID NO: 144 (L4)、SEQ ID NO: 146 (L5)、SEQ ID NO: 148 (L6)、SEQ ID NO: 150 (L7)、SEQ ID NO: 152 (L8)、SEQ ID NO: 154 (L9)、SEQ ID NO: 156 (L10)、SEQ ID NO: 158 (L11)、SEQ ID NO: 160 (L12)、SEQ ID NO: 162 (L13)、及SEQ ID NO: 164 (L14)、及與其有至少80%、至少85%、至少90%、或至少95%相同之胺基酸序列;及
b. 重鏈可變域胺基酸序列:SEQ ID NO: 166 (H1)、SEQ ID NO: 168 (H2)、SEQ ID NO: 170 (H3)、SEQ ID NO: 172 (H4)、SEQ ID NO: 174 (H5)、SEQ ID NO: 176 (H6)、SEQ ID NO: 178 (H7)、SEQ ID NO: 180 (H8)、SEQ ID NO: 182 (H9)、SEQ ID NO: 184 (H10)、SEQ ID NO: 186 (H11)、SEQ ID NO: 188 (H12)、SEQ ID NO: 190 (H13)、及SEQ ID NO: 192 (H14)、及與其有至少80%、至少85%、至少90%、或至少95%相同之胺基酸序列。
在另一個實施方式中,本文提供之ET
AR抗體之多聚核苷酸編碼序列包含一個或兩個多聚核苷酸序列,其中各多聚核苷酸序列獨立地選自於以下所列多聚核苷酸序列:
a. 輕鏈可變域之多聚核苷酸編碼序列:SEQ ID NO: 137、SEQ ID NO: 139、SEQ ID NO: 141、SEQ ID NO: 143、SEQ ID NO: 145、SEQ ID NO: 147、SEQ ID NO: 149、SEQ ID NO: 151、SEQ ID NO: 153、SEQ ID NO: 155、SEQ ID NO: 157、SEQ ID NO: 159、SEQ ID NO: 161、及SEQ ID NO: 163、及與其有至少80%、至少85%、至少90%、或至少95%相同之多聚核苷酸序列;及
b. 重鏈可變域之多聚核苷酸編碼序列:SEQ ID NO: 165、SEQ ID NO: 167、SEQ ID NO: 169、SEQ ID NO: 171、SEQ ID NO: 173、SEQ ID NO: 175、SEQ ID NO: 177、SEQ ID NO: 179、SEQ ID NO: 181、SEQ ID NO: 183、SEQ ID NO: 185、SEQ ID NO: 187、SEQ ID NO: 189、及SEQ ID NO: 191、及與其有至少80%、至少85%、至少90%、或至少95%相同之多聚核苷酸序列。
在另一個實施方式中,本文提供之ET
AR抗體,其包含:
a. 一個獨立地選自於以下所列之輕鏈可變域胺基酸序列:SEQ ID NO: 138 (L1)、SEQ ID NO: 140 (L2)、SEQ ID NO: 142 (L3)、SEQ ID NO: 144 (L4)、SEQ ID NO: 146 (L5)、SEQ ID NO: 148 (L6)、SEQ ID NO: 150 (L7)、SEQ ID NO: 152 (L8)、SEQ ID NO: 154 (L9)、SEQ ID NO: 156 (L10)、SEQ ID NO: 158 (L11)、SEQ ID NO: 160 (L12)、SEQ ID NO: 162 (L13)、及SEQ ID NO: 164 (L14)、及與其有至少80%、至少85%、至少90%、或至少95%相同之胺基酸序列;及
b. 一個獨立地選自於以下所列之重鏈可變域胺基酸序列:SEQ ID NO: 166 (H1)、SEQ ID NO: 168 (H2)、SEQ ID NO: 170 (H3)、SEQ ID NO: 172 (H4)、SEQ ID NO: 174 (H5)、SEQ ID NO: 176 (H6)、SEQ ID NO: 178 (H7)、SEQ ID NO: 180 (H8)、SEQ ID NO: 182 (H9)、SEQ ID NO: 184 (H10)、SEQ ID NO: 186 (H11)、SEQ ID NO: 188 (H12)、SEQ ID NO: 190 (H13)、及SEQ ID NO: 192 (H14)、及與其有至少80%、至少85%、至少90%、或至少95%相同之胺基酸序列。
在另一個實施方式中,本文提供之ET
AR抗體,其包含:
a. 一個獨立地選自於以下所列之輕鏈可變域胺基酸序列:SEQ ID NO: 138 (L1)、SEQ ID NO: 140 (L2)、SEQ ID NO: 142 (L3)、SEQ ID NO: 144 (L4)、SEQ ID NO: 146 (L5)、SEQ ID NO: 148 (L6)、SEQ ID NO: 150 (L7)、SEQ ID NO: 152 (L8)、SEQ ID NO: 154 (L9)、SEQ ID NO: 156 (L10)、SEQ ID NO: 158 (L11)、SEQ ID NO: 160 (L12)、SEQ ID NO: 162 (L13)、及SEQ ID NO: 164 (L14);及
b. 一個獨立地選自於以下所列之重鏈可變域胺基酸序列:SEQ ID NO: 166 (H1)、SEQ ID NO: 168 (H2)、SEQ ID NO: 170 (H3)、SEQ ID NO: 172 (H4)、SEQ ID NO: 174 (H5)、SEQ ID NO: 176 (H6)、SEQ ID NO: 178 (H7)、SEQ ID NO: 180 (H8)、SEQ ID NO: 182 (H9)、SEQ ID NO: 184 (H10)、SEQ ID NO: 186 (H11)、SEQ ID NO: 188 (H12)、SEQ ID NO: 190 (H13)、及SEQ ID NO: 192 (H14)。
在另一個實施方式中,本文提供之ET
AR抗體包含一個獨立地選自於以下所列之輕鏈與重鏈可變域胺基酸序列之組合:SEQ ID NO: 138及SEQ ID NO: 166 (L1H1)、SEQ ID NO: 140及SEQ ID NO: 168 (L2H2)、SEQ ID NO: 142及SEQ ID NO: 170 (L3H3)、SEQ ID NO: 144及SEQ ID NO: 172 (L4H4)、SEQ ID NO: 146及SEQ ID NO: 174 (L5H5)、SEQ ID NO: 148及SEQ ID NO: 176 (L6H6)、SEQ ID NO: 150及SEQ ID NO: 178 (L7H7)、SEQ ID NO: 152及SEQ ID NO: 180 (L8H8)、SEQ ID NO: 154及SEQ ID NO: 182 (L9H9)、SEQ ID NO: 156及SEQ ID NO: 184 (L10H10)、SEQ ID NO: 158及SEQ ID NO: 186 (L11H11)、SEQ ID NO: 160及SEQ ID NO: 188 (L12H12)、SEQ ID NO: 162及SEQ ID NO: 190 (L13H13)、及SEQ ID NO: 164及SEQ ID NO: 192 (L14H14)。
本文亦可用「LxHy」符號來表示本文提供之ET
AR抗體,其中「x」對應於輕鏈可變區並且「y」對應於重鏈可變區。例如,L2H1指具有包含SEQ ID NO: 140 (L2)胺基酸序列之輕鏈可變區及包含SEQ ID NO: 166 (H1)胺基酸序列之重鏈可變區的抗體。
在另一個實施方式中,本文提供之ET
AR抗體包含選自L1-L14之輕鏈可變區或選自H1-H14之重鏈可變區及其片段、衍生物、突變蛋白、或變異體之抗體。
在另一個實施方式中,本文提供之ET
AR抗體包含一個獨立地選自於以下所列之輕鏈與重鏈CDR3胺基酸序列之組合:SEQ ID NO: 138與SEQ ID NO: 166、SEQ ID NO: 150與SEQ ID NO: 178、SEQ ID NO: 152與SEQ ID NO: 180、SEQ ID NO: 154與SEQ ID NO: 182、SEQ ID NO: 156與SEQ ID NO: 184、SEQ ID NO: 158與SEQ ID NO: 186、SEQ ID NO: 160與SEQ ID NO: 188、SEQ ID NO: 162與SEQ ID NO: 190、及SEQ ID NO: 164與SEQ ID NO: 192。
在一個實施方式中,本文提供之ET
AR抗體包含SEQ ID NO: 138輕鏈可變域胺基酸序列或SEQ ID NO: 166重鏈可變域胺基酸序列。在另一個實施方式中,本文提供之ET
AR抗體包含SEQ ID NO: 138輕鏈可變域胺基酸序列及SEQ ID NO: 166之重鏈可變域胺基酸序列之組合。
在另一個實施方式中,本文提供之ET
AR抗體亦包含恆定區胺基酸序列,其中各恆定區胺基酸序列獨立地選自於以下所列之胺基酸序列:
a. 輕鏈恆定區胺基酸序列:SEQ ID NO: 194及SEQ ID NO: 196;及
b. 重鏈恆定區胺基酸序列:SEQ ID NO: 198。
在另一個實施方式中,本文提供之ET
AR抗體亦包含恆定區胺基酸序列,其中各恆定區胺基酸序列獨立地選自於以下所列之輕鏈及重鏈恆定區胺基酸序列之組合:
a. 輕鏈恆定區胺基酸序列SEQ ID NO: 194及重鏈恆定區胺基酸序列SEQ ID NO: 198之組合;
b. 輕鏈恆定區胺基酸序列SEQ ID NO: 196及重鏈恆定區胺基酸序列SEQ ID NO: 198之組合。
在一個實施方案中,本文提供之抗體包含本文所列輕鏈及重鏈CDR及FR (構架)之胺基酸序列。在一個實施方案中,該抗體包含本文所列之輕鏈CDR1序列。在另一個實施方案中,該抗體包含本文所列之輕鏈CDR2序列。在另一個實施方案中,該抗體包含本文所列之輕鏈CDR3序列。在另一個實施方案中,該抗體包含本文所列之重鏈CDR1序列。在另一個實施方案中,該抗體包含本文所列之重鏈CDR2序列。在另一個實施方案中,該抗體包含本文所列之重鏈CDR3序列。在另一個實施方案中,該抗體包含本文所列之輕鏈FR1序列。在另一個實施方案中,該抗體包含本文所列之輕鏈FR2序列。在另一個實施方案中,該抗體包含本文所列輕鏈之FR3序列。在另一個實施方案中,該抗體包含本文所列之輕鏈FR4序列。在另一個實施方案中,該抗體包含本文所列之重鏈FR1序列。在另一個實施方案中,該抗體包含本文所列重鏈之FR2序列。在另一個實施方案中,該抗體包含本文所列之重鏈FR3序列。在另一個實施方案中,該抗體包含本文所列之重鏈FR4序列。
在一個實施方案中,該抗體之CDR3序列與本文所列輕重鏈CDR3胺基酸序列SEQ ID NO: 50與SEQ ID NO: 116之組合相差最多不超過6、5、4、3、2、或1個單胺基酸添加、替換及/或缺失。在另一個實施方案中,該抗體之輕鏈CDR3序列與本文所列輕鏈CDR3胺基酸序列SEQ ID NO: 50相差不得超過6、5、4、3、2、或1個單胺基酸添加、替換及/或缺失。在另一個實施方案中,該抗體之輕鏈CDR3序列與本文所列輕鏈CDR3胺基酸序列SEQ ID NO: 50相差不得超過6、5、4、3、2、或1個單胺基酸添加、替換及/或缺失,並且該抗體之重鏈CDR3序列與本文所列重鏈CDR3胺基酸序列SEQ ID NO: 116或SEQ ID NO: 118相差最多不超過6、5、4、3、2、或1個單胺基酸添加、替換及/或缺失。在另一個實施方案中,該抗體進一步包含1、2、3、4、5、或6個本文所列輕重鏈CDR輕重鏈序列組合。在另一個實施方案中,該抗體進一步包含1、2、3、4、5、或6個CDR輕重鏈序列組合,各序列獨自與本文所列輕重鏈CDR3胺基酸序列SEQ ID NO: 50與SEQ ID NO: 116之組合相差最多不超過6、5、4、3、2、或1個單胺基酸。在另一個實施方案中,該抗體包含本文所列輕鏈可變區之CDR及重鏈可變區之CDR。在另一實施方案中,該抗體包含本文所列之1、2、3、4、5、及/或6個CDR輕重鏈序列組合。
在一個實施方案中,該抗體(例如抗體或抗體片段)包含本文所列L1輕鏈可變域序列。在一個實施方案中,該輕鏈可變域包含與L1之輕鏈可變域序列存在15、14、13、12、11、10、9、8、7、6、5、4、3、2、或1個胺基酸差異之胺基酸序列,其中各該序列之差異獨立為一個胺基酸殘基之缺失、插入或替換。在另一個實施方案中,該輕鏈可變域包含與L1之輕鏈可變域序列有至少70%、至少75%、至少80%、至少85%、至少90%、至少95%、至少97%、或至少99%相同之胺基酸序列。在另一個實施方案中,該輕鏈可變域多聚核苷酸編碼序列包含與L1多聚核苷酸編碼序列有至少70%、至少75%、至少80%、至少85%、至少90%、至少95%、至少97%、或至少99%相同之核苷酸編碼序列。在另一個實施方案中,該輕鏈可變域多聚核苷酸編碼序列包含在中等條件下與L1之輕鏈可變域之多聚核苷酸編碼序列互補序列雜交的多聚核苷酸序列。在另一個實施方棠中,該輕鏈可變域多聚核苷酸編碼序列包含在嚴格條件下與L1之輕鏈可變域之多聚核苷酸編碼序列互補序列雜交的多聚核苷酸序列。
在一個實施方案中,該抗體(例如抗體或抗體片段)包含本文所列H1重鏈可變域序列。在另一個實施方案中,該可變域包含與H1之重鏈可變域序列存在15、14、13、12、11、10、9、8、7、6、5、4、3、2、或1個胺基酸差異之胺基酸序列,其中各該序列之差異獨立為一個胺基酸殘基之缺失、插入或替換。在另一個實施方案中,該重鏈可變域包含與H1之重鏈可變域序列有至少70%、至少75%、至少80%、至少85%、至少90%、至少95%、至少97%、或至少99%相同之胺基酸序列。在另一個實施方案中,該重鏈可變域多聚核苷酸編碼序列包含與H1多聚核苷酸編碼序列有至少70%、至少75%、至少80%、至少85%、至少90%、至少95%、至少97%、或至少99%相同之核苷酸編碼序列。在另一個實施方案中,該重鏈可變域多聚核苷酸編碼序列包含在中等嚴格條件下與H1之重鏈可變域之多聚核苷酸編碼序列互補序列雜交的多聚核苷酸序列。在一個實施方案中,該重鏈可變域多聚核苷酸編碼序列包含在嚴格條件下與H1之重鏈可變域之多聚核苷酸編碼序列互補序列雜交的多聚核苷酸序列。
在一個實施方案中,本文提供之抗體包括包含組合L1H1、L2H2、L3H3、L4H4、L5H5、L6H6、L7H7、L8H8、L9H9、L10H10、L11H11、L12H12、L13H13、或L14H14之抗體,或其期望表型(例如,IgA、IgG1、IgG2a、IgG2b、IgG3、IgM、IgE及IgD),或其Fab或F(ab')
2片段。
在一個實施方案中,本文提供之抗體包括包含組合L1H1之抗體,或其類轉換的抗體(例如,IgA、IgG1、IgG2a、IgG2b、IgG3、IgM、IgE及IgD),或其Fab或F(ab')
2片段。
本文提供之抗體(例如,抗體、抗體片段、及抗體衍生物)可包含此項技術已知之恆定區中任何一個。輕鏈恆定區可為例如κ或λ型輕鏈恆定區,例如小鼠κ或λ型輕鏈恆定區。重鏈恆定區可為例如α、δ、ε、γ、或μ型重鏈恆定區,例如小鼠α、δ、ε、γ、或μ型重鏈恆定區。在一個實施方案中,該輕鏈或重鏈恆定區為天然恆定區之片段、衍生物、變異體、或突變蛋白。
在一個實施方案中,本文提供之抗體進一步包含恆定輕鏈κ或λ域或此等之片段。輕鏈恆定區序列及他們的多聚核苷酸編碼序列提供如下:
多聚核苷酸(κ),(SEQ ID NO: 193);胺基酸(κ),(SEQ ID NO: 194);
多聚核苷酸(λ),(SEQ ID NO: 195);胺基酸(λ),(SEQ ID NO: 196)。
在另一個實施方案中,本文提供之抗體進一步包含重鏈恆定域或其片段。重鏈恆定區序列及他的多聚核苷酸編碼序列提供如下:
多聚核苷酸(IgG1),(SEQ ID NO: 197);胺基酸(IgG1),(SEQ ID NO: 198)。
在一個實施方式中,本文所提供之ET
AR抗體選自鼠源抗體、人源化抗體、嵌合抗體、單株抗體、多株抗體、重組抗體、抗原結合抗體片段、單鏈抗體、雙鏈抗體、三鏈抗體、四鏈抗體、Fab片段、F(ab')
x片段、域抗體、IgD抗體、IgE抗體、IgM抗體、IgGl抗體、IgG2抗體、IgG3抗體、及IgG4抗體。在另一個實施方式中,本文提供之ET
AR抗體為ET
AR單株抗體。在另一個實施方式中,本文提供之ET
AR抗體為鼠源ET
AR抗體。本文提供之ET
AR抗體為人源化ET
AR抗體。
在一個實施方式中,本文提供之ET
AR抗體為單株抗體A-1 (其包含SEQ ID NO: 138與SEQ ID NO: 166)、A-7 (其包含SEQ ID NO: 150與SEQ ID NO: 178)、A-8 (其包含SEQ ID NO: 152與SEQ ID NO: 180)、A-9 (其包含SEQ ID NO: 154與SEQ ID NO: 182)、A-10 (其包含SEQ ID NO: 156與SEQ ID NO: 184)、A-11 (其包含SEQ ID NO: 158與SEQ ID NO: 186)、A-12 (其包含SEQ ID NO: 160與SEQ ID NO: 188)、A-13 (其包含SEQ ID NO: 162與SEQ ID NO: 190)、或A-14 (其包含SEQ ID NO: 164與SEQ ID NO: 192)。
抗體及抗體片段
在一個實施方案中,本文提供之抗體為完整抗體(包括具有全長重及/或輕鏈之多株、單株、嵌合、人源化或人類抗體)。在另一個實施方案中,本文提供之抗體為抗體片段,例如F(ab')2、Fab、Fab'、Fv、Fc、或Fd片段,並可整合入單域抗體、單鏈抗體、最大抗體(maxibody)、微抗體(minibody)、內抗體(intrabody)、二鏈抗體、三鏈抗體、四鏈抗體、v-NAR及bis-scFv (參見,例如Hollinger及Hudson,2005,Nature Biotechnology 23:1126-1136)。在另一個實施方案中,本文提供之抗體亦包括抗體多肽例如美國專利號6703199中所揭示之彼等,包括纖維結合素多肽單抗體。在另一個實施方案中,本文提供之抗體亦包括其他抗體多肽揭示於美國專利出版物2005/0238646,其為單鏈多肽。
在一個實施方案中,使用核苷酸引物擴增在雜交瘤中表現相關單株抗體之基因之可變區。此等引物可由一般熟習此項技術者合成或自商業來源購買(參見,例如Stratagene,La Jolla,California),此等廠商銷售鼠及人可變區引物包括V
Ha、V
Hb、V
Hc、V
Hd、C
H1、V
L及C
L區之引物。此等引物可用於擴增重鏈或輕鏈可變區,然後將其分別插入載體例如IMMUNOZAP
TMH或ILLLFFLUNOZAP
TML (Stratagene)中。然後將此等載體引入大腸桿菌、酵母或哺乳動物為基礎之表現系統。可使用此等方法生產大量包含V
H及V
L域融合之單鏈蛋白(參見Bird等,1988,
Science242:423-426)。
一旦使用上述任何免疫及其他技術獲得了根據本文生產抗體之細胞,可根據本文所述標準方法藉由分離並自其擴增DNA或mRNA將特異抗體基因選殖。定序自其生產之抗體並鑑定CDR,可如之前所述對編碼CDR之DNA進行操作以生成根據本文提供之其他抗體。
本文提供之抗體較佳在本文描述之基於細胞之測定法中及/或本文描述之體內測定法中調節內皮素信號傳導及/或交叉阻斷本申請所述抗體之一的結合及/或經本申請所述抗體之一被結合ET
AR交叉阻斷。因此可使用本文所述測定法鑑定該類結合劑。
在一些實施方案中,藉由首先鑑定在本文描述之基於細胞的及/或體內測定法中與過表現ET
AR之細胞結合及/或中和及/或交叉阻斷本申請描述之抗體及/或經本申請描述之抗體之一被結合ET
AR交叉阻斷的抗體以生成抗體。
熟習此項技術者應理解的係一些蛋白質,例如抗體,可能進行可多種轉錄後修飾。此等修飾之類型及程度取決於用於表現該蛋白之宿主細胞株以及培養條件。該類修飾包括糖基化作用、甲硫胺酸氧化、二酮哌𠯤形成、天冬胺酸異構化及天冬醯胺脫醯胺作用之變化。由於羧肽酶之作用頻繁修飾導致羧端鹼性殘基(例如離胺酸或精胺酸)之丟失(如Harris,1995,
Journal of Chromatography705:129-134中所述)。
生產鼠單株抗體之可選擇方法為將雜交瘤細胞注入同系基因小鼠之腹膜腔,例如經處理(例如姥鮫烷初次免疫)促進形成包含單株抗體之腹水之小鼠。可藉由多種已確立之技術分離及純化單株抗體。該類分離技術包括使用蛋白A-瓊脂糖之親和層析法、分子排阻層析法及離子交換層析法,參見,例如,Coligan第2.7.1-2.7.12頁及第2.9.1-2.9.3頁;Baines等,「Purification of Immunoglobulin G (IgG)」, Methods in Molecular Biology,第10卷,第79-104頁(The Humana Press,Inc.,1992)。可使用基於抗體之特殊性質(例如,重鏈或輕鏈同種型、結合特異性等)篩選的適當配基藉由親和層析法純化單株抗體。固定化於固體載體之適當配基之實例包括蛋白A、蛋白G、抗恆定區(輕鏈或重鏈)抗體、抗獨特型抗體以及TGF-p結合蛋白或其片段或變異體。
可使用抗體結合位點中央的互補決定區(CDR)之分子進化分離親和性增加之抗體,例如對c-erbB-2親和性增加之抗體,如Schier等,1996,J. Mol. Biol. 263:551-567所述。因此,該類技術可用於製備人內皮素受體之抗體。
例如可在偵測是否存在內皮素受體之體外或體內測定法中使用針對人內皮素受體之抗體。
亦可藉由任何傳統技術製備抗體。例如,可自天然表現此等抗體之細胞將其純化(例如,可自生產抗體之雜交瘤將其純化)或使用此項技術任何已知之技術在重組表現系統中生產。參見,例如,Monoclonal Antibodies, Hybridomas: A New Dimension in Biological Analyses, Kennet等編輯,Plenum Press (1980);及Antibodies: A Laboratory Manual, Harlow及Land編輯, Cold Spring Harbor Laboratory Press (1988)。此在下文之核酸部分討論。
可藉由任何已知技術製備抗體並篩選期望性質。一些技術係關於分離編碼相關抗體(例如,抗內皮素受體抗體)之多肽鏈(或其部分)的核酸,並藉由重組DNA技術操作核酸。該核酸可與另一相關核酸融合或經修飾(例如藉由誘變或其他傳統技術)以添加、缺失或替換一或多個胺基酸殘基。
當需要提高根據本文包含一或多個上述CDR之抗體的親和性時,可藉由多種親和成熟方案包括維持CDR (Yang等,1995,
J. Mol. Biol.254:392-403)、鏈替換(Marks等,1992,
Bio/Technology10:779-783)、使用大腸桿菌之突變株(Low等,1996,
J. Mol. Biol.250:350-368) DNA重排(Patten等,1997,
Curr. Opin. Biotechnol.8:724-733)、噬菌體展示(Thompson等,1996,
J. Mol. Biol.256:7-88)以及其他PCR技術(Crameri等,1998,
Nature391:288-291)。所有此等親和力成熟方法討論於Vaughan等,1998,
Nature Biotechnology16:535-539中。
在一個實施方案中,本文提供之抗體為抗內皮素受體片段。該片段可完全由抗體衍生序列組成或可包含附加序列。抗原結合片段之實例包括Fab、F(ab')2、單鏈抗體、雙鏈抗體、三鏈抗體、四鏈抗體及域抗體,其他實例提供於Lunde等,2002,
Biochem. Soc. Trans.30:500-06。
可經胺基酸橋(短肽接頭)連接重鏈及輕鏈可變域(Fv區)形成單鏈抗體,從而得到單多肽鏈。已藉由將編碼肽接頭之DNA融合在編碼兩個可變域多肽(V
L及V
H)的DNA之間製備該單鏈FV (scFv)。所得多肽可摺疊回自身形成抗原結合單體,或他們可形成多聚體(例如,二聚體、三聚體或四聚體),取決於兩個可變域之間的可撓性接頭之長度(Kortt等,1997,
Prot. Eng.10:423;Kortt等2001,
Biomol. Eng.18:95-108)。藉由組合包含多肽之不同V
L及V
H,可形成與不同表型結合之多體scFv (Kriangkum等,2001,
Biomol. Eng.18:31-40)。已研發的用於生產單鏈抗體之技術包括美國專利號4946778;Bird,1988,
Science242:423;Huston等,1988,
Proc. Natl. Acad. Sci. USA85:5879-5883;Ward等,1989,
Nature334:544-546;de Graaf等,2002,
Methods Mol Biol.178:379-87中描述之彼等。來源於本文提供之抗體之單鏈抗體包括但不限於包含可變域組合L1H1之scFv,均涵蓋於本文。
亦可藉由抗體之蛋白水解作用例如根據傳統方法用胃蛋白酶或木瓜蛋白酶消化完整的抗體獲得來源於抗體之抗原結合片段。舉例而言,可用胃蛋白酶酶裂解抗體提供稱作F(ab')2之SS片段生產抗體片段。可使用巰基還原劑進一步裂解這一片段產生3.5S Fab'單價片段。可選擇的方案有,使用巰基保護基團進行該裂解反應得到二硫鍵之裂解;另外亦可以使用木瓜蛋白酶之酶裂解直接產生兩個單價Fab片段及一個Fc片段。此等方法描述於例如Goldenberg,美國專利號4,331,647,Nisonoff等,1960,Arch. Biochem. Biophys. 89:230;Porter,1959,Biochem. J. 73:119;Edelman等,Methods in Enzymology l:422 (Academic Press,1967);以及Andrews及Titus, J.A. Current Protocols in Immunology (Coligan等編輯,John Wiley&Sons, 2003),第2.8,1-2.8.10頁及第2.10A.1-2.10A.5頁。其他裂解抗體之方法,例如製備重鏈以形成單價重、輕鏈片段(Fd),進一步裂解片段或亦可使用其他酶、化學或基因技術,只要片段與可被該完整抗體識別之抗原結合。
另一種形式的抗體片段為包含一或多個抗體互補決定區(CDR)之肽。可藉由構築編碼相關CDR之多肽獲得CDR。例如可藉由使用聚合酶鏈式反應用抗體生成細胞之mRNA作為模板合成可變區製備該類多肽,參見,例如,Larrick等,1991,Methods: A Companion to Methods in Enzymology 2:106;Courtenay-Luck,「Genetic Manipulation of Monoclonal Antibodies」, Monoclonal Antibodies:Production, Engineering and Clinical Application,Ritter等編輯,166頁(Cambridge University Press,1995);及Ward等,「Genetic Manipulation and Expression of Antibodies」, Monoclonal Antibodies: Principles and Applications,Birch等編輯,137頁(Wiley-Liss,Inc.,1995)。該抗體片段可進一步包含本文所述抗體之至少一個可變域。因此,例如,V區域可為單體並且為V
H或V
L域,其可以如下文所述之至少等於1 × 10
-7M或更低的親和度獨立與內皮素受體結合。
該可變區域可為任何天然可變域或其基因工程形式。基因工程形式指使用重組DNA工程技術生產之可變區域。該基因工程形式包括例如藉由向特異抗體之胺基酸序列插入、缺失或改變自特異抗體可變區產生的。具體實例包括包含只含一個CDR以及視情況來自一個抗體之一或多個構架胺基酸及來自另一抗體之可變區域剩餘部分,並由基因工程組裝成的可變區域。
可變區域可與至少一個其他抗體域或其片段在C端胺基酸共價連接。因此,舉例而言,存在於可變區域之V
H域可與免疫球蛋白CH1域或其片段相連。相似地,V
L域可與C
K域或其片段相連。以此種方式,例如,該抗體可為Fab片段,其中抗原結合域包含他們的C端分別與CH1及C
K域共價連接之聯合V
H及V
L域。可用其他胺基酸延長CH1域,例如以提供鉸鏈區或如Fab'片段中之部分鉸鏈域或提供其他域,例如抗體CH2及CH3域。
抗體之衍生物及變異體
例如可藉由隨機誘變或藉由定點誘變(例如寡聚核苷酸誘導之定點誘變)改變編碼對應於胺基酸序列A-1之核苷酸序列L1及H1以產生與未突變多聚核苷酸相比包含一或多個具體核苷酸替換、缺失或插入的經改變之多聚核苷酸。用於產生該類改變之技術實例描述於Walder等,1986,
Gene42:133;Bauer等,1985,
Gene37:73;Craik, 1985,
BioTechniques, 3:12-19;Smith等,1981,
Genetic Engineering: Principles and Methods,Plenum Press;以及美國專利號4518584及4737462。此等及其他方法可用於產生例如與未衍生化抗體相比具有期望性質例如親和性、親和力或對內皮素受體之特異性增強、體內或體外活性或穩定性增強或體內副作用降低的抗內皮素受體抗體之衍生物。
本文領域之其他抗內皮素受體抗體衍生物包括抗內皮素受體抗體或其片段與其他蛋白或多肽之共價或聚集結合物,例如藉由表現包含與抗內皮素受體抗體多肽之N端或C端融合的異源多肽之重組融合蛋白。例如,該結合肽可為異源信號(或引導)多肽,例如酵母α因子前導肽或例如表位標籤之肽。包含融合蛋白之抗體可包含被添加以輔助抗體之純化或鑑定的肽(例如多聚組胺酸)。抗體亦可與FLAG肽連接,如Hopp等,1988,
Bio/Technology6:1204及美國專利5011912所述。FLAG肽具有高抗原性並提供被特異單株抗體(mAb)可逆結合之表位,允許已表現重組蛋白之快速偵測及方便純化。可商業購買(Sigma-Aldrich,St. Louis,MO)用於製備其中FLAG肽與給定多肽融合之融合蛋白的試劑,在另一個實施方案中,包含一或多個抗體之寡聚體可用作內皮素受體拮抗劑或用更高級的寡聚體。寡聚體可為共價連接的或非共價連接的二聚體、三聚體或更高之寡聚體形式。可使用包含兩個或更多個抗體之寡聚體,其中一個實例為同型二聚體。其他寡聚體包括異二聚體、同型三聚體、異三聚體、同型四聚體、雜四聚體等。
一個實施方案係針對包含多個抗體之寡聚體,他們藉由與抗體融合的肽部分之間的共價或非共價相互作用連接。該類肽可為肽接頭(spacer)或具有促進寡聚化作用性質之肽。白胺酸拉鏈及某些來源於抗體之多肽為可促進抗體寡聚化之肽,如下文詳細描述。
在具體的實施方案中,寡聚體包含兩個至四個抗體。寡聚體之抗體可為任何形式,如上文所述任何形式,例如變異體或片段。較佳地,該寡聚體包含具有內皮素受體結合活性之抗體。
在一個實施方案中,使用來源於免疫球蛋白之多肽製備寡聚體。製備包含一些與抗體衍生多肽(包括Fc域)之不同部位融合的異源多肽已描述於例如Ashkenazi等,1991,
PNAS USA88:10535;Byrn等,1990,
Nature344:677;及Hollenbaugh等,
Construction of Immunoglobulin Fusion Proteins, Current Protocols in Immunology, Suppl. 4,第10.19.1-10.19.11頁。本文之一個實施方案係針對包含兩個由融合抗內皮素受體抗體之內皮素結合片段與抗體之Fc區產生的融合蛋白之二聚體。可藉由以下方式製備二聚體:例如在適當之表現載體中插入編碼融合蛋白之基因融合,在用重組表現載體轉化之宿主細胞中表現該融合基因並允許已表現融合蛋白像抗體分子一樣組裝,其中Fc部分之間的鏈間二硫鍵形成二聚體。
如本文所使用術語「Fc多肽」包括來源於抗體Fc區之天然及突變蛋白形式之多肽。亦包括包含促進二聚體化之鉸鏈區之該類多肽的截短形式。包含Fc部分(以及由其形成之寡聚體)之融合蛋白提供了在蛋白A或蛋白G管柱上進行親和層析法方便純化之優勢。
PCT申請W0 93/10151 (以參考形式併於本文)中一種適當的Fc多肽為自N端鉸鏈區延伸至人IgG1抗體之Fc區之天然C端的單鏈多肽。另一種可用的Fc多肽為美國專利5457035及Baum等,1994, EMBO J. 13:3992-4001中描述之Fc突變蛋白。該突變蛋白之胺基酸序列與W0 93/10151中所示天然Fc序列之胺基酸序列相同,除了胺基酸19自白胺酸變為丙胺酸,胺基酸20自白胺酸變為麩醯胺酸以及胺基酸22自甘胺酸變為丙胺酸。該突變蛋白表現出對Fc受體之親和力降低。在其他實施方案中,抗內皮素受體抗體之重鏈及/或輕鏈可經取代為抗體重鏈及/或輕鏈之可變部分。或者,該寡聚體為包含多個抗體之融合蛋白,包含或不包含接頭肽(spacer peptide)。此等適當的接頭肽描述於美國專利4751180及4935233。
製備寡聚抗體之另一種方法係關於使用白胺酸拉鏈。白胺酸拉鏈域為促進他們所存在之蛋白寡聚化作用的肽。最初發現白胺酸拉鏈存在於數種DNA結合蛋白中(Landschulz等,1988,
Science240:1759),此後發現存在於各種不同蛋白中。在已知的白胺酸拉鏈中為可二聚體化或三聚體化之天然肽或其衍生物。適用於生產可溶寡聚蛋白之白胺酸拉鏈域之實例描述於PCT申請W0 94/10308,來源於肺表面活性蛋白D (SPD)之白胺酸拉鏈描述於Hoppe等,1994,
FEBS Letters344:191,以參考形式併於本文。允許與其融合的異源蛋白穩定三聚體化之經修飾之白胺酸拉鏈的使用描述於Fanslow等,1994,
Semin. Immunol.6:267-78。在一種方法中,在適當的宿主細胞中表現包含與白胺酸拉鏈肽融合的抗內皮素受體抗體片段或衍生物之重組融合蛋白,自培養物上清中收集可溶寡聚抗內皮素受體抗體片段或其衍生物。
在另一個實施方案中,該抗體衍生物可包含至少本文揭示之CDR之一。舉例而言,可將一或多個CDR整合入已知的抗體骨架區(IgG1,IgG2等)或與適當的載體結合以增強其半衰期。適當載體包括但不限於Fc、白蛋白、轉鐵蛋白及類似物質。此等及其他適當的載體為此項技術已知。該結合CDR肽可為單體、二聚體、四聚體或其他形式。在一個實施方案中,一或多個水溶性多聚體在結合劑之一或多個特異位點結合,例如在胺基端。在一個實例中,抗體衍生物包含一或多個水溶性多聚體附著物包括但不限於聚乙二醇、聚氧乙烯二醇或聚丙二醇。參見,例如,美國專利號4640835、4496689、4301144、4670417、4791192及4179337,在一些實施方案中,衍生物包含一或多個一甲氧基.聚乙二醇、葡聚糖、纖維素或其他基於碳水化合物之聚合物,聚(N-乙烯基吡咯酮).聚乙二醇、聚氧乙烯多元醇(例如甘油)及聚乙烯醇,以及該類聚合物之混合物。在一些實施方案中,一或多個水溶性聚合物與一或多個側鏈隨機結合。在一些實施方案中。PEG可提高結合劑例如抗體之治療作用。一些該類方法描述於例如美國專利號6133426,其以參考形式以任何目的併於本文。
應當理解的是本文提供之抗體可具有至少一個胺基酸替換,只要該抗體保留了結合特異性。因此,抗體結構之修飾包含於本文範疇。此等可包括不破壞抗體內皮素受體結合能力之胺基酸替換,其可為保守或非保守的。保守胺基酸替換可包括非天然胺基酸殘基,其通常經化學肽合成整合而非生物系統合成。此等包括擬肽及其他反向或倒轉形式之胺基酸部分。保守胺基酸替換亦可涉及採用非天然殘基替換天然胺基酸殘基這樣對該位點胺基酸殘基之極性或電荷作用很小或沒有作用。非保守替換可涉及一類胺基酸或胺基酸類似物之一個成員與具有不同物理性質(例如,體積、極性、疏水性、電荷)之另一類胺基酸之成員交換。
而且,熟習此項技術者可生成在各期望胺基酸殘基上包含胺基酸替換之待測變異體。可使用熟習此項技術者已知之活性測定法篩選該類變異體。該類變異體可用於收集關於適當變異體之資訊。舉例而言,若發現某一胺基酸殘基會引起活性破壞、非期望之降低或不當之活性,可避免具有該類變化之變異體。換言之,基於自此等習知試驗收集之資訊,熟習此項技術者可輕鬆確定應避免進一步替換(單獨或與其他突變組合)之胺基酸。
技術人員可使用已知技術確定如本文所列之多肽之適當變異體。在一些實施方案中,熟習此項技術者可藉由靶向對於活性不重要的區域鑑定經改變後不會破壞活性之分子適當區域。在一些實施方案中,可鑑定在相似多肽中保守的殘基或分子部分。在一些實施方案中,甚至可保守替換對於生物活性或結構重要的區域而不破壞生物活性或不會有不利作用於多肽結構。此外,熟習此項技術者可考察結構-功能研究來鑑定對活性或結構重要的相似多肽中之殘基。鑒於這一對比,可預測對應於在相似蛋白中對活性或結構重要的胺基酸殘基之蛋白質中胺基酸殘基之重要性。熟習此項技術者可為此等經預測重要的胺基酸殘基選擇化學相似胺基酸替換。
熟習此項技術者亦可分析與相似多肽之結構相關的三維結構及胺基酸序列。鑒於該類資訊,熟習此項技術者可預測就三維結構而言抗體之胺基酸殘基比對。在一些實施方案中,熟習此項技術者可選擇不對經預測在蛋白質表面之胺基酸殘基進行顯著改變,因為該類殘基可能參與與其他分子之重要相互作用。許多科學出版物致力於二級結構之預測。參見,Moult,1996,
Curr. Op. Biotech.7:422-427,Chou等,1974,
Biochemistry13:222-245;Chou等,1974,
Biochemistry113:211-222;Chou等,1978,
Adv. Enzymol. Relat. Areas Mol. Biol.47:45-148;Chou等,1979,
Ann. Rev. Biochem.47:251-276;及Chou等,
Biophys. J.26:367-384。此外,目前可使用電腦程式輔助預測二級結構。舉例而言,序列同一性大於30%或相似性大於40%的兩個多肽或蛋白質通常具有相似的高級結構。近期蛋白結構資料庫(PDB)之增長增強了二級結構之可預測性,包括多肽或蛋白結構中潛在的摺疊數目。參見,Holm等,1999,
Nucl. Acid. Res.27:244-247。已表明(Brenner等,1997,
Curr. Op. Struct. Biol.7:369-376)在給定多肽或蛋白質中存在有限數目之摺疊並且一旦確定了臨界數目之結構,結構預測將變得顯著更加精確。
預測二級結構之其他方法包括「穿接(threading)」(Jones,1997,
Curr. Opin. Struct. Biol., 7:377-87;Sippl等,1996,
Structure4:15-19;「圖譜分析(profile analysis)」(Bowie等,1991,
Science253:164-170;Gribskov等,1990,
Meth. Enzym.183:146-159;Gribskov等,1987,
Proc. Nat. Acad. Sci. USA84:4355-4358及「進化聯繫(evolutionary linkage)」(參見Holm, 見上文(1999)及Brenner, 見上文(1997))。在一些實施方案中,抗體變異體包括糖基化變異體,其中與母體多肽之胺基酸序列相比改變了糖基化位點之數目及/或類型。在一些實施方案中,變異體與天然蛋白質相比具有更多或更少數目之N連接糖基化位點。或者,移除該序列之替換可移除現有的N連接糖鏈。亦提供了N連接糖鏈之重排,其中移除了一或多個N連接糖鏈位點(通常為天然存在之彼等)並創造了一或多個新的N連接位點。其他較佳抗體變異體包括半胱胺酸變異體,與母體胺基酸序列相比其中缺失或由另一胺基酸(例如絲胺酸)替換一或多個半胱胺酸殘基。當抗體必須摺疊成生物活性構象時(例如在分離可溶包涵體之後)可用半胱胺酸變異體。半胱胺酸變異體通常比天然蛋白質具有較少的半胱胺酸殘基,並通常具有偶數個半胱胺酸以最小化未配對半胱胺酸引起的相互作用。
熟習此項技術者可在需要該類替換時確定期望的胺基酸替換(保守或非保守)。在一些實施方案中,胺基酸替換可用於鑑定人內皮素受體抗體之重要殘基或者增加或降低本文所述人內皮素受體抗體之親和力。
根據一些實施方案,較佳的胺基酸替換為以下:(1)降低蛋白質水解敏感性,(2)降低氧化敏感性,(3)改變形成蛋白質複合物之結合親和力,(4)改變結合親和力及/或(4)賦予或修飾該類多肽上之其他物理化學或功能性質。根據一些實施方案,可在天然存在序列中(在一些實施方案中,在形成分子間接觸之域之外的多肽部分)進行單個或多個胺基酸替換(在一些實施方案中為保守胺基酸替換)。在一些實施方案中,保守胺基酸替換通常不會本質上改變母體序列之結構特性(例如,替換胺基酸不應破解存在於母體序列中之螺旋或干擾特徵化母體序列之其他類型二級結構)。此項技術認可之多肽二級及三級結構之實例描述於Proteins,Structures and Molecular Principles,Creighton編輯,W.H. Freeman and Company (1984);Introduction to Protein Structure,Branden及Tooze編輯, Garland Publishing (1991);以及Thornton等,1991,
Nature354:105,其以參考形式併於本文。
在一些實施方案中,本文提供之抗體可與多聚體、脂類或其他部分(moiety)化學鍵合。
抗原結合試劑可包含至少一個本文描述之CDR,其摻入生物相容性骨架結構中。在一個實例中,該生物相容性骨架結構包含足以形成構象穩定結構支持或骨架或支架之多肽或其部分,其可在侷限的表面區域展示可與抗原結合之一或多個胺基酸序列(例如,CDR、可變區等)。該類結構可為天然存在多肽或多肽「摺疊」(結構基序),或相對與天然多肽或摺疊可具有一或多個修飾,例如胺基酸添加、缺失或替換。此等支架可來源於任何物種(或多於一個物種)之多肽,例如,人類、其他哺乳動物、其他脊椎動物、無脊椎動物、細菌或病毒。
生物可溶性骨架結構通常係基於蛋白質支架或骨架而非免疫球蛋白域。舉例而言,可使用基於纖維結合素、錨蛋白、脂質運載蛋白(lipocalin)、新抑癌蛋白、細胞色素b、CP1鋅指蛋白、PST1、捲曲螺旋、LACI-D1、Z域及澱粉酶抑肽域(參見,例如,Nygren及Uhlen, 1997,
Current Opinion in Structural Biology7:463-469)。
此外,熟習此項技術者可認識到適當的結合劑包括此等抗體之部分,例如一或多個重鏈CDR1、CDR2、CDR3,輕鏈CDR1、CDR2及CDR3,如本文所具體揭示。至少一個重鏈CDR1、CDR2、CDR3、CDR1,CDR2及CDR3區具有至少一個胺基酸替換,只要該抗體保留了非替換CDR之結合特異性。該抗體之非CDR部分可為非蛋白分子,其中該結合劑交叉阻斷本文揭示之抗體與人ET
AR之結合及/或抑制經該受體之內皮素信號傳導。該抗體之非CDR部分可為非蛋白質分子,其中該抗體在競爭結合測定法中顯示出與至少抗體A-1/A-2之一所顯示相似的與人ET
AR肽之結合類型,及/或中和內皮素之活性。抗體之非CDR部分可由胺基酸組成,其中該抗體為重組結合蛋白或合成肽,並且該重組結合蛋白交叉阻斷本文揭示之抗體與人ET
AR之結合及/或中和體內或體外內皮素活性。抗體之非CDR部分可由胺基酸組成,其中該抗體為重組抗體,並且該重組抗體在競爭結合測定法中顯示出與至少抗體A-1/A-2之一所顯示相似的與人ET
AR肽之結合類型,及/或中和內皮素信號傳導。
核酸
一方面,本文提供分離之核酸分子。該核酸分子包含例如編碼全部或部分抗體之多聚核苷酸,例如本文抗體之一條鏈或兩條鏈,或其片段、衍生物、突變蛋白或變異體;足以用作雜交探針之多聚核苷酸;PCR引物或用於鑑定、分析、突變或擴增編碼多肽之多聚核苷酸的定序引物;用於抑制多聚核苷酸表現之反義核酸以及其互補序列。該核酸可為任何長度。例如他們的長度可為5、10、15、20、25、30、35、40、45、50、75、100、125、150、175、200、250、300、350、400、450、500、750、1000、1500、3000、5000或更多個核苷酸,及/或包含一或多個附加序列,例如調控序列,及/或為較大核酸例如載體之一部分。該核酸可為單鏈或雙鏈並包含RNA及/或DNA核苷酸以及其人工變異體(例如,肽核酸)。
可自經ET
AR抗原免疫之小鼠B細胞中分離編碼抗體多肽(例如,重鏈或輕鏈、僅可變域或全長)之核酸。可藉由習知方法例如聚合酶鏈式反應(PCR)分離該核酸。
編碼重鏈及輕鏈可變區之核酸序列如上文所示。熟練之技術人員可理解由於遺傳密碼之簡併性,本文揭示之各多肽序列可由更多數目之其他核酸序列編碼。本文提供編碼本文提供之抗體的各簡併核苷酸序列。
本文進一步提供在具體雜交條件下與其他核酸(例如,包含任何A-1/A-2之核苷酸序列之核酸)雜交的核酸。雜交核酸之方法為此項技術熟知的。參見,例如,Current Protocols in Molecular Biology,John Wiley & Son (1989),6.3.1-6.3.6。如本文定義,例如,中等嚴格條件使用包含5X氯化鈉/檸檬酸鈉(SSC)之預洗溶液、0.5% SDS、1.0 mM EDTA (pH 8.0)、約50%甲醯胺之雜交緩衝液、6X SSC及55℃之雜交溫度(或其他相似之雜交溶液,例如包含絢50%甲醯胺的,以42℃雜交),並且溶離條件為60℃,使用0.5X SSC、0.1% SDS。嚴格雜交條件在6X SSC中於45℃雜交,然後於68℃在0.1X SSC、0.2% SDS中洗滌一次或多次。此外,熟習此項技術者可操作雜交及/或洗滌條件以增加或降低雜交嚴格度這樣包含相互之間至少65、70、75、80、85、90、95、98或99%同源之核苷酸序列的核酸通常仍可以相互雜交。影響雜交條件選擇之基本參數及設計適當條件之指導列於例如Sambrook,Fritsch及Maniatis,1989, Molecular Cloning:A Laboratory Manual, Cold Spring Harbor Laboratory Press,第9及11章;Current Protocols in Molecular Biology,1995,Ausubel等編輯,John Wiley&Sons,Inc.,第2.10及6.3-6.4節)並可由一般熟習此項技術者基於例如DNA之長度及/或鹼基組成輕鬆確定。可藉由突變在核酸中引入變化,藉此導致其編碼之多肽(例如,抗原結舍蛋白)胺基酸序列之變化。可使用此項技術已知之任何技術引入突變。在一個實施方案中,使用例如定點誘變方案改變一或多個具體胺基酸殘基。在另一個實施方案中,使用例如隨機誘變方案改變一或多個隨機選擇之殘基。無論其如何生成,可表現突變多肽並篩選期望性質。
可將突變引入核酸而不顯著改變其編碼多肽之生物學活性。例如,可進行引起非必需胺基酸殘基處胺基酸替換之核苷酸替換。在一個實施方案中,突變本文為L-1至L-2及H-1至H-2提供之核苷酸序列或其片段、變異體或衍生物這樣其編碼包含本文所示L-1至L-2及H-1至H-2之胺基酸殘基的一或多個缺失或替換,成為兩個或多個序列相異之殘基。在另一個實施方案中,誘變作用在本文所示L-1至L-2及H-1至H-2之一或多個胺基酸殘基附近插入一個胺基酸成為兩個或多個序列相異之殘基。或者,可將一或多個突變引入核酸以選擇性改變其編碼多肽之生物學活性(例如,與ET
AR結合)。例如,該突變可在數目上或性質上改變生物學活性。量變之實例包括增加、降低或消除該活性。質變之實例包括改變抗體之抗原特異性。
在另一方面,本文提供適於用作引物或偵測本文核酸序列之雜交探針的核酸分子。本文之核酸分子可僅包含編碼本文全長多肽之核酸序列之一部分,例如,可用作探針或引物或編碼本文多肽活性部分之片段(例如,ET
AR結合部分)的片段。
基於本文核酸序列之探針可用於偵測該核酸或相似核酸,例如編碼本文多肽之轉錄物。該探針可包含標記基團,例如放射性同位素、螢光化合物、酶或酶輔因子。該類探針可用於鑑定表現該多肽之細胞。
在另一方面本文提供包含編碼本文多肽或其部分之核酸的載體。載體之實例包括但不限於質體、病毒載體、非游離基因哺乳動物載體及表現載體,例如重組表現載體。
本文之重組表現載體可包含適於該核酸在宿主細胞中表現之形式的本文核酸。該重組表現載體包括一或多個調控序列,基於用於表現之宿主細胞進行篩選,其與該預表現之核酸序列可操作性相連。調控序列包括引導核苷酸序列在多個種類宿主細胞中組成型表現的(例如,SV40早期基因增強劑、勞斯氏肉瘤病毒啟動子及細胞巨化病毒啟動子),引導僅在某些宿主細胞中核苷酸序列之表現的(例如,組織特異調控序列,參見Voss等,1986,
Trends Biochem. Sci.11:287,Maniatis等,1987,
Science236:1237,其完整內容以參考形式併於本文)以及引導核苷酸序列響應具體處理或條件之誘導型表現的(例如,哺乳動物細胞中之金屬硫堇啟動子及原核及真核系統二者中之四環黴素反應(tet-sesponsive)啟動子及/或鏈黴素反應啟動子(同前))。熟習此項技術者應理解表現載體之設計取決於例如用於轉化之宿主細胞的選擇、所需蛋白表現量等因素。本文之表現載體可引入宿主細胞,藉此生產由本文所述核酸編碼之蛋白或肽,包括融合蛋白或肽。
另一方面,本文提供可引入本文表現載體之宿主細胞。宿主細胞可為任何原核或真核細胞。原核宿主細胞包括革蘭氏陰性或革蘭氏陽性生物體,例如大腸桿菌或桿菌。更高級的真核細胞包括昆蟲細胞、酵母細胞以及哺乳動物源之確立細胞株。適當哺乳動物宿主細胞株之實例包括中國倉鼠卵巢(CHO)細胞或他們的衍生物例如Veggie CHO及在無血清培養基中生長之相關細胞株(參見Rasmussen等,1998,Cytotechnology 28:31)或CHO株DXB-11,其缺失DHFR (參見Urlaub等,1980,
Proc. Natl. Acad, Sci. USA77:4216-20)。其他CHO細胞株包括CHO-K1 (ATCC #CCL-61)、EM9 (ATCC #CRL-1861),及UV20 (ATCC# CRL-1862),其他宿主細胞包括猴腎細胞之COS-7株(ATCC #CRL-1651) (參見Gluzman等,1981,Cell 23:175)、L細胞、C127細胞、3T3細胞(ATCC CCL-163),AM-1/D細胞(描述於美國專利序列號6210924)、HeLa細胞、BHK (ATCC CRL-10)細胞株、來源於非洲綠猴腎細胞株CV1之CV1/EBNA細胞株(ATCC CCL-70) (參見McMahan等,1991,EMBO J. 10:2821)、人胚腎細胞例如293,293 EBNA或MSR 293、人上皮A431細胞、人C010205細胞、其他經轉化靈長動物細胞株、正常二倍體細胞、來源於初生組織體外培養物之細胞株、初移植體、HL-60、U937、HaK或Jurkat細胞。用於細菌、真菌、酵母及哺乳細胞宿主之適當純系及表現載體描述於Pouwels等(Cloning Vectors: A Laboratory Manual, Elsevier, 1985)。
可藉由傳統轉化或轉染技術將載體DNA引入原核或真核細胞中。對於穩定的哺乳動物轉染而言,取決於使用之表現載體及轉染技術,已知只有一小部分細胞可將外源DNA鏊合入他們的基因組中。為了鑑定及篩選此等整合子,通常將編碼篩選標記(例如抗生素抗性)之基因與所關注基因一起引入宿主細胞。較佳的篩選標記包括可賦予藥物(如G418、潮黴素及甲胺喋呤)抗性之彼等。在其他方法中可藉由藥物篩選鑑別包含被引入核酸之穩定轉染細胞(例如,整合了篩選基因之細胞可存活,而其他細胞則死亡)。
可在提高多肽表現之條件下培養已轉化細胞,可藉由習知蛋白純化方法回收多肽。一種該純化方法描述於下文實施例。預用於本文之多肽包括基本同源的重組哺乳動物抗內皮素受體抗體多肽,其基本不含污染性內源材料。
抗體之活性
在一個實施方案中,本文提供之抗體與內皮素受體特異性結合,抑制信號傳導。在另一個實施方案中,本文提供了能與人內皮素受體特異性結合之鼠源抗體或人源化抗體。該類抗體包括可減少或中和內皮素信號傳導之拮抗或中和抗體。
在一個實施方案中,本文提供之抗體與人內皮素受體ET
AR結合時的K
d大約為0.01 nM至1000 nM、0.1 nM至500 nM、0.5 nM至200 nM、1 nM至200 nM、或10 nM至100 nM。在另一個實施方案中,本文提供之抗體與人內皮素受體ET
AR結合時的K
d大約為1 nM至200 nM。在另一個實施方案中,本文提供之抗體與人內皮素受體ET
AR結合時的K
d大約為10 nM至100 nM。在另一個實施方案中,本文提供之抗體與人內皮素受體ET
AR結合時的K
d大約為1 nM、2 nM、5 nM、10 nM、20 nM、30 nM、40 nM、50 nM、60 nM、70 nM、80 nM、90 nM、或100 nM。
在一個實施方案中,本文提供之抗體在降低人內皮素信號傳導之IC
50值大約為0.01 nM至500 nM、0.1 nM至200 nM、0.5 nM至200 nM、1 nM至200 nM、或10 nM至100 nM。在另一個實施方案中,本文提供之抗體在降低人內皮素信號傳導之IC
50值大約為1 nM至200 nM。在另一個實施方案中,本文提供之抗體在降低人內皮素信號傳導之IC
50值大約為10 nM至100 nM。在另一個實施方案中,本文提供之抗體在降低人內皮素信號傳導之IC
50值大約為1 nM、2 nM、5 nM、10 nM、20 nM、30 nM、40 nM、50 nM、60 nM、70 nM、80 nM、90 nM、或100 nM。
在一個實施方式中,本文提供之ET
AR抗體與人內皮素受體ET
AR結合時,具有一或多個以下所列之性質:
a. 以與該參比抗體相同之K
d當與人內皮素受體ET
AR結合時;
b. 以與該參比抗體相同之IC
50當抑制人內皮素受體ET
AR之內皮素活化;及
c. 在人內皮素受體ET
AR上與上述參比抗體交叉競爭結合。
在一方面,該參比抗體包含輕鏈可變域胺基酸序列SEQ ID NO: 138及重鏈可變域胺基酸序列SEQ ID NO: 166之組合。在另一方面,上述參比抗體為單株抗體A-1、A-2、A-7、A-9、或A-12。
在本文中,術語「基本相似」意為與參比抗體之IC
50或K
d可比或大約為參比抗體之IC
50或K
b值之200%、180%、160%、150%、140%、120%、110%、100%、99%、98%、97%、95%、90%、85%、80%、75%、70%、65%、或50%。在一個實施方案中,參比抗體包括,例如,具有重鏈及輕鏈組合L1H1或L2H2之抗體。在另一個實施方案中,參比抗體包括ET
AR抗體A-1。
適應症
在一個實施方案中,ET
AR抗體之生物學活性變化為用鈣流偵測之方法來偵測ET
AR抗體在體外抑制ET
AR之功能。
在一個實施方案中,ET
AR抗體之體內生物學活性為用急性腎損傷模型及糖尿病腎病動物模型來偵測ET
AR抗體對腎臟疾病之治療效果。
本發明提供可與人內皮素受體特異性結合,阻斷ET-1及ET
AR之信號轉傳導,從而達到治療糖尿病腎病、慢性腎病以及伴隨蛋白尿或腎小球濾過率降低之疾病的作用。
治療方法
本文中,術語「受試者」指哺乳動物,包括人類,可與術語「患者」交替使用。術語「治療」包括減輕或預防至少一種症狀或病症之其他態樣,或者減輕疾病嚴重性,等等。本文提供之抗體不需要產生完全治癒之效果,或根除疾病之所有症狀或表現,亦即可構成有效治療劑。如相關領域所公認,作為治療劑之藥物可減少給定疾病狀態之嚴重程度,但不需消除疾病之所有表現亦即可被認為是有效的治療劑。相似地,預防投與治療不需在預防症狀出現上完全有效亦即可構成有效預防劑。只減少疾病之影響(例如,藉由減少其症狀之數目或嚴重度,或藉由提高另一治療效果,或藉由產生另一有效作用),或者減少受試者中疾病發生或加重之可能性就已經足夠。本文之一個實施方案係關於包含以足以誘導反應具體病症嚴重性之指示劑高於基線水準之持續改善的量及時間投與患者抗體的方法。
醫藥組合物可採用任意適當技術包括但不限於腸道外、局部或吸入投與。若為注射,可藉由例如關節內、靜脈內、肌肉內、損傷區內、腹膜內或皮下途徑,以快速注射或連續輸注投與醫藥組合物。可考慮例如在疾病或損傷部位局部投與,如透皮投與及埋植劑持續釋放投與。吸入投與包括例如鼻腔或口腔吸入、採用噴霧劑、以氣霧劑形式吸入抗體等等。其他選擇包括口腔製劑包括片劑、糖漿劑或錠劑。
以包含一個或更多其他組分例如生理學可接受載劑、輔料或稀釋劑之組合物形式投與本文提供之抗體係有利的。組合物可視情況額外包含一個或更多如下所述之生理學活性劑。在多個具體實施方案中,組合物包含除一個或更多本文提供之抗體(例如鼠源抗體或人源化抗體)之外的一個、兩個、三個、四個、五個或六個生理學活性劑。
投與劑量及頻率可根據以下因素而改變:投與途徑、所用具體抗體、所治疾病之性質及嚴重度、症狀為急性抑或慢性以及患者之體積及總體症狀。可藉由此項技術熟知之方法確定適當劑量,例如在臨床試驗中包括劑量放大研究。
本文提供之抗體可在例如一段時間內按規律間隔投與一次或多次。在具體實施方案中,在至少一個月或更長時間投與一次投與鼠源抗體或人源化抗體,例如一個、兩個或三個月或者甚至不確定。對於治療慢性症狀,長期治療通常最有效。但是,對於治療急性症狀,短期投與例如自一週至六週就已足夠。通常,投與人類抗體直至患者表現出所選體徵或指示劑高於基線水準之醫學相關改善度為止。
可在使用抗體例如人類抗體治療之前、進行中及/或之後監測病人症狀之任何變化。對於某些病症,蛋白尿、腎小球濾過率之變化可隨例如疾病進程等因素而變化。
本文之方法及組合物之具體實施方案涉及使用例如抗體及一或多個內皮素拮抗劑、兩個或更多本文提供之抗體,或者本發明抗體及一個或更多其他內皮素拮抗劑。在進一步之實施方案中,單獨或與其他用於治療使患者痛苦之症狀之藥劑組合投與抗體。此等藥劑之實例包括蛋白質以及非蛋白質藥物。當聯合投與多種藥物時,如此項技術所熟知其劑量應相應調整。「聯合投與」組合療法不限於同時投與,亦包括在涉及投與患者至少一種其他治療劑之療程中至少投與一次抗原及蛋白之治療方案。
本文提供可特異性結合至人內皮素受體之抗體相關的組合物、套組及方法。亦提供了核酸分子及其衍生物及片段,其包含編碼與內皮素受體結合之多肽之全部或部分的多聚核苷酸,例如編碼全部或部分抗內皮素受體抗體、抗體片段或抗體衍生物的核酸。本文進一步提供包含該類核酸之載體及質體以及包含該類核酸及/或載體及質體之細胞及細胞株。所提供方法包括,例如,製備、鑑定或分離與人ET
AR結合之抗體例如抗ET
AR抗體之方法,測定該抗體是否與ET
AR結合之方法。
下面藉由具體實施例,對本文之技術方案作進一步的具體說明。
具體實施例:本文中,若非特指,所採用的原料及設備等均可自市場購得或為此項技術常用的。下述實施例中之方法,如無特別說明,均為此項技術之習知方法。
1、免疫用抗原細胞穩定株之構築
接種CHO-DHFR-細胞至6孔盤中,培養24小時後轉染選殖有hET
AR基因(核苷酸序列見SEQ ID NO: 1,胺基酸序列見SEQ ID NO: 2)之pIRES質體(Clontech)入6孔盤中之細胞。轉染按照Invitrogen公司推薦Lipofectamine 2000之轉染條件進行。48小時後,將培養液換為含有10 nM MTX (甲胺碟呤)之完全培養基,每隔3天換液。培養兩週左右,穩定生長的純系出現。消化分散細胞集落,將細胞傳代,繼續培養細胞。待傳代細胞長至50%癒合度時,逐漸提高MTX之濃度進行分別加壓篩選,直至MTX之濃度為10 µM。利用多株ET
AR抗體(Abcam)對構築的穩定細胞株分別進行FACS偵測,根據FACS偵測結果鑑定加壓後之細胞群體。篩選後的CHO-DHFR-hET
AR細胞膜上有大量hET
AR表現。最後經過次選殖及進一步鑑定,6株ET
AR細胞為高表現穩定細胞株。
2、抗體之製備
將在弗氏佐劑中乳化之CHO-DHFR-hET
AR全細胞,以2×10
6細胞/隻的劑量皮下注射BALB/c小鼠(6-8週齡)。2週後,使用不完全弗氏佐劑乳化免疫原,加強免疫小鼠,此後每週加強一次。經過總共6次免疫後,藉由剪尾之方式採血。離心分離血清,用FACS偵測血清效價。達到適合抗體滴度時,斷頸處死小鼠,無菌狀態下獲取脾臟細胞。另外收集生長狀態處於對數生長期之SP2/0細胞,以2000 rpm,3 min離心細胞,將沈澱細胞用無血清培養至重懸,再次離心-重懸,計數。混合脾臟細胞及SP2/0細胞,保證SP2/0:脾臟細胞≥1:1,混合以後再「洗滌-離心」3次。彈散最後一次離心後之細胞沈澱,逐滴加入1 mL預溫的PEG-1350 (30s內滴完),上下吹吸1分鐘,緩慢加入30 mL預熱的無血清培養基以終止PEG之融合作用。再用1500 rpm,5 min離心,彈散細胞沈澱,加入融合培養基,按每孔20000個脾細胞及5000個飼養層細胞鋪於96孔盤中,每孔100 µL培養基。融合後之雜交瘤細胞及飼養層細胞一起在96孔盤中進行培養,並進行HAT (次黃嘌呤、胺甲喋呤及胸苷)篩選,以除去非融合的細胞。10天後收取培養盤中之雜交瘤細胞上清進行ELISA偵測。
3、全細胞ELISA篩選
將CHO-DHFR-hET
AR過表現hET
AR細胞及不表現hET
AR之CHO-DHFR-細胞分別接種至96孔盤。待細胞長至90%癒合度,除去細胞培養上清,PBS洗兩遍,加入100 µL 100%甲醇4℃固定10 min。再加入100 µL新鮮配製的0.6% H
2O
2-PBS,室溫處理20 min,PBS洗滌2遍。經過PBS-1%BSA封閉後,加入雜交瘤細胞上清4℃孵育90 min。多次洗滌後,每孔加入100 µL稀釋的GxM-HRP-Fc二抗(Sigma-Aldrich),37℃孵育0.5 hr。洗滌5次後,每孔加入100 µL TMB顯色基質,37℃反應15 min,加入2M H
2SO
4終止顯色,讀取OD
450值。陽性對照為免疫小鼠之血清;陰性對照為細胞培養基上清。經過ELISA之初步偵測,篩選到了數個分泌抗hET
AR抗體之陽性雜交瘤細胞株。選取此等分泌抗hET
AR抗體之雜交瘤株,進行選殖以獲得能穩定分泌抗hET
AR抗體之細胞株。最後選取雜交瘤細胞分泌之抗體上清進行FACS驗證。
4、抗體基因之選殖及次選殖
收集分泌抗體之雜交瘤細胞,按照QIAGEN之mRNA抽提套組操作規程,提取雜交瘤細胞之mRNA。然後將提取後的mRNA反轉錄成cDNA,反轉錄引物為小鼠輕、重鏈恆定區之特異性引物,重鏈反轉錄引物為(5'-TTTGGRGGGAAGATGAAGAC -3') (SEQ ID NO: 199),輕鏈反轉錄引物為(5'- TTAACACTCTCCCCTGTTGAA-3') (SEQ ID NO: 200)及(5'- TTAACACTCATTCCTGTTGAA-3') (SEQ ID NO: 201)。RT-PCR之反應條件為:25℃ 5 min;50℃ 60 min;70℃ 15 min。將反轉錄的cDNA用0.1 mM的TE稀釋至500 µL,加入至超濾離心管(Amicon Ultra-0.5)中,2000 g離心10 min;棄濾液,再加500 µL之0.1 mM的TE,2000 g離心10 min;棄濾液,將製備管倒置到新的離心管中,2000 g離心10 min,得到純化後的cDNA;取10 µL純化後的cDNA作為模板,加入4 µL之5 ×尾添加緩衝液(tailing buffer) (Promega),4 µL之dATP (1 mM)及10U之末端轉移酶(Promega,市售)後混勻,37℃孵育5 min後再65℃孵育5 min;然後以加上PolyA尾之cDNA為模板,PCR擴增抗體之輕、重鏈可變區基因。上游引物均為OligodT,重鏈下游引物為(5'-TGGACAGGGATCCAGAGTTCC-3') (SEQ ID NO: 202)及(5'- TGGACAGGGCTCCATAGTTCC-3') (SEQ ID NO: 203),輕鏈下游引物為(5'- ACTCGTCCTTGGTCAACGTG-3') (SEQ ID NO: 204)。PCR反應條件:95℃ 5 min;95℃ 30 s,56℃ 30 s,72℃ 1 min 40次循環;72℃ 7 min;PCR產物連接至PMD 18-T載體(Takara Bio)後進行定序。選殖之抗體序列見表2。
基於已定序得到的抗體之DNA序列設計PCR引物,從而將完整輕鏈、重鏈信號肽及可變域以及小鼠IgG1恆定區與表現載體pTM5相連。
5. 抗體之人源化及最佳化
首先,得到篩選的鼠源抗體輕、重鏈可變區序列,並使用NCBI之在線抗體可變區序列比對工具Ig Blast,搜尋與輸入之抗體可變區序列同源的人源抗體生殖細胞株基因序列(Ig Germline Gene sequence),並將除CDR序列外,同源性最高的人源基因序列作為模板序列進行CDR嫁接,得到人源化抗體可變區序列。藉由外包合成人源化抗體輕、重鏈之基因。根據序列設計PCR引物,在合成序列之5'端及3'端引入合適的限制性內切酶位點,並藉由PCR擴增後將其與人IgG2或者IgG4恆定區序列拼接後得到完整的重組人源化抗體序列。重組之抗體根據步驟7進行表現,並按照步驟9中之FACS技術驗證其針對ET
AR之親和力。在保留了針對ET
AR親和力之人源化抗體群中,遴選出親和力表現最優秀的抗體,並藉由定點突變,對其可變區序列進行進一步的改造,更進一步提高其針對ET
AR之親和力。
6. ET
AR人源化抗體之基因選殖與次選殖
最佳化後之人源化抗體重鏈及輕鏈可變區序列由金斯瑞生物科技有限公司合成,合成時重鏈可變區5'端帶入Nhe1酶切位點,3'端帶入Sal1酶切位點,從而將完整的重鏈可變區序列與已裝入重鏈恆定區之表現載體pTM5相連;同樣,合成時輕鏈可變區5'端帶入Nhe1酶切位點,3'端帶入Bsiw1酶切位點,從而將完整的輕鏈可變區序列與已裝入輕鏈恆定區之表現載體pTM5相連。
7. 抗體之短暫表現
接種5×10
5/mL之懸浮HEK293或者CHO表現細胞株至轉瓶中,經過24小時37℃,5% CO
2旋轉培養後,密度達到1×10
6/mL後被用於轉染。轉染過程中使用聚乙烯亞胺(PEI)作為轉染介質,將其與DNA (DNA用量為每1×10
6個細胞0.5 µg,其中抗體輕鏈及重鏈之比重為3:2)混合,PEI及DNA之質量混合較佳配比為3:1。兩者混合物在靜置孵育15分鐘後被加入至細胞培養中。細胞在接受PEI與DNA混合物後繼續37℃,5% CO
2旋轉培24小時後,向細胞培養液中加入0.5%之胰蛋白腖作為表現需要的添加物,最後在表現完成後(96小時以上)收集細胞上清用於抗體之純化分離。
8、抗體之純化分離
收集的細胞上清經過高速(8000 rpm,15分鐘)離心移除細胞以及細胞碎片後,再用0.45 um濾膜過濾澄清。澄清後的上清被用於純化。純化過程由層析儀完成。上清首先流過蛋白G親和層析管柱,上清中包含之抗體在此期間與蛋白G親和層析管柱之配基相結合後滯留於管柱內,然後用低pH值(小於等於3.0)之溶離緩衝液灌洗層析管柱解離與層析管柱結合之抗體。收集到的抗體溶離液之低pH值用1M之Tris-HCl迅速中和以保護抗體不變性失活。得到的抗體溶離液經過16小時之透析後置換成PBS緩衝體系。
9、流式細胞儀分析驗證功能性抗體(FACS)
用含10 mM EDTA之PBS消化、收集10
5個CHO-DHFR-hET
AR細胞,分別加入1.5 mL EP管,離心後棄上清,陰性對照樣本用流式上樣緩衝液(PBS,2% FBS)重懸。陽性處理組細胞每管加200 µL抗體上清,室溫孵育;孵育完成後1500 rpm離心,棄上清,用流式上樣緩衝液洗一次細胞沈澱,再離心,將細胞重懸;向細胞重懸液加入1:50稀釋的FITC標記之羊抗鼠螢光二抗(BD Pharmingen),200 µL/孔,室溫避光孵育30 min;離心,棄上清,再用流式上樣緩衝液洗一次,離心,最後用流式上樣緩衝液將細胞沈澱重懸,上機偵測。表現有重組抗ET
AR功能性抗體之上清及表現有ET
AR之CHO-DHFR-ET
AR細胞有特異性結合。灰色峰及虛線峰為陰性對照,雜交瘤細胞上清對應的實線峰有明顯右移。
10、鈣流實驗驗證功能性抗體
以每孔25000個接種共表現hET
AR-Aequorin之CHO-DHFR-細胞至黑色96孔細胞培養盤,37℃培養過夜。第二天除去細胞上清,加入50 µL基質coelenterazine h (Promega)避光孵育2 hr,再加入50 µL雜交瘤細胞上清或純化後的抗體繼續孵育30分鐘。在Molecular Devices之SpectraMax L酶標儀上採用自動進樣器灌注Endothelin-1,在灌注後之40s內偵測瞬間鈣流變化,記錄出峰時間及峰值。不同雜交瘤上清顯示出不同的抑制細胞內人ET
AR介導之Ca
2+變化之結果,A-1抗體顯著地抑制ET
AR介導之Ca
2+變化。隨著重組抗ET
AR功能性抗體濃度之提高,抗體對細胞內人ET
AR介導之Ca
2+變化之抑制性效果在顯著增強。
11、鈣流實驗偵測抗體A-1在體外拮抗不同種屬ET
AR之生物學活性
用含2 mM EDTA之PBS消化、收集共表現水母發光蛋白Aequorin及兔ET
AR、金黃地鼠ET
AR或大鼠ET
AR之CHO-A1細胞,按計數結果,每種細胞分別按照3.5×10
4個細胞/孔或4×10
4個細胞/孔接種至無菌96孔細胞培養盤,100μL/孔,周邊孔用PBS以100μL/孔補足。37℃培養箱隔夜培養。-20℃取出一管Coelenterazine-h待其完全融化後離心使液體聚集於EP管底部,在5mL離心管內加入3.2mL之無酚紅DMEM/F12,將100μL Colenterazine-h加入其中,顛倒混勻後320μL每孔分於加樣盤內備用。取出細胞培養盤,吸去原有培養基,用排槍加入50 μL/孔之Coelenterazine-h (避光操作),將96孔細胞培養盤置於避光條件下,室溫孵育2-2.5小時。梯度稀釋抗體A-1,避光加藥,50μL/孔藥物加至50μL/孔之腔腸素裏,每個濃度做兩個複孔。不加抗體A-1之無酚紅DMEM/F12作為空白對照。加藥完畢,將96孔細胞培養盤置於避光條件下,室溫孵育30分鐘。孵育結束後,在酶標儀上讀取各孔螢光強度,每孔灌100μL 10nM ET-1。採用prism軟體進行作圖,由軟體自動計算藥物之IC50值及曲線擬合相關係數R
2。如圖5所示,抗體A-1可有效拮抗ET-1誘導的兔ET
AR、金黃地鼠ET
AR之活化,不能拮抗ET-1誘導的大鼠ET
AR之活化。
12、抗體A-1在食蟹獼猴中之藥物動力學研究
18隻食蟹獼猴(9雌:9雄)隨機分入3個組,每組3隻雌性及3隻雄性食蟹獼猴。各組動物分別單次靜脈注射5mg/kg、15mg/kg或50mg/kg抗體A-1,並在投與前、投與後即刻(±1min)、投與後0.5h、2h、4h、8h、1天、2天、3天、4天、7天、14天、21天及28天採血,離心提取血清,用ELISA方法偵測血清中藥物濃度,並藉由軟體分析確定A-1在食蟹獼猴中之半衰期。如表1所示,食蟹獼猴中單次靜脈注射5mg/kg、15mg/kg或50mg/kg抗體A-1之半衰期分別為244.74h、173.15h及173.41h。
表1、食蟹獼猴中抗體A-1單次投與之藥物動力學
抗體A-1 (mg/kg) | t 1/2(h) | C max(μg/mL) |
5 | 244.74±30.29 | 98.22±16.81 |
15 | 173.15±63.14 | 317.57±38.19 |
50 | 173.41±24.65 | 1,014.96±73.63 |
13、建立順鉑誘導之兔子急性腎損傷模型以評價抗體A-1之體內藥效
按5mg/kg之劑量單次耳緣靜脈注射順鉑誘導建立兔子急性腎損傷模型,並在該模型中評價抗體A-1每週兩次靜脈注射之藥效。隨機挑選24隻動物,順鉑注射前或投與抗體A-1前,稱量兔子體重,並收集兔子之24小時尿液及血清以偵測尿總蛋白(U-TP)、尿白蛋白(U-Alb)、尿素氮(BUN)及血肌酐(sCr)含量。24隻動物按照體重進行隨機分組,每組8隻,共3組,第2組動物首次投與時間為順鉑注射後24h (D1),第2次投與時間為順鉑注射後第4天(D4)。第3組動物首次投與時間為順鉑注射前2h (-2h),第2次投與時間為順鉑注射後第3天(D3)。在順鉑注射後第1、2、3及5天再次收集血清以偵測BUN及sCr。在實驗終點收集24小時尿液以偵測U-TP及U-Alb。如圖6、圖7、表2及表3所示,於-2h及D3投與抗體A-1治療顯著降低或阻斷了順鉑誘導之BUN及sCr升高。如圖8及表4所示,於-2h及D3投與抗體A-1治療顯著降低或阻斷了順鉑誘導之U-TP及U-Alb升高。以上資料表明,抗體A-1 (-2h及D3)在順鉑誘導之兔子急性腎損傷模型中具有優越的腎臟保護作用。
表2、各組兔子在不同時間點之BUN (平均值±SD)
備註:第2組與第1組相比,自D1至D5,P>0.05;第3組與第1組相比,*表示P<0.05,**表示P<0.01;第2組與第3組相比,#表示P<0.05,##表示P<0.01。
表3、各組兔子在不同時間點之sCr (平均值±SD)
備註:第2組與第1組相比,自D1至D5,P>0.05;第3組與第1組相比,*表示P<0.05,**表示P<0.01;第2組與第3組相比,#表示P<0.05,##表示P<0.01。
表4、各組兔子在不同時間點之U-TP及U-Alb (平均值±SD)
備註:第2組與第1組相比,自D1至D5,P>0.05;第3組與第1組相比,*表示P<0.05,**表示P<0.01;第2組與第3組相比,#表示P<0.05,##表示P<0.01。
表5、各組金黃地鼠在不同時間點之U-TP、U-Alb及尿液體積(平均值±SD)
備註:與第1組相比,#表示P<0.05,##表示P<0.01,###表示P<0.001;與第2組相比,*表示P<0.05,**表示P<0.01,***表示P<0.001。
組別 | D0 | D1 | D2 | D3 | D5 |
第1組, 溶媒 IV, D1, 4 | 5.76±0.86 | 10.94±2.64 | 18.54±6.68 | 31.53±12.27 | 39.27±27.82 |
第2組, 抗體A-1 15mg/kg, IV, D1, 4 | 5.57±0.64 | 11.97±1.77## | 22.46±5.40## | 38.16±10.87## | 49.56±36.44# |
第3組, 抗體A-1 15mg/kg, -2h, D3 | 5.80±0.91 | 7.07±0.94** | 7.50±0.86** | 7.64±0.83** | 8.13±1.21* |
組別 | D0 | D1 | D2 | D3 | D5 |
第1組, 溶媒 IV, D1, 4 | 99.14±8.09 | 104.24±15.76 | 242.65±128.94 | 429.04±248.30 | 537.39±445.35 |
第2組, 抗體A-1 15mg/kg, IV, D1, 4 | 93.10±9.56 | 111.50±12.13## | 283.55±78.84## | 498.80±204.91## | 605.28±481.84# |
第3組, 抗體A-1 15mg/kg, -2h, D3 | 100.88±9.37 | 76.71±10.03** | 75.65±9.53* | 78.66±10.99* | 74.69±11.85 |
組別 | U-TP(mg/24h) | U-Alb(mg/24h) | ||
基線 | 投與後第一週 | 基線 | 投與後第一週 | |
第1組 溶媒, IV, D1, 4 | 12.78±2.26 | 94.42±81.96 | 0.00±0.00 | 11.95±14.89 |
第2組 抗體A-1, 15mg/kg, IV, D1, 4 | 11.18±3.12 | 62.68±50.74 | 0.00±0.00 | 9.02±10.44 |
第3組 抗體A-1, 15mg/kg, -2h, D3 | 12.25±3.41 | 20.06±3.39* | 0.00±0.00 | 0.00±0.00 |
組別 | U-TP(mg/24h) | U-Alb(mg/24h) | 尿液體積(mL/24h) | |||
基線 | 投與後2週 | 基線 | 投與後2週 | 基線 | 投與後2週 | |
第1組,空白組 | 7.6±3.1 | 5.9±2.4 | 0.06±0.04 | 0.18±0.13 | 5.8±4.5 | 6±4.6 |
第2組,模型組 | 9.4±9 | 21.1±5.3 ### | 0.12±0.1 | 1.93±0.77 ### | 7±2.7 | 29.1±9.1 ### |
第3組,抗體A-1,6mg/kg, i.p., BIW*2 | 8.2±7.6 | 17.8±7.6 ## | 0.07±0.04 | 1.35±1.14 | 5.8±2.7 | 20.2±9.8 ##* |
第4組,抗體A-1,18mg/kg, i.p., BIW*2 | 11.3±6.9 | 13±6 * | 0.07±0.09 | 1.34±0.84 # | 8.7±2.9 | 16.8±15.1 #** |
第5組,抗體A-1,54mg/kg, i.p., BIW*2 | 6.4±4.9 | 13.5±4.6 #* | 0.03±0.02 | 1.37±0.58 ## | 5.3±3.2 | 11.5±6.1 *** |
14、建立金黃地鼠之糖尿病腎病模型以評價抗體A-1之體內藥效
按30mg/kg之劑量連續3天腹腔注射鏈脲菌素(STZ)聯合高脂高膽固醇飼料誘導建立金黃地鼠之糖尿病腎病模型,並在該模型中評價抗體A-1每週兩次腹腔注射之藥效。隨機挑選50隻金黃地鼠,收集尿液偵測尿肌酐(U-Cr)、U-TP及U-Alb,收集血清偵測空腹血糖、BUN及sCr;按照體重進行隨機分組,空白組10隻,剩餘動物按照30mg/kg之劑量腹腔注射STZ,連續注射三天後,第四天進行分組,每組10隻。分組後分別投與溶媒(空白組及模型組)、6mg/kg、18mg/kg或54mg/kg抗體A-1,投與當天定義為D0,以普通飼料飼養10天,第11天將飼料更換成高脂高膽固醇飼料飼養至實驗結束。投與兩週後收集尿液偵測U-Cr、U-TP及U-Alb。如圖9至圖11、表5所示,與空白組相比,STZ注射後模型組動物24小時尿量、尿總蛋白及尿白蛋白升高,提示早期糖尿病腎病模型建模成功;與模型組相比,抗體A-1顯著降低了糖尿病腎病動物之24小時尿量及尿總蛋白,同時,抗體A-1治療後糖尿病腎病動物之24小時尿白蛋白亦降低了約30%,表現出了良好的腎臟保護作用。
提供以上實施例用於向一般熟習此項技術者充分揭示及說明如何製造及使用所主張之實施方式,而不意謂限制本文揭示之範疇。對熟習此項技術者而言顯而易見之修飾皆在本文申請專利範圍之範疇內。將本說明書中引用之所有出版物、專利及專利申請都藉由參考併入本文,就如同每個出版物、專利或專利申請均具體及單獨地藉由參考併入本文一樣。
圖1:顯示了ELISA實驗篩選不同雜交瘤細胞上清與CHO-DHFR-ET
AR (圖中標為CHO-ET
AR)細胞結合之結果。其中,自15F3雜交瘤細胞選殖至了ET
AR抗體A-1 (其包含SEQ ID NO: 138與SEQ ID NO: 166)。
圖2:顯示了流式細胞術(FACS)偵測重組表現之ET
AR抗體(A-1、A-2 (其包含SEQ ID NO: 140及SEQ ID NO: 168)、A-7 (其包含SEQ ID NO: 150與SEQ ID NO: 178)、及A-12 (其包含SEQ ID NO: 160與SEQ ID NO: 188))與人ET
AR之特異性結合結果。其中灰色峰及虛線峰為陰性對照,虛線峰表示ET
AR抗體與CHO-DHFR-之結合曲線,實線峰表示ET
AR抗體與CHO-DHFR-ET
AR之結合曲線。
圖3:顯示了鈣流實驗篩選不同雜交瘤細胞上清抑制細胞內人ET
AR介導之Ca
2+變化結果。
圖4:顯示了鈣流實驗偵測重組表現之ET
AR抗體與人ET
AR之濃度梯度抑制曲線(IC
50= 38 nM,R
2= 0.97) (A-1)、(IC
50= 88 nM,R
2= 0.97) (A-9 (其包含SEQ ID NO: 154與SEQ ID NO: 182))。
圖5:顯示了鈣流實驗偵測抗體A-1與兔ET
AR、金黃地鼠ET
AR及大鼠ET
AR之濃度梯度抑制曲線。
圖6:顯示了抗體A-1之兔子急性腎損傷模型藥效實驗中動物之尿素氮(BUN)變化曲線。
圖7:顯示了抗體A-1之兔子急性腎損傷模型藥效實驗中動物之血肌酐(sCr)變化曲線。
圖8:顯示了抗體A-1之兔子急性腎損傷模型藥效實驗中動物之24小時尿白蛋白(U-Alb)排泄量。
圖9:顯示了抗體A-1之金黃地鼠糖尿病腎病模型藥效實驗中動物之24小時尿總蛋白(U-TP)排泄量。
圖10:顯示了抗體A-1之金黃地鼠糖尿病腎病模型藥效實驗中動物之24小時尿白蛋白(U-Alb)排泄量。
圖11:顯示了抗體A-1之金黃地鼠糖尿病腎病模型藥效實驗中動物之24小時尿量。
<![CDATA[<110> 中國大陸商鴻運華寧(杭州)生物醫藥有限公司(GMAX BIOPHARM LLC)]]> <![CDATA[<120> 一種能與人內皮素受體特異性結合的抗體及其在糖尿病腎病及慢性腎病治療中的應用]]> <![CDATA[<140> 111112218]]> <![CDATA[<141> 2022-03-30]]> <![CDATA[<150> CN 202110353110.6]]> <![CDATA[<151> 2021-03-31]]> <![CDATA[<160> 204 ]]> <![CDATA[<170> PatentIn version 3.5]]> <![CDATA[<210> 1]]> <![CDATA[<211> 1868]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人]]> <![CDATA[<400> 1]]> gaattcggga aaaagtgaag gtgtaaaagc agcacaagtg caataagaga tatttcctca 60 aatttgcctc aagatggaaa ccctttgcct cagggcatcc ttttggctgg cactggttgg 120 atgtgtaatc agtgataatc ctgagagata cagcacaaat ctaagcaatc atgtggatga 180 tttcaccact tttcgtggca cagagctcag cttcctggtt accactcatc aacccactaa 240 tttggtccta cccagcaatg gctcaatgca caactattgc ccacagcaga ctaaaattac 300 ttcagctttc aaatacatta acactgtgat atcttgtact attttcatcg tgggaatggt 360 ggggaatgca actctgctca ggatcattta ccagaacaaa tgtatgagga atggccccaa 420 cgcgctgata gccagtcttg cccttggaga ccttatctat gtggtcattg atctccctat 480 caatgtattt aagctgctgg ctgggcgctg gccttttgat cacaatgact ttggcgtatt 540 tctttgcaag ctgttcccct ttttgcagaa gtcctcggtg gggatcaccg tcctcaacct 600 ctgcgctctt agtgttgaca ggtacagagc agttgcctcc tggagtcgtg ttcagggaat 660 tgggattcct ttggtaactg ccattgaaat tgtctccatc tggatcctgt cctttatcct 720 ggccattcct gaagcgattg gcttcgtcat ggtacccttt gaatataggg gtgaacagca 780 taaaacctgt atgctcaatg ccacatcaaa attcatggag ttctaccaag atgtaaagga 840 ctggtggctc ttcgggttct atttctgtat gcccttggtg tgcactgcga tcttctacac 900 cctcatgact tgtgagatgt tgaacagaag gaatggcagc ttgagaattg ccctcagtga 960 acatcttaag cagcgtcgag aagtggcaaa aacagttttc tgcttggttg taatttttgc 1020 tctttgctgg ttccctcttc atttaagccg tatattgaag aaaactgtgt ataacgagat 1080 ggacaagaac cgatgtgaat tacttagttt cttactgctc atggattaca tcggtattaa 1140 cttggcaacc atgaattcat gtataaaccc catagctctg tattttgtga gcaagaaatt 1200 taaaaattgt ttccagtcat gcctctgctg ctgctgttac cagtccaaaa gtctgatgac 1260 ctcggtcccc atgaacggaa caagcatcca gtggaagaac cacgatcaaa acaaccacaa 1320 cacagaccgg agcagccata aggacagcat gaactgacca cccttagaag cactcctcgg 1380 tactcccata atcctctcgg agaaaaaaat cacaaggcaa ctgtgagtcc gggaatctct 1440 tctctgatcc ttcttcctta attcactccc acacccaaga agaaatgctt tccaaaaccg 1500 caagggtaga ctggtttatc cacccacaac atctacgaat cgtacttctt taattgatct 1560 aatttacata ttctgcgtgt tgtattcagc actaaaaaat ggtgggagct gggggagaat 1620 gaagactgtt aaatgaaacc agaaggatat ttactacttt tgcatgaaaa tagagctttc 1680 aagtacatgg ctagctttta tggcagttct ggtgaatgtt caatgggaac tggtcaccat 1740 gaaactttag agattaacga caagattttc tacttttttt aagtgatttt tttgtccttc 1800 agccaaacac aatatgggct caagtcactt ttatttgaaa tgtcatttgg tgccagtatc 1860 ccgaattc 1868 <![CDATA[<210> 2]]> <![CDATA[<211> 427]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人]]> <![CDATA[<400> 2]]> Met Glu Thr Leu Cys Leu Arg Ala Ser Phe Trp Leu Ala Leu Val Gly 1 5 10 15 Cys Val Ile Ser Asp Asn Pro Glu Arg Tyr Ser Thr Asn Leu Ser Asn 20 25 30 His Val Asp Asp Phe Thr Thr Phe Arg Gly Thr Glu Leu Ser Phe Leu 35 40 45 Val Thr Thr His Gln Pro Thr Asn Leu Val Leu Pro Ser Asn Gly Ser 50 55 60 Met His Asn Tyr Cys Pro Gln Gln Thr Lys Ile Thr Ser Ala Phe Lys 65 70 75 80 Tyr Ile Asn Thr Val Ile Ser Cys Thr Ile Phe Ile Val Gly Met Val 85 90 95 Gly Asn Ala Thr Leu Leu Arg Ile Ile Tyr Gln Asn Lys Cys Met Arg 100 105 110 Asn Gly Pro Asn Ala Leu Ile Ala Ser Leu Ala Leu Gly Asp Leu Ile 115 120 125 Tyr Val Val Ile Asp Leu Pro Ile Asn Val Phe Lys Leu Leu Ala Gly 130 135 140 Arg Trp Pro Phe Asp His Asn Asp Phe Gly Val Phe Leu Cys Lys Leu 145 150 155 160 Phe Pro Phe Leu Gln Lys Ser Ser Val Gly Ile Thr Val Leu Asn Leu 165 170 175 Cys Ala Leu Ser Val Asp Arg Tyr Arg Ala Val Ala Ser Trp Ser Arg 180 185 190 Val Gln Gly Ile Gly Ile Pro Leu Val Thr Ala Ile Glu Ile Val Ser 195 200 205 Ile Trp Ile Leu Ser Phe Ile Leu Ala Ile Pro Glu Ala Ile Gly Phe 210 215 220 Val Met Val Pro Phe Glu Tyr Arg Gly Glu Gln His Lys Thr Cys Met 225 230 235 240 Leu Asn Ala Thr Ser Lys Phe Met Glu Phe Tyr Gln Asp Val Lys Asp 245 250 255 Trp Trp Leu Phe Gly Phe Tyr Phe Cys Met Pro Leu Val Cys Thr Ala 260 265 270 Ile Phe Tyr Thr Leu Met Thr Cys Glu Met Leu Asn Arg Arg Asn Gly 275 280 285 Ser Leu Arg Ile Ala Leu Ser Glu His Leu Lys Gln Arg Arg Glu Val 290 295 300 Ala Lys Thr Val Phe Cys Leu Val Val Ile Phe Ala Leu Cys Trp Phe 305 310 315 320 Pro Leu His Leu Ser Arg Ile Leu Lys Lys Thr Val Tyr Asn Glu Met 325 330 335 Asp Lys Asn Arg Cys Glu Leu Leu Ser Phe Leu Leu Leu Met Asp Tyr 340 345 350 Ile Gly Ile Asn Leu Ala Thr Met Asn Ser Cys Ile Asn Pro Ile Ala 355 360 365 Leu Tyr Phe Val Ser Lys Lys Phe Lys Asn Cys Phe Gln Ser Cys Leu 370 375 380 Cys Cys Cys Cys Tyr Gln Ser Lys Ser Leu Met Thr Ser Val Pro Met 385 390 395 400 Asn Gly Thr Ser Ile Gln Trp Lys Asn His Asp Gln Asn Asn His Asn 405 410 415 Thr Asp Arg Ser Ser His Lys Asp Ser Met Asn 420 425 <![CDATA[<210> 3]]> <![CDATA[<211> 2696]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 3]]> gtctaggagc ctgtggagtc taaggaagat cgcgggaggc gtgttcctcc ggagtttgct 60 tttccttggg agcctcgcgc gcacacccat cccttctagt ctggcaactg tgtctaggag 120 gtggggagcc tctctctgat ccaccggacc atcgctggag cttgcaggct gagcaagatc 180 tccccctaga gaagcctggc tgtccgggga agtttccccg agctgagact gtgctgcagc 240 cctggtcacc cgccaccctg cgcgccaccc tcgttctcca gctcaggctc cggctggccc 300 gtgcgcggac ctggagctgt ctgcttccga ggagctctaa ggtgaaaaaa agaaaggcgt 360 gagaccaaca taagaagact taaaatccag gttaagatga gtatcttttg ccttgcggca 420 tacttttggc tgaccatggt gggaggcgta atggctgaca atccggagag atacagcgct 480 aatctaagca gccacatgga agacttcacc ccttttccgg ggacggagat caactttctg 540 ggcaccaccc atcgaccccc taatttggcc ctgcctagca atggctcaat gcacggctat 600 tgcccacagc agactaaaat cacgacagct ttcaaatata ttaacactgt gatatcctgc 660 accattttca tcgtgggaat ggtggggaac gcaactctac tacgaatcat ttaccaaaac 720 aagtgtatga ggaacggccc caatgcgctc atagccagcc tggcccttgg agaccttatc 780 tacgtggtca ttgacctccc catcaacgtg tttaagctct tggcaggacg ctggcctttc 840 gaccacaatg attttggagt gtttctctgc aagctgttcc ccttcctgca gaagtcctcc 900 gtgggcatca ccgtcttgaa cctctgtgct ctcagtgtgg acaggtacag agcagtggct 960 tcctggagcc gagttcaagg aatcgggatc cccttgatta ccgccattga aatcgtctcc 1020 atctggattc tttccttcat cttggccatc ccggaagcaa tcggcttcgt catggtaccc 1080 ttcgaataca agggcgagct gcataggacc tgcatgctca acgccacgtc caagttcatg 1140 gagttttacc aagatgtgaa ggactggtgg ctctttgggt tctacttctg catgcccttg 1200 gtgtgcacag caatcttcta caccctcatg acctgtgaga tgctcaacag gaggaacggc 1260 agcttgcgga tcgcccttag tgagcacctc aaacagcgtc gagaagtggc aaagactgtc 1320 ttctgcttgg ttgtcatctt cgccctgtgc tggttccctc ttcacttaag ccgcattttg 1380 aagaaaactg tatatgatga gatggataag aaccggtgtg aactgctcag cttcttgctg 1440 ctaatggatt acatcggcat taacctggca accatgaatt cttgcataaa cccaatagct 1500 ctatattttg tgagcaagaa attcaaaaat tgttttcagt cctgcctctg ttgctgttgt 1560 caccagtcca aaagcctcat gacctcggtc cccatgaatg gaacgagtat ccagtggaag 1620 aaccaagagc agaacaacca caacacggaa cggagcagcc acaaggacag catgaactaa 1680 ccctccgcag aaacaccgag acgtgtgcct tcaagtccta ggatggaaac aaccattacg 1740 ccacagatgc gctcccaaaa cctcccaagt ctctcccatg ctccttttct aagtccatcc 1800 taggaaaagc tctcctgccc tcccaacagc acgtggtgga ccggtcccag ctatagccaa 1860 tgggtctttc ctgagtactg tatatgattt gcataccgcg catgtcattt ccaacacttg 1920 aaaattagag ctgggagaaa ggagatgatg gttcaaagaa gccacctagc tgccgccttt 1980 gcatgaacac agagtttgca agttcatgac cagcttccgt gcagttctat ggaccagctg 2040 gtgggaactg tccatcctaa gattctagag cagtgggtct caaccttccc aatgctgcag 2100 ccccttaata cagttcttca ttttccagtg acccccccca accacaatat tattttttgt 2160 tgctacttca attattttga attgttataa ttgtctgata tttctgatag tcttagcctg 2220 cccctgttaa agggtcatta gcaacccaca agttgagaac cactgcccta gaaattctgt 2280 tgcgtttcat ggcccatgac tacaatccta aaattggaga ggtgagggaa gatggtcagg 2340 tgttcaaggt tagcctcatc aacatagttc ggaaaagcca gggctacctg ttctcacaag 2400 acacaaacag acaaaaagtg tttcaaagtt atggcagatt cattattatt aattattatt 2460 atcttatagc caaacacatt gtgaggttaa agtactcttt tggaaatgtc accgagtgtt 2520 ggtactttat aactgcatgg taccctagaa atgatcgttt catcttcttt caatgtactc 2580 tgaagaaaag aaataggaga gttccagaag ggagatctgg aaaggagata atgtttgaaa 2640 tgtaaagaag gaaaatatcc aataaaaaaa ttcaaagtct aaaaaaaaaa aaaaaa 2696 <![CDATA[<210> 4]]> <![CDATA[<211> 427]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 4]]> Met Ser Ile Phe Cys Leu Ala Ala Tyr Phe Trp Leu Thr Met Val Gly 1 5 10 15 Gly Val Met Ala Asp Asn Pro Glu Arg Tyr Ser Ala Asn Leu Ser Ser 20 25 30 His Met Glu Asp Phe Thr Pro Phe Pro Gly Thr Glu Ile Asn Phe Leu 35 40 45 Gly Thr Thr His Arg Pro Pro Asn Leu Ala Leu Pro Ser Asn Gly Ser 50 55 60 Met His Gly Tyr Cys Pro Gln Gln Thr Lys Ile Thr Thr Ala Phe Lys 65 70 75 80 Tyr Ile Asn Thr Val Ile Ser Cys Thr Ile Phe Ile Val Gly Met Val 85 90 95 Gly Asn Ala Thr Leu Leu Arg Ile Ile Tyr Gln Asn Lys Cys Met Arg 100 105 110 Asn Gly Pro Asn Ala Leu Ile Ala Ser Leu Ala Leu Gly Asp Leu Ile 115 120 125 Tyr Val Val Ile Asp Leu Pro Ile Asn Val Phe Lys Leu Leu Ala Gly 130 135 140 Arg Trp Pro Phe Asp His Asn Asp Phe Gly Val Phe Leu Cys Lys Leu 145 150 155 160 Phe Pro Phe Leu Gln Lys Ser Ser Val Gly Ile Thr Val Leu Asn Leu 165 170 175 Cys Ala Leu Ser Val Asp Arg Tyr Arg Ala Val Ala Ser Trp Ser Arg 180 185 190 Val Gln Gly Ile Gly Ile Pro Leu Ile Thr Ala Ile Glu Ile Val Ser 195 200 205 Ile Trp Ile Leu Ser Phe Ile Leu Ala Ile Pro Glu Ala Ile Gly Phe 210 215 220 Val Met Val Pro Phe Glu Tyr Lys Gly Glu Leu His Arg Thr Cys Met 225 230 235 240 Leu Asn Ala Thr Ser Lys Phe Met Glu Phe Tyr Gln Asp Val Lys Asp 245 250 255 Trp Trp Leu Phe Gly Phe Tyr Phe Cys Met Pro Leu Val Cys Thr Ala 260 265 270 Ile Phe Tyr Thr Leu Met Thr Cys Glu Met Leu Asn Arg Arg Asn Gly 275 280 285 Ser Leu Arg Ile Ala Leu Ser Glu His Leu Lys Gln Arg Arg Glu Val 290 295 300 Ala Lys Thr Val Phe Cys Leu Val Val Ile Phe Ala Leu Cys Trp Phe 305 310 315 320 Pro Leu His Leu Ser Arg Ile Leu Lys Lys Thr Val Tyr Asp Glu Met 325 330 335 Asp Lys Asn Arg Cys Glu Leu Leu Ser Phe Leu Leu Leu Met Asp Tyr 340 345 350 Ile Gly Ile Asn Leu Ala Thr Met Asn Ser Cys Ile Asn Pro Ile Ala 355 360 365 Leu Tyr Phe Val Ser Lys Lys Phe Lys Asn Cys Phe Gln Ser Cys Leu 370 375 380 Cys Cys Cys Cys His Gln Ser Lys Ser Leu Met Thr Ser Val Pro Met 385 390 395 400 Asn Gly Thr Ser Ile Gln Trp Lys Asn Gln Glu Gln Asn Asn His Asn 405 410 415 Thr Glu Arg Ser Ser His Lys Asp Ser Met Asn 420 425 <![CDATA[<210> 5]]> <![CDATA[<211> 1436]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 大鼠]]> <![CDATA[<400> 5]]> gtgagaccaa cataacagga cgtttcttca gatccacatt aagatgggtg tcctttgctt 60 tctggcgtcc ttttggctgg ccctggtggg aggcgcaatc gctgacaatg ctgagagata 120 cagtgctaat ctaagcagcc acgtggagga cttcacccct tttccaggga cagagttcga 180 ctttctgggc accacccttc gaccccctaa tttggccctg cctagcaatg gctcaatgca 240 tggctattgc ccacagcaga caaaaatcac gacggctttc aaatatatca acactgtgat 300 atcctgtacc attttcatcg tgggaatggt ggggaacgcc actctcctaa gaatcattta 360 ccaaaacaag tgtatgagga acggccccaa tgcgctcata gccagcctgg cccttggaga 420 ccttatctac gtggtcattg atctccccat caatgtgttt aagctgttgg cggggcgctg 480 gccttttgac cacaatgatt ttggagtgtt tctctgcaag ctgttcccct ttttgcagaa 540 gtcgtccgtg ggcatcactg tcctgaatct ctgcgctctc agtgtggaca ggtacagagc 600 agtggcttcc tggagccggg ttcaaggaat cgggatcccc ttgattaccg ccattgaaat 660 tgtctccatc tggatccttt cctttatctt ggccatccca gaagcaatcg gcttcgtcat 720 ggtacccttc gaatacaagg gcgagcagca caggacctgc atgctcaacg ccacgaccaa 780 gttcatggag ttttaccaag acgtgaagga ctggtggctc tttggattct acttctgcat 840 gcccttggtg tgcacagcaa tcttctatac cctcatgacc tgtgagatgc tcaacagaag 900 gaatgggagc ttgcggattg ccctcagcga acacctcaag cagcgtcgag aggtggcaaa 960 gaccgtcttc tgcttggttg tcatcttcgc cctgtgctgg ttccctcttc acttaagccg 1020 aattttgaag aaaaccgtct atgatgagat ggataagaac cggtgtgaac tgctcagctt 1080 cttgctgctc atggattaca ttggcattaa cctggcaacc atgaactctt gcataaaccc 1140 aatagctctg tattttgtga gcaagaaatt caaaaattgt tttcagtcat gcctctgttg 1200 ctgttgtcac cagtccaaaa gcctcatgac ctcggtcccc atgaatggaa cgagtatcca 1260 gtggaagaac caggagcaga accacaacac agaacggagc agccacaagg acagcatgaa 1320 ctaaccctgt gcagaagcac cgagcagtgt gccttcgagt cccaggatga aacggtcacg 1380 cagcagctgc gctcccaaaa cctcccaggt ctctcccctg ctttttgtct aagctt 1436 <![CDATA[<210> 6]]> <![CDATA[<211> 426]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 大鼠]]> <![CDATA[<400> 6]]> Met Gly Val Leu Cys Phe Leu Ala Ser Phe Trp Leu Ala Leu Val Gly 1 5 10 15 Gly Ala Ile Ala Asp Asn Ala Glu Arg Tyr Ser Ala Asn Leu Ser Ser 20 25 30 His Val Glu Asp Phe Thr Pro Phe Pro Gly Thr Glu Phe Asp Phe Leu 35 40 45 Gly Thr Thr Leu Arg Pro Pro Asn Leu Ala Leu Pro Ser Asn Gly Ser 50 55 60 Met His Gly Tyr Cys Pro Gln Gln Thr Lys Ile Thr Thr Ala Phe Lys 65 70 75 80 Tyr Ile Asn Thr Val Ile Ser Cys Thr Ile Phe Ile Val Gly Met Val 85 90 95 Gly Asn Ala Thr Leu Leu Arg Ile Ile Tyr Gln Asn Lys Cys Met Arg 100 105 110 Asn Gly Pro Asn Ala Leu Ile Ala Ser Leu Ala Leu Gly Asp Leu Ile 115 120 125 Tyr Val Val Ile Asp Leu Pro Ile Asn Val Phe Lys Leu Leu Ala Gly 130 135 140 Arg Trp Pro Phe Asp His Asn Asp Phe Gly Val Phe Leu Cys Lys Leu 145 150 155 160 Phe Pro Phe Leu Gln Lys Ser Ser Val Gly Ile Thr Val Leu Asn Leu 165 170 175 Cys Ala Leu Ser Val Asp Arg Tyr Arg Ala Val Ala Ser Trp Ser Arg 180 185 190 Val Gln Gly Ile Gly Ile Pro Leu Ile Thr Ala Ile Glu Ile Val Ser 195 200 205 Ile Trp Ile Leu Ser Phe Ile Leu Ala Ile Pro Glu Ala Ile Gly Phe 210 215 220 Val Met Val Pro Phe Glu Tyr Lys Gly Glu Gln His Arg Thr Cys Met 225 230 235 240 Leu Asn Ala Thr Thr Lys Phe Met Glu Phe Tyr Gln Asp Val Lys Asp 245 250 255 Trp Trp Leu Phe Gly Phe Tyr Phe Cys Met Pro Leu Val Cys Thr Ala 260 265 270 Ile Phe Tyr Thr Leu Met Thr Cys Glu Met Leu Asn Arg Arg Asn Gly 275 280 285 Ser Leu Arg Ile Ala Leu Ser Glu His Leu Lys Gln Arg Arg Glu Val 290 295 300 Ala Lys Thr Val Phe Cys Leu Val Val Ile Phe Ala Leu Cys Trp Phe 305 310 315 320 Pro Leu His Leu Ser Arg Ile Leu Lys Lys Thr Val Tyr Asp Glu Met 325 330 335 Asp Lys Asn Arg Cys Glu Leu Leu Ser Phe Leu Leu Leu Met Asp Tyr 340 345 350 Ile Gly Ile Asn Leu Ala Thr Met Asn Ser Cys Ile Asn Pro Ile Ala 355 360 365 Leu Tyr Phe Val Ser Lys Lys Phe Lys Asn Cys Phe Gln Ser Cys Leu 370 375 380 Cys Cys Cys Cys His Gln Ser Lys Ser Leu Met Thr Ser Val Pro Met 385 390 395 400 Asn Gly Thr Ser Ile Gln Trp Lys Asn Gln Glu Gln Asn His Asn Thr 405 410 415 Glu Arg Ser Ser His Lys Asp Ser Met Asn 420 425 <![CDATA[<210> 7]]> <![CDATA[<211> 33]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 7]]> agggccagtc agaacattgg cacaagcata cac 33 <![CDATA[<210> 8]]> <![CDATA[<211> 11]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 8]]> Arg Ala Ser Gln Asn Ile Gly Thr Ser Ile His 1 5 10 <![CDATA[<210> 9]]> <![CDATA[<211> 33]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 9]]> cgagcaagtg aaaatattta cagttattta gca 33 <![CDATA[<210> 10]]> <![CDATA[<211> 11]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 10]]> Arg Ala Ser Glu Asn Ile Tyr Ser Tyr Leu Ala 1 5 10 <![CDATA[<210> 11]]> <![CDATA[<211> 39]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 11]]> cagagcctct ttgatattga tggaaagaca tatttgaat 39 <![CDATA[<210> 12]]> <![CDATA[<211> 13]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 12]]> Gln Ser Leu Phe Asp Ile Asp Gly Lys Thr Tyr Leu Asn 1 5 10 <![CDATA[<210> 13]]> <![CDATA[<211> 33]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 13]]> cgggcaagtc aggacattgg tggtagctta aac 33 <![CDATA[<210> 14]]> <![CDATA[<211> 11]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 14]]> Arg Ala Ser Gln Asp Ile Gly Gly Ser Leu Asn 1 5 10 <![CDATA[<210> 15]]> <![CDATA[<211> 33]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 15]]> agggccagcc agactattag cgacttctta cac 33 <![CDATA[<210> 16]]> <![CDATA[<211> 11]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 16]]> Arg Ala Ser Gln Thr Ile Ser Asp Phe Leu His 1 5 10 <![CDATA[<210> 17]]> <![CDATA[<211> 33]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 17]]> agggcaagtg aggacataca cactcaatta gcc 33 <![CDATA[<210> 18]]> <![CDATA[<211> 11]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 18]]> Arg Ala Ser Glu Asp Ile His Thr Gln Leu Ala 1 5 10 <![CDATA[<210> 19]]> <![CDATA[<211> 48]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 19]]> agatctagtc agtacattgt tcatagtact ggaaccacct atttagaa 48 <![CDATA[<210> 20]]> <![CDATA[<211> 16]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 20]]> Arg Ser Ser Gln Tyr Ile Val His Ser Thr Gly Thr Thr Tyr Leu Glu 1 5 10 15 <![CDATA[<210> 21]]> <![CDATA[<211> 48]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 21]]> agatctagtc attaccttgt tcatgataac ggaaacacct atgttgaa 48 <![CDATA[<210> 22]]> <![CDATA[<211> 16]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 22]]> Arg Ser Ser His Tyr Leu Val His Asp Asn Gly Asn Thr Tyr Val Glu 1 5 10 15 <![CDATA[<210> 23]]> <![CDATA[<211> 48]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 23]]> agatctagtc agaacattgt ccatagtact ggaaacacct atttagaa 48 <![CDATA[<210> 24]]> <![CDATA[<211> 16]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 24]]> Arg Ser Ser Gln Asn Ile Val His Ser Thr Gly Asn Thr Tyr Leu Glu 1 5 10 15 <![CDATA[<210> 25]]> <![CDATA[<211> 30]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 25]]> agtgtcagct caagtgtaag ttacatacac 30 <![CDATA[<210> 26]]> <![CDATA[<211> 10]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 26]]> Ser Val Ser Ser Ser Val Ser Tyr Ile His 1 5 10 <![CDATA[<210> 27]]> <![CDATA[<211> 3]]>0 <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 27]]> agtgccagct caagtgtaag ttacatgtgc 30 <![CDATA[<210> 28]]> <![CDATA[<211> 10]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 28]]> Ser Ala Ser Ser Ser Val Ser Tyr Met Cys 1 5 10 <![CDATA[<210> 29]]> <![CDATA[<211> 18]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 29]]> cagggcatta acaattat 18 <![CDATA[<210> 30]]> <![CDATA[<211> 6]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 30]]> Gln Gly Ile Asn Asn Tyr 1 5 <![CDATA[<210> 31]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 31]]> tatgcttcta agtctatatc t 21 <![CDATA[<210> 32]]> <![CDATA[<211> 7]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 32]]> Tyr Ala Ser Lys Ser Ile Ser 1 5 <![CDATA[<210> 33]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 33]]> aatgcaaaaa ccttagcaga a 21 <![CDATA[<210> 34]]> <![CDATA[<211> 7]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 34]]> Asn Ala Lys Thr Leu Ala Glu 1 5 <![CDATA[<210> 35]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 35]]> ctggtgtctg aattggactc t 21 <![CDATA[<210> 36]]> <![CDATA[<211> 7]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 36]]> Leu Val Ser Glu Leu Asp Ser 1 5 <![CDATA[<210> 37]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400]]>> 37]]> <br/><![CDATA[gccacatcca gcttagattc t 21 <![CDATA[<210> 38]]> <![CDATA[<211> 7]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 38]]> Ala Thr Ser Ser Leu Asp Ser 1 5 <![CDATA[<210> 39]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 39]]> tatgcttccc aatccatctc t 21 <![CDATA[<210> 40]]> <![CDATA[<211> 7]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 40]]> Tyr Ala Ser Gln Ser Ile Ser 1 5 <![CDATA[<210> 41]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 41]]> ggtgcagcca gtttgaaaag t 21 <![CDATA[<210> 42]]> <![CDATA[<211> 7]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 42]]> Gly Ala Ala Ser Leu Lys Ser 1 5 <![CDATA[<210> 43]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 43]]> aaagtttcca accgattttc t 21 <![CDATA[<210> 44]]> <![CDATA[<211> 7]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 44]]> Lys Val Ser Asn Arg Phe Ser 1 5 <![CDATA[<210> 45]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 45]]> gacacatcca aactggcttc t 21 <![CDATA[<210> 46]]> <![CDATA[<211> 7]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 46]]> Asp Thr Ser Lys Leu Ala Ser 1 5 <![CDATA[<210> 47]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 47]]> tatacatcaa ctttacagtc a 21 <![CDATA[<210> 48]]> <![CDATA[<211> 7]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 48]]> Tyr Thr Ser Thr Leu Gln Ser 1 5 <![CDATA[<210> 49]]> <![CDATA[<211> 27]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 49]]> caacatagtt atagcttccc gtggacg 27 <![CDATA[<210> 50]]> <![CDATA[<211> 9]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 50]]> Gln His Ser Tyr Ser Phe Pro Trp Thr 1 5 <![CDATA[<210> 51]]> <![CDATA[<211> 27]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 51]]> cagcatcatt atggtattcc gttcacg 27 <![CDATA[<210> 52]]> <![CDATA[<211> 9]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 52]]> Gln His His Tyr Gly Ile Pro Phe Thr 1 5 <![CDATA[<210> 53]]> <![CDATA[<211> 27]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 53]]> tggcaaggta cacattttcc gctcacg 27 <![CDATA[<210> 54]]> <![CDATA[<211> 9]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 54]]> Trp Gln Gly Thr His Phe Pro Leu Thr 1 5 <![CDATA[<210> 55]]> <![CDATA[<211> 27]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 55]]> ctacaatatg ctagttctcc gtatacg 27 <![CDATA[<210> 56]]> <![CDATA[<211> 9]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 56]]> Leu Gln Tyr Ala Ser Ser Pro Tyr Thr 1 5 <![CDATA[<210> 57]]> <![CDATA[<211> 27]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 57]]> caaagtggta acacctttcc gtggacg 27 <![CDATA[<210> 58]]> <![CDATA[<211> 9]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小]]>鼠 <![CDATA[<400> 58]]> Gln Ser Gly Asn Thr Phe Pro Trp Thr 1 5 <![CDATA[<210> 59]]> <![CDATA[<211> 27]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 59]]> caacagtata ggagtattcc gtggacg 27 <![CDATA[<210> 60]]> <![CDATA[<211> 9]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 60]]> Gln Gln Tyr Arg Ser Ile Pro Trp Thr 1 5 <![CDATA[<210> 61]]> <![CDATA[<211> 27]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 61]]> tttcaaggtt cacattttcc attcacg 27 <![CDATA[<210> 6]]>2 <![CDATA[<211> 9]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 62]]> Phe Gln Gly Ser His Phe Pro Phe Thr 1 5 <![CDATA[<210> 63]]> <![CDATA[<211> 27]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 63]]> tttcaaggtt cacatttccc attcacg 27 <![CDATA[<210> 64]]> <![CDATA[<211> 9]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 64]]> His Gln Trp Ser Thr Asn Pro Pro Thr 1 5 <![CDATA[<210> 65]]> <![CDATA[<211> 27]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 65]]> cagcagtgga gtagtaaccc acccacg 27 <![CDATA[<210> 66]]> <![CDATA[<211> 9]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 66]]> Gln Gln Trp Ser Ser Asn Pro Pro Thr 1 5 <![CDATA[<210> 67]]> <![CDATA[<211> 24]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 67]]> cagcagttta gtaaacttcg gaca 24 <![CDATA[<210> 68]]> <![CDATA[<211> 8]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 68]]> Gln Gln Phe Ser Lys Leu Arg Thr 1 5 <![CDATA[<210> 69]]> <![CDATA[<211> 36]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 69]]> gggttctcac tgaccacttc tggcttgggt gttgcc 36 <![CDATA[<210> 70]]> <![CDATA[<211> 12]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 70]]> Gly Phe Ser Leu Thr Thr Ser Gly Leu Gly Val Ala 1 5 10 <![CDATA[<210> 71]]> <![CDATA[<211> 30]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 71]]> ggctacacct ttactagcta ctggatacac 30 <![CDATA[<210> 72]]> <![CDATA[<211> 10]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 72]]> Gly Tyr Thr Phe Thr Ser Tyr Trp Ile His 1 5 10 <![CDATA[<210> 73]]> <![CDATA[<211> 30]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 73]]> ggcctcaaca ttaaagacat ctatattcac 30 <![CDATA[<210> 74]]> <![CDATA[<211> 10]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 74]]> Gly Leu Asn Ile Lys Asp Ile Tyr Ile His 1 5 10 <![CDATA[<210> 75]]> <![CDATA[<211> 30]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 75]]> ggttactcat tcaccaacta ctggatacac 30 <![CDATA[<210> 76]]> <![CDATA[<211> 10]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 76]]> Gly Tyr Ser Phe Thr Asn Tyr Trp Ile His 1 5 10 <![CDATA[<210> 77]]> <![CDATA[<211> 30]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 77]]> ggattcactt tcagtgacta tcccatgtct 30 <![CDATA[<210> 78]]> <![CDATA[<211> 10]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 78]]> Gly Phe Thr Phe Ser Asp Tyr Pro Met Ser 1 5 10 <![CDATA[<210> ]]> 79 <![CDATA[<211> 30]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 79]]> ggattcactt tcagtagctt tggcatgtct 30 <![CDATA[<210> 80]]> <![CDATA[<211> 10]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 80]]> Gly Phe Thr Phe Ser Ser Phe Gly Met Ser 1 5 10 <![CDATA[<210> 81]]> <![CDATA[<211> 30]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 81]]> ggattcactt tcagtaccta tggcatgtct 30 <![CDATA[<210> 82]]> <![CDATA[<211> 10]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 82]]> Gly Phe Thr Phe Ser Thr Tyr Gly Met Ser 1 5 10 <![CDATA[<210> 83]]> <![CDATA[<211> 30]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 83]]> ggattcactt tcagtagtta tggcatgtct 30 <![CDATA[<210> 84]]> <![CDATA[<211> 10]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 84]]> Gly Phe Thr Phe Ser Ser Tyr Gly Met Ser 1 5 10 <![CDATA[<210> 85]]> <![CDATA[<211> 36]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 85]]> gggttttcac tgaccacttc tggtatgggt gtaggc 36 <![CDATA[<210> 86]]> <![CDATA[<211> 12]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 86]]> Gly Phe Ser Leu Thr Thr Ser Gly Met Gly Val Gly 1 5 10 <![CDATA[<210> 87]]> <![CDATA[<211> 36]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 87]]> ggattttcac tgagcacttc tggtttgggt gtaggc 36 <![CDATA[<210> 88]]> <![CDATA[<211> 12]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 88]]> Gly Phe Ser Leu Ser Thr Ser Gly Leu Gly Val Gly 1 5 10 <![CDATA[<210> 89]]> <![CDATA[<211> 24]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 89]]> ggattcacct tcagtgatta ttac 24 <![CDATA[<210> 90]]> <![CDATA[<211> 8]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 90]]> Gly Phe Thr Phe Ser Asp Tyr Tyr 1 5 <![CDATA[<210> 91]]> <![CDATA[<211> 48]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 91]]> cacatttggt cggatggtga cacgcgctat tacccagccc tgaagaac 48 <![CDATA[<210> 92]]> <![CDATA[<211> 16]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 92]]> His Ile Trp Ser Asp Gly Asp Thr Arg Tyr Tyr Pro Ala Leu Lys Asn 1 5 10 15 <![CDATA[<210> 93]]> <![CDATA[<211> 36]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 93]]> tacattaatc ctgacactga ttatagtgag tacaat 36 <![CDATA[<210> 94]]> <![CDATA[<211> 12]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 94]]> Tyr Ile Asn Pro Asp Thr Asp Tyr Ser Glu Tyr Asn 1 5 10 <![CDATA[<210> 95]]> <![CDATA[<211> 36]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 95]]> aggattgatc ctgcgaacgg taagactgca tatgac 36 <![CDATA[<210> 96]]> <![CDATA[<211> 12]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 96]]> Arg Ile Asp Pro Ala Asn Gly Lys Thr Ala Tyr Asp 1 5 10 <![CDATA[<210> 97]]> <![CDATA[<211> 36]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 97]]> atgattgatc cttccgatgc tgaaactggg ttaaat 36 <![CDATA[<210> 98]]> <![CDATA[<211> 12]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 98]]> Met Ile Asp Pro Ser Asp Ala Glu Thr Gly Leu Asn 1 5 10 <![CDATA[<210> 99]]> <![CDATA[<211> 24]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 99]]> gttagtgatg gtggtggttc cacc 24 <![CDATA[<210> 100]]> <![CDATA[<211> 8]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 100]]> Val Ser Asp Gly Gly Gly Ser Thr 1 5 <![CDATA[<210> 101]]> <![CDATA[<211> 24]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 101]]> attagtagtg ctggtagttt cacc 24 <![CDATA[<210> 102]]> <![CDATA[<211> 8]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 102]]> Ile Ser Ser Ala Gly Ser Phe Thr 1 5 <![CDATA[<210> 103]]> <![CDATA[<211> 51]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 103]]> accattaata ctaatggtgg taccacctat tatcgagaca gtgtgaaggg c 51 <![CDATA[<210> 104]]> <![CDATA[<211> 17]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 104]]> Thr Ile Asn Thr Asn Gly Gly Thr Thr Tyr Tyr Arg Asp Ser Val Lys 1 5 10 15 Gly <![CDATA[<210> 105]]> <![CDATA[<211> 51]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 105]]> accataaata ctaatggtgg taacacctat tattcagaca atgtgaaggg c 51 <![CDATA[<210> 106]]> <![CDATA[<211> 17]]> <![CDATA[<212> PRT]]> <![CDATA[<213>]]> 小鼠 <![CDATA[<400> 106]]> Thr Ile Asn Thr Asn Gly Gly Asn Thr Tyr Tyr Ser Asp Asn Val Lys 1 5 10 15 Gly <![CDATA[<210> 107]]> <![CDATA[<211> 51]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 107]]> accattagta ctaatggtgc caccgccaat tatccagaca gtgtgaaggg c 51 <![CDATA[<210> 108]]> <![CDATA[<211> 17]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 108]]> Thr Ile Ser Thr Asn Gly Ala Thr Ala Asn Tyr Pro Asp Ser Val Lys 1 5 10 15 Gly <![CDATA[<210> 109]]> <![CDATA[<211> 48]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 109]]> cacatttggt gggatgatga taagtactat aatccatccc tgaagagc 48 <![CDATA[<210> 110]]> <![CDATA[<211> 16]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 110]]> His Ile Trp Trp Asp Asp Asp Lys Tyr Tyr Asn Pro Ser Leu Lys Ser 1 5 10 15 <![CDATA[<210> 111]]> <![CDATA[<211> 48]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 111]]> cacatttggt gggatgatga taagtactat aatccatccc ttaagaga 48 <![CDATA[<210> 112]]> <![CDATA[<211> 16]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 112]]> His Ile Trp Trp Asp Asp Asp Lys Tyr Tyr Asn Pro Ser Leu Lys Arg 1 5 10 15 <![CDATA[<210> 113]]> <![CDATA[<211> 30]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 113]]> attagaaatc gggctaatgg ttacacaaca 30 <![CDATA[<210> 114]]> <![CDATA[<211> 10]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 114]]> Ile Arg Asn Arg Ala Asn Gly Tyr Thr Thr 1 5 10 <![CDATA[<210> 115]]> <![CDATA[<211> 30]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 115]]> atgaaggatg atagtcttta ctttgacaac 30 <![CDATA[<210> 116]]> <![CDATA[<211> 10]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 116]]> Met Lys Asp Asp Ser Leu Tyr Phe Asp Asn 1 5 10 <![CDATA[<210> 117]]> <![CDATA[<211> 30]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 117]]> gcaagtgctg gttattattt ttttgacttc 30 <![CDATA[<210> 118]]> <![CDATA[<211> 10]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 118]]> Ala Ser Ala Gly Tyr Tyr Phe Phe Asp Phe 1 5 10 <![CDATA[<210> 119]]> <![CDATA[<211> 15]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 119]]> ggtagggggg cccac 15 <![CDATA[<210> 120]]> <![CDATA[<211> 5]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 120]]> Gly Arg Gly Ala His 1 5 <![CDATA[<210> 121]]> <![CDATA[<211> 33]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 121]]> gcaagaattg gcgattacta taatatggac tac 33 <![CDATA[<210> 122]]> <![CDATA[<211> 11]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 122]]> Ala Arg Ile Gly Asp Tyr Tyr Asn Met Asp Tyr 1 5 10 <![CDATA[<210> 123]]> <![CDATA[<211> 45]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 123]]> acaagacatg cttcctacta tagctacgac cattctatgg actac 45 <![CDATA[<210> 124]]> <![CDATA[<211> 15]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 124]]> Thr Arg His Ala Ser Tyr Tyr Ser Tyr Asp His Ser Met Asp Tyr 1 5 10 15 <![CDATA[<210> 125]]> <![CDATA[<211> 36]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 125]]> gcaagacggg ggtacgacgt tgggtgcttt gaccac 36 <![CDATA[<210> 126]]> <![CDATA[<211> 12]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 126]]> Ala Arg Arg Gly Tyr Asp Val Gly Cys Phe Asp His 1 5 10 <![CDATA[<210> 127]]> <![CDATA[<211> 27]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 127]]> gcaagagact acggggctat ggactac 27 <![CDATA[<210> 128]]> <![CDATA[<211> 9]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 128]]> Ala Arg Asp Tyr Gly Ala Met Asp Tyr 1 5 <![CDATA[<210> 129]]> <![CDATA[<211> 27]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 129]]> gcaactgaaa agggagctat gggctac 27 <![CDATA[<210> 130]]> <![CDATA[<211> 9]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 130]]> Ala Thr Glu Lys Gly Ala Met Gly Tyr 1 5 <![CDATA[<210> 131]]> <![CDATA[<211> 57]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 131]]> gctcgaagaa ctgagactat gattacgaca gtgctatatt actatgctat ggactac 57 <![CDATA[<210> 132]]> <![CDATA[<211> 19]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 132]]> Ala Arg Arg Thr Glu Thr Met Ile Thr Thr Val Leu Tyr Tyr Tyr Ala 1 5 10 15 Met Asp Tyr <![CDATA[<210> 133]]> <![CDATA[<211> 54]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 133]]> gctcgaagga gggaagttaa cttcggtatt aactattact attctatgga ctac 54 <![CDATA[<210> 134]]> <![CDATA[<211> 18]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 134]]> Ala Arg Arg Arg Glu Val Asn Phe Gly Ile Asn Tyr Tyr Tyr Ser Met 1 5 10 15 Asp Tyr <![CDATA[<210> 135]]> <![CDATA[<211> 36]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 135]]> gtaagagatt cctatcacta cgggtacttc gatgtc 36 <![CDATA[<210> 136]]> <![CDATA[<211> 12]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 136]]> Val Arg Asp Ser Tyr His Tyr Gly Tyr Phe Asp Val 1 5 10 <![CDATA[<210> 137]]> <![CDATA[<211> 324]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 137]]> gacatcttgc tgactcagtc tccagccatc ctgtctgtga gtccaggaaa aagagtcagt 60 ttctcctgca gggccagtca gaacattggc acaagcatac actggtatca gcaaagaaca 120 aatggttctc caaggcttct cataaagtat gcttctaagt ctatatctgg gatttcttcc 180 aggtttagtg gcagtggctc agggacagat tttactctta gtatcaacag tgtggagtct 240 gaagatattg cagcttatta ctgtcaacat agttatagct tcccgtggac gttcggtgga 300 ggcaccaagc tggaaatcaa acgg 324 <![CDATA[<210> 138]]> <![CDATA[<211> 108]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 138]]> Asp Ile Leu Leu Thr Gln Ser Pro Ala Ile Leu Ser Val Ser Pro Gly 1 5 10 15 Lys Arg Val Ser Phe Ser Cys Arg Ala Ser Gln Asn Ile Gly Thr Ser 20 25 30 Ile His Trp Tyr Gln Gln Arg Thr Asn Gly Ser Pro Arg Leu Leu Ile 35 40 45 Lys Tyr Ala Ser Lys Ser Ile Ser Gly Ile Ser Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Ser Ile Asn Ser Val Glu Ser 65 70 75 80 Glu Asp Ile Ala Ala Tyr Tyr Cys Gln His Ser Tyr Ser Phe Pro Trp 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg 100 105 <![CDATA[<210> 139]]> <![CDATA[<211> 324]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 139]]> gacatccaga tgactcagtc tccagcctcc ctatctacat ctgtgggaga aactgtcacc 60 atcacatgtc gagcaagtga aaatatttac agttatttag catggtatca gcagagacag 120 ggaaaatctc ctcacctcct ggtcaataat gcaaaaacct tagcagaagg tgtgccatca 180 aggttcagtg gcagtggatc aggcacacat ttttctctga ggatcagcgg cctgcagcct 240 gaagattttg ggagttatta ctgtcagcat cattatggta ttccgttcac gttcggaggg 300 gggaccaagt tgtcaataaa acgg 324 <![CDATA[<210> 140]]> <![CDATA[<211> 108]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 140]]> Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Thr Ser Val Gly 1 5 10 15 Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Glu Asn Ile Tyr Ser Tyr 20 25 30 Leu Ala Trp Tyr Gln Gln Arg Gln Gly Lys Ser Pro His Leu Leu Val 35 40 45 Asn Asn Ala Lys Thr Leu Ala Glu Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr His Phe Ser Leu Arg Ile Ser Gly Leu Gln Pro 65 70 75 80 Glu Asp Phe Gly Ser Tyr Tyr Cys Gln His His Tyr Gly Ile Pro Phe 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Ser Ile Lys Arg 100 105 <![CDATA[<210> 141]]> <![CDATA[<211> 339]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 141]]> gatgttgtga tgacccagat tccactcact ttgtcggtta ccattggaca accagcctcc 60 atctcttgca agtcaagtca gagcctcttt gatattgatg gaaagacata tttgaattgg 120 ttgttacaga ggccaggcca gtctccaaag cgcctaatct atctggtgtc tgaattggac 180 tctggagtcc ctgacaggtt cactggcagt ggatcaggga cagatttcac actgaaaatc 240 agcagagtgg aggctgagga tttgggagtt tactattgtt ggcaaggtac acattttccg 300 ctcacgttcg gtgctgggac caagctggag ctgaaacgg 339 <![CDATA[<210> 142]]> <![CDATA[<211> 113]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 142]]> Asp Val Val Met Thr Gln Ile Pro Leu Thr Leu Ser Val Thr Ile Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Phe Asp Ile 20 25 30 Asp Gly Lys Thr Tyr Leu Asn Trp Leu Leu Gln Arg Pro Gly Gln Ser 35 40 45 Pro Lys Arg Leu Ile Tyr Leu Val Ser Glu Leu Asp Ser Gly Val Pro 50 55 60 Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Tyr Cys Trp Gln Gly 85 90 95 Thr His Phe Pro Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys 100 105 110 Arg <![CDATA[<210> 143]]> <![CDATA[<211> 324]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 143]]> gacatccaga tgacccagtc tccatcctcc ttatctgcct ctctgggaga aagagtcagt 60 ctcacttgtc gggcaagtca ggacattggt ggtagcttaa actggcttca gcagaaacca 120 gatggaacta ttaaacgcct gatctacgcc acatccagct tagattctgg tgtccccaaa 180 aggttcagtg gcagtaggtc tgggtcagtt ttttctctca ccatcaccag ccttgagtct 240 gaagattttg tagactattt ctgtctacaa tatgctagtt ctccgtatac gttcggaggg 300 gggaccaagc tggaaataaa acgg 324 <![CDATA[<210> 144]]> <![CDATA[<211> 108]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 144]]> Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly 1 5 10 15 Glu Arg Val Ser Leu Thr Cys Arg Ala Ser Gln Asp Ile Gly Gly Ser 20 25 30 Leu Asn Trp Leu Gln Gln Lys Pro Asp Gly Thr Ile Lys Arg Leu Ile 35 40 45 Tyr Ala Thr Ser Ser Leu Asp Ser Gly Val Pro Lys Arg Phe Ser Gly 50 55 60 Ser Arg Ser Gly Ser Val Phe Ser Leu Thr Ile Thr Ser Leu Glu Ser 65 70 75 80 Glu Asp Phe Val Asp Tyr Phe Cys Leu Gln Tyr Ala Ser Ser Pro Tyr 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg 100 105 <![CDATA[<210> 145]]> <![CDATA[<211> 324]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 145]]> gacattgtga tgactcagtc tccagccacc ctgtctgtga ctccaggaga tagagtctct 60 ctttcctgca gggccagcca gactattagc gacttcttac actggtatca acaaaaatca 120 catgagtctc caaggcttct catcaaatat gcttcccaat ccatctctgg gatcccctcc 180 aggttcagtg gcactggatc agggtcagat ttcactctca ctatcaacag tgtggaacct 240 gaagatgttg gagtgtatta ctgtcaaagt ggtaacacct ttccgtggac gttcggtgga 300 ggcaccaagc tggaaatcaa acgg 324 <![CDATA[<210> 146]]> <![CDATA[<211> 108]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 146]]> Asp Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Thr Pro Gly 1 5 10 15 Asp Arg Val Ser Leu Ser Cys Arg Ala Ser Gln Thr Ile Ser Asp Phe 20 25 30 Leu His Trp Tyr Gln Gln Lys Ser His Glu Ser Pro Arg Leu Leu Ile 35 40 45 Lys Tyr Ala Ser Gln Ser Ile Ser Gly Ile Pro Ser Arg Phe Ser Gly 50 55 60 Thr Gly Ser Gly Ser Asp Phe Thr Leu Thr Ile Asn Ser Val Glu Pro 65 70 75 80 Glu Asp Val Gly Val Tyr Tyr Cys Gln Ser Gly Asn Thr Phe Pro Trp 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg 100 105 <![CDATA[<210> 147]]> <![CDATA[<211> 324]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 147]]> gacatccaga tgacacaatc ttcatcctcc ttttctggat ttctaggaga cagagtcacc 60 attacttgca gggcaagtga ggacatacac actcaattag cctggtatca gcagaaacca 120 ggaaatgctc ctaggctctt aatatctggt gcagccagtt tgaaaagtgg ggttccttca 180 agattcagtg gcactggatc tggaaaggat tacactctca gcattaccag tcttcagact 240 gaagatgttg ctacatatta ctgtcaacag tataggagta ttccgtggac gttcggtgga 300 ggcaccaagc tggaaatcaa acgg 324 <![CDATA[<210> 148]]> <![CDATA[<211> 108]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 148]]> Asp Ile Gln Met Thr Gln Ser Ser Ser Ser Phe Ser Gly Phe Leu Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Glu Asp Ile His Thr Gln 20 25 30 Leu Ala Trp Tyr Gln Gln Lys Pro Gly Asn Ala Pro Arg Leu Leu Ile 35 40 45 Ser Gly Ala Ala Ser Leu Lys Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Thr Gly Ser Gly Lys Asp Tyr Thr Leu Ser Ile Thr Ser Leu Gln Thr 65 70 75 80 Glu Asp Val Ala Thr Tyr Tyr Cys Gln Gln Tyr Arg Ser Ile Pro Trp 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg 100 105 <![CDATA[<210> 149]]> <![CDATA[<211> 339]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 149]]> gatgttttga tgacccaaac tccgctctcc ctgcctgtca gtcttggaga tcacgcctcc 60 atctcttgca gatctagtca gtacattgtt catagtactg gaaccaccta tttagaatgg 120 tacctacaga aaccaggcca gtctccacag ctcctgatct acaaagtttc caaccgattt 180 tctggggtcc cagacaggtt cactggcagt ggatcaggga cagatttcac actcaggatc 240 agcagagtgg aggctgagga tctgggagtt tatttctgct ttcaaggttc acattttcca 300 ttcacgttcg gctcggggac aaagttggaa ataaaacgg 339 <![CDATA[<210> 150]]> <![CDATA[<211> 113]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 150]]> Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly 1 5 10 15 Asp His Ala Ser Ile Ser Cys Arg Ser Ser Gln Tyr Ile Val His Ser 20 25 30 Thr Gly Thr Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Arg Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Leu Gly Val Tyr Phe Cys Phe Gln Gly 85 90 95 Ser His Phe Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 100 105 110 Arg <![CDATA[<210> 151]]> <![CDATA[<211> 339]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 151]]> gaagttgtga tgacccaaac tccactctcc ttgcctgtca gtcttggaga tcaagcctcc 60 atctcttgca gatctagtca ttaccttgtt catgataacg gaaacaccta tgttgaatgg 120 tacctgcaga agccaggcca gtctccaaag ctcctgatct acaaggtttc caaccgattt 180 tctggagtcc cagacaggtt tactggcagt ggttcaggga cagatttcac actcaagatc 240 agcagagtgg agtctgagga tctgggaatt tattactgct ttcaaggttc acatttccca 300 ttcacgttcg gctcggggac agagttggaa ataaaacgg 339 <![CDATA[<210> 152]]> <![CDATA[<211> 113]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 152]]> Glu Val Val Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly 1 5 10 15 Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser His Tyr Leu Val His Asp 20 25 30 Asn Gly Asn Thr Tyr Val Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ser Glu Asp Leu Gly Ile Tyr Tyr Cys Phe Gln Gly 85 90 95 Ser His Phe Pro Phe Thr Phe Gly Ser Gly Thr Glu Leu Glu Ile Lys 100 105 110 Arg <![CDATA[<210> 153]]> <![CDATA[<211> 339]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 153]]> gatgttttga tgacccaaac tccactctcc ctgcctgtca gtcttggaga tcaagcctcc 60 atctcttgca gatctagtca gaacattgtc catagtactg gaaacaccta tttagaatgg 120 tacctgcaga aaccaggcca gtctccaaag ctcctgattt ataaagtttc caaccgattt 180 tctggggtcc caaacaggtt ccgtggcagt ggatcaggga cagatttcac actcaagatc 240 accagagtgg aggctgagga tctgggaatt tattactgct ttcaaggttc acattttcca 300 ttcacgttcg gctcggggac aaagttggaa ataaaacgg 339 <![CDATA[<210> 154]]> <![CDATA[<211> 113]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 154]]> Asp Val Leu Met Thr Gln Thr Pro Leu Ser Leu Pro Val Ser Leu Gly 1 5 10 15 Asp Gln Ala Ser Ile Ser Cys Arg Ser Ser Gln Asn Ile Val His Ser 20 25 30 Thr Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Lys Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Asn Arg Phe Arg Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Thr Arg Val Glu Ala Glu Asp Leu Gly Ile Tyr Tyr Cys Phe Gln Gly 85 90 95 Ser His Phe Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys 100 105 110 Arg <![CDATA[<210> 155]]> <![CDATA[<211> 321]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 155]]> caaattgttc tcacccagtc tccagcaatc atgtctgcat ctccagggga gaaggtcacc 60 atgacctgca gtgtcagctc aagtgtaagt tacatacact ggtaccaaca gaagtcaggc 120 acctccccca aaagatggat ttatgacaca tccaaactgg cttctggagt ccctgctcgc 180 ttcagtggca gtgggtctgg gacctcttac tctctcacaa tcagcagcat ggaggctgaa 240 gatgctgcca cttattactg ccaccagtgg agtactaacc cacccacgtt cggagggggg 300 accaagctgg aaataagacg g 321 <![CDATA[<210> 156]]> <![CDATA[<211> 107]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 156]]> Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly 1 5 10 15 Glu Lys Val Thr Met Thr Cys Ser Val Ser Ser Ser Val Ser Tyr Ile 20 25 30 His Trp Tyr Gln Gln Lys Ser Gly Thr Ser Pro Lys Arg Trp Ile Tyr 35 40 45 Asp Thr Ser Lys Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser 50 55 60 Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu 65 70 75 80 Asp Ala Ala Thr Tyr Tyr Cys His Gln Trp Ser Thr Asn Pro Pro Thr 85 90 95 Phe Gly Gly Gly Thr Lys Leu Glu Ile Arg Arg 100 105 <![CDATA[<210> 157]]> <![CDATA[<211> 321]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 157]]> caaattgttc tcacccagtc tccagcactc atgtctgcat ctccagggga gaaggtcacc 60 atgacctgca gtgccagctc aagtgtaagt tacatgtgct ggtaccagca gaagccaaga 120 tcctccccca aaccctggat ttatctcaca tccaacctgg cttctggagt ccctgctcgc 180 ttcagtggca gtgggtctgg gacctcttac tctctcacaa tcagtagcat ggaggctgaa 240 gatgctgcca cttattactg ccagcagtgg agtagtaacc cacccacgtt cggtgctggg 300 accaagctgg agctgaaacg g 321 <![CDATA[<210> 158]]> <![CDATA[<211> 107]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 158]]> Gln Ile Val Leu Thr Gln Ser Pro Ala Leu Met Ser Ala Ser Pro Gly 1 5 10 15 Glu Lys Val Thr Met Thr Cys Ser Ala Ser Ser Ser Val Ser Tyr Met 20 25 30 Cys Trp Tyr Gln Gln Lys Pro Arg Ser Ser Pro Lys Pro Trp Ile Tyr 35 40 45 Leu Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser 50 55 60 Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Ser Met Glu Ala Glu 65 70 75 80 Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Trp Ser Ser Asn Pro Pro Thr 85 90 95 Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg 100 105 <![CDATA[<210> 159]]> <![CDATA[<211> 321]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 159]]> gaaatccaga tgacacagac tccatcctcc ctgtctgcct ctctgggaga cagagtcacc 60 atcacttgca gtgcaagtca gggcattaac aattatttga actggtatca gcagaaacca 120 ggtggaaaga ctagactcct catctattat acatcaactt tacagtcagg agtcccatca 180 aggttcagtg gcagtgggtc tgggacacat tattctctca ccatcagcaa tctggaacct 240 gaagatattg ccacttacta ttgtcagcag tttagtaaac ttcggacatt cggtggaggc 300 accaggctgg aaatcaaacg g 321 <![CDATA[<210> 160]]> <![CDATA[<211> 107]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 160]]> Glu Ile Gln Met Thr Gln Thr Pro Ser Ser Leu Ser Ala Ser Leu Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Gly Ile Asn Asn Tyr 20 25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gly Lys Thr Arg Leu Leu Ile 35 40 45 Tyr Tyr Thr Ser Thr Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr His Tyr Ser Leu Thr Ile Ser Asn Leu Glu Pro 65 70 75 80 Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Phe Ser Lys Leu Arg Thr 85 90 95 Phe Gly Gly Gly Thr Arg Leu Glu Ile Lys Arg 100 105 <![CDATA[<210> 161]]> <![CDATA[<211> 324]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人]]> <![CDATA[<220>]]> <![CDATA[<221> 可突變位置]]> <![CDATA[<222> (128)..(128)]]> <![CDATA[<223> 第128位之X可為c或a ]]> <![CDATA[<400> 161]]> gagattgtgc tgactcagag tccagacttc cagtcagtga cccccaagga gaaagtcacc 60 atcacatgcc gggcaagcca gaacatcggc acaagcattc actggtacca gcagaagccc 120 gatcagtxcc ctaagctgct gatcaaatat gcctctaaga gtatttcagg ggtgccctct 180 agattcagcg gctccgggtc tggaacagac tttactctga ccattaactc cctggaggct 240 gaagatgccg ctacttacta ttgtcagcat agctactcat tcccttggac attcgggcag 300 gggaccaaag tggaaatcaa acgt 324 <![CDATA[<210> 162]]> <![CDATA[<211]]>> 108]]> <br/><![CDATA[<212> PRT]]> <br/><![CDATA[<213> 人]]> <br/> <br/><![CDATA[<220>]]> <br/><![CDATA[<221> 可突變位置]]> <br/><![CDATA[<222> (43)..(43)]]> <br/><![CDATA[<223> 第43位之Xaa可為Ser或Tyr ]]> <br/> <br/><![CDATA[<400> 162]]> <br/> <br/><![CDATA[Glu Ile Val Leu Thr Gln Ser Pro Asp Phe Gln Ser Val Thr Pro Lys 1 5 10 15 Glu Lys Val Thr Ile Thr Cys Arg Ala Ser Gln Asn Ile Gly Thr Ser 20 25 30 Ile His Trp Tyr Gln Gln Lys Pro Asp Gln Xaa Pro Lys Leu Leu Ile 35 40 45 Lys Tyr Ala Ser Lys Ser Ile Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn Ser Leu Glu Ala 65 70 75 80 Glu Asp Ala Ala Thr Tyr Tyr Cys Gln His Ser Tyr Ser Phe Pro Trp 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg 100 105 <![CDATA[<210> 163]]> <![CDATA[<211> 339]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人]]> <![CDATA[<400> 163]]> gatattgtga tgacccaaac tccgctctcc ctgtccgtca cccctggaca gccggcctcc 60 atctcttgca gatctagtca gaacattgtt catagtactg gaaacaccta tttagaatgg 120 tacctacaga aaccaggcca gtctccacag ctcctgatct acaaagtttc caaccgattt 180 tctggggtcc cagacaggtt cagtggcagt ggatcaggga cagatttcac actcaaaatc 240 agcagagtgg aggctgagga tgttggagtt tattactgct ttcaaggttc acattttcca 300 ttcacgttcg gccaagggac caaggtggaa atcaaacgt 339 <![CDATA[<210> 164]]> <![CDATA[<211> 113]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人]]> <![CDATA[<400> 164]]> Asp Ile Val Met Thr Gln Thr Pro Leu Ser Leu Ser Val Thr Pro Gly 1 5 10 15 Gln Pro Ala Ser Ile Ser Cys Arg Ser Ser Gln Asn Ile Val His Ser 20 25 30 Thr Gly Asn Thr Tyr Leu Glu Trp Tyr Leu Gln Lys Pro Gly Gln Ser 35 40 45 Pro Gln Leu Leu Ile Tyr Lys Val Ser Asn Arg Phe Ser Gly Val Pro 50 55 60 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile 65 70 75 80 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Phe Gln Gly 85 90 95 Ser His Phe Pro Phe Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 110 Arg <![CDATA[<210> 165]]> <![CDATA[<211> 360]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 165]]> caggttactc tgaaagagtc tggccctggg atattgcagc cctcccagac cctcagtctg 60 acttgttctt tctctgggtt ctcactgacc acttctggct tgggtgttgc ctggattcgt 120 cagccttcag ggaagggtct ggagtggctg gcacacattt ggtcggatgg tgacacgcgc 180 tattacccag ccctgaagaa ccgactgaca atctccaagg attcctccag caaccaggtc 240 ttcctcaaga tcgcccgtgt ggacactgca gatactgcca catactactg tgctcgaatg 300 aaggatgata gtctttactt tgacaactgg ggccaaggca ctattttcac agtctcctca 360 <![CDATA[<210> 166]]> <![CDATA[<211> 120]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 166]]> Gln Val Thr Leu Lys Glu Ser Gly Pro Gly Ile Leu Gln Pro Ser Gln 1 5 10 15 Thr Leu Ser Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Leu Gly Val Ala Trp Ile Arg Gln Pro Ser Gly Lys Gly Leu Glu 35 40 45 Trp Leu Ala His Ile Trp Ser Asp Gly Asp Thr Arg Tyr Tyr Pro Ala 50 55 60 Leu Lys Asn Arg Leu Thr Ile Ser Lys Asp Ser Ser Ser Asn Gln Val 65 70 75 80 Phe Leu Lys Ile Ala Arg Val Asp Thr Ala Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Met Lys Asp Asp Ser Leu Tyr Phe Asp Asn Trp Gly Gln 100 105 110 Gly Thr Ile Phe Thr Val Ser Ser 115 120 <![CDATA[<210> 167]]> <![CDATA[<211> 351]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 167]]> cagatccagt tggtgcagtc tggggctgaa ctggcaaaac ctggggcctc agtgaggatg 60 tcctgcgaga cttctggcta cacctttact agctactgga tacactggat aaaagagagg 120 cctggacagg gtctggaatg gattggatac attaatcctg acactgatta tagtgagtac 180 aatcagaaat tcaaggacaa ggccagattg actgcagaca aatcctccac cacagcctac 240 atggagctga acagcctgac atttgatgat tctgcagtct attactgtgc aagtgctggt 300 tattattttt ttgacttctg gggccaaggc accactctca cagtctcctc a 351 <![CDATA[<210> 168]]> <![CDATA[<211> 117]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 168]]> Gln Ile Gln Leu Val Gln Ser Gly Ala Glu Leu Ala Lys Pro Gly Ala 1 5 10 15 Ser Val Arg Met Ser Cys Glu Thr Ser Gly Tyr Thr Phe Thr Ser Tyr 20 25 30 Trp Ile His Trp Ile Lys Glu Arg Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Tyr Ile Asn Pro Asp Thr Asp Tyr Ser Glu Tyr Asn Gln Lys Phe 50 55 60 Lys Asp Lys Ala Arg Leu Thr Ala Asp Lys Ser Ser Thr Thr Ala Tyr 65 70 75 80 Met Glu Leu Asn Ser Leu Thr Phe Asp Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ala Ser Ala Gly Tyr Tyr Phe Phe Asp Phe Trp Gly Gln Gly Thr Thr 100 105 110 Leu Thr Val Ser Ser 115 <![CDATA[<210> 169]]> <![CDATA[<211> 336]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 169]]> gaggttcagc tgcagcagtc tggggcagaa cttgtgaaac caggggcctc agtcaagttg 60 tcctgtacaa cttctggcct caacattaaa gacatctata ttcactgggt gaagcagagg 120 cctgaacagg gcctggagtg gattgggagg attgatcctg cgaacggtaa gactgcatat 180 gacctgaagt tccaggccaa ggccactata acagcagaca catcttccaa aacagcctac 240 ctgcacctca gcagcctgac atctgaggac actgccgtct attactgtgg taggggggcc 300 cactggggcc aaggcaccac tctcacagtc tcctca 336 <![CDATA[<210> 170]]> <![CDATA[<211> 112]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 170]]> Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Thr Thr Ser Gly Leu Asn Ile Lys Asp Ile 20 25 30 Tyr Ile His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile 35 40 45 Gly Arg Ile Asp Pro Ala Asn Gly Lys Thr Ala Tyr Asp Leu Lys Phe 50 55 60 Gln Ala Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Lys Thr Ala Tyr 65 70 75 80 Leu His Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Gly Arg Gly Ala His Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser 100 105 110 <![CDATA[<210> 171]]> <![CDATA[<211> 354]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 171]]> cagatccagt tggtgcagtc tgggcctcag ctggttaggc ctggggcttc agtgaagata 60 tcctgcgagg cttctggtta ctcattcacc aactactgga tacactgggt gaagcagagg 120 cctggacagg gtcttgagtg gattggcatg attgatcctt ccgatgctga aactgggtta 180 aatcagaagt tcaaggacaa ggccacattg actgtagaca aatcctccag cacagcctac 240 atgcaactca gcagcccgac atctgaagac tctgcggtct attactgtgc aagaattggc 300 gattactata atatggacta ctggggtcaa ggaacctcag tcaccgtctc ctca 354 <![CDATA[<210> 172]]> <![CDATA[<211> 118]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 172]]> Gln Ile Gln Leu Val Gln Ser Gly Pro Gln Leu Val Arg Pro Gly Ala 1 5 10 15 Ser Val Lys Ile Ser Cys Glu Ala Ser Gly Tyr Ser Phe Thr Asn Tyr 20 25 30 Trp Ile His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Met Ile Asp Pro Ser Asp Ala Glu Thr Gly Leu Asn Gln Lys Phe 50 55 60 Lys Asp Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Gln Leu Ser Ser Pro Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Ile Gly Asp Tyr Tyr Asn Met Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Ser Val Thr Val Ser Ser 115 <![CDATA[<210> 173]]> <![CDATA[<211> 366]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 173]]> gaagtgaagg tggtggagtc tgggggaggt ttagtgcagc ctggagggtc cctgaaactc 60 tcctgtgcag cctctggatt cactttcagt gactatccca tgtcttgggt tcgccagact 120 ccagagaaga gactggagtg ggtcgcatac gttagtgatg gtggtggttc cacctactat 180 ccagacattg taaagggccg attcaccatc tcccgagaca atgccaagaa caccctgtac 240 cttcaaatga gcagtctgaa gtctgaggac acggccatgt atttctgtac aagacatgct 300 tcctactata gctacgacca ttctatggac tactggggtc agggaacctc agtcaccgtc 360 tcatca 366 <![CDATA[<210> 174]]> <![CDATA[<211> 122]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 174]]> Glu Val Lys Val Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asp Tyr 20 25 30 Pro Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val 35 40 45 Ala Tyr Val Ser Asp Gly Gly Gly Ser Thr Tyr Tyr Pro Asp Ile Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Ser Ser Leu Lys Ser Glu Asp Thr Ala Met Tyr Phe Cys 85 90 95 Thr Arg His Ala Ser Tyr Tyr Ser Tyr Asp His Ser Met Asp Tyr Trp 100 105 110 Gly Gln Gly Thr Ser Val Thr Val Ser Ser 115 120 <![CDATA[<210> 175]]> <![CDATA[<211> 357]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 175]]> cagatccagt tggtgcagtc tgggggagac ttagtgaggc ctggagggtc cctgaaactc 60 tcctgtgcag cctctggatt cactttcagt agctttggca tgtcttggat tcgccagact 120 ccagacaaga ggctggagtg ggtcgcaacc attagtagtg ctggtagttt cacctactat 180 ccagacagtg tgaagggccg attcaccatc tccagagaca atgccaggaa caccctgtat 240 ctacaaatga acagtctgaa gtctgaggac tcagccatgt attactgtgc aagacggggg 300 tacgacgttg ggtgctttga ccactggggc cgaggcacca ctctcacagt ctcctca 357 <![CDATA[<210> 176]]> <![CDATA[<211> 119]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 176]]> Gln Ile Gln Leu Val Gln Ser Gly Gly Asp Leu Val Arg Pro Gly Gly 1 5 10 15 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe 20 25 30 Gly Met Ser Trp Ile Arg Gln Thr Pro Asp Lys Arg Leu Glu Trp Val 35 40 45 Ala Thr Ile Ser Ser Ala Gly Ser Phe Thr Tyr Tyr Pro Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Arg Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Lys Ser Glu Asp Ser Ala Met Tyr Tyr Cys 85 90 95 Ala Arg Arg Gly Tyr Asp Val Gly Cys Phe Asp His Trp Gly Arg Gly 100 105 110 Thr Thr Leu Thr Val Ser Ser 115 <![CDATA[<210> 177]]> <![CDATA[<211> 348]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 177]]> gaggtgcacc tggtggagtc tgggggaggc ttagtgcagc ctggagggtc cctgaaactc 60 tcctgtgcag cctctggatt cactttcagt acctatggca tgtcttgggt tcgccagact 120 ccagacaaga ggctggagtt ggtcgcgacc attaatacta atggtggtac cacctattat 180 cgagacagtg tgaagggccg attcaccatc tccagagaca atgccaagaa caccctgtac 240 ctgcaaatga gcagtctgaa gtctgatgac acagccatgt attactgtgc aagagactac 300 ggggctatgg actactgggg tcaaggaacc tcagtcaccg tctcctca 348 <![CDATA[<210> 178]]> <![CDATA[<211> 116]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 178]]> Glu Val His Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr 20 25 30 Gly Met Ser Trp Val Arg Gln Thr Pro Asp Lys Arg Leu Glu Leu Val 35 40 45 Ala Thr Ile Asn Thr Asn Gly Gly Thr Thr Tyr Tyr Arg Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Ser Ser Leu Lys Ser Asp Asp Thr Ala Met Tyr Tyr Cys 85 90 95 Ala Arg Asp Tyr Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val 100 105 110 Thr Val Ser Ser 115 <![CDATA[<210> 179]]> <![CDATA[<211> 345]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 179]]> gatgtgcacc tggtggagtc tgggggaggc ttagtgcagc ctggagggtc cctgacagtc 60 tcctgcgcag cctctggatt cactttcagt acctatggca tgtcttgggt tcgccagact 120 cgagacaaga ggctggagtt ggtcgcaacc ataaatacta atggtggtaa cacctattat 180 tcagacaatg tgaagggccg attcaccatt tccagagaca atgccaagaa caccctgtat 240 ttggaaatga gaggtctgag gtctggggac acagccatgt attactgtgc aagagactac 300 ggggctatgg actactgggg tcaaggaacc tcagtcaccg tctct 345 <![CDATA[<210> 180]]> <![CDATA[<211> 115]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 180]]> Asp Val His Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Thr Val Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr 20 25 30 Gly Met Ser Trp Val Arg Gln Thr Arg Asp Lys Arg Leu Glu Leu Val 35 40 45 Ala Thr Ile Asn Thr Asn Gly Gly Asn Thr Tyr Tyr Ser Asp Asn Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 65 70 75 80 Leu Glu Met Arg Gly Leu Arg Ser Gly Asp Thr Ala Met Tyr Tyr Cys 85 90 95 Ala Arg Asp Tyr Gly Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val 100 105 110 Thr Val Ser 115 <![CDATA[<210> 181]]> <![CDATA[<211> 348]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 181]]> gaggtgcagc tgcagcagcc tgggggaggc ttagtacagc ctggagggtc cctgacactc 60 tcctgtgcaa cctctggatt cactttcagt agttatggca tgtcttgggt tcgccagact 120 ccagccaaga ggctggagtt ggtcgcaacc attagtacta atggtgccac cgccaattat 180 ccagacagtg tgaagggccg attcaccatc tccagagaca atgccaagag caccctgtac 240 ctacaaatgc gcagtctgaa gtctgaggac acagccatgt attactgtgc aactgaaaag 300 ggagctatgg gctactgggg tcaaggaacc tcagtcaccg tctcctca 348 <![CDATA[<210> 182]]> <![CDATA[<211> 116]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 182]]> Glu Val Gln Leu Gln Gln Pro Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Thr Leu Ser Cys Ala Thr Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Gly Met Ser Trp Val Arg Gln Thr Pro Ala Lys Arg Leu Glu Leu Val 35 40 45 Ala Thr Ile Ser Thr Asn Gly Ala Thr Ala Asn Tyr Pro Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Ser Thr Leu Tyr 65 70 75 80 Leu Gln Met Arg Ser Leu Lys Ser Glu Asp Thr Ala Met Tyr Tyr Cys 85 90 95 Ala Thr Glu Lys Gly Ala Met Gly Tyr Trp Gly Gln Gly Thr Ser Val 100 105 110 Thr Val Ser Ser 115 <![CDATA[<210> 183]]> <![CDATA[<211> 381]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 183]]> caagttactc taaaagagtc tggccctggg atattgaagc cctcacagac cctcagtctg 60 acttgttctt tctctgggtt ttcactgacc acttctggta tgggtgtagg ctggattcgt 120 cagccttcag ggaagggtct ggagtggctg gcacacattt ggtgggatga tgataagtac 180 tataatccat ccctgaagag ccaggtcaca atctccaagg acacctccag aaaccaggta 240 ttcctcaaga tcaccagtgt ggacactgca gatactgcca cttactactg tgctcgaaga 300 actgagacta tgattacgac agtgctatat tactatgcta tggactactg gggtcaagga 360 acctcagtca ccgtctcctc a 381 <![CDATA[<210> 184]]> <![CDATA[<211> 127]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 184]]> Gln Val Thr Leu Lys Glu Ser Gly Pro Gly Ile Leu Lys Pro Ser Gln 1 5 10 15 Thr Leu Ser Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Met Gly Val Gly Trp Ile Arg Gln Pro Ser Gly Lys Gly Leu Glu 35 40 45 Trp Leu Ala His Ile Trp Trp Asp Asp Asp Lys Tyr Tyr Asn Pro Ser 50 55 60 Leu Lys Ser Gln Val Thr Ile Ser Lys Asp Thr Ser Arg Asn Gln Val 65 70 75 80 Phe Leu Lys Ile Thr Ser Val Asp Thr Ala Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Arg Thr Glu Thr Met Ile Thr Thr Val Leu Tyr Tyr Tyr 100 105 110 Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser 115 120 125 <![CDATA[<210> 185]]> <![CDATA[<211> 378]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 185]]> caagttactc taaaagagtc tggccctggg atattgaagc cctcacagac cctcagtctg 60 acttgttctt tctctggatt ttcactgagc acttctggtt tgggtgtagg ctggattcgt 120 cagccttcag ggaagggtct ggagtggctg gcacacattt ggtgggatga tgataagtac 180 tataatccat cccttaagag acagatcaca atctccaagg attcctccag aaaccaggta 240 ttcctcaaga tcaccaatgt ggacactgca gatactgcca cttactactg tgctcgaagg 300 agggaagtta acttcggtat taactattac tattctatgg actactgggg tcaaggaacc 360 tcagtcaccg tctcctca 378 <![CDATA[<210> 186]]> <![CDATA[<211> 126]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 186]]> Gln Val Thr Leu Lys Glu Ser Gly Pro Gly Ile Leu Lys Pro Ser Gln 1 5 10 15 Thr Leu Ser Leu Thr Cys Ser Phe Ser Gly Phe Ser Leu Ser Thr Ser 20 25 30 Gly Leu Gly Val Gly Trp Ile Arg Gln Pro Ser Gly Lys Gly Leu Glu 35 40 45 Trp Leu Ala His Ile Trp Trp Asp Asp Asp Lys Tyr Tyr Asn Pro Ser 50 55 60 Leu Lys Arg Gln Ile Thr Ile Ser Lys Asp Ser Ser Arg Asn Gln Val 65 70 75 80 Phe Leu Lys Ile Thr Asn Val Asp Thr Ala Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala Arg Arg Arg Glu Val Asn Phe Gly Ile Asn Tyr Tyr Tyr Ser 100 105 110 Met Asp Tyr Trp Gly Gln Gly Thr Ser Val Thr Val Ser Ser 115 120 125 <![CDATA[<210> 187]]> <![CDATA[<211> 363]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 187]]> gaggtgaagc tggtggagtc tggaggacgc ttggtacagc ctgggaattc tctgagactc 60 tcctgtgcaa cttctggatt caccttcagt gattattaca tgagttgggt ccgccagact 120 ccaggaaggg cacttgagtg gttgagtttt attagaaatc gggctaatgg ttacacaaca 180 gagtacagtg catctgtgaa gggtcgattc accatctcca gagataattc ccaaagcatc 240 ctctatcttc acatgagcac cctgagacct gaggacagtg ccacttatta ctgtgtaaga 300 gattcctatc actacgggta cttcgatgtc tggggcgcag ggaccacggt caccgtctcc 360 tca 363 <![CDATA[<210> 188]]> <![CDATA[<211> 121]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 188]]> Glu Val Lys Leu Val Glu Ser Gly Gly Arg Leu Val Gln Pro Gly Asn 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Phe Thr Phe Ser Asp Tyr 20 25 30 Tyr Met Ser Trp Val Arg Gln Thr Pro Gly Arg Ala Leu Glu Trp Leu 35 40 45 Ser Phe Ile Arg Asn Arg Ala Asn Gly Tyr Thr Thr Glu Tyr Ser Ala 50 55 60 Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Gln Ser Ile 65 70 75 80 Leu Tyr Leu His Met Ser Thr Leu Arg Pro Glu Asp Ser Ala Thr Tyr 85 90 95 Tyr Cys Val Arg Asp Ser Tyr His Tyr Gly Tyr Phe Asp Val Trp Gly 100 105 110 Ala Gly Thr Thr Val Thr Val Ser Ser 115 120 <![CDATA[<210> 189]]> <![CDATA[<211> 360]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人]]> <![CDATA[<400> 189]]> caggtgaccc tgaaggaatc cgggcctact ctggtgaaac ctacccagac tctgactctg 60 acttgtactt ttagcggctt ctcactgacc acatctggac tgggagtggc ttggatcaga 120 cagcctcctg gaaaggccct ggagtggctg gctcacattt ggagcgacgg cgatactcgg 180 tactatccag ccctgaaaaa cagactgact atcaccaagg acacatccaa aaaccaggtg 240 gtcctgacaa tgactaatat ggaccccgtc gataccgcaa catactattg cgcccatatg 300 aaggatgact ctctgtactt tgataactgg gggcagggaa ctctggtgac cgtgagcagc 360 <![CDATA[<210> 190]]> <![CDATA[<211> 120]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人]]> <![CDATA[<400> 190]]> Gln Val Thr Leu Lys Glu Ser Gly Pro Thr Leu Val Lys Pro Thr Gln 1 5 10 15 Thr Leu Thr Leu Thr Cys Thr Phe Ser Gly Phe Ser Leu Thr Thr Ser 20 25 30 Gly Leu Gly Val Ala Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu 35 40 45 Trp Leu Ala His Ile Trp Ser Asp Gly Asp Thr Arg Tyr Tyr Pro Ala 50 55 60 Leu Lys Asn Arg Leu Thr Ile Thr Lys Asp Thr Ser Lys Asn Gln Val 65 70 75 80 Val Leu Thr Met Thr Asn Met Asp Pro Val Asp Thr Ala Thr Tyr Tyr 85 90 95 Cys Ala His Met Lys Asp Asp Ser Leu Tyr Phe Asp Asn Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser 115 120 <![CDATA[<210> 191]]> <![CDATA[<211> 348]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 人]]> <![CDATA[<400> 191]]> gaggtgcagc tgctggaatc tgggggggga ctggtgcagc ctggaggaag cctgagactg 60 agttgtgccg caagtgggtt tacatttagc tcctacggaa tgagctgggt gaggcaggct 120 ccaggcaagg gactggagtg ggtctctgca atcagtacca acggagccac agcttactat 180 gccgactccg tgaagggccg gttcactatc tcaagagata acagcaagaa caccctgtat 240 ctgcagatga attctctgcg ggcagaagac acagccgtct actattgcgc tactgagaaa 300 ggggcaatga gccactgggg acagggcaca ctggtgaccg tgagttcc 348 <![CDATA[<210> 192]]> <![CDATA[<211> 116]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 人]]> <![CDATA[<400> 192]]> Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30 Gly Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Ala Ile Ser Thr Asn Gly Ala Thr Ala Tyr Tyr Ala Asp Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Thr Glu Lys Gly Ala Met Ser His Trp Gly Gln Gly Thr Leu Val 100 105 110 Thr Val Ser Ser 115 <![CDATA[<210> 193]]> <![CDATA[<211> 318]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 193]]> gctgatgctg caccaactgt atccatcttc ccaccatcca gtgagcagtt aacatctgga 60 ggtgcctcag tcgtgtgctt cttgaacaac ttctacccca aagacatcaa tgtcaagtgg 120 aagattgatg gcagtgaacg acaaaatggc gtcctgaaca gttggactga tcaggacagc 180 aaagacagca cctacagcat gagcagcacc ctcacgttga ccaaggacga gtatgaacga 240 cataacagct atacctgtga ggccactcac aagacatcaa cttcacccat tgtcaagagc 300 ttcaacagga atgagtgt 318 <![CDATA[<210> 194]]> <![CDATA[<211> 106]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 194]]> Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu Gln 1 5 10 15 Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe Tyr 20 25 30 Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg Gln 35 40 45 Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser Thr 50 55 60 Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu Arg 65 70 75 80 His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser Pro 85 90 95 Ile Val Lys Ser Phe Asn Arg Asn Glu Cys 100 105 <![CDATA[<210> 195]]> <![CDATA[<211> 315]]> <![CDATA[<212> ]]> DNA <![CDATA[<213> 小鼠]]> <![CDATA[<400> 195]]> ggtcagccca agtccactcc cactctcacc gtgtttccac cttcctctga ggagctcaag 60 gaaaacaaag ccacactggt gtgtctgatt tccaactttt ccccgagtgg tgtgacagtg 120 gcctggaagg caaatggtac acctatcacc cagggtgtgg acacttcaaa tcccaccaaa 180 gagggcaaca agttcatggc cagcagcttc ctacatttga catcggacca gtggagatct 240 cacaacagtt ttacctgtca agttacacat gaaggggaca ctgtggagaa gagtctgtct 300 cctgcagaat gtctc 315 <![CDATA[<210> 196]]> <![CDATA[<211> 105]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 196]]> Gly Gln Pro Lys Ser Thr Pro Thr Leu Thr Val Phe Pro Pro Ser Ser 1 5 10 15 Glu Glu Leu Lys Glu Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asn 20 25 30 Phe Ser Pro Ser Gly Val Thr Val Ala Trp Lys Ala Asn Gly Thr Pro 35 40 45 Ile Thr Gln Gly Val Asp Thr Ser Asn Pro Thr Lys Glu Gly Asn Lys 50 55 60 Phe Met Ala Ser Ser Phe Leu His Leu Thr Ser Asp Gln Trp Arg Ser 65 70 75 80 His Asn Ser Phe Thr Cys Gln Val Thr His Glu Gly Asp Thr Val Glu 85 90 95 Lys Ser Leu Ser Pro Ala Glu Cys Leu 100 105 <![CDATA[<210> 197]]> <![CDATA[<211> 975]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 197]]> gccaaaacaa cagccccatc ggtctatcca ctggcccctg tgtgtggaga tacaactggc 60 tcctcggtga ctctaggatg cctggtcaag ggttatttcc ctgagccagt gaccttgacc 120 tggaactctg gatccctgtc cagcggtgtg cacaccttcc cagctgtcct gcagtctgac 180 ctctacactc tgagcagctc agtgactgtc ccctccagca cctggcccag cgagaccgtc 240 acctgcaacg ttgcccaccc ggccagcagc accaaggtgg acaagaaaat tgtgcccagg 300 gattgtggtt gtaagccttg catatgtaca gtcccagaag tatcatctgt cttcatcttc 360 cccccaaagc ccaaggatgt gctcaccatt actctgactc ctaaggtcac gtgtgttgtg 420 gtagacatca gcaaggatga tcccgaggtc cagttcagct ggtttgtaga tgatgtggag 480 gtgcacacag ctcagacgca accccgggag gagcagttca acagcacttt ccgctcagtc 540 agtgaacttc ccatcatgca ccaggactgg ctcaatggca aggagttcaa atgcagggtc 600 aacagtgcag ctttccctgc ccccatcgag aaaaccatct ccaaaaccaa aggcagaccg 660 aaggctccac aggtgtacac cattccacct cccaaggagc agatggccaa ggataaagtc 720 agtctgacct gcatgataac agacttcttc cctgaagaca ttactgtgga gtggcagtgg 780 aatgggcagc cagcggagaa ctacaagaac actcagccca tcatggacac agatggctct 840 tacttcgtct acagcaagct caatgtgcag aagagcaact gggaggcagg aaatactttc 900 acctgctctg tgttacatga gggcctgcac aaccaccata ctgagaagag cctctcccac 960 tctcctggta aaggc 975 <![CDATA[<210> 198]]> <![CDATA[<211> 325]]> <![CDATA[<212> PRT]]> <![CDATA[<213> 小鼠]]> <![CDATA[<400> 198]]> Ala Lys Thr Thr Ala Pro Ser Val Tyr Pro Leu Ala Pro Val Cys Gly 1 5 10 15 Asp Thr Thr Gly Ser Ser Val Thr Leu Gly Cys Leu Val Lys Gly Tyr 20 25 30 Phe Pro Glu Pro Val Thr Leu Thr Trp Asn Ser Gly Ser Leu Ser Ser 35 40 45 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu 50 55 60 Ser Ser Ser Val Thr Val Pro Ser Ser Thr Trp Pro Ser Glu Thr Val 65 70 75 80 Thr Cys Asn Val Ala His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys 85 90 95 Ile Val Pro Arg Asp Cys Gly Cys Lys Pro Cys Ile Cys Thr Val Pro 100 105 110 Glu Val Ser Ser Val Phe Ile Phe Pro Pro Lys Pro Lys Asp Val Leu 115 120 125 Thr Ile Thr Leu Thr Pro Lys Val Thr Cys Val Val Val Asp Ile Ser 130 135 140 Lys Asp Asp Pro Glu Val Gln Phe Ser Trp Phe Val Asp Asp Val Glu 145 150 155 160 Val His Thr Ala Gln Thr Gln Pro Arg Glu Glu Gln Phe Asn Ser Thr 165 170 175 Phe Arg Ser Val Ser Glu Leu Pro Ile Met His Gln Asp Trp Leu Asn 180 185 190 Gly Lys Glu Phe Lys Cys Arg Val Asn Ser Ala Ala Phe Pro Ala Pro 195 200 205 Ile Glu Lys Thr Ile Ser Lys Thr Lys Gly Arg Pro Lys Ala Pro Gln 210 215 220 Val Tyr Thr Ile Pro Pro Pro Lys Glu Gln Met Ala Lys Asp Lys Val 225 230 235 240 Ser Leu Thr Cys Met Ile Thr Asp Phe Phe Pro Glu Asp Ile Thr Val 245 250 255 Glu Trp Gln Trp Asn Gly Gln Pro Ala Glu Asn Tyr Lys Asn Thr Gln 260 265 270 Pro Ile Met Asp Thr Asp Gly Ser Tyr Phe Val Tyr Ser Lys Leu Asn 275 280 285 Val Gln Lys Ser Asn Trp Glu Ala Gly Asn Thr Phe Thr Cys Ser Val 290 295 300 Leu His Glu Gly Leu His Asn His His Thr Glu Lys Ser Leu Ser His 305 310 315 320 Ser Pro Gly Lys Gly 325 <![CDATA[<210> 199]]> <![CDATA[<211> 20]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 合成的序列]]> <![CDATA[<400> 199]]> tttggrggga agatgaagac 20 <![CDATA[<210> 200]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 合成的序列]]> <![CDATA[<400> 200]]> ttaacactct cccctgttga a 21 <![CDATA[<210> 201]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 合成的序列]]> <![CDATA[<400> 201]]> ttaacactca ttcctgttga a 21 <![CDATA[<210> 202]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 合成的序列]]> <![CDATA[<400> 202]]> tggacaggga tccagagttc c 21 <![CDATA[<210> 203]]> <![CDATA[<211> 21]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 合成的序列]]> <![CDATA[<400> 203]]> tggacagggc tccatagttc c 21 <![CDATA[<210> 204]]> <![CDATA[<211> 20]]> <![CDATA[<212> DNA]]> <![CDATA[<213> 合成的序列]]> <![CDATA[<400> 204]]> actcgtcctt ggtcaacgtg 20
Claims (30)
- 一種能與ET AR特異性結合之抗體,其特徵在於:該抗體包含一個、兩個、三個、四個、五個、或六個胺基酸序列,其中各胺基酸序列獨立地選自於以下所列之胺基酸序列: a. 輕鏈CDR1胺基酸序列:SEQ ID NO: 8、SEQ ID NO: 10、SEQ ID NO: 12、SEQ ID NO: 14、SEQ ID NO: 16、SEQ ID NO: 18、SEQ ID NO: 20、SEQ ID NO: 22、SEQ ID NO: 24、SEQ ID NO: 26、SEQ ID NO: 28、及SEQ ID NO: 30; b. 輕鏈CDR2胺基酸序列:SEQ ID NO: 32、SEQ ID NO: 34、SEQ ID NO: 36、SEQ ID NO: 38、SEQ ID NO: 40、SEQ ID NO: 42、SEQ ID NO: 44、SEQ ID NO: 46、及SEQ ID NO: 48; c. 輕鏈CDR3胺基酸序列:SEQ ID NO: 50、SEQ ID NO: 52、SEQ ID NO: 54、SEQ ID NO: 56、SEQ ID NO: 58、SEQ ID NO: 60、SEQ ID NO: 62、SEQ ID NO: 64、SEQ ID NO: 66、及SEQ ID NO: 68; d. 重鏈CDR1胺基酸序列:SEQ ID NO: 70、SEQ ID NO: 72、SEQ ID NO: 74、SEQ ID NO: 76、SEQ ID NO: 78、SEQ ID NO: 80、SEQ ID NO: 82、SEQ ID NO: 84、SEQ ID NO: 86、SEQ ID NO: 88、及SEQ ID NO: 90; e. 重鏈CDR2胺基酸序列:SEQ ID NO: 92、SEQ ID NO: 94、SEQ ID NO: 96、SEQ ID NO: 98、SEQ ID NO: 100、SEQ ID NO: 102、SEQ ID NO: 104、SEQ ID NO: 106、SEQ ID NO: 108、SEQ ID NO: 110、SEQ ID NO: 112、及SEQ ID NO: 114;及 f. 重鏈CDR3胺基酸序列:SEQ ID NO: 116、SEQ ID NO: 118、SEQ ID NO: 120、SEQ ID NO: 122、SEQ ID NO: 124、SEQ ID NO: 126、SEQ ID NO: 128、SEQ ID NO: 130、SEQ ID NO: 132、SEQ ID NO: 134、及SEQ ID NO: 136。
- 如請求項1之能與ET AR特異性結合之抗體,其中:該抗體包含一或兩個胺基酸序列,其中各胺基酸序列獨立地選自於以下所列之胺基酸序列: a. 輕鏈CDR1胺基酸序列:SEQ ID NO: 8、SEQ ID NO: 10、SEQ ID NO: 12、SEQ ID NO: 14、SEQ ID NO: 16、SEQ ID NO: 18、SEQ ID NO: 20、SEQ ID NO: 22、SEQ ID NO: 24、SEQ ID NO: 26、SEQ ID NO: 28、及SEQ ID NO: 30;及 b. 重鏈CDR1胺基酸序列:SEQ ID NO: 70、SEQ ID NO: 72、SEQ ID NO: 74、SEQ ID NO: 76、SEQ ID NO: 78、SEQ ID NO: 80、SEQ ID NO: 82、SEQ ID NO: 84、SEQ ID NO: 86、SEQ ID NO: 88、及SEQ ID NO: 90。
- 如請求項1之能與ET AR特異性結合之抗體,其中:該抗體包含一或兩個胺基酸序列,其中各胺基酸序列獨立地選自於以下所列之胺基酸序列: a. 輕鏈CDR2胺基酸序列:SEQ ID NO: 32、SEQ ID NO: 34、SEQ ID NO: 36、SEQ ID NO: 38、SEQ ID NO: 40、SEQ ID NO: 42、SEQ ID NO: 44、SEQ ID NO: 46、及SEQ ID NO: 48;及 b. 重鏈CDR2胺基酸序列:SEQ ID NO: 92、SEQ ID NO: 94、SEQ ID NO: 96、SEQ ID NO: 98、SEQ ID NO: 100、SEQ ID NO: 102、SEQ ID NO: 104、SEQ ID NO: 106、SEQ ID NO: 108、SEQ ID NO: 110、SEQ ID NO: 112、及SEQ ID NO: 114。
- 如請求項1之能與ET AR特異性結合之抗體,其中:該抗體包含一或兩個胺基酸序列,其中各胺基酸序列獨立地選自於以下所列之胺基酸序列: a. 輕鏈CDR3胺基酸序列:SEQ ID NO: 50、SEQ ID NO: 52、SEQ ID NO: 54、SEQ ID NO: 56、SEQ ID NO: 58、SEQ ID NO: 60、SEQ ID NO: 62、SEQ ID NO: 64、SEQ ID NO: 66、及SEQ ID NO: 68;及 b. 重鏈CDR3胺基酸序列:SEQ ID NO: 116、SEQ ID NO: 118、SEQ ID NO: 120、SEQ ID NO: 122、SEQ ID NO: 124、SEQ ID NO: 126、SEQ ID NO: 128、SEQ ID NO: 130、SEQ ID NO: 132、SEQ ID NO: 134、及SEQ ID NO: 136。
- 如請求項1之能與ET AR特異性結合之抗體,其中:該抗體包含一或兩個胺基酸序列,其中各胺基酸序列獨立地選自於以下所列之胺基酸序列:SEQ ID NO: 8、SEQ ID NO: 20、SEQ ID NO: 22、SEQ ID NO: 24、SEQ ID NO: 26、SEQ ID NO: 28、SEQ ID NO: 30、SEQ ID NO: 32、SEQ ID NO: 44、SEQ ID NO: 46、SEQ ID NO: 48、SEQ ID NO: 50、SEQ ID NO: 62、SEQ ID NO: 64、SEQ ID NO: 66、及SEQ ID NO: 68。
- 如請求項1之能與ET AR特異性結合之抗體,其中:該抗體包含一或兩個胺基酸序列,其中各胺基酸序列獨立地選自於以下所列之胺基酸序列:SEQ ID NO: 70、SEQ ID NO: 82、SEQ ID NO: 84、SEQ ID NO: 86、SEQ ID NO: 88、SEQ ID NO: 90、SEQ ID NO: 92、SEQ ID NO: 104、SEQ ID NO: 106、SEQ ID NO:108、SEQ ID NO: 110、SEQ ID NO: 112、SEQ ID NO: 114、SEQ ID NO: 116、SEQ ID NO: 128、SEQ ID NO: 130、SEQ ID NO: 132、SEQ ID NO: 134、及SEQ ID NO: 136。
- 如請求項1之能與ET AR特異性結合之抗體,其中:該抗體包含一個獨立地選自於以下所列之輕鏈與重鏈CDR3胺基酸序列的組合:SEQ ID NO: 50與SEQ ID NO: 116、SEQ ID NO: 62與SEQ ID NO: 128、SEQ ID NO: 62與SEQ ID NO: 130、SEQ ID NO: 64與SEQ ID NO: 132、SEQ ID NO: 66與SEQ ID NO: 134、及SEQ ID NO: 68與SEQ ID NO: 136。
- 如請求項1之能與ET AR特異性結合之抗體,其中:該抗體包含一或兩個胺基酸序列,其中各胺基酸序列獨立地選自於以下所列之胺基酸序列: a. 輕鏈可變域胺基酸序列:SEQ ID NO: 138、SEQ ID NO: 140、SEQ ID NO: 142、SEQ ID NO: 144、SEQ ID NO: 146、SEQ ID NO: 148、SEQ ID NO: 150、SEQ ID NO: 152、SEQ ID NO: 154、SEQ ID NO: 156、SEQ ID NO: 158、SEQ ID NO: 160、SEQ ID NO: 162、及SEQ ID NO: 164;及 b. 重鏈可變域胺基酸序列:SEQ ID NO: 166、SEQ ID NO: 168、SEQ ID NO: 170、SEQ ID NO: 172、SEQ ID NO: 174、SEQ ID NO: 176、SEQ ID NO: 178、SEQ ID NO: 180、SEQ ID NO: 182、SEQ ID NO: 184、SEQ ID NO: 186、SEQ ID NO: 188、SEQ ID NO: 190、及SEQ ID NO: 192。
- 如請求項1之能與ET AR特異性結合之抗體,其中:該抗體之多聚核苷酸編碼序列包含一或兩個多聚核苷酸序列,其中各多聚核苷酸序列獨立地選自於以下所列多聚核苷酸序列: a. 輕鏈可變域多聚核苷酸編碼序列:SEQ ID NO: 137、SEQ ID NO: 139、SEQ ID NO: 141、SEQ ID NO: 143、SEQ ID NO: 145、SEQ ID NO: 147、SEQ ID NO: 149、SEQ ID NO: 151、SEQ ID NO: 153、SEQ ID NO: 155、SEQ ID NO: 157、SEQ ID NO: 159、SEQ ID NO: 161、及SEQ ID NO: 163;及 b. 重鏈可變域多聚核苷酸編碼序列:SEQ ID NO: 165、SEQ ID NO: 167、SEQ ID NO: 169、SEQ ID NO: 171、SEQ ID NO: 173、SEQ ID NO: 175、SEQ ID NO: 177、SEQ ID NO: 179、SEQ ID NO: 181、SEQ ID NO: 183、SEQ ID NO: 185、SEQ ID NO: 187、SEQ ID NO: 189、及SEQ ID NO: 191。
- 如請求項1之能與ET AR特異性結合之抗體,其中:該抗體包含一個獨立地選自於以下所列之胺基酸序列之組合:SEQ ID NO: 138及SEQ ID NO: 166、SEQ ID NO: 140及SEQ ID NO: 168、SEQ ID NO: 142及SEQ ID NO: 170、SEQ ID NO: 144及SEQ ID NO: 172、SEQ ID NO: 146及SEQ ID NO: 174、SEQ ID NO: 148及SEQ ID NO: 176、SEQ ID NO: 150及SEQ ID NO: 178、SEQ ID NO: 152及SEQ ID NO: 180、SEQ ID NO: 154及SEQ ID NO: 182、SEQ ID NO: 156及SEQ ID NO: 184、SEQ ID NO: 158及SEQ ID NO: 186、SEQ ID NO: 160及SEQ ID NO: 188、SEQ ID NO: 162及SEQ ID NO: 190、及SEQ ID NO: 164及SEQ ID NO: 192。
- 如請求項1之能與ET AR特異性結合之抗體,其中:該抗體包含一個獨立地選自於以下所列之胺基酸序列:SEQ ID NO: 138、SEQ ID NO: 150、SEQ ID NO: 152、SEQ ID NO: 154、SEQ ID NO: 156、SEQ ID NO: 158、SEQ ID NO: 160、SEQ ID NO: 162、及SEQ ID NO: 164。
- 如請求項1之能與ET AR特異性結合之抗體,其中:該抗體包含一個獨立地選自於以下所列之胺基酸序列:SEQ ID NO: 166、SEQ ID NO: 178、SEQ ID NO: 180、SEQ ID NO: 182、SEQ ID NO: 184、SEQ ID NO: 186、SEQ ID NO: 188、SEQ ID NO: 190、及SEQ ID NO: 192。
- 如請求項1之能與ET AR特異性結合之抗體,其中:該抗體包含一個獨立地選自於以下所列之輕鏈與重鏈可變區胺基酸序列之組合:SEQ ID NO: 138與SEQ ID NO: 166、SEQ ID NO: 150與SEQ ID NO: 178、SEQ ID NO: 152與SEQ ID NO: 180、SEQ ID NO: 154與SEQ ID NO: 182、SEQ ID NO: 156與SEQ ID NO: 184、SEQ ID NO: 158與SEQ ID NO: 186、SEQ ID NO: 160與SEQ ID NO: 188、SEQ ID NO: 162與SEQ ID NO: 190、及SEQ ID NO: 164與SEQ ID NO: 192。
- 如請求項1之能與ET AR特異性結合之抗體,其中:該抗體包含胺基酸序列SEQ ID NO: 138或SEQ ID NO: 166。
- 如請求項1之能與ET AR受體特異性結合之抗體,其中:該抗體包含SEQ ID NO: 138及SEQ ID NO: 166胺基酸序列之組合。
- 如請求項1之能與ET AR特異性結合之抗體,其中:該抗體包含一或兩個胺基酸序列,其中各胺基酸序列獨立地選自於以下所列之胺基酸序列: a. 輕鏈恆定區胺基酸序列:SEQ ID NO: 194及SEQ ID NO: 196;及 b. 重鏈恆定區胺基酸序列:SEQ ID NO: 198。
- 如請求項1之能與ET AR特異性結合之抗體,其中:該抗體包含鼠源抗體或人源化抗體。
- 如請求項1之能與ET AR特異性結合之抗體,其中:該抗體包含單株抗體。
- 如請求項1之能與ET AR特異性結合之抗體,其中:該抗體包含單株抗體,該單株抗體包含SEQ ID NO: 138與SEQ ID NO: 166、SEQ ID NO: 150與SEQ ID NO: 178、SEQ ID NO: 152與SEQ ID NO: 180、SEQ ID NO: 154與SEQ ID NO: 182、SEQ ID NO: 156與SEQ ID NO: 184、SEQ ID NO: 158與SEQ ID NO: 186、SEQ ID NO: 160與SEQ ID NO: 188、SEQ ID NO: 162與SEQ ID NO: 190、或SEQ ID NO: 164與SEQ ID NO: 192。
- 如請求項1之能與ET AR特異性結合之抗體,其中:該抗體之降低人內皮素信號傳導之IC 50值大約為1 nM至200 nM或10 nM至100 nM。
- 一種醫藥組合物,其包含與醫藥可接受載劑混合的如請求項1之能與ET AR特異性結合之抗體。
- 一種多核苷酸,其編碼如請求項1之能與ET AR特異性結合之抗體。
- 一種重組表現載體,其包含如請求項22之核酸。
- 一種宿主細胞,其包含如請求項23之載體。
- 一種生產能與ET AR特異性結合之抗體的方法,其特徵在於:包括在允許表現該抗體之條件下培養如請求項24之宿主細胞。
- 一種用於治療、預防或改善受試者中糖尿病腎病之一或多種症狀的方法,該方法包括投與受試者治療有效量的如請求項21之醫藥組合物。
- 一種用於治療、預防或改善受試者中慢性腎病之一或多種症狀的方法,該方法包括投與受試者治療有效量的如請求項21之醫藥組合物。
- 一種用於治療、預防或改善受試者中伴隨有蛋白尿之疾病之一或多種症狀的方法,該方法包括投與受試者治療有效量的如請求項21之醫藥組合物。
- 一種用於治療、預防或改善受試者中伴隨有腎小球濾過率下降之疾病之一或多種症狀的方法,該方法包括投與受試者治療有效量的如請求項21之醫藥組合物。
- 如請求項26至29中任一項之方法,其中所述的受試者為人。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110353110.6A CN115141276A (zh) | 2021-03-31 | 2021-03-31 | 一种能与人内皮素受体特异性结合的抗体及其在糖尿病肾病和慢性肾病治疗中的应用 |
CN202110353110.6 | 2021-03-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW202304982A true TW202304982A (zh) | 2023-02-01 |
Family
ID=83405098
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW111112218A TW202304982A (zh) | 2021-03-31 | 2022-03-30 | 一種能與人內皮素受體特異性結合的抗體及其在糖尿病腎病及慢性腎病治療中的應用 |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP4317187A1 (zh) |
JP (1) | JP2024514253A (zh) |
KR (1) | KR20240044382A (zh) |
CN (2) | CN115141276A (zh) |
AR (1) | AR125247A1 (zh) |
AU (1) | AU2022248020A1 (zh) |
BR (1) | BR112023019900A2 (zh) |
CA (1) | CA3215428A1 (zh) |
TW (1) | TW202304982A (zh) |
WO (1) | WO2022206857A1 (zh) |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4737462A (en) | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5011912A (en) | 1986-12-19 | 1991-04-30 | Immunex Corporation | Hybridoma and monoclonal antibody for use in an immunoaffinity purification system |
US5262522A (en) | 1991-11-22 | 1993-11-16 | Immunex Corporation | Receptor for oncostatin M and leukemia inhibitory factor |
PT672141E (pt) | 1992-10-23 | 2003-09-30 | Immunex Corp | Metodos de preparacao de proteinas oligomericas soluveis |
US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
US6133426A (en) | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
ES2301198T3 (es) | 1997-06-12 | 2008-06-16 | Novartis International Pharmaceutical Ltd. | Polipeptidos artificiales de anticuerpos. |
GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
US6210924B1 (en) | 1998-08-11 | 2001-04-03 | Amgen Inc. | Overexpressing cyclin D 1 in a eukaryotic cell line |
GB9928787D0 (en) | 1999-12-03 | 2000-02-02 | Medical Res Council | Direct screening method |
GB0025144D0 (en) | 2000-10-13 | 2000-11-29 | Medical Res Council | Concatenated nucleic acid sequences |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US20040202995A1 (en) | 2003-04-09 | 2004-10-14 | Domantis | Nucleic acids, proteins, and screening methods |
CN105669863B (zh) * | 2014-12-05 | 2019-09-13 | 鸿运华宁(杭州)生物医药有限公司 | 一种能与人内皮素受体特异性结合的抗体及其应用 |
CN107987162A (zh) * | 2016-10-27 | 2018-05-04 | 鸿运华宁(杭州)生物医药有限公司 | Etar抗体,其药物组合物及其应用 |
CN112062857A (zh) * | 2019-06-10 | 2020-12-11 | 鸿运华宁(杭州)生物医药有限公司 | Eta抗体与bnp的融合蛋白质,及其药物组合物和应用 |
CN112239507A (zh) * | 2019-07-17 | 2021-01-19 | 鸿运华宁(杭州)生物医药有限公司 | ETA抗体与TGF-β Trap的融合蛋白质,以及其药物组合物和应用 |
-
2021
- 2021-03-31 CN CN202110353110.6A patent/CN115141276A/zh active Pending
-
2022
- 2022-03-30 EP EP22779039.1A patent/EP4317187A1/en active Pending
- 2022-03-30 BR BR112023019900A patent/BR112023019900A2/pt unknown
- 2022-03-30 TW TW111112218A patent/TW202304982A/zh unknown
- 2022-03-30 JP JP2023560989A patent/JP2024514253A/ja active Pending
- 2022-03-30 CA CA3215428A patent/CA3215428A1/en active Pending
- 2022-03-30 CN CN202280026926.0A patent/CN117120473A/zh active Pending
- 2022-03-30 WO PCT/CN2022/084164 patent/WO2022206857A1/zh active Application Filing
- 2022-03-30 AU AU2022248020A patent/AU2022248020A1/en active Pending
- 2022-03-30 AR ARP220100767A patent/AR125247A1/es unknown
- 2022-05-10 KR KR1020237037450A patent/KR20240044382A/ko unknown
Also Published As
Publication number | Publication date |
---|---|
AR125247A1 (es) | 2023-06-28 |
BR112023019900A2 (pt) | 2023-11-07 |
EP4317187A1 (en) | 2024-02-07 |
CA3215428A1 (en) | 2022-10-06 |
KR20240044382A (ko) | 2024-04-04 |
WO2022206857A1 (zh) | 2022-10-06 |
CN117120473A (zh) | 2023-11-24 |
AU2022248020A1 (en) | 2023-11-09 |
JP2024514253A (ja) | 2024-03-29 |
CN115141276A (zh) | 2022-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107151269B (zh) | 一种pdl-1抗体、其药物组合物及其用途 | |
CN111018987B (zh) | 一种能与人内皮素受体特异性结合的抗体及其应用 | |
EP2074149B1 (en) | Compositions and methods relating to glucagon receptor antibodies | |
KR20150030675A (ko) | 항bmp9 항체를 유효 성분으로 하는, 신장성 빈혈, 암성 빈혈 등의 빈혈에 대한 치료제 | |
US11780916B2 (en) | GIPR antibody and GLP-1 fusion protein thereof, and pharmaceutical composition and application thereof | |
CN112521501A (zh) | Gipr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用 | |
WO2021008519A1 (zh) | ETA抗体与TGF-βTrap的融合蛋白质,以及其药物组合物和应用 | |
KR102549008B1 (ko) | Etar 항체 및 이의 약학 조성물 및 용도 | |
EP3808847A1 (en) | Apj antibody, fusion protein thereof with elabela, and pharmaceutical compositions and use thereof | |
TW202304982A (zh) | 一種能與人內皮素受體特異性結合的抗體及其在糖尿病腎病及慢性腎病治療中的應用 | |
CN112062857A (zh) | Eta抗体与bnp的融合蛋白质,及其药物组合物和应用 | |
RU2800370C2 (ru) | Антитело к gipr и его слитый с glp-1 белок, а также фармацевтическая композиция на его основе и его применение | |
KR102669444B1 (ko) | Etar 항체 및 이의 약학 조성물 및 용도 | |
TWI842699B (zh) | Gcgr抗體及其與glp-1的融合蛋白質,以及其藥物組合物和應用 |